

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 January 2006 (26.01.2006)

PCT

(10) International Publication Number  
**WO 2006/007795 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/50**,  
15/63, 7/00, C07K 14/165, A61K 39/215, A61P 11/00,  
G01N 33/53, C12Q 1/68

(CN). **GUAN, Yi**; 11A, Block 4, Pokfulam Gardens, 180  
Pokfulam Road, Hong Kong (CN).

(21) International Application Number:  
PCT/CN2005/001088

(74) Agent: **CHINA PATENT AGENT (H.K.) LTD.**; 22/F,  
Great Eagle Centre, 23 Harbour Road, Wanchai, Hong  
Kong (CN).

(22) International Filing Date: 20 July 2005 (20.07.2005)

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/895,064 21 July 2004 (21.07.2004) US  
11/129,741 16 May 2005 (16.05.2005) US

(71) Applicant (*for all designated States except US*): **THE  
UNIVERSITY OF HONG KONG** [CN/CN]; Pokfulam  
Road, Hong Kong (CN).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: **YUEN, Kwokying**; Flat C, 19/F, Block  
20, Baguio Villa, 555 Victoria Road, Hong Kong (CN).  
**WOO, Chiuyat, Patrick**; Flat B, 23/F, Block 1, Robnson  
Heights, 8 Robnson Road, Hong Kong (CN). **LAU,  
Karpui, Susanna**; Flat C, 1/F, Block 1, Aquamarine  
Garden, Tuen Mun, New Territories, Hong Kong (CN).  
**CHAN, Kwokhung**; 3A, Wisteria Mansion, Taikoo shing,  
Quarry Bay, Hong Kong (CN). **POON, Litman**; Flat  
21H, Block 2, Phase 3, Belvedere Garden, Tsuen Wan,  
Hong Kong (CN). **PEIRIS, Joseph, Sriyal, Malik**; 19/F,  
Block 29, Baguio Villa, 550 Victoria Road, Hong Kong

**Published:**  
— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF

(57) Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus- HKU1 ("HCoV-HKU1"), isolated in Hong Kong. The virus belongs to the order *Nidovirales* of the family *Coronaviridae*, being a single-stranded RN virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by HCoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the HCoV- HKU1 based on the nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1.

WO 2006/007795 A1

A NOVEL HUMAN VIRUS CAUSING  
RESPIRATORY TRACT INFECTION AND USES THEREOF

---

This is a continuation-in-part application of U.S. patent application serial no. 10/895,064 filed July 21, 2004, which is incorporated by reference in its entirety.

5

**SEQUENCE LISTING**

The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on March 21, 2005, are labeled "CRF", "Copy 1" and "Copy 2", respectively, and each contains only one identical 2.84 MB file (V0690044.APP).

10

**1. INTRODUCTION**

The present invention relates to a novel virus causing respiratory tract infection in humans ["coronavirus-HKU1 (CoV-HKU1)"]. Phylogenetic analysis has revealed that the CoV-HKU1 is a new group 2 coronavirus, which has, at least, two (2) genotypes, A and B. The present invention relates to nucleotide sequences comprising the complete genomic sequences of the CoV-HKU1. The invention further relates to nucleotide sequences comprising a portion of the genomic sequences of the CoV-HKU1. The invention also relates to the deduced amino acid sequences of the complete genomes of the CoV-HKU1. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods, such as for immunogens. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequence. Furthermore, the invention relates to vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus as well as protein extracts and subunits of said virus.

25

**2. BACKGROUND OF THE INVENTION**

Since no microbiological cause has been identified in a significant proportion of patients with respiratory tract infections (Macfarlane, J. T. *et al.*, 1993, Prospective study of

aetiology and outcome of adult lower-respiratory-tract infections in the community, *Lancet* 341:511-514; Ruiz, M., S. *et al.*, 1990, Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity, *Am. J. Respir. Crit. Care Med.* 160:397-405), research has been conducted to identify possible novel agent(s). Of the three novel agents identified  
5 in the recent three years, including human metapneumovirus (Van den Hoogen, *et al.*, 2001, A newly discovered human pneumovirus isolated from young children with respiratory tract disease, *Nat. Med.* 7:719-724), Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV) (Peiris, J. S. *et al.*, 2003, Coronavirus as a possible cause of severe acute respiratory syndrome, *Lancet* 361:1319-1325) and human coronavirus NL63 (HCoV-NL63)  
10 (Fouchier, R. A. *et al.*, 2004, A previously undescribed coronavirus associated with respiratory disease in humans, *Proc. Natl. Acad. Sci. USA.* 101:6212-6216; van der Hoek, *et al.*, 2004, Identification of a new human coronavirus, *Nat. Med.* 10:368-373), two were coronaviruses. Coronaviruses possess the largest genome of about 30 kb among all RNA viruses. As a result of the unique mechanism of viral replication, coronaviruses have a high  
15 frequency of recombination.

Based on genotypic and serological characterization, coronaviruses were divided into three distinct groups, with human coronavirus 229E (HCoV-229E) being a group 1 coronavirus and HCoV-OC43 a group 2 coronavirus (Lai, M. M. *et al.*, 1997, The molecular biology of coronaviruses, *Adv. Virus Res.* 48:1-100). They account for 5-30% of human  
20 respiratory tract infections. In late 2002 and 2003, the epidemic caused by SARS-CoV affected over 8000 people with 750 deaths (for example, Peiris, J. S. *et al.*, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, *Lancet* 361:1767-1772). We have also reported the isolation of SARS-CoV-like viruses from Himalayan palm civets, which suggested that  
25 animals could be the reservoir for the ancestor of SARS-CoV (Guan, Y. *et al.*, 2003, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China, *Science* 302:276-278). On the basis of genome analysis, SARS-CoV belongs to a fourth group of coronavirus, or alternatively, a distant relative of group 2 coronaviruses (Eickmann, M. *et al.*, 2003, Phylogeny of the SARS coronavirus, *Science*  
30 302:1504-1505; Marra, M. A. *et al.*, 2003, The Genome sequence of the SARS-associated coronavirus, *Science* 300:1399-1404; Rota, P. A. *et al.*, 2003, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, *Science* 300:1394-1399;

Snijder, E. J. *et al.*, 2003, Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, *J. Mol. Biol.* 331:991-1004; Yeh, S. H. *et al.*, 2004, Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution, *Proc. Natl. Acad. Sci. USA.* 101:2542-2547). Recently, a novel group 1 human coronavirus associated with respiratory tract infections, HCoV-NL63, has been discovered, and its genome sequenced (37).

In January, 2004, a 71-year-old Chinese man was admitted to hospital because of fever and chills for two days associated with sore throat, rhinorrhoea, productive cough with purulent sputum, headache and nausea. He had history of pulmonary tuberculosis more than 40 years ago complicated by cicatrization of right upper lobe and bronchiectasis with chronic *Pseudomonas aeruginosa* colonization of airways. He was a chronic smoker and also had chronic obstructive airway disease, hyperlipidemia, and asymptomatic abdominal aortic aneurysm. He had just returned from Shenzhen of China three days before admission. During his three-day trip to Shenzhen, he had no history of contact with or consumption of wild animals. On admission, his oral temperature was 37.6°C. Physical examination showed tracheal deviation to the right and inspiratory crackles over the anterior left lower zone. His haemoglobin level was 14.7 g/dL, total white cell count  $12.1 \times 10^9/L$ , with neutrophil  $9.7 \times 10^9/L$ , lymphocyte  $1.6 \times 10^9/L$  and monocyte  $0.5 \times 10^9/L$ , and plate count  $303 \times 10^9/L$ . His liver and renal function tests were within normal limits. Chest radiograph showed right upper lobe collapse and new patchy infiltrates over the left lower zone. Blood culture was performed. Empirical oral amoxicillin/clavulanate and azithromycin were commenced. Nasopharyngeal aspirates for direct antigen detection for respiratory viruses, RT-PCR for influenza A virus, human metapneumovirus and SARS-CoV, and viral cultures were negative. Sputum for bacterial culture only recovered *P. aeruginosa*. Sputum for mycobacterial culture was negative. Blood culture was negative. Paired sera for antibodies against *Mycoplasma*, *Chlamydia*, *Legionella*, and SARS-CoV did not show any rise in antibody titres. His fever subsided two days after admission. His cough improved and he was discharged after five days of hospitalization. Amoxicillin/clavulanate and azithromycin were continued for a total of seven days. The present inventors were the group involved in the investigation of this patient. All tests for identifying commonly recognized viruses and bacteria were negative in these patients. The etiologic agent responsible for this disease was



not known until the complete genome of CoV-HKU1 from this patient by the present inventors as disclosed herein. Further studies disclosed herein have revealed that CoV-HKU1 is a human coronavirus and there are, at least, two (2) genotypes, A and B, within CoV-HKU1. The invention is useful in both clinical and scientific research applications.

5

### 3. SUMMARY OF INVENTION

The present invention is based upon the inventor's complete genome sequencing of a novel virus ("CoV-HKU1") causing pneumonia in humans. The virus was first discovered from a patient suffering from pneumonia in Hong Kong. The virus is a single-  
10 stranded RNA virus of positive polarity which belongs to the order, *Nidovirales*, of the family, *Coronaviridae*. Further studies based on prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period, have revealed that there are, at least, two (2) genotypes for CoV-HKU1. Accordingly, the invention relates to CoV-HKU1 that phylogenetically relates to known  
15 members of *Coronaviridae* and specifically belongs to group 2 coronavirus. In a specific embodiment, the invention provides complete genomic sequences of two (2) genotypes of CoV-HKU1. In a preferred embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In  
20 another specific embodiment, the invention provides nucleic acids isolated from the virus. The virus preferably comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, in its genome. In a specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively,  
25 consisting of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300,  
30 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement

thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:3 or 2919, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or 2919, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. Furthermore, in another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof. In preferred embodiments, such nucleic acid molecules encode amino acid sequences that have biological activities exhibited by the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932,

2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or proteins include those having the amino acid

sequences of SEQ IDNO:2, 34-2918 shown in Figures 2 and 3, and SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in Figures 9. The invention further provides proteins or polypeptides that are isolated from the CoV-HKU1, including viral proteins isolated from cells infected with the virus but not present in comparable uninfected cells. The polypeptides or the proteins of the present invention preferably have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by the nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934. In another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. Furthermore, in another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. In other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000,

7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof.

5 In one aspect, the invention relates to the use of CoV-HKU1 for diagnostic methods. In a specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-HKU1, or any proteins or polypeptides thereof. In another specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-  
10 HKU1-infected cells. In yet another specific embodiment, the invention provides a method of screening for an antibody that immunospecifically binds and neutralizes CoV-HKU1. Such an antibody is useful for a passive immunization or immunotherapy of a subject infected with CoV-HKU1.

The invention further relates to the use of the sequence information of the isolated  
15 virus for diagnostic methods. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or at least a portion of the nucleotide sequence thereof.  
20 In another specific embodiment, the invention provides nucleic acid molecules which are suitable for hybridization to CoV-HKU1 nucleic acid, including, but not limited to, as PCR primers, Reverse Transcriptase primers, probes for Southern or Northern analysis or other nucleic acid hybridization analysis for the detection of CoV-HKU1 nucleic acids, *e.g.*, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922,  
25 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof.

The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924,  
30 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptide having the amino acid sequence of SEQ ID NO:2 or any one of SEQ ID NOS:34-2918

shown in Figures 2 and 3, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in Figures 9, or encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and/or any CoV-HKU1 epitope, having one or more biological activities of a polypeptide of the invention. The invention further provides antibodies that specifically bind cells or tissues that are infected by CoV-HKU1. Such antibodies include, but are not limited to polyclonal, 10 monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, 15 activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, and so forth. The increased or decreased activity or expression of the CoV-HKU1 in a sample relative to a control sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detecting agents 20 are the antibodies or nucleic acid molecules of the present invention. Antibodies of the invention may also be used to detect and/or treat other coronaviruses, such as Severe Acute Respiratory Syndrome ("SARS") viruses.

In another embodiment, the invention provides vaccine preparations, comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or protein subunits of the virus. 25 In a specific embodiment, the present invention provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific invention, the vaccine preparations of the present invention comprise a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 30 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides isolated from or produced from nucleic acid of CoV-HKU1. In a specific embodiment, the vaccine

preparations comprise a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID  
5 NO:2 or any one of SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing or preventing respiratory tract infections caused by CoV-HKU1 by administering to a subject in need thereof the anti-viral agents of the present  
10 invention, alone or in combination with various anti-viral agents as well as adjuvants, and/or other pharmaceutically acceptable excipients.

In another aspect, the present invention provides methods for preventing or inhibiting, under a physiological condition, binding to a host cell, or infection of a host cell, or replication in a host cell, of CoV-HKU1 or a virus comprising a nucleic acid molecule  
15 comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, by administering to the host cell the anti-viral agents of the present invention, alone or in combination with other anti-viral agents. In a specific embodiment, the anti-viral agent of the invention includes the  
20 immunogenic preparations of the invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and/or neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the present invention or a nucleic acid molecule of the invention. In a specific embodiment, the host cell is a mammalian cell, including a cell of human, primates, cows, horses, sheep, pigs, fowl (*e.g.*,  
25 chickens), goats, cats, dogs, hamsters, mice and rats. Preferably a host cell is a primate cell, and most preferably a human cell. Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The invention also provides kits containing a pharmaceutical composition of the present invention.

30

### 3.1 Definitions

The term "an antibody or an antibody fragment that immunospecifically binds a polypeptide of the invention" as used herein refers to an antibody or a fragment thereof that immunospecifically binds to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 5 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, and does not non-specifically bind to other polypeptides. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention may cross-react with other antigens. Preferably, an antibody or a fragment thereof that immunospecifically binds to a polypeptide of the invention does not cross-react with other 10 antigens. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention, can be identified by, for example, immunoassays or other techniques known to those skilled in the art.

An "isolated" or "purified" peptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is 15 derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of a polypeptide/protein in which the polypeptide/protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a polypeptide/protein that is substantially free of cellular material includes preparations of the 20 polypeptide/protein having less than about 30%, 20%, 10%, 5%, 2.5%, or 1%, (by dry weight) of contaminating protein. When the polypeptide/protein is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When polypeptide/protein is produced by chemical synthesis, it is preferably substantially free of 25 chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide/protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than polypeptide/protein fragment of interest. In a preferred embodiment of the present invention, polypeptides/proteins are 30 isolated or purified.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule.



Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment of the invention, nucleic acid molecules encoding polypeptides/proteins of the invention are isolated or purified. The term "isolated" nucleic acid molecule does not include a nucleic acid that is a member of a library that has not been purified away from other library clones containing other nucleic acid molecules.

The term "portion" or "fragment" as used herein refers to a fragment of a nucleic acid molecule containing at least about 10, 15, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, or more contiguous nucleic acids in length of the relevant nucleic acid molecule and having at least one functional feature of the nucleic acid molecule (or the encoded protein has one functional feature of the protein encoded by the nucleic acid molecule); or a fragment of a protein or a polypeptide containing at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,100, 4,200, 4,300, 4,350, 4,360, 4,370, 4,380 amino acid residues in length of the relevant protein or polypeptide and having at least one functional feature of the protein or polypeptide.

The term "having a biological activity of the protein" or "having biological activities of the polypeptides of the invention" refers to the characteristics of the polypeptides or proteins having a common biological activity similar or identical structural domain and/or having sufficient amino acid identity to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the polypeptide having any one of the amino acid sequences of SEQ ID NOS:2, 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236, or a

complement thereof. Such common biological activities of the polypeptides of the invention include antigenicity and immunogenicity.

The term "under stringent condition" refers to hybridization and washing conditions under which nucleotide sequences having at least 70%, at least 75%, at least 80%, at least 5 85%, at least 90%, or at least 95% identity to each other remain hybridized to each other. Such hybridization conditions are described in, for example but not limited to, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.; Basic Methods in Molecular Biology, Elsevier Science Publishing Co., Inc., N.Y. (1986), pp. 75-78, and 84-87; and Molecular Cloning, Cold Spring Harbor Laboratory, N.Y. (1982), pp. 10 387-389, and are well known to those skilled in the art. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC), 0.5% SDS at about 68°C followed by one or more washes (*e.g.*, about 5 to 30 min each) in 2X SSC, 0.5% SDS at room temperature. Another preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X SSC at about 45°C followed by 15 one or more washes (*e.g.*, about 5 to 30 min each) in 0.2X SSC, 0.1% SDS at about 45-65°C.

The term "variant" as used herein refers either to a naturally occurring genetic mutant of CoV-HKU1 or a recombinantly prepared variation of CoV-HKU1 each of which contain one or more mutations in its genome compared to CoV-HKU1. The term "variant" may also refers either to a naturally occurring variation of a given peptide or a 20 recombinantly prepared variation of a given peptide or protein in which one or more amino acid residues have been modified by amino acid substitution, addition, or deletion.

#### 4. BRIEF DESCRIPTION OF FIGURES

Figure 1 shows a partial DNA sequence (SEQ ID NO:1) and its deduced amino acid 25 sequence (SEQ ID NO:2) obtained from CoV-HKU1 that has 91% amino acid identity to the RNA-dependent RNA polymerase protein of known *Coronaviruses*.

Figure 2 shows the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid 30 sequences: SEQ ID NOS:34-456; the second-frame translation and amino acid sequences:

SEQ ID NOS:457-723; and the third-frame translation and amino acid sequences: SEQ ID NOS:724-1318.

Figure 3 shows the complement (SEQ ID NO:1319) of the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 in 3'→5' orientation and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:1319-1907; the second-frame translation and amino acid sequences: SEQ ID NO:1908-2453; and the third-frame translation and amino acid sequences: SEQ ID NOS:2454-2918.

Figure 4 shows genome organization of CoV-HKU1. Overall organization of the 29926-nucleotide CoV-HKU1 genomic RNA. Predicted ORFs 1a and 1b, encoding the nonstructural polyproteins (p28, p65 and nsp1-13) and those encoding the hemagglutinin-esterase, spike, envelope, membrane and nucleocapsid structural proteins are indicated. Arrows indicate putative cleavage sites (with the corresponding nucleotide positions) of the replicase polyprotein encoded by ORF 1a and ORF 1b. ATR, PL1<sup>pro</sup> and PL2<sup>pro</sup> represent the acidic tandem repeat and the two papain-like proteases, respectively, in nsp1.

Figure 5A shows the phylogenetic analysis of the chymotrypsin like protease (3CL<sup>pro</sup>), RNA-dependent RNA polymerase (Pol), helicase, and hemagglutinin-esterase (HE); and Figure 5B shows that of the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1. The trees were constructed by the neighbor joining method using the Jukes-Cantor correction and bootstrap values were calculated from 1000 trees. A total of 303, 928, 595, 418, 1356, 75, 225 and 406 amino acid positions in 3CL<sup>pro</sup>, Pol, helicase, HE, S, E, M, and N, respectively, were included in the analysis. The scale bar indicates the estimated number of substitutions per 10 amino acids. HCoV-229E: human coronavirus 229E; PEDV: porcine epidemic diarrhea virus; PTGV: porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63: human coronavirus NL63; HCoV-OC43: human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; SDAV: rat sialodacryoadnitis coronavirus; ECoV: equine coronavirus NC99; PHEV: porcine hemagglutinating encephalomyelitis virus; IBV: infectious bronchitis virus; SARS-CoV: SARS coronavirus.

Figure 6 shows the spike protein of CoV-HKU1 (residues 7-336 of SEQ ID NO: 420) and those of other group 2 coronaviruses (SEQ ID NOS 21-26, respectively, in order of

appearance). The spike protein (1356 amino acids) of CoV-HKU1 is depicted by the horizontal bar [SS = N terminal signal sequence (amino acid residues 1 to 13), HR1 = heptad repeat 1 (amino acid residues 982 to 1083), HR2 = heptad repeat 2 (amino acid residues 1250 to 1297), TM = transmembrane domain (amino acid residues 1301 to 1323)], (the seven sequences below the horizontal bar disclose residues 752-766 of SEQ ID NO: 420 and SEQ ID NOS 28-33, respectively, in order of appearance). Alignment of the N-terminal region important for receptor binding (amino acid residues 1 to 330) and the region upstream to the cleavage site between S1 and S2 of CoV-HKU1 and other group 2 coronaviruses was generated with ClustalX 1.83. Residues that match the CoV-HKU1 exactly are boxed. The three conserved regions (sites I, II, and III) for receptor binding in MHV are shaded. The positions of the four conserved amino acids important for receptor binding in MHV are indicated with arrows. (GenBank accession nos. MHV: P11224; BCoV: NP 150077; HCoV-OC43: NP 937950; SDAV: AAF97738; PHEV: AAL80031; ECoV: AAQ67205).

Figure 7 shows the sequential quantitative RT-PCR (closed squares; copies/ml) for CoV-HKU1 in nasopharyngeal aspirates; and serum IgG antibody titers against N protein of CoV-HKU1 (closed triangles).

Figure 8 shows the Western blot analysis of purified recombinant CoV-HKU1 N protein antigen. Prominent immunoreactive protein bands of about 53 kDa (*i.e.*, purified recombinant CoV-HKU1 N protein) were detected by the Western blot using the patient's sera obtained during the second and fourth weeks of the illness (lanes 2 and 3). Only very faint bands were observed with the serum samples obtained from the patient during the first week of the illness (lane 1) and two healthy blood donors (lane 4 and 5), respectively.

Figure 9 shows the entire genomic DNA sequence (SEQ ID NO:2919) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS: 2970-3474; the second-frame translation and amino acid sequences: SEQ ID NOS: 3475-3721; and the third-frame translation and amino acid sequences: SEQ ID NOS: 3722-4236.

Figure 10 shows arrangements of proteins in replicase polyprotein in CoV-HKU1 compared with those in HCoV-OC43, BCoV, and MHV. Alignment of the AC domains of HCoV-OC43 (SEQ ID NO: 4239), BCoV (SEQ ID NO: 4238), and MHV (SEQ ID NO:

4237) and the AC domains and ATR (underlined) of CoV-HKU1 in the two patients (SEQ ID NOS 4240 and 4241) was generated with ClustalX 1.83. AC domain = acidic domain, ATR = acidic tandem repeat. (GenBank accession no. MHV: NC\_001846; BCoV: NC\_003045; HCoV-OC43: AY585229).

5            Fig. 11 shows the multiple alignments of the replicase genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2920 which encodes SEQ ID NO: 2921), 2 (SEQ ID NO: 2922 which encodes SEQ ID NO: 2923), 4 (SEQ ID NO: 2924 which encodes SEQ ID NO: 2925), 5 (SEQ ID NO: 4242 which encodes SEQ ID NO: 4243), 6 (SEQ ID NO: 2926 which encodes SEQ ID NO: 2927), 7 (SEQ ID NO: 2928 which encodes SEQ ID NO: 2929), 8 (SEQ ID NO: 2930 which encodes SEQ ID NO: 2931), 9 (SEQ ID NO: 2932 which encodes SEQ ID NO: 2933) and 10 (SEQ ID NO: 2934 which encodes SEQ ID NO: 2935).

15            Fig. 12 shows the chest radiographs of the two patients who died of community acquired pneumonia associated with CoV-HKU1. The chest radiograph of the first patient (Fig. 12A; patient no. 2 in Table 5) showed patchy airspace shadows in both lungs with predominant involvement of the lower zones. The chest radiograph of the second patient (Fig. 12B; patient no. 10 in Table 5), with Luque instrumentation in situ, showed extensive airspace shadows in both lungs with the middle zones more severely involved.

20            Fig. 13 shows the multiple alignments of the spike genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2936 which encodes SEQ ID NO: 2937), 2 (SEQ ID NO: 2938 which encodes SEQ ID NO: 2939), 4 (SEQ ID NO: 2940 which encodes SEQ ID NO: 2941), 5 (SEQ ID NO: 4244 which encodes SEQ ID NO: 4245), 6 (SEQ ID NO: 2942 which encodes SEQ ID NO: 2943), 7 (SEQ ID NO: 2944 which encodes SEQ ID NO: 2945), 8 (SEQ ID NO: 2946 which encodes SEQ ID NO: 2947), 9 (SEQ ID NO: 2948 which encodes SEQ ID NO: 2949) and 10 (SEQ ID NO: 2950 which encodes SEQ ID NO: 2951).

30            Fig. 14 shows the multiple alignments of the nucleocapsid genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2952 which encodes SEQ ID NO: 2953), 2 (SEQ ID NO: 2954 which encodes SEQ ID NO: 2955), 4 (SEQ ID NO: 2956 which encodes SEQ ID NO: 2957), 5 (SEQ ID NO: 4246 which encodes SEQ ID NO: 4247), 6 (SEQ ID NO: 2958 which encodes SEQ ID NO: 2959), 7 (SEQ ID NO: 2960 which encodes SEQ ID NO: 2961), 8 (SEQ ID NO: 2962 which encodes SEQ ID NO: 2963), 9 (SEQ ID NO: 2964

which encodes SEQ ID NO: 2965) and 10 (SEQ ID NO: 2966 which encodes SEQ ID NO: 2967).

Fig. 15 shows phylogenetic trees and non-synonymous mutations and corresponding amino acid changes of complete *pol*, S and N gene sequences of HCoV-HKU1 from nine patients with community acquired pneumonia. The trees were inferred from *pol* (Fig. 15A), S (Fig. 15B) and N (Fig. 15C) gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The trees were rooted using *pol*, S and N gene sequences of HCoV-OC43, respectively. 2784 nucleotide positions in each *pol* gene, 4071 nucleotide positions in each S gene, and 1326 nucleotide positions in each N gene, were included in the analysis. The scale bar indicates the estimated number of substitutions per 100 (Fig. 15A) and 50 (Figs. 15B and 15C) bases, respectively, using Jukes-Cantor correction. The shaded nucleotides are those that differ from the majority at the corresponding locations. Due to the large number of non-synonymous mutations in the S gene, only the NH<sub>2</sub> terminal 45, out of the total of 306, non-synonymous mutations are shown.

Fig. 16 shows the multiple alignments of nucleotides 1806-1835 and 2229-2258 of the *pol* genes in the nine HCoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV. Marked differences between the 3' ends of the two primers for RT-PCR (LPW1926; SEQ ID NO: 4248 and LPW1927; SEQ ID NO: 4249) and the corresponding bases in HCoV-OC43 (SEQ ID NOS 4250 and 4251), HCoV-229E (SEQ ID NOS 4254 and 4255), HCoV-NL63 (SEQ ID NOS 4256 and 4257) and SARS-CoV (SEQ ID NOS 4252 and 4253) are observed, indicating the high specificity of the two primers for HCoV-HKU1. The positions of LPW1926 (SEQ ID NO: 4248) and LPW1927 (SEQ ID NO: 4249) are boxed. The bases in HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV that were different from those in the sequence of the primers, were shaded.

Fig. 17 show a phylogenetic tree of *pol* gene sequences of the 10 HCoV-HKU1 from patients with community acquired pneumonia. The tree was inferred from *pol* gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The tree was rooted using *pol* gene sequence of HCoV-229E and 393 nucleotide positions (primer sequences excluded) in each *pol* gene were included in the analysis. The scale bar indicates the estimated number of substitutions per 50 bases using Jukes-Cantor correction. HCoV-HKU1: human coronavirus HKU1; HCoV-229E: human coronavirus 229E; HCoV-OC43:

human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; PHEV: porcine hemagglutinating encephalomyelitis virus.

## 5. DETAILED DESCRIPTION OF THE INVENTION

5           The present invention relates to the CoV-HKU1 that phylogenetically relates to known *Coronaviruses*. In a specific embodiment, CoV-HKU1 comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a specific embodiment, the present invention provides isolated nucleic acid  
10 molecules of the CoV-HKU1, comprising, or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof or a portion thereof. In another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent  
15 conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or specific genes of known member of *Coronaviridae*, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a  
20 nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1,  
25 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300,  
30 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900,

3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or the proteins of the present invention preferably have one or more biological activities of the proteins encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the native viral proteins containing the amino acid sequences encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides the entire nucleotide sequence of CoV-HKU1 (SEQ ID NO:3 or 2919), or fragments, or complement thereof. Furthermore, the present invention relates to a nucleic acid molecule that hybridizes any portion of the genome of the CoV-HKU1 (SEQ ID NO:3 or 2919) under the stringent conditions. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932,



2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, or a portion thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for use as hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof. The invention further encompasses chimeric or recombinant viruses or viral proteins encoded by said nucleotide sequences.

10 The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, or any CoV-HKU1 epitope as well as the polypeptides having the amino acid sequences of any one of SEQ ID NO:2, SEQ ID NOS:34-2918 shown in Figures 2 and 3, SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in Figures 9. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, 15 disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, sputum, nasopharyngeal aspirates, and so forth. The presence of the CoV-HKU1 in a sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detection agents are the antibodies of the present invention. In another embodiment, the detection agent is a nucleic acid of the present invention. 25 30 invention.

In another embodiment, the invention provides vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or subunits of the virus.

The present invention further provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific embodiment, the vaccine preparations of the present invention comprise one or more nucleic acid molecules comprising or consisting of the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 5 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 10 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236. Furthermore, the present invention provides methods for treating, 15 ameliorating, managing, or preventing respiratory tract infections by administering to a subject in need thereof the anti-viral agents of the present invention, alone or in combination with other antivirals [*e.g.*, amantadine, rimantadine, gancyclovir, acyclovir, ribavirin, penciclovir, oseltamivir, foscarnet zidovudine (AZT), didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, delavirdine, indinavir, 20 ritonavir, vidarabine, nelfinavir, saquinavir, relenza, tamiflu, pleconaril, interferons, etc.], steroids and corticosteroids such as prednisone, cortisone, fluticasone and glucocorticoid, antibiotics, analgesics, bronchodialaters, or other treatments for respiratory and/or viral infections. In one aspect, the anti-viral agent of the present invention prevents or inhibit the binding of the virus or viral proteins to a host cell under a physiological condition, thereby 25 preventing or inhibiting the infection of the host cell by the virus. In another aspect, the anti-viral agent of the invention prevents or inhibits replication of the viral nucleic acid molecules in the host cell under a physiological condition by interacting with the viral nucleic acid molecules or its transcription mechanisms. In a specific embodiment, the anti-viral agent of the invention includes the vaccine or immunogenic preparations of the 30 invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and may neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the invention or a nucleic acid molecule of the invention.

In addition, the present invention provides a method of preventing or inhibiting replication in a host cell of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or inhibiting the  
5 activities of the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof, including the polypeptides having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939,  
10 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, by administering to said host cell the anti-viral agent of the invention. In a specific embodiment the host cell is a mammalian cell, such as a cell of humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents. Preferably, the cell is a primate cell and most preferably a human cell.

15 Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The present invention also provides kits comprising pharmaceutical compositions of the present invention.

### 20 **5.1 Recombinant and Chimeric CoV-HKU1**

The present invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genome of CoV-HKU1 or natural variants thereof. In a specific embodiment, a recombinant virus is one derived from the CoV-HKU1. In a specific embodiment, the virus has a nucleotide sequence of SEQ ID NO:3 or 2919. In  
25 another specific embodiment, a recombinant virus is one derived from a natural variant of CoV-HKU1. A natural variant of CoV-HKU1 has a sequence that is different from the genomic sequence (SEQ ID NO:3 or 2919) of CoV-HKU1, due to one or more naturally occurred mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a  
30 phenotypic change. In accordance with the present invention, a viral vector which is derived from the genome of the CoV-HKU, is one that contains a nucleic acid sequence that encodes at least a part of one ORF of the CoV-HKU1. In a specific embodiment, the ORF

comprises or consists of a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In a specific embodiment, there are more than one ORF within the nucleotide sequence of SEQ ID NO:3 or 2919, or a  
5 fragment thereof. In another embodiment, the polypeptides encoded by the ORF comprises or consists of amino acid sequences of SEQ ID NO:34-2918 shown in Fig. 2 and 8, or SEQ ID NO:2, SEQ ID NO:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or a fragment thereof. In accordance with the present invention these viral  
10 vectors may or may not include nucleic acids that are non-native to the viral genome.

In another specific embodiment, a chimeric virus of the invention is a recombinant CoV-HKU1 which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous  
15 or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

According to the present invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance  
20 with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric virus may be encoded by nucleotide sequences derived from different strains or variants of CoV-HKU1. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides  
25 derived from different strains or variants of CoV-HKU1.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., *J. Virol.* 72, 2955-2961; Durbin et al., 2000, *J. Virol.* 74, 6821-6831; Skiadopoulos et al., 1998, *J. Virol.* 72, 1762-1768 (1998); Teng et al., 2000, *J. Virol.* 74, 9317-9321). For example, it can be envisaged that a virus  
30 vector derived from the CoV-HKU1 expressing one or more proteins of variants of CoV-HKU1, or vice versa, will protect a subject vaccinated with such vector against infections by both the native CoV-HKU1 and the variant. Attenuated and replication-defective viruses

may be of use for vaccination purposes with live vaccines as has been suggested for other viruses.

In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains or variants of CoV-HKU1.

In certain embodiments, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been inserted or added to the vector.

The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection.

In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by the CoV-HKU1 and natural variants thereof. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses.

The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial antigens, tumor antigens, allergen antigens, and auto antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with CoV-HKU1 and variants thereof.

In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and autoantigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing CoV-HKU1 genes to contain foreign sequences in their respective external domains. Where the

heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

Thus, the present invention relates to the use of viral vectors and recombinant or  
5 chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The present invention also encompasses recombinant viruses comprising a viral vector derived from the CoV-HKU1 or variants thereof which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer  
10 sequences of the virus.

The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of CoV-HKU1 are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing  
15 full-length or partial copies of the CoV-HKU1 genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

20 In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial CoV-HKU1 proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication- defective or chimeric viruses.

25 The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

## 30 5.2 Formulation of Vaccines and Antivirals

In a preferred embodiment, the invention provides a proteinaceous molecule or CoV-HKU1 specific viral protein or functional fragment thereof encoded by a nucleic acid

according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from the virus according to the invention, including envelop protein (E protein), integral membrane protein (M protein), spike protein (S protein), nucleocapsid protein (N protein), hemagglutinin esterase (HE protein), and  
5 RNA-dependent RNA polymerase. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as subunit vaccines. Particularly useful are polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962,  
10 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-2918 in Fig. 2 and 3, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 in Fig. 9, or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly  
15 useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments of the CoV-HKU1 genome; of course preferred are those that are within the preferred bounds and metes of ORFs, in particular, for eliciting CoV-HKU1 specific antibody or T cell responses, whether in vivo (e.g. for protective or therapeutic purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another  
20 technique useful for generating synthetic antibodies).

The invention provides vaccine formulations for the prevention and treatment of infections with CoV-HKU1. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the CoV-HKU1.

In another aspect, the present invention also provides DNA vaccine formulations  
25 comprising a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another specific embodiment, the DNA vaccine formulations of the present invention comprises a nucleic acid or fragment thereof encoding  
30 the antibodies which immunospecifically binds CoV-HKU1. In DNA vaccine formulations, a vaccine DNA comprises a viral vector, such as that derived from the CoV-HKU1, bacterial plasmid, or other expression vector, bearing an insert comprising a nucleic acid

molecule of the present invention operably linked to one or more control elements, thereby allowing expression of the vaccinating proteins encoded by said nucleic acid molecule in a vaccinated subject. Such vectors can be prepared by recombinant DNA technology as recombinant or chimeric viral vectors carrying a nucleic acid molecule of the present invention.

Various heterologous vectors are described for DNA vaccinations against viral infections. For example, the vectors described in the following references may be used to express CoV-HKU1 sequences instead of the sequences of the viruses or other pathogens described; in particular, vectors described for hepatitis B virus (Michel, M.L. *et al.*, 1995, DAN-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans, *Proc. Natl. Aca. Sci. USA* 92:5307-5311; Davis, H.L. *et al.*, 1993, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody, *Human Molec. Genetics* 2:1847-1851), HIV virus (Wang, B. *et al.*, 1993, Gene inoculation generates immune responses against human immunodeficiency virus type 1, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; Lu, S. *et al.*, 1996, Simian immunodeficiency virus DNA vaccine trial in macaques, *J. Virol.* 70:3978-3991; Letvin, N.L. *et al.*, 1997, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, *Proc Natl Acad Sci U S A.* 94(17):9378-83), and influenza viruses (Robinson, HL *et al.*, 1993, Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA, *Vaccine* 11:957-960; Ulmer, J.B. *et al.*, Heterologous protection against influenza by injection of DNA encoding a viral protein, *Science* 259:1745-1749), as well as bacterial infections, such as tuberculosis (Tascon, R.E. *et al.*, 1996, Vaccination against tuberculosis by DNA injection, *Nature Med.* 2:888-892; Huygen, K. *et al.*, 1996, Immunogenicity and protective efficacy of a tuberculosis DNA vaccine, *Nature Med.*, 2:893-898), and parasitic infection, such as malaria (Sedegah, M., 1994, Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein, *Proc. Natl. Acad. Sci. USA* 91:9866-9870; Doolan, D.L. *et al.*, 1996, Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8<sup>+</sup> T cell-interferon  $\delta$ , and nitric oxide-dependent immunity, *J. Exper. Med.*, 1183:1739-1746).



Many methods may be used to introduce the vaccine formulations described above. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes. Alternatively, it may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the pathogen for which the vaccine is designed. The DNA vaccines of the present invention may be administered in saline solutions by injections into muscle or skin using a syringe and needle (Wolff J.A. *et al.*, 1990, Direct gene transfer into mouse muscle in vivo, *Science* 247:1465-1468; Raz, E., 1994, Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses, *Proc. Natl. Acad. Sci. USA* 91:9519-9523). Another way to administer DNA vaccines is called "gene gun" method, whereby microscopic gold beads coated with the DNA molecules of interest is fired into the cells (Tang, D. *et al.*, 1992, Genetic immunization is a simple method for eliciting an immune response, *Nature* 356:152-154). For general reviews of the methods for DNA vaccines, see Robinson, H.L., 1999, DNA vaccines: basic mechanism and immune responses (Review), *Int. J. Mol. Med.* 4(5):549-555; Barber, B., 1997, Introduction: Emerging vaccine strategies, *Seminars in Immunology* 9(5):269-270; and Robinson, H.L. *et al.*, 1997, DNA vaccines, *Seminars in Immunology* 9(5):271-283.

### 5.3 Adjuvants and Carrier Molecules

CoV-HKU1-associated antigens are administered with one or more adjuvants. In one embodiment, the CoV-HKU1-associated antigen is administered together with a mineral salt adjuvants or mineral salt gel adjuvant. Such mineral salt and mineral salt gel adjuvants include, but are not limited to, aluminum hydroxide (ALHYDROGEL, REHYDRAGEL), aluminum phosphate gel, aluminum hydroxyphosphate (ADJU-PHOS), and calcium phosphate.

In another embodiment, CoV-HKU1-associated antigen is administered with an immunostimulatory adjuvant. Such class of adjuvants, include, but are not limited to, cytokines (*e.g.*, interleukin-2, interleukin-7, interleukin-12, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon- $\gamma$  interleukin-1 $\beta$  (IL-1 $\beta$ ), and IL-1 $\beta$  peptide or Sclavo Peptide), cytokine-containing liposomes, triterpenoid glycosides or saponins (*e.g.*, QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), Muramyl Dipeptide (MDP) derivatives, such as N-acetyl-muramyl-L-threonyl-D-isoglutamine

(Threonyl-MDP, sold under the trademark TERMURTIDE), GMMP, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxy phosphoryloxy)-ethylamine, muramyl tripeptide phosphatidylethanolamine (MTP-PE), unmethylated CpG dinucleotides and  
5 oligonucleotides, such as bacterial DNA and fragments thereof, LPS, monophosphoryl Lipid A (3D-MLA sold under the trademark MPL), and polyphosphazenes.

In another embodiment, the adjuvant used is a particular adjuvant, including, but not limited to, emulsions, *e.g.*, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalane oil-in-water adjuvant formulations, such as SAF and MF59, *e.g.*,  
10 prepared with block-copolymers, such as L-121 (polyoxypropylene/polyoxyethylene) sold under the trademark PLURONIC L-121, Liposomes, Virosomes, cochleates, and immune stimulating complex, which is sold under the trademark ISCOM.

In another embodiment, a microparticulate adjuvant is used. Microparticulate adjuvants include, but are not limited to biodegradable and biocompatible polyesters, homo-  
15 and copolymers of lactic acid (PLA) and glycolic acid (PGA), poly(lactide-co-glycolides) (PLGA) microparticles, polymers that self-associate into particulates (poloxamer particles), soluble polymers (polyphosphazenes), and virus-like particles (VLPs) such as recombinant protein particulates, *e.g.*, hepatitis B surface antigen (HbsAg).

Yet another class of adjuvants that may be used include mucosal adjuvants,  
20 including but not limited to heat-labile enterotoxin from *Escherichia coli* (LT), cholera holotoxin (CT) and cholera Toxin B Subunit (CTB) from *Vibrio cholerae*, mutant toxins (*e.g.*, LTK63 and LTR72), microparticles, and polymerized liposomes.

In other embodiments, any of the above classes of adjuvants may be used in combination with each other or with other adjuvants. For example, non-limiting examples  
25 of combination adjuvant preparations that can be used to administer the CoV-HKU1-associated antigens of the invention include liposomes containing immunostimulatory protein, cytokines, or T-cell and/or B-cell peptides, or microbes with or without entrapped IL-2 or microparticles containing enterotoxin. Other adjuvants known in the art are also included within the scope of the invention (see *Vaccine Design: The Subunit and Adjuvant*  
30 *Approach*, Chap. 7, Michael F. Powell and Mark J. Newman (eds.), Plenum Press, New York, 1995, which is incorporated herein in its entirety).

The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing a CoV-HKU1 polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

5           The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid additional salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic  
10 bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

15           Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, *e.g.*, using a bifurcated needle).

The patient to which the vaccine is administered is preferably a mammal, most  
20 preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (*e.g.*, chickens), goats, cats, dogs, hamsters, mice and rats.

#### 5.4 Preparation of Antibodies

25           Antibodies which specifically recognize a polypeptide of the invention, such as, but not limited to, polypeptides comprising the sequence of SEQ ID NO:2 or any of SEQ ID NOS: 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or CoV-HKU1 epitope, or antigen-binding fragments thereof, can be used for  
30 detecting, screening, and isolating the polypeptide of the invention or fragments thereof, or similar sequences that might encode similar enzymes from the other organisms. For example, in one specific embodiment, an antibody which immunospecifically binds CoV-

HKU1 epitope, or a fragment thereof, can be used for various in vitro detection assays, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, Western blot, etc., for the detection of a polypeptide of the invention or, preferably, CoV-HKU1, in samples, for example, a biological material, including cells, cell culture media (e.g.,  
5 bacterial cell culture media, mammalian cell culture media, insect cell culture media, yeast cell culture media, etc.), blood, plasma, serum, tissues, sputum, nasopharyngeal aspirates, etc.

Antibodies specific for a polypeptide of the invention or any epitope of CoV-HKU1 may be generated by any suitable method known in the art. Polyclonal antibodies to an  
10 antigen-of-interest, for example, the CoV-HKU1 epitopes or polypeptides encoded by a nucleotide sequence of SEQ ID NO:1 or 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides shown in Fig. 2 (SEQ ID NOS:34-1318), Fig. 3 (SEQ ID NOS:1319-2918), as well as SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931,  
15 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, can be produced by various procedures well known in the art. For example, an antigen can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc., to induce the production of antisera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase  
20 the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful adjuvants for humans such as BCG (Bacille Calmette-Guerin) and *Corynebacterium parvum*. Such  
25 adjuvants are also well known in the art (*see* Section 5.4, *supra*).

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow  
30 et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, pp. 563-681 (Elsevier, N.Y., 1981) (both of which are incorporated by reference in their entireties). The

term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

5           Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are  
10 then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by inoculating mice intraperitoneally with positive hybridoma clones.

15           Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the complete light chain, and the variable region, the CH1 region and the hinge region of the  
20 heavy chain.

The antibodies of the invention or fragments thereof can be also produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

The nucleotide sequence encoding an antibody may be obtained from any  
25 information available to those skilled in the art (i.e., from Genbank, the literature, or by routine cloning and sequence analysis). If a clone containing a nucleic acid encoding a particular antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable  
30 source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic

primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., supra; and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence by, for example, introducing amino acid substitutions, deletions, and/or insertions into the epitope-binding domain regions of the antibodies or any portion of antibodies which may enhance or reduce biological activities of the antibodies.

Recombinant expression of an antibody requires construction of an expression vector containing a nucleotide sequence that encodes the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art as discussed in the previous sections. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The nucleotide sequence encoding the heavy-chain variable region, light-chain variable region, both the heavy-chain and light-chain variable regions, an epitope-binding fragment of the heavy- and/or light-chain variable region, or one or more complementarity determining regions (CDRs) of an antibody may be cloned into such a vector for expression. Thus-prepared expression vector can be then introduced into appropriate host cells for the expression of the antibody. Accordingly, the invention includes host cells containing a polynucleotide encoding an antibody specific for the polypeptides of the invention or fragments thereof.

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature*, 322:52, 1986; and Kohler, *Proc. Natl. Acad. Sci. USA*, 77:2 197, 1980). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

In another embodiment, antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods*, 182:41-50, 1995; Ames et al., *J. Immunol. Methods*, 184:177-186, 1995; Kettleborough et al., *Eur. J. Immunol.*, 24:952-958, 1994; Persic et al., *Gene*, 187:9-18, 1997; Burton et al., *Advances in Immunology*, 57:191-280, 1994; PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including

human antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab)<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in  
5 PCT publication WO 92/22324; Mullinax et al., *BioTechniques*, 12(6):864-869, 1992; and Sawai et al., *AJRI*, 34:26-34, 1995; and Better et al., *Science*, 240:1041-1043, 1988 (each of which is incorporated by reference in its entirety). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology*, 203:46-88, 1991; Shu et  
10 al., *PNAS*, 90:7995-7999, 1993; and Skerra et al., *Science*, 240:1038-1040, 1988.

Once an antibody molecule of the invention has been produced by any methods described above, it may then be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A or Protein G purification, and  
15 sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for the purification of proteins. Further, the antibodies of the present invention or fragments thereof may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

For some uses, including in vivo use of antibodies in humans and in vitro detection  
20 assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison,  
25 *Science*, 229:1202, 1985; Oi et al., *BioTechniques*, 4:214 1986; Gillies et al., *J. Immunol. Methods*, 125:191-202, 1989; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties. Humanized antibodies are antibody molecules from non-human species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and  
30 framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework



substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al.,  
5 Nature, 332:323, 1988, which are incorporated herein by reference in their entireties.

Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology, 28(4/5):489-498, 1991; Studnicka et al., Protein  
10 Engineering, 7(6):805-814, 1994; Roguska et al., Proc Natl. Acad. Sci. USA, 91:969-973, 1994), and chain shuffling (U.S. Patent No. 5,565,332), all of which are hereby incorporated by reference in their entireties.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art  
15 including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol., 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal  
25 antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entireties. In addition, companies such as Abgenix, Inc. (Fremont, CA), Medarex  
30 (NJ) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology*, 12:899-903, 5 1988).

Antibodies fused or conjugated to heterologous polypeptides may be used in in vitro immunoassays and in purification methods (e.g., affinity chromatography) well known in the art. See e.g., PCT publication Number WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.*, 39:91-99, 1994; U.S. Patent 5,474,981; Gillies et al., *PNAS*, 89:1428-10 1432, 1992; and Fell et al., *J. Immunol.*, 146:2446-2452, 1991, which are incorporated herein by reference in their entireties.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the polypeptides of the invention or fragments, derivatives, analogs, or variants thereof, or similar molecules having the similar enzymatic activities as 15 the polypeptide of the invention. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

### 5.5 Pharmaceutical Compositions and Kits

The present invention encompasses pharmaceutical compositions comprising anti-20 viral agents of the present invention. In a specific embodiment, the anti-viral agent is an antibody which immunospecifically binds CoV-HKU1 or variants thereof, or any proteins derived therefrom. In another specific embodiment, the anti-viral agent is a polypeptide or nucleic acid molecule of the invention. The pharmaceutical compositions have utility as an anti-viral prophylactic agent and may be administered to a subject where the subject has 25 been exposed or is expected to be exposed to a virus.

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu and Wu, 1987, *J. Biol. Chem.* 262:4429 30 4432). Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus

injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In a preferred embodiment, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, by means of nasal spray, or by means of an implant, said implant being of a porous, non porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) infected tissues.

In another embodiment, the pharmaceutical composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, *Science* 249:1527-1533; Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

In yet another embodiment, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald et al., 1980, *Surgery* 88:507; and Saudek et al., 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., 1985, *Science* 228:190; Daring et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, i.e., the lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of recombinant or chimeric CoV-HKU1, and a pharmaceutically acceptable carrier. In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in “Remington’s Pharmaceutical Sciences” by E.W. Martin. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a

hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline  
5 can be provided so that the ingredients may be mixed prior to administration.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium,  
10 ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2 ethylamino ethanol, histidine, procaine, etc.

The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In  
15 addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500  
20 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose response curves derived from *in vitro* or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by  
25 weight; oral formulations preferably contain 10% to 95% active ingredient.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of  
30 pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a preferred embodiment, the kit contains an anti-viral agent of the invention, e.g., an antibody specific for the polypeptides

encoded by a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966 or any CoV-HKU1 epitope, or a polypeptide or protein of the present invention, including those shown in Fig. 2 (SEQ ID NOS:34-1318), Fig. 3 (SEQ ID  
5 NOS:1319-2918), Fig. 9 (SEQ ID NOS: 2970-4236) and SEQ ID NO:2, or a nucleic acid molecule of the invention, alone or in combination with adjuvants, antivirals, antibiotics, analgesic, bronchodialaters, or other pharmaceutically acceptable excipients.

The present invention further encompasses kits comprising a container containing a pharmaceutical composition of the present invention and instructions for use.

10

### 5.6 Detection Assays

The present invention provides a method for detecting an antibody, which immunospecifically binds to the CoV-HKU1, in a biological sample, for example blood, serum, plasma, saliva, urine, etc., from a patient suffering from respiratory tract infection.

15 In a specific embodiment, the method comprising contacting the sample with the polypeptides or protein encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-1318 shown in Fig. 2, SEQ ID NOS:1319-  
20 2918 shown in Fig. 3, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 shown in Figs. 9, directly immobilized on a substrate and detecting the virus-bound antibody directly or indirectly by a labeled heterologous anti-isotype antibody. In another specific embodiment, the sample is contacted with a host cell  
25 comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and expressing the polypeptides encoded thereby, and the bound antibody can be detected by immunofluorescent assay.

30 An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of

detecting an epitope or nucleic acid (e.g., mRNA, genomic RNA) of CoV-HKU1 such that the presence of CoV-HKU1 is detected in the sample. A preferred agent for detecting CoV-HKU1 mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof, or a complement thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1,000 or more contiguous nucleotides in length and sufficient to specifically hybridize under stringent conditions to a CoV-HKU1 mRNA or genomic RNA.

In another preferred specific embodiment, the presence of CoV-HKU1 is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the genome of CoV-HKU1 or a genomic nucleic acid sequence of SEQ ID NO:3 or 2919, or based on a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a non-limiting specific embodiment, preferred primers to be used in a RT-PCR method are: 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5), or 5'-AAAGGATGTTGAC-AACCCTGTT-3' (LPW1926; SEQ ID NO: 2968) and 5'-ATCATCATACTAAAATGCT-TACA-3' (LPW1927; SEQ ID NO: 2969), in the presence of 3 mM MgCl<sub>2</sub> and the thermal cycles are, for example, but not limited to, 94°C for 8 min followed by 40 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min. In more preferred specific embodiment, the present invention provides a real-time quantitative PCR assay to detect the presence of CoV-HKU1 in a biological sample by subjecting the cDNA obtained by reverse transcription of the extracted total RNA from the sample to PCR reactions using the specific primers, such as those having nucleotide sequences of SEQ ID NOS:4, 5, 2968 and 2969, and a fluorescence dye, such as SYBR<sup>®</sup> Green I, which fluoresces when bound non-specifically to double-stranded DNA. The fluorescence signals from these reactions are captured at the end of extension steps as PCR product is generated over a range of the

thermal cycles, thereby allowing the quantitative determination of the viral load in the sample based on an amplification plot.

A preferred agent for detecting CoV-HKU1 is an antibody that specifically binds a polypeptide of the invention or any CoV-HKU1 epitope, preferably an antibody with a  
5 detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used.

The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by  
10 reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The detection method of the invention can be used to detect mRNA, protein (or any epitope), or genomic RNA in a sample in vitro as well as in vivo. For  
15 example, in vitro techniques for detection of mRNA include northern hybridizations, in situ hybridizations, RT-PCR, and RNase protection. In vitro techniques for detection of an epitope of CoV-HKU1 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic RNA include northern hybridizations, RT-PCR, and RNase protection.  
20 Furthermore, in vivo techniques for detection of CoV-HKU1 include introducing into a subject organism a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in the subject organism can be detected by standard imaging techniques, including autoradiography.

25 In a specific embodiment, the methods further involve obtaining a control sample from a control subject, contacting the control sample with a compound or agent capable of detecting CoV-HKU1, e.g., a polypeptide of the invention or mRNA or genomic RNA encoding a polypeptide of the invention, such that the presence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide is detected in the sample,  
30 and comparing the absence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide in the control sample with the presence of CoV-HKU1, or the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.



The invention also encompasses kits for detecting the presence of CoV-HKU1 or a polypeptide or nucleic acid of the invention in a test sample. The kit, for example, can comprise a labeled compound or agent capable of detecting CoV-HKU1 or the polypeptide or a nucleic acid molecule encoding the polypeptide in a test sample and, in certain  
5 embodiments, a means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for use.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g.,  
10 attached to a solid support) which binds to a polypeptide of the invention or CoV-HKU1 epitope; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic  
15 acid sequence encoding a polypeptide of the invention or to a sequence within the CoV-HKU1 genome or (2) a pair of primers useful for amplifying a nucleic acid molecule containing an CoV-HKU1 sequence. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can  
20 also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for use.

25

## 6. EXAMPLES

The following examples illustrate the identification of the novel CoV-HKU1. These examples should not be construed as limiting.

### METHODS AND RESULTS

30

As a general reference, Wiedbrauk DL & Johnston SLG. (Manual of Clinical Virology, Raven Press, New York, 1993) was used.

## 6.1 Example 1

### 6.1.1 Clinical subject

The patient is an in-patient of the United Christian Hospital in Hong Kong.

- 5 Nasopharyngeal aspirates were collected from the patient weekly from the first till the fifth week of the illness, stool and urine in the first and second week of the illness, and sera in the first, second, and fourth weeks of the illness.

### 6.1.2 Antibody detection

- 10 To produce a fusion plasmid for protein purification, primers, 5'- TTTTCCTTTT GCGGCCGCTTAAGCAACAGAGTCTTCTA-3' (SEQ ID NO:6) and 5'- CGGAATTC GATGTCTTATACTCCCGGT-3'(SEQ ID NO:7) were used to amplify the gene encoding the N protein of the CoV-HKU1 by RT-PCR. The sequence coding for amino acid residues 1 to 441 of the N protein was amplified and cloned into the *EcoRI* and *NotI* sites of  
15 expression vector pET-28b(+) (Novagen, Madison, WI, USA) in frame and downstream of the series of six histidine residues. The (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein was expressed in *E. coli* and purified using the Ni<sup>2+</sup>-loaded HiTrap Chelating System (Amersham Pharmacia, USA) according to the manufacturer's instructions.

- Western blot analysis was performed as follows: Two-hundred ng of purified (His)<sub>6</sub>-  
20 tagged (SEQ ID NO:27) recombinant N protein of CoV-HKU1 were loaded into each well of a sodium dodecyl sulfate (SDS)-10% polyacrylamide gel and subsequently electroblotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The blot was cut into strips and the strips were incubated separately with 1:2000 dilution of serum samples obtained during the first, second, and fourth weeks of the patient's illness. Serum samples of two  
25 healthy blood donors were used as controls. Antigen-antibody interaction was detected with an ECL fluorescence system (Amersham Life Science, Buckinghamshire, UK).

- Several prominent immunoreactive bands were visible for serum samples collected during the second and fourth weeks of the patient's illness (Fig. 8, lanes 2 and 3). The sizes of the largest bands were about 53 kDa, consistent with the expected size of 52.8 kDa for  
30 the full-length (His)<sub>6</sub>-tagged (SEQ ID NO:27) N protein, whereas the other bands were consistent with the degradation products of the (His)<sub>6</sub>-tagged (SEQ ID NO:27) N protein.

Only very faint bands were observed for serum samples obtained from the patient during the first week of the illness (Fig. 8, lane 1) and two healthy blood donors (Fig. 8, lanes 4 and 5).

ELISA was performed using the recombinant N protein of CoV-HKU1 prepared as described above. Each well of a Nunc immunoplate (Roskilde, Denmark) was coated with  
5 20 ng of purified (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein for 12 h and then blocked in phosphate-buffered saline with 2% bovine serum albumin. The serum samples obtained from the patient during the first, second, and fourth weeks of the illness were serially diluted and were added to the wells of the (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein-coated plates in a total volume of 100  $\mu$ l per well and incubated at  
10 37°C for 2 h. After washing with washing buffer five times, 100  $\mu$ l per well of 1:4000 diluted horse radish peroxidase-conjugated goat anti-human IgG antibody (Zymed Laboratories Inc., South San Francisco, CA, USA) were added to the wells and incubated at 37°C for 1 h. After washing with washing buffer five times, 100  $\mu$ l of diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at  
15 room temperature for 15 min. One hundred microliters of 0.3 M H<sub>2</sub>SO<sub>4</sub> were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

Box titration was carried out with different dilutions of (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein coating antigen and serum obtained from the fourth week of  
20 the patient's illness. The results identified 20 ng and 80 ng of purified (His)<sub>6</sub>-tagged recombinant N protein per ELISA well as the ideal amount for plate coating and 1:1000 and 1:20 as the most optimal serum dilution for IgG and IgM detection, respectively.

To establish the baseline for the tests, serum samples (diluted at 1:1000 and 1:20 for IgG and IgM, respectively) from 100 healthy blood donors were tested in the CoV-HKU1 antibody ELISA. For the 100 sera from healthy blood donors, the mean ELISA  
25 OD<sub>450</sub> values for IgG and IgM detection were 0.178 and 0.224, with standard deviations of 0.070 and 0.117. Absorbance values of 0.387 and 0.576 were selected as the cutoff values (that equal the sum of the mean value from the healthy control and three times the standard deviation) for IgG and IgM, respectively. Using these cutoff values, the titers for IgG of the  
30 patient's serum samples obtained during the first, second, and fourth weeks of the illness were <1:1000, 1:2000, and 1:8000, respectively (Fig. 7), and those for IgM were 1:20, 1:40, and 1:80, respectively (data not shown).

### 6.1.3 RT-PCR and real time quantitative PCR

#### RT-PCR Assay

An RT-PCR was developed to detect the CoV-HKU1 sequence from NPA samples.

- 5 Total RNA from clinical samples was reverse transcribed using random hexamers and  
cDNA was amplified using primers 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID  
NO:4) and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5), which were  
constructed based on the RNA-dependent RNA polymerase-encoding sequence (SEQ ID  
NO:1) of the CoV-HKU1 in the presence of 2.5 mM MgCl<sub>2</sub> (94°C for 8 min followed by 40  
10 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min).

The summary of a typical RT-PCR protocol is as follows:

#### 1. RNA extraction

- RNA from 140 µl of NPA samples was extracted by QIAquick<sup>®</sup> viral RNA  
15 extraction kit and was eluted in 50 µl of elution buffer.

#### 2. Reverse transcription

	RNA	11.5 µl
	0.1 M DTT	2 µl
20	5x buffer	4 µl
	10 mM dNTP	1 µl
	Superscript II, 200 U/µl (Invitrogen)	1 µl
	Random hexamers, 0.3 µg/ µl	0.5 µl

- 25 Reaction condition 42°C, 50 min  
94°C, 3 min  
4°C

#### 3. PCR

- 30 cDNA generated by random primers was amplified in a 50 µl reaction as follows:

cDNA	2 µl
------	------

	10 mM dNTP	0.5 $\mu$ l
	10x buffer	5 $\mu$ l
	25 mM MgCl <sub>2</sub>	5 $\mu$ l
	25 $\mu$ M Forward primer	0.5 $\mu$ l
5	25 $\mu$ M Reverse primer	0.5 $\mu$ l
	Ampli $Taq$ Gold <sup>®</sup> polymerase, 5U/ $\mu$ l (Applied Biosystems)	0.25 $\mu$ l
	Water	36.25 $\mu$ l

Thermal-cycle condition: 95°C, 10 min, followed by 40 cycles of 95 °C, 1 min;  
 10 50°C 1 min; 72 °C, 1 min.

#### 4. Primer sequences

Primers were designed based on the RNA-dependent RNA polymerase encoding sequence (SEQ ID NO:1) of the CoV-HKU1.

15 Forward primer: 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4)  
 Reverse primer: and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5)  
 Product size: 440 bps

#### Real-Time Quantitative PCR Assay

20 Total RNA from 140  $\mu$ l of nasopharyngeal aspirate (NPA) was extracted by QIAamp<sup>®</sup> virus RNA mini kit (Qiagen) as instructed by the manufacturer. Ten  $\mu$ l of eluted RNA samples were reverse transcribed by 200 U of Superscript<sup>®</sup> II reverse transcriptase (Invitrogen) in a 20  $\mu$ l reaction mixture containing 0.15  $\mu$ g of random hexamers, 10 mmol/L DTT, and 0.5 mmol/L dNTP, as instructed. Complementary DNA was then amplified in a  
 25 SYBR<sup>®</sup> Green I fluorescence reaction (Roche, IN) mixtures. Briefly, 20  $\mu$ l reaction mixtures containing 2 $\mu$ l of cDNA, 3.5 mmol/L MgCl<sub>2</sub>, 0.25  $\mu$ mol/L of forward primer [5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4)] and 0.25  $\mu$ mol/L reverse primer [5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5)] were thermal-cycled by a LightCycler<sup>®</sup> (Roche) with the PCR program, [95°C, 10 min followed by 50 cycles of 95°C,  
 30 10 min; 57°C, 5 sec; 72°C 9 sec]. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were captured at the end of extension step in each cycle. To determine the specificity of the assay, PCR products (440

base pairs) were subjected to a melting curve analysis at the end of the assay (65°C to 95°C, 0.1°C per second) (data not shown).

The amount of CoV-HKU1 RNA in the nasopharyngeal aspirates was followed weekly. Quantitative RT-PCR showed that the amounts of CoV-HKU1 RNA were  $8.5 \times 10^5$  and  $9.6 \times 10^6$  copies per ml in two nasopharyngeal aspirates collected in the first week of the illness,  $1.5 \times 10^5$  copies per ml of NPA, respectively, at two time points collected in the second week of the illness, but CoV-HKU1 RNA was undetectable in the NPA collected in the third, fourth and fifth weeks of the illness (Fig. 7). CoV-HKU1 RNA was also undetectable in the urine and stool of the patient collected in the first and second weeks of the illness.

## DISCUSSION

The genome of CoV-HKU1 is a 29926-nucleotide long, polyadenylated RNA. The G + C content is 32%, which is the lowest among all known coronaviruses with genome sequences available, with a GC skew of 0.19. Table 1 shows comparison of genomic features of CoV-HKU1 and other coronaviruses and amino acid identities between the predicted chymotrypsin-like protease (3CL<sup>pro</sup>), RNA dependent RNA polymerase (Pol), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses

Tabke 1

Coronaviruses <sup>a</sup>	Genome features		Pairwise amino acid identity (%)							
	Size (bases)	G + C content	3CL <sup>pro</sup>	Pol	Hel	HE	S	E	M	N
<b>Group 1</b>										
HCoV-229E	27317	0.38	45	54	55	-	31	26	35	28
PEDV	28033	0.42	44	56	55	-	30	34	37	37
PTGV	28586	0.38	45	57	57	-	32	34	37	27
CCoV	-	-	-	-	-	-	31	32	36	27
HCoV-NL63	27553	0.34	43	54	54	-	30	28	32	28
<b>Group 2</b>										
CoV-HKU1	29926	0.32	-	-	-	-	-	-	-	-
HCoV-OC43	30738	0.37	82	87	88	57	60	54	76	58
MHV	31357	0.42	85	90	89	50	61	57	84	68
BCoV	31028	0.37	84	88	88	56	61	55	76	57
SDAV	-	-	-	-	-	50	61	60	77	62
ECoV	-	-	-	-	-	53	61	56	78	59
PHEV	-	-	-	-	-	54	61	54	77	57
<b>Group 3</b>										
IBV	27608	0.38	41	60	57	-	32	28	38	27
SARS-CoV	29751	0.41	48	65	63	-	33	27	34	31

<sup>a</sup>HCoV-229E, human coronavirus 229E; PEDV, porcine epidemic diarrhea virus; PTGV, porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63, human coronavirus NL63; HCoV-OC43, human coronavirus OC43; MHV, murine hepatitis virus; BCoV, bovine coronavirus; SDAV, rat sialodacryoadenitis coronavirus; ECov, equine coronavirus NC99; PHEV, porcine hemagglutinating encephalomyelitis virus; IBV, infectious bronchitis virus; SARS-CoV, SARS coronavirus

The genome organization is the same as other coronaviruses, with the characteristic gene order 5'-replicase, S, E, M, N-3'. Both 5' and 3' ends contain short untranslated regions. The 5' end of the genome consists of a putative 5' leader sequence. A putative transcription regulatory sequences (TRS) motif, 5'-CUAAAC-3', was found at the 3' end of the leader sequence and precedes each translated ORF except ORF4 and ORF6 which encodes the putative E protein. Table 2 shows the putative transcription regulatory sequences in the genome of CoV-HKU1.

**Table 2**

Number of base upstream of AUG	ORF	TRS sequence	SEQ ID NO.
-140	Leader	UUAAAUCUAAACUUUUAAA (127) AUG	8
-7	Hemagglutinin esterase	UUAAAUCUAAACUAUG	9
-6	Spike	UUAAAUCUAAACAUG	10
-13	ORF 5	UUAAAUCUAAACUUAUUUAUG	11
-9	Membrane	CUAAAUCUAAACAUAUG	12
-13	Nucleocapsid	UUAAAUCUAAACUAUUAGGAUG	13
-35	ORF 9	UUAAAUCUAAACUAUUAGGAUGUCUUAU ACUCCCGGUCAUAUG	14

10

As in SDAV (Sialodacryoadenitis virus) and MHV (mouse hepatitis virus), ORF6 may share the same TRS with ORF 5, suggesting that the translation of the E protein is cap-independent, possibly via an internal ribosomal entry site. The 3' untranslated region contains a predicted pseudoknot structure 59-119 bp downstream of N gene. This pseudoknot structure is highly conserved among coronaviruses and plays a role in coronavirus RNA replication.

15

The coding potential of the CoV-HKU1 genome is shown in Fig. 4 and Table 3 and the phylogenetic analyses of the chymotrypsin-like protease (3CL<sup>PRD</sup>), replicase, helicase, haemagglutinin-esterase (HE), S, E, M and N, are shown in Figures 5A and 5B.

20



Table 3

ORFs	Start-end (base)	No. of bases	No. of amino acids	Frame	Candidate TRS
ORF 1a	206-13600	13395	4465	+2	-
ORF 1b	13600-21753	8154	2717	+1	-
HE (ORF 2)	21773-22933	1161	386	+2	Strong
S (ORF 3)	22942-27012	4071	1356	+1	Strong
ORF 4	26960-27070	111	36	+2	None
ORF 5	27051-27380	330	109	+3	Strong
E (ORF 6)	27373-27621	249	82	+1	None
M (ORF 7)	27633-28304	672	223	+3	Strong
N (ORF 8)	28320-29645	1326	441	+3	Strong
ORF 9	28342-28959	618	205	+1	Strong

The replicase 1a ORF (bases 206-13600) and replicase 1b ORF (bases 13600-21753) occupy 21.5 kb of the CoV-HKU1 genome. Similar to other coronaviruses, a frame shift interrupts the protein-coding regions and separates the 1a and 1b ORFs. This ORF encodes a number of putative proteins, including papain-like protease (PLP) with two copies of the PLP domain, PLP1<sup>pro</sup> and PLP2<sup>pro</sup>, 3CL<sup>pro</sup>, replicase, helicase, and other proteins of unknown functions. These proteins are produced by proteolytic cleavages of a large polyprotein (Fig. 4). The sequence of the resulting putative proteins is the same as that in the MHV genome. This polyprotein is synthesized by a -1 ribosomal frameshift at a conserved site (UUUAAAC) upstream of a pseudoknot structure at the junction of ORF 1a and ORF 1b. This ribosomal frameshift would result in a polyprotein of 7182 amino acids, which has 75-77% amino acid identities with the polyprotein in other Group 2 coronaviruses and 43-47% amino acid identities with the polyprotein in other non-Group 2 coronaviruses. The replicase gene of CoV-HKU1, which encodes 928 amino acids, has 87-89% amino acid identities with the replicase of other Group 2 coronaviruses and 54-65% amino acid identities with the replicase of other non-Group 2 coronaviruses (Table 4 and Fig. 5A). Table 4 shows amino acid identities between the predicted chymotrypsin-like protease (3CL<sup>pro</sup>), replicase (Rep), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses.

Table 4

Group	Virus	Pairwise amino acid identity (%)							
		3CL <sup>PRO</sup>	Rep	Hel	HE	S	E	M	N
1	HCoV-229E	45	54	55	-	31	26	35	28
	PEDV	44	56	55	-	30	34	37	37
	PTGV	45	57	57	-	32	34	37	27
	CCoV	-	-	-	-	31	32	36	27
	HCoV-NL63	43	54	54	-	30	28	32	28
2	HCoV-OC43	82	87	88	57	60	54	76	58
	MHV	85	89	87	50	58	55	78	60
	BCoV	84	88	88	56	61	55	76	57
	SDAV	-	-	-	50	61	60	77	62
	ECoV	-	-	-	53	61	56	78	59
	PHEV	-	-	-	54	61	54	77	57
3	IBV	41	60	57	-	32	28	38	27
SARS-CoV	SARS-CoV	48	65	63	-	33	27	34	31

HCoV-229E=human coronavirus 229E; PEDV=porcine epidemic diarrhea virus;

PTGV=porcine transmissible gastroenteritis virus; CCoV=canine enteric coronavirus;

5 HCoV-NL63=human coronavirus NL63; HCoV-OC43=human coronavirus OC43;

MHV=murine hepatitis virus; BCoV=bovine coronavirus; SDAV=rat sialodacryoadenitis coronavirus; ECoV=equine coronavirus NC99; PHEV=porcine hemagglutinating

encephalomyelitis virus; IBV=infectious bronchitis virus; SARS-CoV=SARS coronavirus

10 The catalytic histidine and cysteine amino acid residues, conserved among the  
3CL<sup>PRO</sup> in all coronaviruses, are present in the predicted 3CL<sup>PRO</sup> of CoV-HKU1 (amino acids  
His<sup>3375</sup> and Cys<sup>3479</sup> of ORF 1a). In the N-terminal of the putative PLP (amino acid residues  
945 to 1104 of ORF 1a), there are 14 tandem copies of a 30-base repeat, which encode  
15 NNDEDVVTGD (SEQ ID NO:15), followed by two 30-base regions that encode  
NNDEEIVTGD (SEQ ID NO:16) and NDDQIVVTGD (SEQ ID NO:17), located upstream  
to the first copy of PLP domain, PLP1<sup>PRO</sup>. This repeat is not observed in other coronaviruses.

ORF 2 (bases 21773-22933) encodes the predicted HE glycoprotein with 386 amino  
acids. The HE protein of CoV-HKU1 has 50-57% amino acid identities with the HE  
proteins of other Group 2 coronaviruses (Table 4 and Fig. 5A). PFAM and InterProScan  
20 analyses of the ORF show that amino acid residues 1 to 349 of the predicted protein is a  
member of the haemagglutinin esterase family (PFAM accession no.: PF03996 and

INTERPRO accession no. IPR007142). This family contains membrane glycoproteins that are present on viral surface and are involved with the cell infection process. It contains haemagglutinin chain 1 (HE1) and haemagglutinin chain 2 (HE2), and forms a homotrimer with each monomer being formed by two chains linked by a disulphide bond. Furthermore, 5 PFAM and InterProScan analyses of the ORF show that amino acid residues 122 to 236 of the predicted protein are the haemagglutinin domain of HE-fusion glycoprotein family (PFAM accession no.: PF02710 and INTERPRO accession no. IPR003860). HE is also present in other Group 2 coronaviruses and influenza C virus. SignalP analysis reveals a signal peptide probability of 0.738, with a cleavage site between residues 13 and 14. 10 Although TMpred and TMHMM analyses of the ORF show four and three transmembrane domains, respectively, PHDhtm analysis of the ORF shows only one transmembrane domain at positions 354 to 376. This concurs with only one transmembrane region reported in the C terminal of the HE of BCoV (bovine coronavirus) and puffinosis virus. PrositeScan analysis of the HE protein of CoV-HKU1 reveals eight potential N-linked 15 glycosylation (six NXS and two NXT) sites. These are located at positions 83 (NYT), 110, (NGS), 145 (NVS), 168 (NYS), 193 (NFS), 286 (NSS), 314 (NVS, and 328 (NFT). The putative active site for neuraminidase O-acetyl-esterase activity, FGDS (SEQ ID NO:18), is located at positions 31-34.

ORF 3 (bases 22942-27012) encodes the predicted S glycoprotein (PFAM accession 20 no. PF01601) with 1356 amino acids. The S protein of CoV-HKU1 has 58-61% amino acid identities with the S proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the S proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B). InterProScan analysis predicts it as a type I membrane glycoprotein. Important features of the S protein of CoV-HKU1 are depicted in Fig. 6. PrositeScan of the S protein 25 of CoV-HKU1 reveals 28 potential N-linked glycosylation (12 NXS and 16 NXT) sites. SignalP analysis reveals a signal peptide probability of 0.909, with a cleavage site between residues 13 and 14. By multiple alignments with the S proteins of other Group 2 coronaviruses, a potential cleavage site located after RRKRR (SEQ ID NO:19), between residues 760 and 761, where S will be cleaved into S1 and S2, is identified. Immediately 30 upstream to RRKRR (SEQ ID NO:19), there is a series of five serine residues that are not present in any other known coronaviruses (Fig. 6). Most of the S protein (residues 15 to 1300) is exposed on the outside of the virus, with a transmembrane domain at the C

terminus (TMHMM analysis of the ORF shows one transmembrane domain at positions 1301 to 1356), followed by a cytoplasmic tail rich in cysteine residues. Two heptad repeats (HR), located at residues 982 to 1083 (HR1) and 1250 to 1297 (HR2), identified by multiple alignments with other coronaviruses, are present. In MHV, it has been confirmed that the receptor for its S protein binding is CEACAM1, a member of the carcinoembryonic antigen (CEA) family of glycoproteins in the immunoglobulin superfamily. Furthermore, it has been shown, by site-directed mutagenesis, that three conserved regions (sites I, II, and III) and some amino acid residues (Thr<sup>62</sup>, Thr<sup>212</sup>, Tyr<sup>214</sup>, and Tyr<sup>216</sup> in MHV) in the N-terminal of the S protein are particularly important for its receptor-binding activity. By multiple alignments with the N-terminal 330 amino acids of the S protein of MHV and other group 2 coronaviruses, it is observed that these conserved regions and amino acids are present in CoV-HKU1 (Fig. 6). This infers that the receptor for CoV-HKU1 could be a member of the CEA family on the surface of the cells in the respiratory tract. On the other hand, for HCoV-OC43, it has been shown in vitro that the receptor for the S protein is a sialic acid. However, the amino acid residues on the S protein of HCoV-OC43 that are important for receptor binding are not well defined.

ORF 4 (bases 26960-27070) encodes a predicted protein with 36 amino acids. This ORF overlaps with the ORF that encodes the S protein. This ORF is not present in other coronaviruses and BlastP analysis of the ORF does not show any hits.

ORF 5 (bases 27051-27380) encodes a predicted protein with 109 amino acids. This ORF overlaps with the ORF that encodes the E protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus non-structural protein NS2 family (PFAM accession no.: PF04753). TMpred and TMHMM analysis do not reveal any transmembrane helix. This predicted protein of CoV-HKU1 has 44-51% amino acid identities with the corresponding proteins of other Group 2 coronaviruses.

ORF 6 (bases 27373-27621) encodes the predicted E protein with 82 amino acids. The E protein of CoV-HKU1 has 54-60% amino acid identities with the E proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the E proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B). PFAM and InterProScan analyses of the ORF show that the predicted E protein is a member of the non-structural protein NS3/Small envelope protein E (NS3\_envE) family (PFAM accession no.: PF02723). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.995).

TMpred analysis of the ORF shows two transmembrane domains at positions 16 to 34 and 39 to 59, and TMHMM analysis of the ORF shows two transmembrane domains at positions 10 to 32 and 39 to 58, consistent with the anticipated association of the E protein with the viral envelope. Both programs predict that both the N and C termini are located on the surface of the virus.

ORF 7 (bases 27633-28304) encodes the predicted M protein with 223 amino acids. The M protein of CoV-HKU1 has 76-78% amino acid identities with the M proteins of other Group 2 coronavirus, but has fewer than 40% amino acid identities with the M proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B). PFAM analysis of the ORF shows that the predicted M protein is a member of the coronavirus matrix glycoprotein (Corona\_M) family (PFAM accession no.: PF01635). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.926). TMpred analysis of the ORF shows three transmembrane domains at positions 21 to 42, 53 to 74, and 77 to 98. TMHMM analysis of the ORF shows three transmembrane domains at positions 20 to 39, 46 to 68, and 78 to 100. The N terminal 19-20 amino acids are located on the outside and the C terminal 123-125-amino acid hydrophilic domain on the inside of the virus.

ORF 8 (bases 28320-29645) encodes the predicted N protein (PFAM accession no.: PF00937) with 441 amino acids. The N protein of CoV-HKU1 has 57-62% amino acid identities with the N proteins of other Group 2 coronaviruses, but has fewer than 40% amino acid identities with the N proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B).

ORF 9 (bases 28342-28959) encodes a hypothetical protein (N2) of 205 amino acids within the ORF that encodes the predicted N protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus nucleocapsid I protein (Corona\_I) family (PFAM accession no.: PF03187). This hypothetical N2 protein of CoV-HKU1 has 32-39% amino acid identities with the N2 proteins of other Group 2 coronaviruses.

We report the characterization and complete genome sequence of a novel coronavirus detected in the nasopharyngeal aspirates of patients with pneumonia. The clinical significance of the virus in the first patient was evident by the high viral loads in the patient's nasopharyngeal aspirates during the first week of his illness, which coincided with the acute symptoms developed in the patient. The viral load decreased during the second week of the illness and was undetectable in the third week of the illness. In addition, the

fall in viral load was accompanied by the recovery from the illness and development of specific antibody response to the recombinant N protein of the virus. Similar to other recently discovered viruses, such as hepatitis C virus, GB virus C, transfusion transmitted virus, and SEN virus, the present virus could not be recovered from cell cultures using the standard cell lines. This could be related to the inherently low recovery rate of coronaviruses. Human coronaviruses are particularly difficult to culture in vitro. Many decades after the recognition of HCoV-229E and HCoV-OC43, there are still only a handful of primary virus isolates available and organ culture is required for primary isolation of HCoV-OC43. In our experience, SARS-CoV can only be recovered from less than 20% of patients with serologically and RT-PCR documented SARS-CoV pneumonia. Therefore, it is not surprising that the new coronavirus CoV-HKU1 has been so far proven difficult to culture in vitro. After the discovery of CoV-HKU1 in the first patient, we conducted a preliminary study on 400 nasopharyngeal aspirates that were collected last year during the SARS epidemic period. Among these 400 nasopharyngeal aspirates, CoV-HKU1 was detected in one specimen, with a viral load comparable to that of the first patient. These results have suggested that CoV-HKU1 is not only incidentally found in one patient, but a previously unrecognized coronavirus associated with pneumonia.

Genomic analysis has revealed that CoV-HKU1 is a Group 2 coronavirus. The genome organization of CoV-HKU1 concurs with those of other coronaviruses, with the characteristic gene order, *i.e.*, 5'-replicase, S, E, M, N-3', short untranslated regions in both 5' and 3' ends, 5' conserved coronavirus core leader sequence, putative TRS upstream to multiple ORFs, and conserved pseudoknot in the 3' untranslated region. In contrast to coronaviruses of other groups, CoV-HKU1 contains certain features that are characteristics of Group 2 coronaviruses, including the presence of HE, ORF 5, and N2. Phylogenetic analysis of the 3CL<sup>pro</sup>, replicase, helicase, S, E, M, and N proteins showed that these genes of CoV-HKU1 were clustered with the corresponding genes in other Group 2 coronaviruses. However, the proteins of CoV-HKU1 formed distinct branches in the phylogenetic trees, indicating that CoV-HKU1 is a distinct member of the group, and is not very closely related to any other known members of Group 2 coronaviruses (Figures 4A and 4B).

In addition to phylogenetic analysis of the putative proteins, CoV-HKU1 exhibits certain features that are distinct from other Group 2 coronaviruses. Compared to other Group 2 coronaviruses, there is a deletion of about 800 bps between the replicase ORF 1b

and the HE ORF 2 in CoV-HKU1. In other Group 2 coronaviruses, including MHV, SDAV, HCoV-OC43 and BCoV, an ORF of 798-837 bp (273-278 amino acids) is present between the replicase 1b ORF and the HE ORF 2. This ORF encodes a protein of the coronavirus non-structural protein NS2a family (PFAM accession no.: PF05213). The absence of this ORF in CoV-HKU1 indicates that this is probably a non-essential gene of coronavirus. In addition to the deletion, the N-terminal of the putative PLP in ORF 1a contains 14 tandem copies of a 30-bp repeat that codes for a highly acidic domain. Similar repeats, with different amino acid compositions, have been found in the genomes of human, rat and parasites, but have not been found in other coronaviruses. The function of these repeats is not well understood, although some authors have suggested that the repeats could be important antigens, and their biological role may be related to their special three-dimensional structures. The vitellaria antigenic protein of *Clonorchis sinensis* contains 23 tandem copies of a 30-bp repeat that codes for DGGAQPPKSG (SEQ ID NO:20). In the case of *Plasmodium falciparum*, it has been shown that the antigenicity of the circumsporozoite protein is due to its repeating epitope structure. It has also been suggested that the tandemly repeated peptide may induce strong humoral immune response in the infected host and thus may also be useful in serological diagnosis. Further experiments should be performed to delineate the antigenic properties, biological role, and possible clinical usefulness of the repeat in the PLP of CoV-HKU1.

The geographical, political, and economic location of Hong Kong makes it a unique place for the study of emerging infectious disease. Hong Kong, as the gateway of southern China, with thousands of people crossing the border on surface and by air every day, has a high potential of importing and exporting infectious diseases to and from China, countries in Southeast Asia and from the rest of the world. In 1997, the first 18 human cases of avian influenza A H5N1 virus infection were reported in Hong Kong. In early 2003, two cases of human infection caused by avian influenza A (H5N1) that was acquired in Fujian, were diagnosed in Hong Kong, which provided an early warning of the impending disease threat for humans and poultry in Southeast Asia that followed in 2004. For the SARS epidemic, although both epidemiological and genomic evidence revealed that the disease had first occurred in southern China in November 2002, it did not receive as much international attention until the disease was spread to Hong Kong and through Hong Kong to Singapore, Toronto, Vietnam, and the United States of America. As for emerging bacterial infections,

50% of the patients with gastroenteritis associated with the recovery of *Laribacter hongkongensis* had recent history of travel to southern China. In this report, one of the patients also had recent history of travel to Shenzhen of China prior to the development of the respiratory illness. We speculate that he might have contacted the virus in Shenzhen.

5 More intensive surveillance of emerging infectious pathogens in this locality is warranted.

## 6.2 Example 2

We prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period. A 453-bp fragment of the *pol* gene of CoV-HKU1 was amplified from the extracted RNA by RT-PCR using CoV-HKU1 specific primers. The epidemiological, clinical, laboratory and radiological features of patients with pneumonia associated with CoV-HKU1 were analyzed. Specific antibodies were detected using a recombinant CoV-HKU1 N protein based ELISA. The complete *pol*, S and N genes of the CoV-HKU1 were amplified and sequenced. RNA extracted from 208 nasopharyngeal swabs and fecal samples from 56 wild and domestic animals in Hong Kong and southern China were subject to RT-PCR of *pol* gene of CoV-HKU1 using CoV-HKU1 specific primers.

10  
15

### 6.2.1 Patients and microbiological methods

All prospectively collected NPAs from patients with community-acquired pneumonia sent to the clinical microbiology laboratories of four regional hospitals in Hong Kong during a 12-month period [March 22 2003 (beginning of SARS epidemic in Hong Kong) – March 21 2004] for detection of SARS-CoV but negative for SARS-CoV RNA by RT-PCR were included in the study. Community-acquired pneumonia is defined as symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which there is no other explanation that develop prior to or within 48 h after presentation to hospital. Once CoV-HKU1 was detected from NPAs, the hospital records, laboratory results and chest radiographs of the corresponding patients were retrieved and examined by two infectious disease physicians. The RNA extracted from the NPAs was subject to RT-PCR for influenza A virus and human metapneumovirus (Peiris JSM *et.al.*, *Lancet* 2003; 361: 1319-25). Available stored serum samples were

20  
25  
30



subject to serological assays for detection of antibodies against *Mycoplasma*, *Chlamydia*, *Legionella* and SARS-CoV by SERODIA-MYCO II (Fujirebio Inc., Tokyo, Japan), *Chlamydia pneumoniae* MIF IgG (Focus technologies, Cypress, CA, USA), indirect immunofluorescence (MRL, San Diego, CA, USA) and our recently developed enzyme-linked immunosorbent assay (ELISA), respectively (Woo PCY *et al.*, *Lancet* 2004; 363:841-5).

To determine the possible risk factors associated with CoV-HKU1 pneumonia, two age- and sex-matched controls per patient with CoV-HKU1 pneumonia were randomly selected from those with community-acquired pneumonia but their NPAs negative for CoV-HKU1. Controls were within five years older or younger than the corresponding patients with CoV-HKU1 pneumonia, and were admitted within 15 days before or after admission of the corresponding patients with CoV-HKU1 pneumonia. The hospital records, laboratory results and chest radiographs of the controls were retrieved and examined by the two infectious disease physicians.

15

### 6.2.2 RNA extraction

Viral RNA was extracted from NPAs using QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions within 10 h upon receipt of specimens. The eluted RNA was used as the template for RT-PCR. All extracted RNA was stored immediately at -70°C until use.

20

### 6.2.3 RT-PCR of RNA-dependent RNA polymerase gene of coronavirus-HKU1 using coronavirus-HKU1 specific primers and DNA sequencing

A 453-bp fragment of the RNA dependent RNA polymerase (*pol*) gene of CoV-HKU1 was amplified by RT-PCR using CoV-HKU1 specific primers, 5'-AAAGGATGT-TGACAACCCTGTT-3' (LPW1926; SEQ ID NO:2968) and 5'-ATCATCATACTAAAATGC-TTACA-3' (LPW1927; SEQ ID NO:2969) designed by multiple alignment of the nucleotide sequences of the *pol* genes of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and those of the available *pol* genes of other known human coronaviruses. RT was performed using the SuperScript II kit (Invitrogen, San Diego, CA, USA) according to manufacturer's instructions. The PCR mixture (50 µl)

30

contained cDNA, PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 3 mM MgCl<sub>2</sub> and 0.01% gelatin), 200 μM of each dNTPs and 1.0 U *Taq* polymerase (Boehringer Mannheim, Germany). The mixtures were amplified in 40 cycles of 94°C for 1 min, 48°C for 1 min and 72°C for 1 min, and a final extension at 72°C for 10 min in an automated thermal cycler (Perkin-Elmer Cetus, Gouda, The Netherlands). Distilled water was used as the negative control. To ensure the high specificity of the CoV-HKU1 specific primers, RNA extracted from 200 NPAs positive for influenza A and B viruses, parainfluenza viruses 1-3, respiratory syncytial virus (RSV), or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV were also subject to RT-PCR using the two CoV-HKU1 specific primers.

Ten microlitres of each amplified product was electrophoresed in 1.5% (w/v) agarose gel, with a molecular size marker (ΦX-174 DNA *Hae*III digest, Boehringer Mannheim, Germany) in parallel. Electrophoresis in Tris-borate-EDTA buffer was performed at 100 V for 1.5 h. The gel was stained with ethidium bromide (0.5 μg/ml) for 15 minutes, rinsed and photographed under ultraviolet light illumination.

The PCR products were gel-purified using the QIAquick gel extraction kit (QIAGEN, Hilden, Germany). Both strands of the PCR products were sequenced twice with an ABI Prism 3700 DNA Analyzer according to manufacturers' instructions (Applied Biosystems, Foster City, CA, USA), using the two PCR primers. The sequences of the PCR products were compared with the sequences of the *pol* genes of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and those of the *pol* genes of coronaviruses in the GenBank database.

#### 6.2.4 ELISA using recombinant nucleocapsid protein of CoV-HKU1

The ELISA-based IgG and IgM antibody tests were performed according to our published protocol (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). Briefly, each well of a Nunc immunoplate (Roskilde, Denmark) was coated with purified (His)<sub>6</sub>-tagged recombinant N protein (20 ng for IgG and 80 ng for IgM) for 1 h and then blocked in phosphate-buffered saline with 5% skim milk. The serum samples obtained from the patients during the acute and convalescent phase of the illness were serially diluted and were added to the wells of the (His)<sub>6</sub>-tagged (SEQ ID NO: 27) recombinant N protein-coated plates in a total volume of 100 μl and incubated at 37°C for 2 h. After washing with

washing buffer five times, 100 µl of diluted horse radish peroxidase-conjugated goat anti-human IgG (1:4000) and mouse anti-human IgM (1:1000) antibodies (Zymed Laboratories Inc., South San Francisco, CA, USA) were added to the wells and incubated at 37°C for 1 h. After washing with washing buffer five times, 100 µl diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at room temperature for 15 min. One hundred microlitres of 0.3 M H<sub>2</sub>SO<sub>4</sub> were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

#### 10      **6.2.5 RT-PCR and sequencing of the complete RNA-dependent RNA polymerase, spike and nucleocapsid genes of coronavirus-HKU1 and phylogenetic analysis**

The complete *pol*, spike (S) and N genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced using the RNA extracted from the NPAs as template. The RNA was converted to cDNA by a combined random-priming and oligo(dT) priming strategy. The cDNA was amplified by degenerate primers designed by multiple alignment of the regions encoding the *pol*, S and N genes in the genomes of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and those of other group 2 coronaviruses and additional primers designed from the results of the first and subsequent rounds of sequencing. Sequences were assembled and manually edited to produce the complete sequences of the *pol*, S and N genes of CoV-HKU1 from different patients. The nucleotide and the deduced amino acid sequences of the *pol*, S and N genes were compared to those of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and other group 2 coronaviruses. Phylogenetic tree construction was performed using PileUp method with GrowTree (Genetics Computer Group, Inc.).

25

#### **6.2.6 Animal surveillance**

Two hundred and eight nasopharyngeal swabs and faecal samples from 56 wild and domestic animals [including Chinese ferret-badger (*Melogale moschata*), domestic cat (*Felis catus*), hog-badger (*Arctonyx collaris*), masked palm civet (*Paguma larvata*), racoon dog (*Nyctereutes procyonoides*), Chinese pygmy dormouse (*Typhlomys cinereus*), common pangolin (*Manis pentadactyla*), nutria (*Myocastor coypus*), dog (*Canis familiaris*), rabbit

30

(*Leporidae* family), snake (*Serpentes* suborder) and bat (*Microchiroptera* suborder)] in Hong Kong and southern China (Guan Y, et al., *Science* 2003; **302**: 276-8) were subjected to RNA extraction and RT-PCR of *pol* gene of CoV-HKU1 using the CoV-HKU1 specific primers (LPW1926; SEQ ID NO:2968 and LPW1927; SEQ ID NO:2969) and protocol  
5 described above.

## 6.2.7 Results

### Clinical and laboratory characteristics

During the 12-month period, NPAs from 418 patients [male:female = 198:220, age  
10 (mean  $\pm$  SD) = 49  $\pm$  26] with community-acquired pneumonia, for detection of SARS-CoV but were negative for SARS-CoV RNA by RT-PCR, were identified in the four hospitals. A 453-bp fragment of the *pol* gene of CoV-HKU1 was amplified and sequenced in 10 (2.5%) patients. Sequence analysis revealed 0-2% nucleotide differences between the sequences of the fragments and the sequence of the *pol* gene of the CoV-HKU1 from the  
15 reported index patient (patient no. 5) described in Example 1 above (Fig. 11) (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). In contrast, using our CoV-HKU1 specific primers, none of the 200 NPAs that were positive for influenza A and B viruses, parainfluenza viruses 1-3, RSV, or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV, was RT-PCR positive.

20 The epidemiological, clinical and radiological characteristics of the 10 patients, including patient no. 5 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895), with community-acquired pneumonia associated with CoV-HKU1 are summarized in Table 5. No epidemiological linkage was identified among the 10 cases. All cases occurred in either winter or spring (January – May). The median age was 71.5 (range: 13-96). Seven were  
25 males and three were females. Nine were Chinese and one was an Arabian. Eight had underlying diseases, and four had underlying diseases of the respiratory tract. Four had recent travel histories to southern China. Five were smokers. Clinically, the illness was not distinguishable from other community-acquired pneumonia. Fever, productive cough and dyspnoea were common presenting symptoms. Upper respiratory tract symptoms were  
30 present in only two patients (patient nos. 1 and 5). One patient (patient no. 7) had loose stool diarrhea. Oxygen saturation on room air upon admission was <95% in two. Airspace shadows were observed in the right lungs of six patients and the left lungs of six patients.

The upper, middle and lower zones were affected in two, four and nine patients respectively. All patients, except patient no. 10, had normal platelet counts and normal liver and renal function tests. Bacterial or mycobacterial pathogens were not detected in any of the sputum samples from the patients. Direct antigen detection for influenza A and B viruses, parainfluenza viruses 1-3, RSV, adenovirus (Woo PCY *et al.*, *J Clin Microbiol* 1997; 35: 1579-81) and RT-PCR for influenza A virus and metapneumovirus, was negative in all NPAs. Antibodies against *M. pneumoniae*, *C. pneumoniae*, *C. psittaci*, *L. pneumophila* and SARS-CoV were negative in all the six patients (patient nos. 1, 4, 5, 6, 8 and 9) whose serum samples were available. All these six patients showed a four-fold change in IgG titer (patient nos. 4, 5 and 6) and/or the presence of IgM (patient nos. 1, 5, 8 and 9) against CoV-HKU1.

Table 5

Characteristics	Patient no.										
	1	2	3	4	5	6	7	8	9	10	
Month/Year	Mar/03	Apr/03	May/03	Jan/04	Jan/04	Jan/04	Jan/04	Jan/04	Mar/04	Mar/04	
Sex/Age	F/35	M/66	M/13	M/75	M/71	E/96	M/78	M/68	F/83	M/72	
Ethnic origin	Chinese	Arabian	Chinese	Chinese	Chinese	Chinese	Chinese	Chinese	Chinese	Chinese	
Underlying diseases	-	Diabetes mellitus, old myocardial infarction, gastric lymphoma	Asthma, situs inversus, dextrocardia	Hypertension	Chronic obstructive airway disease, hyperlipidemia, abdominal aortic aneurysm	Hypertension	Chronic obstructive airway disease, diabetes mellitus	Chronic obstructive airway disease, diabetes mellitus	Chronic obstructive airway disease, parathyroid adenoma, dementia	Chronic obstructive airway disease, diabetes mellitus	Prostate carcinoma, cerebrovascular accident, diabetes mellitus
History of travel within two weeks of disease onset	-	-	Shenzhen, China	Guangdong, China	Shenzhen, China	-	-	Guangdong, China	-	-	
History of smoking	-	-	-	+	+	-	+	-	+	+	
Clinical features											
Fever	+	-	+	-	+	+	+	+	+	+	
Chills	-	-	-	-	+	-	-	-	-	-	
Rigor	-	-	-	-	-	-	-	-	-	-	
Myalgia	-	-	-	-	-	-	-	-	-	-	
Headache	-	-	-	-	+	-	-	-	-	-	
Cough	+	-	+	+	+	-	+	+	+	+	
Sputum production	-	+	-	+	-	-	+	+	+	+	
Dyspnoea	-	-	-	-	-	-	-	-	-	-	
Pleurisy	-	-	-	-	+	-	-	-	-	-	
Rhinorrhoea	-	-	-	-	+	-	-	-	-	-	
Sore throat	+	-	-	-	+	-	-	-	-	-	
Oxygen saturation on room air (%)	99	83	100	99	99	97	97	95	99	88	
Chest radiograph features	RLZ airspace shadows	Bilateral airspace shadows	LMZ and LLZ airspace shadows	LLZ airspace shadows	LLZ airspace shadows	RLZ airspace shadows	LLZ airspace shadows	RMZ airspace shadows	RLZ airspace shadows	Bilateral airspace shadows	
Outcome	Survived	Died	Survived	Survived	Survived	Survived	Survived	Survived	Survived	Died	
Duration of hospitalization (no. of days)	2	Died on day 12	3	7	5	7	13	5	6	Died on day 6	

+ = present; - = absent; RUZ = right upper zone; LUZ = left upper zone; RLUZ = right middle zone; LULZ = left middle zone; RLZ = right lower zone; LLZ = left lower zone

In comparison with age- and sex-matched controls with non-CoV-HKU1 pneumonia, no epidemiological, clinical, haematological, serum biochemical and radiological risk factors were identified in patients with CoV-HKU1 pneumonia (Table 6).

5

Table 6

Characteristics	Pneumonia*		P value
	HCoV-HKU1 (n=10)	Non-HCoV- HKU1 (n=20)	
Underlying diseases	8	12	0.42
History of travel within two weeks of disease onset	4	6	0.69
History of smoking	5	7	0.46
Clinical features			
Fever	8	14	0.68
Cough	7	17	0.37
Sputum production	6	12	1.00
Dyspnoea	6	6	0.12
Rhinorrhoea	1	2	1.00
Sore throat	2	2	0.58
Haematological features			
Haemoglobin (g/dl)	12.4	13.2	0.27
Leukocyte count ( $\times 10^9/l$ )	9.9	9.7	0.95
Neutrophil count ( $\times 10^9/l$ )	7.35	7.4	0.71
Lymphocyte count ( $\times 10^9/l$ )	0.95	1.02	0.48
Monocyte count ( $\times 10^9/l$ )	0.55	0.65	0.35
Platelet count ( $\times 10^9/l$ )	240	292	0.20
Serum biochemical features			
Sodium (mmol/l)	136	137	0.59
Potassium (mmol/l)	3.9	4.0	0.42
Creatinine ( $\mu\text{mol/l}$ )	92	76.5	0.06
Urea (mmol/l)	5.25	4.9	0.62
Albumin (g/l)	37	38	0.59
Globulin (g/l)	36.5	30	0.07
Bilirubin ( $\mu\text{mol/l}$ )	12	10	1.00
ALT (U/l)	20	17	0.42
Alkaline phosphatase (U/l)	102	91	0.95
Oxygen saturation on room air (%)	96	98	0.86
Radiological features			
Bilateral involvement	2	5	1.00
No. of zones involved	1	1	0.81
Mortality	2	0	0.10

\*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

Two of the 10 patients died of CoV-HKU1 pneumonia. The first patient (patient no. 2) was a 66-year old man who presented with dyspnoea for one day. He had type 2 diabetes mellitus, old myocardial infarction and gastric lymphoma with total gastrectomy in 2002 and was put on chemotherapy. He had severe lymphopenia ( $0.2 \times 10^9/L$ ) and an oxygen saturation of only 83% on admission. Chest radiograph revealed patchy airspace shadows in both lungs with predominant involvement of the lower zones (Fig. 12A). He died 11 days after admission. The other patient (patient no. 10) was a 72-year old man who presented with fever and productive cough for one week. He had type 2 diabetes mellitus, cerebrovascular accident and prostatic carcinoma with bone metastasis complicated by spinal cord compression with laminectomy and Luque instrumentation performed. He had lymphopenia ( $0.9 \times 10^9/L$ ), thrombocytopenia ( $33 \times 10^9/L$ ), deranged liver and renal function tests and an oxygen saturation of only 88% on admission. Chest radiograph revealed extensive airspace shadows in both lungs, with the middle zones more severely involved (Fig. 12B). He died 5 days after admission.

The clinical, laboratory and radiological characteristics of patients who survived and those who died with community acquired pneumonia associated with CoV-HKU1 were compared (Table 7). Patients who died had lower hemoglobin concentration ( $P=0.04$ ), monocyte count ( $P=0.04$ ), serum albumin ( $P=0.04$ ) and oxygen saturation on admission ( $P=0.03$ ) and bilateral involvement ( $P=0.003$ ) and more number of zones involved ( $P=0.01$ ) on chest radiograph.



Table 7

Characteristics	Outcome*		P value
	Survived (n=8)	Died (n=2)	
Sex (M:F)	5:3	2:0	1.00
Age	73	69	0.60
Underlying diseases	6	2	0.45
History of travel within two weeks of disease onset	4	0	0.24
History of smoking	4	1	1.00
Clinical features			
Fever	7	1	0.26
Cough	6	1	0.51
Sputum production	5	1	0.76
Dyspnoea	4	2	0.22
Rhinorrhoea	1	0	0.62
Sore throat	2	0	0.45
Haematological features			
Haemoglobin (g/dl)	13.4	9	0.04
Leukocyte count ( $\times 10^9/l$ )	9.7	7.85	0.43
Neutrophil count ( $\times 10^9/l$ )	7.4	6.9	0.79
Lymphocyte count ( $\times 10^9/l$ )	1.35	0.55	0.15
Monocyte count ( $\times 10^9/l$ )	0.7	0.3	0.04
Platelet count ( $\times 10^9/l$ )	292	200.5	0.79
Serum biochemical features			
Sodium (mmol/l)	137.5	134	0.11
Potassium (mmol/l)	3.9	4.5	0.06
Creatinine ( $\mu\text{mol/l}$ )	79	76.5	0.69
Urea (mmol/l)	4.6	10.75	0.19
Albumin (g/l)	38.5	26	0.04
Globulin (g/l)	30	30	1.00
Bilirubin ( $\mu\text{mol/l}$ )	10	30.5	0.79
ALT (U/l)	16.5	30.5	0.36
Alkaline phosphatase (U/l)	86	190.5	0.07
Oxygen saturation on room air (%)	99	85.5	0.03
Radiological features			
Bilateral involvement	0	2	0.003
No. of zones involved	1	6	0.01

\*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

**RT-PCR and sequencing of the complete RNA-dependent RNA polymerase, spike and nucleocapsid genes of coronavirus-HKU1 and phylogenetic analysis**

The complete *pol* (Fig. 11), S (Fig. 13) and N (Fig. 14) genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced. The phylogenetic trees and non-synonymous mutations and the corresponding amino acid changes are shown in Fig. 15. In all three genes, the phylogenetic trees using nucleotides or amino acids for construction showed the same topologies. For the S gene, there were 317 and 306 nucleotide positions with synonymous and non-synonymous mutations respectively (Fig. 15B). For the N gene, there were 42 and 53 nucleotide positions with synonymous and non-synonymous mutations respectively (Fig. 15C). The nucleotide sequences of seven of the nine S or N genes showed similar sequences (genotype A, Figs. 16B and 16C) and those of the other two also showed similar sequences (genotype B, Figs. 16B and 16C). For the CoV-HKU1 from patient 1, two peaks (T and C) were consistently observed at nucleotide position 1300 of the N gene, suggesting the presence of quasi-species (Fig. 15C). For the *pol* gene, there were 95 and 13 nucleotide positions with synonymous and non-synonymous mutations respectively (Fig. 15A). The nucleotide sequences of the *pol* genes in the seven CoV-HKU1 of genotype A were also clustered together (Fig. 15A). Interestingly, the seven CoV-HKU1 of genotype A were from seven patients with underlying diseases and the two of genotype B were from the two patients without underlying diseases (Table 5). Furthermore, multiple alignments of the nucleotides sequences of the *pol* genes of the nine CoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV revealed that the primers we used in the present study should be specific for CoV-HKU1 (Fig. 16).

**Animal surveillance**

None of the 208 nasopharyngeal swabs and faecal samples from 56 wild and domestic animals in Hong Kong and southern China was positive for CoV-HKU1 RNA.

**6.2.8 Discussion**

CoV-HKU1, a novel group 2 coronavirus, is associated with community-acquired pneumonia. Since the SARS epidemic in 2003, we have started to prospectively collect NPAs and store the extracted RNA from patients with community-acquired pneumonia so

that when a novel virus is discovered, the epidemiology and hence the clinical, laboratory and radiological features of the disease can be studied timely. In January 2004, we discovered a novel coronavirus, CoV-HKU1, from a patient with community-acquired pneumonia (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). The RNA extracted from prospectively collected NPAs were immediately retrieved and the presence of CoV-HKU1 RNA looked for. Ten of the 418 NPAs were positive for RNA of CoV-HKU1, giving an incidence of 2.5%. The presence of CoV-HKU1 RNA in these specimens was genuine, instead of due to contamination, as amplification and sequencing of multiple genes (*pol*, S and N) of CoV-HKU1 indicated the presence of CoV-HKU1 with different nucleotide sequences in the NPAs from the different patients. Moreover, the clinical significance of CoV-HKU1 was further confirmed by the presence of specific antibody responses in all six patients whose serum samples were available.

Similar to HCoV-229E, HCoV-OC43 and HCoV-NL63, CoV-HKU1 is probably a human coronavirus that is endemic in human. Similar to other human coronavirus infections, cases of CoV-HKU1 pneumonia also occurred in winter and spring. Most patients with CoV-HKU1 pneumonia were old (80% older than 65) with major underlying diseases, especially those of the respiratory and cardiovascular systems. In order to study the phylogeny and relationships among the 10 CoV-HKU1, we sequenced the *pol*, S and N genes of the nine CoV-HKU1 cases which provided adequate amount of RNA. Combined with the data of partial sequencing of the *pol* genes of the 10 CoV-HKU1 (Fig. 17), results showed that unlike the epidemiology of SARS-CoV, the 10 CoV-HKU1 were not clonal and the topology of the phylogenetic trees did not follow the pattern of a clonal outbreak (Fig. 15). Interestingly, the phylogenetic trees constructed using the sequences of both the S and N genes showed that CoV-HKU1 of genotype B was associated with the two patients without underlying diseases, but CoV-HKU1 of genotype A was associated with patients with underlying diseases (Table 5; and Figs. 16B and 16C). Sequencing of more CoV-HKU1 may reveal the presence of genotypes or clades of CoV-HKU1 with differential virulence. To investigate for the possibility of an animal reservoir of CoV-HKU1, we tried to look for the presence of CoV-HKU1 RNA from wild and domestic animals in Hong Kong and southern China by RT-PCR. Our results revealed that none of the specimens showed the presence of CoV-HKU1 RNA. With the results of these clinical epidemiology, molecular epidemiology and eco-epidemiology studies, we conclude that CoV-HKU1 is

probably a human coronavirus, and propose to rename CoV-HKU1 as human coronavirus HKU1 (HCoV-HKU1).

Compared with SARS-CoV pneumonia, HCoV-HKU1 pneumonia is a monophasic disease and most patients had relatively mild symptoms that were localized to the respiratory tract and were only briefly hospitalized. SARS-CoV pneumonia is often described as a biphasic disease, with the first phase due to cell lysis as a result of active viral replication, and the second phase may be due to immunopathological damage (Peiris JSM *et al.*, *Lancet* 2003; 361: 1319-25; Peiris JSM *et al.*, *Lancet* 2003; 361: 1767-72). On the other hand, all 10 patients with HCoV-HKU1 pneumonia showed the pattern of a monophasic disease. Although dyspnoea was present in half of the patients with HCoV-HKU1 pneumonia at initial presentation, as compared to only about 20% of patients with SARS-CoV pneumonia at initial presentation (Peiris JSM *et al.*, *Lancet* 2003; 361: 1319-25), patients with HCoV-HKU1 pneumonia often recovered quickly, but patients with SARS-CoV pneumonia deteriorated after 7-10 days (Peiris JSM *et al.*, *Lancet* 2003; 361: 1319-25; Peiris JSM *et al.*, *Lancet* 2003; 361: 1767-72). For the eight patients who recovered, the median duration of hospitalization was only 5.5 days. This rapid recovery of patients with HCoV-HKU1 pneumonia could be related to the rapid control of the virus by the immune system. This is in line with our previous study showing the index patient (patient 5) with HCoV-HKU1 pneumonia had his peak viral load at around day 3 after onset of illness (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). Moreover, only one of the patients had extrapulmonary symptoms and all available extrapulmonary specimens (stool, urine and serum) were RT-PCR negative for CoV-HKU1 (unpublished data). On the other hand, for SARS-CoV pneumonia, patients usually had their peak viral loads 7-10 days after the onset of illness (Peiris JSM *et al.*, *Lancet* 2003; 361: 1767-72). Furthermore, the virus can be readily detected in extrapulmonary specimens, in which the viral loads correlated with the manifestations in the corresponding systems (Hung, IFN *et al.*, *Emerg Infect Dis* 2004; 10: 1550-1557). These imply that the virus was not well controlled by the immune system in the initial phase of the illness.

Despite the relatively mild disease in most patients, HCoV-HKU1 pneumonia is associated with mortality in a minority of patients who had lower haemoglobin concentration, monocyte count, serum albumin and oxygen saturation on admission and more extensive involvement on chest radiograph. As in most cases of pneumonia, more

extensive involvement in the lungs will result in poor gaseous exchange and hence hypoxia and eventually fatality. The lower haemoglobin concentration, monocyte count and serum albumin could represent poorer premorbid states and narrower margins to fight against infections. Both patients who died had underlying diabetes mellitus, malignancy (gastric lymphoma in one and carcinoma of the prostate in the other) and cardiovascular disease (old myocardial infarct in one and cerebrovascular accident in the other).

## 7. MARKET POTENTIAL

The two genomic types of CoV-HKU1 are completely sequenced. These sequences allow the development of various diagnostic tests and therapeutic methods as described hereinabove. In addition, the genetic information of CoV-HKU1 is extremely important  
5 and valuable for clinical and scientific research applications.

## 8. EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain many equivalents to the specific embodiments of the invention described herein using no more than routine  
10 experimentation. Such equivalents are intended to be encompassed by the following claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification.

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

15

**CLAIMS****WHAT IS CLAIMED:**

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.
2. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.
3. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2 or a complement of said nucleotide sequence.
4. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3 or a complement thereof.
5. An isolated nucleic acid molecule comprising the nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, or 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or a complement thereof.
6. An isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, or a complement thereof, wherein the nucleic acid molecule encodes an amino acid sequence which has a biological activity exhibited by a polypeptide encoded by the nucleotide sequence of SEQ ID NO:1 or 3.
7. The nucleic acid molecule of any one of claims 1-6, wherein the molecule is RNA.
8. The nucleic acid molecule of any one of claims 1-6, wherein the molecule is DNA.
9. A vector comprising the nucleic acid molecule of claim 8.

10. A host cell comprising the vector of claim 9
11. A host cell comprising the nucleic acid molecule of claim 8 operably linked to a heterologous promoter.
12. The host cell of claim 11 being a prokaryotic cell.
13. The host cell of claim 11 is an eukaryotic cell.
14. The host cell of claim 13 is a mammalian cell.
15. A method for producing a polypeptide comprising expressing the polypeptide encoded by the DNA from the host cell of claim 10, and recovering the polypeptide.
16. A method for producing a polypeptide comprising expressing the polypeptide encoded by the DNA from the host cell of claim 11, and recovering the polypeptide.
17. A method for preparing a cell or progeny thereof capable of expressing a polypeptide comprising transfecting the cell with the vector of claim 9.
18. An isolated polypeptide encoded by the nucleic acid molecule of any one of claims 1-6.
19. An isolated polypeptide comprising the amino acid sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110 and 120 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.
20. An isolated polypeptide comprising the amino acid sequence having any one of the amino acid sequence of SEQ ID NOS:34-2918.
21. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 18.
22. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 19 or 20.
23. A method for detecting the presence of the polypeptide of claim 18 in a biological sample, said method comprising:



- (a) contacting the biological sample with a compound that selectively binds to said polypeptide; and
  - (b) detecting whether the compound binds to said polypeptide in the sample.
24. The method of claim 23, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.
25. The method of claim 23, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.
26. A method for detecting the presence of the polypeptide of claim 19 or 20 in a biological sample, said method comprising:
- (a) contacting the biological sample with a compound that selectively binds to said polypeptide; and
  - (b) detecting whether the compound binds to said polypeptide in the sample.
27. The method of claim 26, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.
28. The method of claim 26, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.
29. A method for detecting the presence of a first nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a fragment thereof, or a complement thereof in a biological sample, said method comprising:
- (a) contacting the biological sample with a compound that selectively binds to said first nucleic acid molecule; and
  - (b) detecting whether the compound binds to said nucleic acid molecule in the sample.

30. The method of claim 29, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.

31. The method of claim 29, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

32. A method for detecting the presence of a first nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3 or a fragment thereof or a complement thereof in a biological sample, said method comprising:

- (a) contacting the biological sample with a compound that selectively binds to said first nucleic acid molecule; and
- (b) detecting whether the compound binds to said nucleic acid molecule in the sample.

33. The method of claim 32, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.

34. The method of claim 32, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

35. The method of claim 32, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000 or 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or a complement thereof.

36. A method of preventing or inhibiting a replication in a host cell of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 and/or 3, or a portion thereof, or a complement thereof, comprising administering to the host cell an effective amount of a compound that selectively binds to said first nucleic acid molecule under a physiological condition.

37. The method of claim 36, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.

38. The method of claim 36, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

39. The method of claim 36, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000 or 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or a complement thereof.

40. A method of preventing or inhibiting a binding to a host cell of the polypeptide encoded by a nucleotide sequence of SEQ ID NO:1 or 3, or a fragment thereof, or a complement thereof, comprising administering to the host cell an effective amount of a compound that specifically binds to the polypeptide under a physiological condition.

41. The method of claim 40, wherein the compound that specifically binds to the polypeptide is an antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide.

42. A method for detecting the presence of an antibody in a biological sample that immunospecifically binds the polypeptides of claim 18, said method comprising:

- (a) contacting the biological sample with the polypeptide of claim 18; and

- (b) detecting the antibody bound to the polypeptide.
43. A method for detecting the presence of an antibody in a biological sample that immunospecifically binds the polypeptides of claim 19 or 20, said method comprising:
- (a) contacting the biological sample with the polypeptide of claim 19; and
  - (b) detecting the antibody bound to the polypeptide.
44. A method for identifying a subject infected with CoV-HKU1, comprising:
- (a) obtaining total RNA from a biological sample obtained from the subject
  - (b) reverse transcribing the total RNA to obtain cDNA; and
  - (c) amplifying the cDNA using a set of primers derived from the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.
45. The method of claim 44, wherein the set of primers have the nucleotide sequence of SEQ ID NOS:4 and 5, respectively.
46. The method of claim 44, wherein the set of primers have the nucleotide sequence of SEQ ID NOS:6 and 7, respectively.
47. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 18, and a pharmaceutically acceptable carrier.
48. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 19 or 20, and a pharmaceutically acceptable carrier.
49. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, a complement thereof or a fragment thereof, and a pharmaceutically acceptable carrier.
50. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3, a complement thereof or a fragment thereof, and a pharmaceutically acceptable carrier.

51. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2919, a complement thereof, or a fragment thereof.
52. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a replicase gene of CoV-HKU1.
53. The nucleic acid molecule of claim 2 comprising the nucleotide sequence of SEQ ID NO:2920, 2922, 2924, 2926, 2928, 2930, 2932 or 2934.
54. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a spike gene of CoV-HKU1.
55. The nucleic acid molecule of claim 4 comprising the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948 or 2950.
56. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a nucleocapsid gene of CoV-HKU1.
57. The nucleic acid molecule of claim 6 comprising the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964 or 2966.
58. An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes an amino acid sequence which has a biological activity exhibited by a polypeptide encoded by the nucleic acid molecule of claim 51.
59. A vector comprising the nucleic acid molecule of claim 51.
60. A vector comprising the nucleic acid molecule of claim 52.
61. A vector comprising the nucleic acid molecule of claim 54.
62. A vector comprising the nucleic acid molecule of claim 56.
63. A host cell comprising the vector of claim 59.
64. A host cell comprising the vector of claim 60.

65. A host cell comprising the vector of claim 61.
66. A host cell comprising the vector of claim 62.
67. An isolated polypeptide encoded by the nucleic acid molecule of claim 51.
68. An isolated polypeptide encoded by the nucleic acid molecule of claim 52.
69. An isolated polypeptide encoded by the nucleic acid molecule of claim 54.
70. An isolated polypeptide encoded by the nucleic acid molecule of claim 56.
71. A nucleic acid molecule encoding the polypeptide of claim 67.
72. A nucleic acid molecule encoding the polypeptide of claim 68.
73. A nucleic acid molecule encoding the polypeptide of claim 69.
74. A nucleic acid molecule encoding the polypeptide of claim 70.

1/201

SEQ:1	1	TCGTGCTATGCCAAATATTTTCGCGTATTGTTAGTAGTTTAGTTTGGCCCGCAAACAT	58
SEQ:2	1	R A M P N I L R I V S S L V L A R K H	19
	59	GAATTTTGTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTT	118
	20	E F C C S H G D R F Y R L A N E C A Q V	39
	119	TTGAGTGAAATAGTTATGTGTGGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGT	178
	40	L S E I V M C G G C Y Y V K P G G T S S	59
	179	GGTGATGCAACTACTGCTTTTGCTAATTCGTTTTTAATATATGTCAGGCTGTTACTGCT	238
	60	G D A T T A F A N S V F N I C Q A V T A	79
	239	AATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAAT	298
	80	N V C S L M A C N G H K I E D L S I R N	99
	299	TTACAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTT	358
	100	L Q K R L Y S N V Y R T D Y V D Y T F V	119
	359	AATGAGTATTATGAATTTTATGTAAGCATTTTAG	393
	120	N E Y Y E F L C K H F	130

FIG. 1

2/201

SEQ:3 1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGATCTCAT 60  
 E \* E R I A S V P S I S L R S L V R S H  
 N K S E L R P Y R L S A Y D L L S D L I  
 I R A N C V R T V Y Q L T I S C Q I S

61 TAAATCTAAACTTTTTAAACAAGATCCCTGTTATCCATGCTTGTGAGTGTGTTAATC 120  
 \* I \* T F \* T R F P V I H A C E C G L I  
 K S K L F K Q D S L L S M L V S V V \* S  
 L N L N F L N K I P C Y P C L \* V W F N

121 ATAATCTTGTATTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTGGTTGTC 180  
 I I L Y F T F H T F H L S A S D V L V V  
 \* S C I L L S T L F I S L P V T C W L S  
 H N L V F Y F P H F S S L C Q \* R V G C

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAACCAGCAATACGGTCTCGGCTTCAA 240  
 L S V P P I G R N D \* N Q Q I R S R L Q  
 S A S L P \* V A M I K T S K Y G L G F K  
 P Q R P S H R S Q \* L K P A N T V S A S

241 GTGGGCGCCAGAATTTGCTGGCTGCTTCCGGATGCAGCGGAGAGTTGGCTAGTCCCTAT 300  
 V G A R I S L A A S G C S G G V G \* S Y  
 W A P E F R W L L P D A A E E L A S P M  
 S G R Q N F V G C F R M Q R R S W L V L

301 GAAGTCAGATGAGGGTGGGTTATGCCCTCTACTGGTCAAGCGATGGAAGTGTGGATT 360  
 E V R \* G W V M P L Y W S S D G K C W I  
 K S D E G G L C P S T G Q A M E S V G F  
 \* S Q M R V G Y A P L L V K R W K V L D

361 CGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420  
 R L \* \* S C E D R L S L H S W T R M A C  
 V Y D N H V K I D C R C I L G Q E W H V  
 S F M I I M \* R \* I V A A F L D K N G M

421 GCAGTCAAATCTTATCCGTGATTTTTGTTTCATGAAGATCTACATGTTGTAGAAGTTCT 480  
 A V K S Y P \* Y F C S \* R S T C C R S S  
 Q S N L I R D I F V H E D L H V V E V L  
 C S Q I L S V I F L F M K I Y M L \* K F

481 AACTAAAACAGCCGTAAGTCCGGTACGGCAATTTAATTAATCACCTTTGCATAGCTT 540  
 N \* N S R K V R Y G N F N \* I T F A \* L  
 T K T A V K S G T A I L I K S P L H S L  
 \* L K Q P \* S P V R Q F \* L N H L C I A

FIG. 2



3/201

541 GGGTGGTTTTCCCTAAAGGGTATGTTATGGGCTTGTCCGTTTCATACAAGACTAAACGTTA 600  
 G W F S \* R V C Y G L V P F I Q D \* T L  
 G G F P K G Y V M G L F R S Y K T K R Y  
 W V V F L K G M L W A C S V H T R L N V

601 TGGTGTACATCATCTTTCTATGACTACATCTACTACTAATTTTGGTGAAGATTTTTGGG 660  
 C C T S S F Y D Y I Y Y \* F W \* R F F G  
 V V H H L S M T T S T T N F G E D F L G  
 M L Y I I F L \* L H L L L I L V K I F W

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTCACAAATGGTTTCAATTCTGTAG 720  
 L D C T F W F Y A I L C S Q M V S I L \*  
 W I V P F G F M P S Y V H K W F Q F C R  
 V G L Y L L V L C H L M F T N G F N S V

721 GTTGTATATGAGAGAGTGAATTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780  
 V V Y \* R E \* F N N F K F \* I \* \* L \* F  
 L Y I E E S D L I I S N F K F D D Y D F  
 G C I L K R V I \* \* F Q I L N L M I M I

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAATATTCACAAAA 840  
 \* C R R C L C \* G S C \* A \* R \* I F T K  
 S V E D A Y A E V H A E P K G K Y S Q K  
 L V \* K M L M L R F M L S L K V N I H K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAACCCGTACTTTTTGTAGACCAGTA 900  
 S L C E T \* T I S W Y \* T R T F C R P V  
 A Y A L L R Q Y R G I K P V L F V D Q Y  
 K L M L Y L D N I V V L N P Y F L \* T S

901 TGGTGTGACTATTCTGGTAAATTAGCAGATTGCTCTCAAGCTTATGGTCATTATCTTT 960  
 W L \* L F W \* I S R L S S S L W S L F F  
 G C D Y S G K L A D C L Q A Y G H Y S L  
 M V V T I L V N \* Q I V F K L M V I I L

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGTGACTTTGATATTGTACT 1020  
 A R Y E T K A V C M A C Q L \* L \* Y C S  
 Q D M R Q K Q S V W L A N C D F D I V V  
 C K I \* D K S S L Y G L P I V T L I L \*

1021 GGCTTGGCATGTAGTTCGTGATTCACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080  
 G L A C S S \* F T I C Y A P A D Y S Y Y  
 A W H V V R D S R F V M R L Q T I A T I  
 W L G M \* F V I H D L L C A C R L \* L L

FIG. 2 CONT.

4/201

1081 TTGTGGTATTAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGATGTAGTTAT 1140  
 L W Y \* I C C T T Y R R C S R W R C S Y  
 C G I K Y V A Q P T E D V V D G D V V I  
 F V V L N M L H N L Q K M \* \* M E M \* L

1141 ACGTGAACCTGTACATTATTATCTGCTGATGCAATAGTTTTAAAGCTTCCTAGTTTGAT 1200  
 T \* T C T F I I C \* C N S F K A S \* F D  
 R E P V H L L S A D A I V L K L P S L M  
 Y V N L Y I Y Y L L M Q \* F \* S F L V \*

1201 GAAAGTTATGACTCATATGGATGATTTTCTATTAAATCTATATATAATGTTGATTTGTG 1260  
 E S Y D S Y G \* F F Y \* I Y I \* C \* F V  
 K V M T H M D D F S I K S I Y N V D L C  
 \* K L \* L I W M I F L L N L Y I M L I C

1261 TGATTGTGGTTTTGTTATGCAGTATGGTTATGTAGATTGTTTTAATGATAAATTGTGATTT 1320  
 \* L W F C Y A V W L C R L F \* \* \* L \* F  
 D C G F V M Q Y G Y V D C F N D N C D F  
 V I V V L L C S M V M \* I V L M I I V I

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTTCTTGCCATTGTGTTGTACAGT 1380  
 L W L G F R \* Y D G W F F L S I V L Y S  
 Y G W V S G N M M D G F S C P L C C T V  
 F M V G F Q V I \* W M V F L V H C V V Q

1381 TTATGACTCTAGCGAAGTTAAAGCCCAATCATCTGGTGTATTCCCTGAAAATCCTGTGTT 1440  
 L \* L \* R S \* S P I I W C Y S \* K S C V  
 Y D S S E V K A Q S S G V I P E N P V L  
 F M T L A K L K P N H L V L F L K I L C

1441 ATTTACTAATAGTACTGATACTGTAAACCATGATCTTTTAATTGTATGGTTATCTGTG 1500  
 I Y \* \* Y \* Y C \* P \* F F \* F V W L F C  
 F T N S T D T V N H D S F N L Y G Y S V  
 Y L L I V L I L L T M I L L I C M V I L

1501 CACACMTTGGTTCTTGTATATATTTGGTCGCCCGTCCTGGATTGTGGATTCCTATAAT 1560  
 H T I W F L Y I L V A A S W I V D S Y N  
 T P F G S C I Y W S P R P G L W I P I I  
 S H H L V L V Y I G R R V L D C G F L \*

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTCAGGTGTAGTAGTTGTAATC 1620  
 \* I F S Q V L \* \* F G L F R C S R L \* I  
 K S S V K S Y D D L V Y S G V V G C K S  
 L N L Q S S L M M I W F I Q V \* \* V V N

FIG. 2 CONT.

5/201

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACCTTTACTTAGATTATGTTCAATGTAA 1680  
 Y C \* R N C S Y Y S C T L L R L C S M \*  
 I V K E T A L I T H A L Y L D Y V Q C K  
 L L L K K L L L L L M H F T \* I M F N V

1681 GTGTGGTAACTCTTGAACAAAATCATATTCTTGGCGTTAATAATTCTTGGTGTAGGCAACT 1740  
 V W \* S \* T K S Y S W R \* \* F L V \* A T  
 C G N L E Q N H I L G V N N S W C R Q L  
 S V V I L N K I I F L A L I I L G V G N

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTCTRAAAAATATTGACTTGTGTTAAGCG 1800  
 V A \* \* R \* L \* Y A S K K Y \* L V C \* A  
 L L N R G D Y N M L L K N I D L F V K R  
 C C L I E V I I I C F \* K I L T C L L S

1801 TCGTGCTGATTTTGCTTGCAAGTTTGCAGTTTGTGGAGATGGTTTTGTACCTTTTTTACT 1860  
 S C \* F C L Q V C S L W R W F C T F F T  
 R A D F A C K F A V C G D G F V P F L L  
 V V L I L L A S L Q F V E M V L Y L F Y

1861 AGATGGTTAATTCGCCGTAGTATTATCTAATTCAGAGTGGTATTTCTTTACATCTTT 1920  
 R W F N S P \* L L S N S E W Y F L Y I F  
 D G L I P R S Y Y L I Q S G I F F T S L  
 \* M V \* F P V V I I \* F R V V F S L H L

1921 GATGCTCAATTTTCACAAGAAGTTTCTGATATCTGTTTAAAAATGTGTATTTGTTTAT 1980  
 D V S I F T R S F \* Y V F K N V Y F V Y  
 M S Q F S Q E V S D M C L K M C I L F M  
 \* C L N F H K K F L I C V \* K C V F C L

1981 GGACAGATTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040  
 G Q S F S C Y I L Y R A L C \* \* V G Y S  
 D R V S V A T F Y I E H Y V N R L V T Q  
 W T E F Q L L H F I \* S I M L I G W L L

2041 ATTTAAGTTATTGGGTACTACACTTGTAAATAAAATGGTTAATGGTTTAAATACCATGTT 2100  
 I \* V I G Y Y T C \* \* N G \* L V \* Y H V  
 F K L L G T T L V N K M V N W F N T M L  
 N L S Y W V L H L L I K W L I G L I P C

2101 AGATGCTAGTGCACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTTGT 2160  
 R C \* C T C Y R L A S L P I I E W S F C  
 D A S A P A T G W L L Y Q L L N G L F V  
 \* M L V H L L Q A G F F T N Y \* M V F L

FIG. 2 CONT.

6/201

2161 AGTATCTCAAGCCAACCTTAATTTTGTGCTTTAATACCTGATTATGCTAAAATTTAGT 2220  
 S I S S Q L \* F C C F N T \* L C \* N F S  
 V S Q A N F N F V A L I P D Y A K I L V  
 \* Y L K P T L I L L L \* Y L I M L K F \*

2221 TAATAAATTTTACACTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTTAAA 2280  
 \* \* I L H F F \* V I I R V C Y S \* C F K  
 N K F Y T F F K L L L E C V T V D V L K  
 L I N F T L F L S Y Y \* S V L Q L M F \*

2281 AGATATGCCTGTTCTTAAAACCTAATTAATGGTTTGTGTTTGTATTGTAGGCAATAAGTTTTA 2340  
 R Y A C S \* N Y \* W F S L Y C R Q \* V L  
 D M P V L K T I N G L V C I V G N K F Y  
 K I C L F L K L L M V \* F V L \* A I S F

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTTGTTTTACCATGTAATGCACAGGAACAACA 2400  
 \* R \* Y R V N S W F C F T M \* C T G T T  
 N V S T G L I P G F V L P C N A Q E Q Q  
 I T L V Q G \* F L V L F Y H V M H R N N

2401 AATTTATTTTTTTGAGGGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAGAA 2460  
 N L F F \* R R C R I C Y S R R \* C Y \* E  
 I Y F F E G V A E S V I V E D D V I E N  
 K F I F L K A L Q N L L \* \* K M M L L R

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAT 2520  
 C Q I F F I I L \* V L S T T \* I C R K N  
 V K S S L S S Y E Y C Q P P K S V E K I  
 M S N L L Y H L M S I V N H L N L \* K K

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTCCCTATTGTCAT 2580  
 L Y Y R \* Y V H G \* V W \* \* I F P Y C H  
 C I I D N M Y M G K C G D K F F P I V M  
 F V L \* I I C T W V S V V I N F S L L S

2581 GAATGATAAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTTCCATGTCAGGTAGAAA 2640  
 E \* \* K Y L S F R S G L A F S M C R \* K  
 N D K N I C L L D Q A W R F P C A G R K  
 \* M I K I F V F \* I R L G V F H V Q V E

2641 AGTTAATTTTACGAGAAACCTGTTGTTATGGAGATCCGTCCTTTGATGACAGTTAAGGT 2700  
 S \* F \* R E T C C Y G D S V F D D S \* G  
 V N F N E K P V V M E I P S L M T V K V  
 K L I L T R N L L L W R F R L \* \* Q L R

FIG. 2 CONT.

7/201

2701 TATGTTTGATTAGATTCTACTTTTGATGATATTTTAGGTAAAGTTTGTTCAGAATTGA 2760  
 Y V \* F R F Y F \* \* Y F R \* S L F R I \*  
 M F D L D S T F D D I L G K V C S E F E  
 L C L I \* I L L L M I F \* V K F V Q N L

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTGCTGTTGTTTGTGATGCTATAGAGAA 2820  
 S R K G C Y C R \* F C C C C L \* C Y R E  
 V E K G V T V D D F V A V V C D A I E N  
 K \* K R V L L \* M I L L L L F V M L \* R

2821 TGCTTTAAACTCTTGTAAGACCATCCAGTGGTTGGTTATCAAGTTCGTGCATTTTAA 2880  
 C F K L L \* R A S S G W L S S S C I F K  
 A L N S C K E H P V V G Y Q V R A F L N  
 M L \* T L V K S I Q W L V I K F V H F \*

2881 TAACTTAATGAGAATGTTGTTTATTTATTTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940  
 \* T \* \* E C C L F I \* \* G W \* \* S N G L  
 K L N E N V V Y L F D E A G D E A M A S  
 I N L M R M L F I Y L M R L V M K Q W P

2941 TCGTATGTATGTACTTTTGCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000  
 S Y V L Y F C Y \* G C \* R R Y Q \* \* S C  
 R M Y C T F A I E D V E D V I S S E A V  
 L V C I V L L L L R M L K T L S V V K L

3001 CGAAGATACTATTGATGGTGTTCGTTGAAGACACTATTAATGACGATGAAGATGTTGTTAC 3060  
 R R Y Y \* W C R \* R H Y \* \* R \* R C C Y  
 E D T I D G V V E D T I N D D E D V V T  
 S K I L L M V S L K T L L M T M K M L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120  
 W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
 G D N D D E D V V T G D N D D E D V V T  
 L V T M T M K M L L L V T M T M K M L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180  
 W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
 G D N D D E D V V T G D N D D E D V V T  
 L V T M T M K M L L L V T M T M K M L L

3181 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240  
 W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
 G D N D D E D V V T G D N D D E D V V T  
 L V T M T M K M L L L V T M T M K M L L

FIG. 2 CONT.

8/201

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3361 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3420  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3421 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATAACGATGAAGAGATTGTTAC 3480  
W \* Q \* R \* R C C Y W \* Q \* R \* R D C Y  
G D N D D E D V V T G D N N D E E I V T  
L V T M T M K M L L L V T I T M K R L L

3481 TGGTGACAATGATGACCAAAATGTTGTTACTGGTGATGATGATAGATGATATTGAAAGTAT 3540  
W \* Q \* \* P N C C Y W \* \* C R \* Y \* K Y  
G D N D D Q I V V T G D D V D D I E S I  
L V T M M T K L L L L V M M \* M I L K V

3541 TTATGACTTTGATACTTATAAAGCTCTTTTAGTTTTAATGATGCTATAATGATGCTTT 3600  
L \* L \* Y L \* S S F S F \* \* C L \* \* C F  
Y D F D T Y K A L L V F N D V Y N D A L  
F M T L I L I K L F \* F L M M S I M M L

3601 GTTTGTAGTTATGGTTCTAGTGTGAAACAGAAACATATTTTAAAGTTAATGGTTTATG 3660  
V C \* L W F \* C \* N R N I F \* S \* W F M  
F V S Y G S S V E T E T Y F K V N G L W  
C L L V M V L V L K Q K H I L K L M V Y

3661 GTCACCTACTATTACACATACTAATGTTGGTTGCGTTCGTGTTACTTGTAAATGCAGAA 3720  
V T Y Y Y T Y \* L L V A F C V T C N A E  
S P T I T H T N C W L R S V L L V M Q, K  
G H L L L H I L I V G C V L C Y L \* C R

3721 ATTACCTTTTAAAGTTAAGGATTTAGCTATTGAAAATATGTGGTTATCTTATAAGGTGGG 3780  
I T F \* V \* G F S Y \* K Y V V I L \* G G  
L P F K F K D L A I E N M W L S Y K V G  
N Y L L S L R I \* L L K I C G Y L I R W

FIG. 2 CONT.

9/201

3781 TTATAATCAAAGTTTGTGGATTATTTACTGACCACTATTCCTAAAGCTATTGTTTTGCC 3840  
 L \* S K F C \* L F T D H Y S \* S Y C F A  
 Y N Q S F V D Y L L T T I P K A I V L P  
 V I I K V L L I I Y \* P L F L K L L F C

3841 TCAAGGTGGTTTTGTAGCTGATTTTGCTTATTGGTTTTTAAACCAGTTTGATATTAATGC 3900  
 S R W F C S \* F C L L V F K P V \* Y \* C  
 Q G G F V A D F A Y W F L N Q F D I N A  
 L K V V L \* L I L L I G F \* T S L I L M

3901 GTATGCTAATTGGTGTGTTTAAAAATGTTGTTTTCTTTTGATTTAAATGGTTGGATGC 3960  
 V C \* L V L F K M W F F F \* F K W F G C  
 Y A N W C C L K C G F S F D L N G L D A  
 R M L I G V V \* N V V F L L I \* M V W M

3961 TTTGTTTTTTATGGAGATATTGTGCTCATGTTTGTAAAGTGGACATAATATGACTCT 4020  
 F V F L W R Y C V S C L \* V W T \* Y D S  
 L F F Y G D I V S H V C K C G H N M T L  
 L C F F M E I L C L M F V S V D I I \* L

4021 AATAGCAGCGGACTTACCTTGTACATTACATTTTCATTATTGATGACAATTTTGTGC 4080  
 N S S G L T L Y I T F F I I \* \* Q F L C  
 I A A D L P C T L H F S L F D D N F C A  
 \* \* Q R T Y L V H Y I F H Y L M T I F V

4081 TTTTGCACCCCTAAAAAATTTTATTGCTGCATGCTGCTGGATGTAACGTTTGTCA 4140  
 F L H P \* K N F Y C C M C C G C K R L S  
 F C T P K K I F I A A C A V D V N V C H  
 L F A P L K K F L L L H V L W M \* T F V

4141 TTCTGTAGCTGTTATAGGTGATGAACAAATAGATGGTAAGTTTGTACTAAATTTAGTGG 4200  
 F C S C Y R \* \* T N R W \* V C Y \* I \* W  
 S V A V I G D E Q I D G K F V T K F S G  
 I L \* L L \* V M N K \* M V S L L L N L V

4201 TGATAAATTTGATTTTATAGTAGGTTATGGAATGTCATTTAGTATGCTTCTTTTGAGTT 4260  
 \* \* I \* F Y S R L W N V I \* Y V F F \* V  
 D K F D F I V G Y G M S F S M S S F E L  
 V I N L I L \* \* V M E C H L V C L L L S

4261 ACCTCAATTTGATGGTTTGTATATAACACCTAATGTATGTTTTGTTAAAGGFGATATTAT 4320  
 T S I V W F V Y N T \* C M F C \* R \* Y Y  
 P Q L Y G L C I T P N V C F V K G D I I  
 Y L N C M V C V \* H L M Y V L L K V I L

FIG. 2 CONT.

10/201

4321 AAATGTTGCTAGACTTGTTAARGCTGATGTTATTGTTAATCCTGCTAATGGGCATATGCT 4380  
 K C C \* T C \* S \* C Y C \* S C \* W A Y A  
 N V A R L V K A D V I V N P A N G H M L  
 \* M L L D L L K L M L L L I L L M G I C

4381 CCATGGTGGTGGAGTTGCAAAAGCTATAGCTGTAGCTGCAGGTAAAAAATTTCTAAAGA 4440  
 P W W W S C K S Y S C S C R \* K I F \* R  
 H G G G V A K A I A V A A G K K F S K E  
 S M V V E L Q K L \* L \* L Q V K N F L K

4441 AACTGCTGCTATGGTTAAATCTAAAGGTGTTGCCAAGTAGGAGATTGTTATGTTTCTAC 4500  
 N C C Y G \* I \* R C L P S R R L L C F Y  
 T A A M V K S K G V C Q V G D C Y V S T  
 K L L L W L N L K V F A K \* E I V M F L

4501 CGGTGGTAAATTATGTAAACAATTCTTAATATTGTAGGCCCTGATGCTAGACAAGATGG 4560  
 R W \* I M \* N N S \* Y C R P \* C \* T R W  
 G G K L C K T I L N I V G P D A R Q D G  
 P V V N Y V K Q F L I L \* A L M L D K M

4561 AAGACAATCTTATGTTTTGTTAGCACGTCCTATAAGCATCTTAATAATTATGATTGTTG 4620  
 K T I L C F V S T C L \* A S \* \* L \* L L  
 R Q S Y V L L A R A Y K H L N N Y D C C  
 E D N L M F C \* H V L I S I L I I M I V

4621 TTTGCTACTCTCATATCGGCTGATATTTAGTGTTCCTGCTGATGTGTCATTAACCTA 4680  
 F V Y S H I G W Y I \* C S C \* C V I N L  
 L S T L I S A G I F S V P A D V S L T Y  
 V C L L S Y R L V Y L V F L L M C H \* L

4681 CCTTCTAGGTGTTGTTGATAAACRAAGTTATCCTTGTAGTAATAATAAAGAAGATTTTGA 4740  
 P S R C C \* \* T S Y P C \* \* \* \* R R F \*  
 L L G V V D K Q V I L V S N N K E D F D  
 T F \* V L L I N K L S L L V I I K K I L

4741 TATTATTCAAAAATGTCAAATTAATTCAGTTGTTGGTACTAAAGCATTGGCTGTAGATT 4800  
 Y Y S K M S N Y F S C W Y \* S I G C \* I  
 I I Q K C Q I T S V V G T K A L A V R L  
 I L F K N V K L L Q L L V L K H W L L D

4801 AACTGCTAATGTAGGCCGTTTATTAAATTTGAGACAGATGCATACAAACTTTTTTTGAG 4860  
 N C \* C R P C Y \* I \* D R C I Q T F F E  
 T A N V G R V I K F E T D A Y K L F L S  
 \* L L M \* A V L L N L R Q M H T N F F \*

FIG. 2 CONT.



11/201

4861 TGGTGATGATGTTTTGTTTCAAATTCCTCTGTTATACAAGAAGTTTTATTGCTTCGTC 4920  
W \* \* L F C F K F F C Y T R S F I A S S  
G D D C F V S N S S V I Q E V L L L R H  
V V M I V L F Q I L L L Y K K F Y C F V

4921 TGATATACAATTGAATAATGACGTTTCGTGATTATTTGTTGCTAAGATGACTAGTCTTCC 4980  
\* Y T I E \* \* R S \* L F V V \* D D \* S S  
D I Q L N N D V R D Y L L S K M T S L P  
M I Y N \* I M T F V I I C C L R \* L V F

4981 TAAAGATTGGCGTCTTATCAATAAATTTGATGTTATTAACGGTGTAAAACCTGTTAAGTA 5040  
\* R L A S Y Q \* I \* C Y \* R C \* N C \* V  
K D W R L I N K F D V I N G V K T V K Y  
L K I G V L S I N L M L L T V L K L L S

5041 TTTTGAGTGTCTTAATCTATTTATATATGATAGTCAGGGTAAAGACTTTGGTTATGTATG 5100  
F \* V S \* F Y L Y M \* S G \* R L W L C M  
F E C P N S I Y I C S Q G K D F G Y V C  
I L S V L I L F I Y V V R V K T L V M Y

5101 TGATGGTTCTTTTTATAAAGCAACTGTTAATCAAGTTTGTGTTTTATTAGCTAAGAAGAT 5160  
\* W F F L \* S N C \* S S L C F I S \* E D  
D G S F Y K A T V N Q V C V L L A K K I  
V M V L F I K Q L L I K F V F Y \* L R R

5161 AGATGTTTTGCTTACTGTAGATGGTGTAAATTTTAAATCTATTTCTTACTGTAGGTGA 5220  
R C F A Y C R W C \* F \* I Y F S Y C R \*  
D V L L T V D G V N F K S I S L T V G E  
\* M F C L L \* M V L I L N L F L L L \* V

5221 AGTTTTGGTAAAATACTTGGTAATGTTTTCTGTGATGGCATTGATGTTACTAAGTAAA 5280  
S F W \* N T W \* C F L \* W H \* C Y \* V K  
V F G K I L G N V F C D G I D V T K L K  
K F L V K Y L V M F S V M A L M L L S \*

5281 GTGTAGTGATTTTTATGCCGATAAAAATTTATATCAGTATGAAAATTTGTCTTTAGCTGA 5340  
V \* \* F L C R \* N F I S V \* K F V F S \*  
C S D F Y A D K I L Y Q Y E N L S L A D  
S V V I F M P I K F Y I S M K I C L \* L

5341 TATTTCTGCTGTACAAAGTTCATTTGGGTTTGATCAGCAACAATTGCTTGCTTATTATAA 5400  
Y F C C T K F I W V \* S A T I A C L L \*  
I S A V Q S S F G F D Q Q Q L L A Y Y N  
I F L L Y K V H L G L I S N N C L L I I

FIG. 2 CONT.

12/201

5401 TTTTTTAACAGTATGTAATGGTCTGTAGTTGTTAACGGTCCATTTTTTCTTTTGAACA 5460  
 F F N S M \* M V C S C \* R S I F F F \* T  
 F L T V C K W S V V V N G P F F S F E Q  
 I F \* Q Y V N G L \* L L T V H F F L L N

5461 GTCTCATAATAATTGTTATGTGAATGTAGCTTGTCTTATGTTGCAGCATATTAATCTTAA 5520  
 V S \* \* L L C E C S L S Y V A A Y \* S \*  
 S H N N C Y V N V A C L M L Q H I N L K  
 S L I I I V M \* M \* L V L C C S I L I L

5521 ATTTAATAAATGGCAGTGGCAGGAAGCATGGTATGAATTCGTGCTGGCAGACCACATAG 5580  
 I \* \* M A V A G S M V \* I S C W Q T T \*  
 F N K W Q W Q E A W Y E F R A G R P H R  
 N L I N G S G R K H G M N F V L A D H I

5581 GTTAGTTGCTCTGTTTTAGCTAAAGGTCATTTTAAATTTGATGAACCATCAGATGCTAC 5640  
 V S C S C F S \* R S F \* I \* \* T I R C Y  
 L V A L V L A K G H F K F D E P S D A T  
 G \* L L L F \* L K V I L N L M N H Q M L

5641 TGATTTTATTCGTGTTGTTTTGAAACAAGCTGATTTATCAGGTGCAATTTGTGAATTAGA 5700  
 \* F Y S C C F E T S \* F I R C N L \* I R  
 D F I R V V L K Q A D L S G A I C E L E  
 L I L F V L F \* N K L I Y Q V Q F V N \*

5701 ACTTATTTGTGATTGTGGTATTAACAAGAAAGTCGTGTTGGTGTGATGCTGTTATGCA 5760  
 T Y L \* L W Y \* T R K S C W C \* C C Y A  
 L I C D C G I K Q E S R V G V D A V M H  
 N L F V I V V L N K K V V L V L M L L C

5761 TTTTGGTACATTAGCAAAGACTGATCTTTTTAATGGTTATAAGATTGGCTGTAATTGTGC 5820  
 F W Y I S K D \* S F \* W L \* D W L \* L C  
 F G T L A K T D L F N G Y K I G C N C A  
 I L V H \* Q R L I F L M V I R L A V I V

5821 AGGTAGAATTGCCATTGCTACTAAATGGAATGTACCATTTTGTATTGTTCTAATACTCC 5880  
 R \* N C P L Y \* I E C T I F D L F \* Y S  
 G R I V H C T K L N V P F L I C S N T P  
 Q V E L S I V L N \* M Y H F \* F V L I L

5881 TCTGAGTAAGGATTTACCTGATGATGTTGTTGCAGCTAACATGTTTATGGGTGTAGGTGT 5940  
 S E \* G F T \* \* C C C S \* H V Y G C R C  
 L S K D L P D D V V A A N M F M G V G V  
 L \* V R I Y L M M L L Q L T C L W V \* V

FIG. 2 CONT.

13/201

5941 AGGCCATTATACACATTTGAAATGTGGTTCACCTTACCAACATTATGATGCTTGTAGTGT 6000  
R P L Y T F E M W F T L P T L \* C L \* C  
G H Y T H L K C G S P Y Q H Y D A C S V  
\* A I I H I \* N V V H L T N I M M L V V

6001 TAAAAAATATACAGGTGTTAGTGGTGGTTAACTGACTGCTTGTATCTTAAAAATTAAC 6060  
\* K I Y R C \* W L F N \* L L V S \* K F N  
K K Y T G V S G C L T D C L Y L K N L T  
L K N I Q V L V V V \* L T A C I L K I \*

6061 CCAGACTTTTACATCTATGTTGACTAATTATTTTTGGATGATGTTGAAATGGTTGCTTA 6120  
P D F Y I Y V D \* L F F G \* C \* N G C L  
Q T F T S M L T N Y F L D D V E M V A Y  
P R L L H L C \* L I I F W M M L K W L L

6121 TAACCCGTGATCTTTACAAATATTATTGTGATAATGGTAAGTATTATACAAAACCTATTAT 6180  
\* P \* S F T I L L \* \* W \* V L Y K T Y Y  
N P D L S Q Y Y C D N G K Y Y T K P I I  
I T L I F H N I I V I M V S I I Q N L L

6181 AAAGGCTCAGTTTAAACCATTGCTAAAGTTGACGGTGTTTATACTAACTTAAAGTTAGT 6240  
K G S V \* T I C \* S \* R C L Y \* L \* V S  
K A Q F K P F A K V D G V Y T N F K L V  
\* R L S L N H L L K L T V F I L T L S \*

6241 TGGACATGATATTTGTGCTCAATFGAATGATAAGTTAGGTTTTAATGTAGATTGCCGTT 6300  
W T \* Y L C S I E \* \* V R F \* C R F A V  
G H D I C A Q L N D K L G F N V D L P F  
L D M I F V L N \* M I S \* V L M \* I C R

6301 TGTTGAGTACAAAAGTAACAGTCTGGCCTGTAGCTACTGGTGATGTTGTTTTGGCATCTGA 6360  
C \* V Q S N S L A C S Y W \* C C F G I \*  
V E Y K V T V W P V A T G D V V L A S D  
L L S T K \* Q S G L \* L L V M L F W H L

6361 TGATTATATGTGAAACGTTATTTTAAAGGATGTGAAACTTTTGGTAAGCCTGTTATTG 6420  
\* F I C E T L F \* R M \* N F W \* A C Y L  
D L Y V K R Y F K G C E T F G K P V I W  
M I Y M \* N V I L K D V K L L V S L L F

6421 GTTTGTGATGATGAAGCATCATTGAATTCCTTACTTATTTTAAATAAACCTAGTTTAA 6480  
V L S \* \* S I I E F S Y L F \* \* T \* F \*  
F C H D E A S L N S L T Y F N K P S F K  
G F V M M K H H \* I L L L I L I N L V L

FIG. 2 CONT.

14/201

6481 ATCTGAAAATAGATATAGTGTGTTTGTCTGTTGATTCTGTATCTGAGGAGTCACAAGGTAA 6540  
 I \* K \* I \* C F V C \* F C I \* G V T R \*  
 S E N R Y S V L S V D S V S E E S Q G N  
 N L K I D I V F C L L I L Y L R S H K V

6541 TGTGGTTACTTCTGTTATGGAATCGCAGATTAGTACTAAAGAGGTTAAGTTAAGGGTGT 6600  
 C G Y F C Y G I A D \* Y \* R G \* V K G C  
 V V T S V M E S Q I S T K E V K L K G V  
 M W L L L L W N R R L V L K R L S \* R V

6601 TAGAAAGACTGTTAAAATAGAAGATGCTATTATTGTTAATGATGAAAATAGTCTCTATTAA 6660  
 \* K D C \* N R R C Y Y C \* \* \* K \* F Y \*  
 R K T V K I E D A I I V N D E N S S I K  
 L E R L L K \* K M L L L L M M K I V L L

6661 GGTGTTAAAAGTTTATCTTTAGTTGATGTTTGGGATATGTATTTGACAGGTTGTGATTA 6720  
 G C \* K F I F S \* C L G Y V F D R L \* L  
 V V K S L S L V D V W D M Y L T G C D Y  
 R L L K V Y L \* L M F G I C I \* Q V V I

6721 TGTGTTTGGGTTGCTAATGAATTGTCACGCCTAGTTAAATCACCAACAGTTAGGGAATA 6780  
 C C L G C \* \* I V T P S \* I T N S \* G I  
 V V W V A N E L S R L V K S P T V R E Y  
 M L F G L L M N C H A \* L N H Q Q L G N

6781 TATACGATATGGTATTAAACCTATTACTATACCTATAGATTTGTTATGTTTAAAGAGATGA 6840  
 Y T I W Y \* T Y Y Y T Y R F V M F K R \*  
 I R Y G I K P I T I P I D L L C L R D D  
 I Y D M V L N L L L Y L \* I C Y V \* E M

6841 TAATCAAACCTCTTTAGTTCCTAAAATTTTAAAGCAAGAGCTATAGAAATTTATGGTGT 6900  
 \* S N S F S S \* N F \* S K S Y R I L W F  
 N Q T L L V P K I F K A R A I E F Y G F  
 I I K L F \* F L K F L K Q E L \* N F M V

6901 TTTGAAGTGGTGTGTTTATTATGTTTTAGTTTATTACATTTTACAAATGATAAAACCAT 6960  
 F E V V V Y L C F \* F I T F Y K \* \* N H  
 L K W L F I Y V F S L L H F T N D K T I  
 F \* S G C L F M F L V Y Y I L Q M I K P

6961 TTTTATACTACAGAAATAGCTTCTAAGTTTACTTTTAATTTGTTTGTGGCTCTTAA 7020  
 F L Y Y R N S F \* V Y F \* F V L F G S \*  
 F Y T T E I A S K F T F N L F C L A L K  
 F F I L Q K \* L L S L L L I C F V W L L

FIG. 2 CONT.

15/201

7021 AAATGCTTTTCAGACATTTAGATGGAGTATATTTATAAAAGGTTTTCTGTGTAGCCAC 7080  
 K C F S D I \* M E Y I Y K R F S C C S H  
 N A F Q T F R W S I F I K G F L V V A T  
 K M L F R H L D G V Y L \* K V F L L \* P

7081 TGTGTTTTGTTTTGGTTAATTTTTGTATATAAATGTTATTTTTAGTGACTTTTATCT 7140  
 C V F V L V \* F F V Y K C Y F \* \* L L S  
 V F L F W F N F L Y I N V I F S D F Y L  
 L C F C F G L I F C I \* M L F L V T F I

7141 TCCTAATATTAGTGTTCCTATTTTTGTGGGAAGAATTGTTATGTGGATAAAGGCTAC 7200  
 S \* Y \* C F S Y F C G K N C Y V D K G Y  
 P N I S V F P I F V G R I V M W I K A T  
 F L I L V F F L F L W E E L L C G \* R L

7201 TTTTGGTTTGGTTACAATTTGTGATTTTTATCTAAGTTAGGTGTAGGTTTTACAAGTCA 7260  
 F W F G Y N L \* F L F \* V R C R F Y K S  
 F G L V T I C D F Y S K L G V G F T S H  
 L L V W L Q F V I F I L S \* V \* V L Q V

7261 TTTTTGTAATGGTAGTTTTATATGFGAATTGTGTCATTCTGGTTTTGATATGTTGGATAC 7320  
 F L \* W \* F Y M \* I V S F W F \* Y V G Y  
 F C N G S F I C E L C H S G F D M L D T  
 I F V M V V L Y V N C V I L V L I C W I

7321 ATATGCAGCTATAGATTTTTGTTCAGTATGAAGTAGATAGACGTGTTTTATTGATTATGT 7380  
 I C S Y R F C S V \* S R \* T C F I \* L C  
 Y A A I D F V Q Y E V D R R V L F D Y V  
 H M Q L \* I L F S M K \* I D V F Y L I M

7381 TAGTTAGTCAAATTAATTGTTGAACTCGTTATTGGTTATTCATTATACACAGTATGGTT 7440  
 \* F S Q I N C \* T R Y W L F I I H S M V  
 S L V K L I V E L V I G Y S L Y T V W F  
 L V \* S N \* L L N S L L V I H Y T Q Y G

7441 TTATCCATTTTTGTCTTATTGGTTTACAATTATTTACTACATGGTTGCCCTGATTGTT 7500  
 L S I I L S Y W F T I I Y Y M V A \* F V  
 Y P L F C L I G L Q L F T T W L P D L F  
 F I H Y F V L L V Y N Y L L H G C L I C

7501 TATGTTAGAACTATGCATTGGTTGATTAGATTTATTTGTATTTGTAGCTAATATGTTACC 7560  
 Y V R N Y A L V D \* I Y C I C S \* Y V T  
 M L E T M H W L I R F I V F V A N M L P  
 L C \* K L C I G \* L D L L Y L \* L I C Y

FIG. 2 CONT.

16/201

7561 TGCTTTTGTCTTGTGCGGTTTTATATAGTTGTTACTGCTATGTATAAAGTAGTTGGTTT 7620  
 C F C L V A V L Y S C Y C Y V \* S S W F  
 A F V L L R F Y I V V T A M Y K V V G F  
 L L L S C C G F I \* L L L L C I K \* L V

7621 TATTAGGCATATTGCTCTATGGTTGTAATAAAGCTGGTTGTTTATTTGTTATAAACGAAA 7680  
 Y \* A Y C L W L \* \* S W L F I L L \* T K  
 I R H I V Y G C N K A G C L F C Y K R N  
 L L G I L S M V V I K L V V Y F V I N E

7681 TTGTAGTGTTCGTGTTAAGTGTAGTACTATTGTTGGTGGTGAATTCGTTATTATGATAT 7740  
 L \* C S C \* V \* Y Y C W W C N S L L \* Y  
 C S V R V K C S T I V G G V I R Y Y D I  
 I V V F V L S V V L L L V V \* F V I M I

7741 TACTGCTAATGGTGGTACTGGTTTTTGTGTTAAACATCAATGGAATTTTAAATGCCA 7800  
 Y C \* W W Y W F L C \* T S M E L F \* L P  
 T A N G G T G F C V K H Q W N C F N C H  
 L L L M V V L V F V L N I N G I V L I A

7801 TTCTTTTAAACCAGGTAACACTTTTATAACTGTAGAAGCTGCTATAGAAGTTCTTAAAGA 7860  
 F F \* T R \* H F Y N C R S C Y R T F \* R  
 S F K P G N T F I T V E A A I E L S K E  
 I L L N Q V T L L \* L \* K L L \* N F L K

7861 GCTTAAACGACCTGTAATCCAAGTATGCTTACACATTATGATAGTACTGATATTAAGCA 7920  
 A \* T T C K S N \* C F T L C S Y \* Y \* A  
 L K R P V N P T D A S H Y V V T D I K Q  
 S L N D L \* I Q L M L H I M \* L L I L S

7921 AGTTGGTTGTATGATGCGTTTCTTATGATAGAGATGGACAGCGTTTACGATGATGT 7980  
 S W L Y D A F V L \* \* R W T A C L R \* C  
 V G C M M R L F Y D R D G Q R V Y D D V  
 K L V V \* C V C S M I E M D S V F T M M

7981 TGATGCTAGTTTATTTGTAGATATTAATAATCTGTTACATTCTAAAGTTAAAGTTGTTCC 8040  
 \* C \* F I C R Y \* \* S V T F \* S \* S C S  
 D A S L F V D I N N L L H S K V K V V P  
 L M L V Y L \* I L I I C Y I L K L K L F

8041 TAATTTGTATGTAGTTGTAGTAGAGAGTGTGCTGATAGAGCTAATTTTCTGATGCTGT 8100  
 \* F V C S C S R E \* C \* \* S \* F S E C C  
 N L Y V V V V E S D A D R A N F L N A V  
 L I C M \* L \* \* R V M L I E L I F \* M L

FIG. 2 CONT.

17/201

8101 TGTGTTTTATGCACAATCATTGTATAGGCCTATATTACTTGTAGACAAAAAGTTAATTAC 8160  
 C V L C T I I V \* A Y I T C R Q K V N Y  
 V F Y A Q S L Y R P I L L V D K K L I T  
 L C F M H N H C I G L Y Y L \* T K S \* L

8161 TACAGCTTGTAAATGGTATCTCTGTAACCCAGACTATGTTTGTATGTTTATGTTGATACTTT 8220  
 Y S L \* W Y L C N P D Y V \* C L C \* Y F  
 T A C N G I S V T Q T M F D V Y V D T F  
 L Q L V M V S L \* P R L C L M F M L I L

8221 TATGCTCATTGTTGATGTGATAGAAAGAGTTTTAATAATTTTGTAAACATTTGCTCATGC 8280  
 Y V S E \* C \* \* K E F \* \* F C \* H C S C  
 M S H F D V D R K S F N N F V N I A H A  
 L C L I L M L I E R V L I I L L T L L M

8281 TTCTCTTAGAGAGGGTGTGCAATTAGAAAAGTTTTAGATACTTTTGTGGGATGTGTACG 8340  
 F S \* R G C A I R K G F R Y F C G M C T  
 S L R E G V Q L E K V L D T F V G C V R  
 L L L E R V C N \* K R F \* I L L W D V Y

8341 TAAATGTTGTTCCATTGATTCAGATGTTGAAACAAGATTTATTACTAAATCTATGATATC 8400  
 \* M L F H \* F R C \* N K I Y Y \* I Y D I  
 K C C S I D S D V E T R F I T K S M I S  
 V N V V P L I Q M L K Q D L L L N L \* Y

8401 TGCAGTAGCTGCTGGTTTGGAAATTTACTGATGAAAATTATAACAATTTGGTACCTACATA 8460  
 C S S C W F G I Y \* \* K L \* Q F G T Y I  
 A V A A G L E F T D E N Y N N L V P T Y  
 L Q \* L L V W N L L M K I I T I W Y L H

8461 TTTAAGAGTGATAATATTTGTAGCTGCTGATTTAGGTGTTCTTATACAGAATGGTGCTAA 8520  
 F K E \* \* Y C S C \* F R C S Y T E W C \*  
 L K S D N I V A A D L G V L I Q N G A K  
 I \* R V I I L \* L L I \* V F L Y R M V L

8521 GCATGTACAGGGTAATGTTGCTAAGGCAGCTAATATTTCTTGTATATGGTTTATTGATGC 8580  
 A C T G \* C C \* G S \* Y F L Y M V Y \* C  
 H V Q G N V A K A A N I S C I W F I D A  
 S M Y R V M L L R Q L I F L V Y G L L M

8581 TTTTAAATCAACTTACTGCTGATTTACAGCATAAATTAATAAAGCATGTGTTAAACTGG 8640  
 F \* S T Y C \* F T A \* I K K S M C \* N W  
 F N Q L T A D L Q H K L K K A C V K T G  
 L L I N L L L I Y S I N \* K K H V L K L

FIG. 2 CONT.

18/201

8641 CTTGAAGTTAAAATTGACTTTTAAATAAGCAAGAGGCAAGTGTCCCTATTCTTACACACC 8700  
 L E V K I D F \* \* A R G K C P Y S Y N T  
 L K L K L T F N K Q E A S V P I L T T P  
 A \* S \* N \* L L I S K R Q V S L F L Q H

8701 CTTTTCACCTTAAAGGAGGTGTTGATTGAGTAATTTGTTATATATATTATTTTTGTTAG 8760  
 L F T \* R R C C I E \* F V I Y I I F C \*  
 F S L K G G V V L S N L L Y I L F F V S  
 P F H L K E V L Y \* V I C Y I Y Y F L L

8761 TTTAATCTGTTTTATATTATGTGGGCTTTATTGCCTACATATAGTGTTTATAAGTCTGA 8820  
 F N L F Y I I V G F I A Y I \* C L \* V \*  
 L I C F I L L W A L L P T Y S V Y K S D  
 V \* S V L Y Y C G L Y C L H I V F I S L

8821 TATTCATTTGCCTGCTTATGCTAGTTTTAAAGTTATTCGATAATGCTGTTCTTAGACATAT 8880  
 Y S F A C L C \* F \* S Y \* \* W C C \* R Y  
 I H L P A Y A S F K V I D N G V V R D I  
 I F I C L L M L V L K L L I M V L L E I

8881 TTCAGTTAATGATTTATGTTTTGCTAATAAATTTTCCAATTTGATCAATGGTATGAGTC 8940  
 F S \* \* F M F C \* \* I F P I \* S M V \* V  
 S V N D L C F A N K F F Q F D Q W Y E S  
 F Q L M I Y V L L I N F S N L I N G M S

8941 CACTTTTGGGCTGTTTACTATCATAATTCTATGGATTGCCCTATTGTAGTGGCAGTTAT 9000  
 H F W V C L L S \* F Y G L P Y C S G S Y  
 T F G S V Y Y H N S M D C P I V V A V M  
 P L L G L F T I I I L W I A L L \* W Q L

9001 GGATGAAGATATCGGTTCTACTATGTTTAAATGTTCCCTACTAAAGTTTTGAGACATGGCTT 9060  
 G \* R Y R F Y Y V \* C S Y \* S F E T W L  
 D E D I G S T M F N V P T K V L R H G F  
 W M K I S V L L C L M F L L K F \* D M A

9061 TCATGTTTTACATTTTTTAACTTATGCATTTGCTAGTGATAGTGTTCAGTGCTATACACC 9120  
 S C F T F F N L C I C \* \* \* C S V L Y T  
 H V L H F L T Y A F A S D S V Q C Y T P  
 F M F Y I F \* L M H L L V I V F S A I H

9121 ACATATTCAGATTTCTTATAATGATTTTTATGCTAGTGGTTGTTTATCATCTTTGTG 9180  
 T Y S D F L \* \* F L C \* W L C F I I F V  
 H I Q I S Y N D F Y A S G C V L S S L C  
 H I F R F L I M I F M L V V V F Y H L C

FIG. 2 CONT.



19/201

9181 TACTATGTTTAAAAGAGGTGATGGTACACCACATCCTTATTGTTATTCAGATGGTGTAT 9240  
 Y Y V \* K R \* W Y T T S L L L F R W C Y  
 T M F K R G D G T P H P Y C Y S D G V M  
 V L C L K E V M V H H I L I V I Q M V L

9241 GAAGAATGCTTCTTTGTATACATCTTTGGTCCACATACACGTTATAGCCTTGCTAATTC 9300  
 E E C F F V Y I F G S T Y T L \* P C \* F  
 K N A S L Y T S L V P H T R Y S L A N S  
 \* R M L L C I H L W F H I H V I A L L I

9301 TAATGGTTTTATAAGATTTCTGATGTTATTAGTGAAGGTATTGTACGTATTGTAAGAAC 9360  
 \* W F Y K I S \* C Y \* \* R Y C T Y C K N  
 N G F I R F P D V I S E G I V R I V R T  
 L M V L \* D F L M L L V K V L Y V L \* E

9361 GCGCTCTATGACTTATTGTAGAGTGGGTGCATGTGAATACGCCGAGAGGGTATATGTTT 9420  
 A L Y D L L \* S G C M \* I R R R G Y M F  
 R S M T Y C R V G A C E Y A E E G I C F  
 R A L \* L I V E W V H V N T P K R V Y V

9421 TAATTTAATAGTTCCTGGGTTTGAATAATGATTATTATAGAAGTATGCCTGGAACCTT 9480  
 \* F \* \* F L G F E \* \* L L \* K Y A W N F  
 N F N S S W V L N N D Y Y R S M P G T F  
 L I L I V P G F \* I M I I I E V C L E L

9481 TTGTGGTAGAGATCTTTTGATTTGTTTTATCAATTTTTTAGTAGTTTAAATCGTCCTAT 9540  
 L W \* R S F \* F V L S I F \* \* F N S S Y  
 C G R D L F D L F Y Q F F S S L I R P I  
 F V V E I F L I C F I N F L V V \* F V L

9541 AGATTTCTTTCTCTTACTGCTAGTCTATTTTGGAGCTATATTGGCTATAGTTGTGT 9600  
 R F L F S Y C \* F Y F W S Y I G Y S C C  
 D F F S L T A S S I F G A I L A I V V V  
 \* I S F L L L L V L F L E L Y W L \* L L

9601 CTGGTTTTTTATATTTAATAAACTTAAGCGTCTTTTGGAGATTATACTAGTGTGT 9660  
 L G F L L F N K T \* A C F W R L Y \* C C  
 L V F Y Y L I K L K R A F G D Y T S V V  
 S W F P I I \* \* N L S V L L E I I L V L

9661 AGTTATAAATGTTGTTGTTGGTGTATTAATTTCTTATGCTTTTGTPTTTCAAGTTA 9720  
 S Y K C C C L V Y \* F S Y A F C F S S L  
 V I N V V V W C I N F L M L F V F Q V Y  
 \* L \* M L L F G V L I F L C F L F F K F

FIG. 2 CONT.

20/201

9721 TCCTATTTGTCATGTGTTTATGCTTGTGTTTTATTTTTATGTAACATTGTATTTTCCTTC 9780  
 S Y L C M C L C L F L F L C N I V F S F  
 P I C A C V Y A C F Y F Y V T L Y F P S  
 I L F V H V F M L V F I F M \* H C I F L

9781 TGAAATTAGTGAATTATGCATTTGCAATGGATTGTTATGTATGGTGCCTATAATGCCCTT 9840  
 \* N \* C N Y A F A M D C Y V W C Y N A F  
 E I S V I M H L Q W I V M Y G A I M P F  
 L K L V \* L C I C N G L L C M V L \* C L

9841 TTGGTTTTGTGTCACATATGTAGCTATGGTTATTGCAAACCATGTTTTATGGTTATTTTC 9900  
 L V L C H I C S Y G Y C K P C F M V I F  
 W F C V T Y V A M V I A N H V L W L F S  
 F G F V S H M \* L W L L Q T M F Y G Y F

9901 ATATTGTAGGAAAATTGGTGTAAATGTATGTAGTGATAGTACATTTGAAGAACATCTCT 9960  
 I L \* E N W C \* C M \* \* \* Y I \* R N I S  
 Y C R K I G V N V C S D S T F E E T S L  
 H I V G K L V L M Y V V I V H L K K H L

9961 TACTACTTTTATGATTACTAAGATTCTTATTGTAGATTAAGAATTCTGTTTCTGATGT 10020  
 Y Y F Y D Y \* R F L L \* I K E F C F \* C  
 T T F M I T K D S Y C R L K N S V S D V  
 L L L L \* L L K I L I V D \* R I L F L M

10021 TGCCTACAATAGATATTTGAGTTTGTATAATAAGTATCGTTACTATAGTGGTAAAATGGA 10080  
 C L Q \* I F E F V \* \* V S L L \* W \* N G  
 A Y N R Y L S L Y N K Y R Y Y S G K M D  
 L P T I D I \* V C I I S I V T I V V K W

10081 TACTGCTGCCATAGAGAAGCGCGTGTCTCAGTTAGCTAAGCTATGGAACATTTAA 10140  
 Y C C L \* R S G V F S V S \* S Y G N I \*  
 T A A Y R E A A C S Q L A K A M E T F N  
 I L L P I E K R R V L S \* L K L W K H L

10141 TCACAATAATGGTAATGATGCTTATACCAACCTCCTACAGCATCTGTTTCTACATCTTT 10200  
 S Q \* W \* \* C L I P T S Y S I C F Y I F  
 H N N G N D V L Y Q P P T A S V S T S F  
 I T I N V M M S Y T N L L Q H L F L H L

10201 TTTGCAATCAGGTATTGTAAGATGGTATCTCCTACGTCAAAAATTGAACCTTGATTTGT 10260  
 F A I R Y C K D G I S Y V K N \* T L Y C  
 L Q S G I V K M V S P T S K I E P C I V  
 F C N Q V L \* R W Y L L R Q K L N L V L

FIG. 2 CONT.

21/201

10261 TAGTGTACTTATGGTAGTATGACTTTGAATGGTTATGGTTAGATGACAAAGTTTATG 10320  
 \* C Y L W \* Y D F E W F M V R \* Q S L L  
 S V T Y G S M T L N G L W L D D K V Y C  
 L V L L M V V \* L \* M V Y G \* M T K F I

10321 TCCTCGTCATGTTATATGTTTCATCCTCTAATATGAACGAACCTGATTATTCTGCCTTATT 10380  
 S S S C Y M F I L \* Y E R T \* L F C L I  
 P R H V I C S S S N M N E P D Y S A L L  
 V L V M L Y V H P L I \* T N L I I L P Y

10381 GTGTAGAGTTACTCTAGGTGATTTTACTATAATGTCTGGTCGGATGAGTTAACAGTTGT 10440  
 V \* S Y S R \* F Y Y N V W S D E F N S C  
 C R V T L G D E T I M S G R M S L T V V  
 C V E L L \* V I L L \* C L V G \* V \* Q L

10441 GTCTTACCAGATGCAGGGCTGTCAACTTGTTTTGACAGTCTCTTTACAAAATCCTTACAC 10500  
 V L P D A G L S T C F D S L F T K S L H  
 S Y Q M Q G C Q L V L T V S L Q N P Y T  
 C L T R C R A V N L F \* Q S L Y K I L T

10501 TCCAAAATATACTTTTGGTAATGTTAAACCTGGTGAAACTTTTACTGTTTTAGTGCGTA 10560  
 S K I Y F W \* C \* T W \* N F Y C F S C V  
 P K Y T F G N V K P G E T F T V L A A Y  
 L Q N I L L V M L N L V K L L L F \* L R

10561 TAATGGCCGACCACAAGGGCATTTCATGTTACTATGCGTAGTAGTTATACTATTAAGG 10620  
 \* W P T T R G I S C Y Y A \* \* L Y Y \* R  
 N G R P Q G A F H V T M R S S Y T I K G  
 I M A D H K G H F M L L C V V V I L L K

10621 TTCTTTTTTGTGTGGTCAATGTCATGTCGTTGTTATGTATTAACAGGTGATAGTGTAA 10680  
 F F F V W V M W I C W L C I N R \* \* C \*  
 S F L C G S C G S V G Y V L T G D S V K  
 V L F C V G H V D L L V M Y \* Q V I V L

10681 GTTGTATATATGCATCAATTAGAGCTCAGTACTGGTTGTCACACTGGCACTGATTTTAC 10740  
 V C I Y A S I R A Q Y W L S H W H \* F Y  
 F V Y M H Q L E L S T G C H T G T D F T  
 S L Y I C I N \* S S V L V V T L A L I L

10741 TGGTAATTTTATGGTCCATATAGAGATGCTCAAGTTGTACAGTTGCCAGTTAAGGACTA 10800  
 W \* F L W S I \* R C S S C T V A S \* G L  
 G N F Y G P Y R D A Q V V Q L P V K D Y  
 L V I F M V H I E M L K L Y S C Q L R T

FIG. 2 CONT.

22/201

10801 CGTCCAGACTGTTAATGTTATTGCTTGGCTCTATGCAGCTATACTTAATAATGTGCTTG 10860  
R P D C \* C Y C L A L C S Y T \* \* L C L  
V Q T V N V I A W L Y A A I L N N C A W  
T S R L L M L L L G S M Q L Y L I I V L

10861 GTTTGTACAAAATGATGTTGTTCTACTGAAGATTTAATGTTGGGCTATGGCAAATGG 10920  
V C T K \* C L F Y \* R F \* C L G Y G K W  
F V Q N D V C S T E D F N V W A M A N G  
G L Y K M M F V L L K I L M F G L W Q M

10921 TTTTAGCCAAGTAAAAGCAGATCTTGTCTTAGATGCTTTGGCTTCAATGACAGGTGTTTC 10980  
F \* P S K S R S C L R C F G F N D R C F  
F S Q V K A D L V L D A L A S M T G V S  
V L A K \* K Q I L S \* M L W L Q \* Q V F

10981 TATTGAACTTTATTGGCTGCTATTAAGCGTCTATATATGGGATTCAGGTCGTCAAAT 11040  
Y \* N F I G C Y \* A S I Y G I S R S S N  
I E T L L A A I K R L Y M G F Q G R Q I  
L L K L Y W L L L S V Y I W D F K V V K

11041 ACTAGGAAGTGTACTTTTGAAGATGAATTGCCACCTTCTGACGTTTATCAACAATTGGC 11100  
T R K L Y F \* R \* I G T F \* R L S T I G  
L G S C T F E D E L A P S D V Y Q Q L A  
Y \* E V V L L K M N W H L L T F I N N W

11101 TGGTGTTAAATTGCAATCTAAAACAAAAGATTTATTAAGAAACAATTTATTGGATTTT 11160  
W C \* I A I \* N K K I Y \* R N N L L D F  
G V K L Q S K T K R F I K E T I Y W I L  
L V L N C N L K Q K D L L K K Q F I G F

11161 GATATCTACATTTTGTAGTTGTATAATTTCTGCATTTGTTAAATGGACTATATTTAT 11220  
D I Y I F V \* L Y N F C I C \* M D Y I Y  
I S T E L F S C I I S A F V K W T I F M  
\* Y L H F C L V V \* F L H L L N G L Y L

11221 GTATATTAATACACATATGATTGGTGTACATTATGTGACTTTGTTTTGTTAGTTTTAT 11280  
V Y \* Y T Y D W C Y I M C T L F C \* F Y  
Y I N T H M I G V T L C V L C F V S F M  
C I L I H I \* L V L H Y V Y F V L L V L

11281 GATGTTACTAGTTAAACATAAGCATTTTTATTTGACTATGTATATAATTCCTGFACTCTG 11340  
D V T S \* T \* A F L F D Y V Y N S C T L  
M L L V K H K H F Y L T M Y I I P V L C  
\* C Y \* L N I S I F I \* L C I \* F L Y S

FIG. 2 CONT.

23/201

11341 TACCTTGTTTATGTAATAATTTAGTTGTTTATAAGGAAGGTTTAGAGGTTTACTTA 11400  
 Y L V L C K L F S C L \* G R F \* R F Y L  
 T L F Y V N Y L V V Y K E G F R G F T Y  
 V P C F M \* I I \* L F I R K V L E V L L

11401 TGTCTGGCTCTCATAATTTGTTCCCTGCTGGAATTTACTTATGTTTATGAAGTATTTTA 11460  
 C L A L I F C S C C E F Y L C L \* S I L  
 V W L S Y F V P A V N F T Y V Y E V F Y  
 M S G S H I L E L L \* I L L M F M K Y F

11461 TGGTTGATTTTATGTGTTTTGCTATTTTATAACTATGCATAGTATTAAATCATGACAT 11520  
 W L Y F M C F C Y F Y N Y A \* Y \* S \* H  
 G C I L C V F A I F I T M H S I N H D I  
 M V V F Y V F L L F L \* L C I V L I M T

11521 TTTTTCCTTGATGTTTTGGTTGGTAGAATAGTTACTTTAATTTCTATGGGTATTTTGG 11580  
 F F F D V F G W \* N S Y F N F Y V V F W  
 F S L M F L V G R I V T L I S M W Y F G  
 F F L \* C F W L V E \* L L \* F L C G I L

11581 GTCGAATTTAGAAGAGGATGTTTTGTTATTTATTACAGCCTTTTAGTACTTATACATG 11640  
 V E F R R G C F V I Y Y S L F R Y L Y M  
 S N L E E D V L L F I T A F L G T Y T W  
 G R I \* K R M F C Y L L Q P F \* V L I H

11641 GACCACTATTTGTCATTAGCTATAGCAAAAATGTTGCTAATGCTGCTGTTAATAT 11700  
 D H Y F V I S Y S K N C C \* L V V C \* Y  
 T T I L S L A I A K I V A N W L S V N I  
 G P L F C H \* L \* Q K L L L I G C L L I

11701 ATTTTATTTTACAGATGTACCTTATATTAATGATTCTCTTGAGTTACTTATTTATAGG 11760  
 I L F Y R C T L Y \* I D S L E L L I Y R  
 F Y F T D V P Y I K L I L L S Y L F I G  
 Y F I L Q M Y L I L N \* F S \* V T Y L \*

11761 GTATATTTTATCTTGTATGSGGATTTTCTCTCTTTTAAACAGTGTTTTAGAATGCC 11820  
 V Y F I L L L G I F L S F K Q C F \* N A  
 Y I L S C Y W G F F S L L N S V F R M P  
 G I F Y L V I G D F S L F \* T V F L E C

11821 TATGGGTGTTTATAAATTATAAAATTTCTGTTCAAGAATTGCGTTATATGAATGCTAATGG 11880  
 Y G C L \* L \* N F C S R I A L Y E C \* W  
 M G V Y N Y K I S V Q E L R Y M N A N G  
 L W V F I I I K F L F K N C V I \* M L M

FIG. 2 CONT.

24/201

11881 CTTACGTCCACCTCGTAATAGTTTTGAGGCTATTTGTAAATTAAAACCTGCTTGGAAAT 11940  
 L T S T S \* \* F \* G Y F V K F K T A W N  
 L R P P R N S F E A I L L N L K L L G I  
 A Y V H L V I V L R L F C \* I \* N C L E

11941 AGGTGGCGTGCCAGTTATTTGAAGTCTCCCAAATTCAAATCAAATGACTGATGTGAAATG 12000  
 R W R A S Y \* S L P N S I K I D \* C E M  
 G G V P V I E V S Q I Q S K L T D V K C  
 \* V A C Q L L K S P K F N Q N \* L M \* N

12001 TGCTAATGTTGTTTTGTTAAATGTTTACAGCATTTCATGCTTCTAATCTAAGTT 12060  
 C \* C C F V K L F T A F A C C F \* F \* V  
 A N V V L L N C L Q H L H V A S N S K L  
 V L M L F C \* I V Y S I C M L L L I L S

12061 GTGGCAGTATTGTAGTGTTTTACATAATGAAATACTATCTACTTCAGATTTGAGTGTAGC 12120  
 V A V L \* C F T \* \* N T I Y F R F E C S  
 W Q Y C S V L H N E I L S T S D L S V A  
 C G S I V V F Y I M K Y Y L L Q I \* V \*

12121 TTTTGATAAGCTTGCTCAATTATTGATTGTTTTATTGCGCAATCCTGCTGCAGTTGATAC 12180  
 F \* \* A C S I I D C F I R Q S C C S \* Y  
 F D K L A Q L L I V L F A N P A A V D T  
 L L I S L L N Y \* L F Y S P I L L Q L I

12181 TAAGTGTCTTGCAAGTATAGATGAAGTTAGCGATGATTATGTTCAAGATAGTACCGTTTT 12240  
 \* V S C K Y R \* S \* R \* L C S R \* Y R F  
 K C L A S I D E V S D D Y V Q D S T V L  
 L S V L Q V \* M K L A M I M F K I V P F

12241 GCAGGCTTTGCAAAGTGAGTTTGTAATATGGCTAGTTTTGTTGAATATGAAGTCGCAAA 12300  
 A G F A K \* V C K Y G \* F C \* I \* S R K  
 Q A L Q S E F V N M A S F V E Y E V A K  
 C R L C K V S L \* I W L V L L N M K S Q

12301 GAAAAATTTGGCTGATGCTAAAAATAGTGGTTCTGTTAATCAACACAGATAAAACAGTT 12360  
 E K F G \* C \* K \* W F C \* S T T D K T V  
 K N L A D A K N S G S V N Q Q Q I K Q L  
 R K I W L M L K I V V L L I N N R \* N S

12361 AGAAAAAGCATGTAATATAGCTAAGTCTGTGTATGAACGTGATAAAGCTGTAGCTCGCAA 12420  
 R K S M \* Y S \* V C V \* T \* \* S C S S Q  
 E K A C N I A K S V Y E R D K A V A R K  
 \* K K H V I \* L S L C M N V I K L \* L A

FIG. 2 CONT.

25/201

12421 ACTTGAACGTATGGCAGACCTAGCACTTACTAACATGTATAAAGAGGCTCGGATTAATGA 12480  
 T \* T Y G R P S T Y \* H V \* R G S D \* \*  
 L E R M A D L A L T N M Y K E A R I N D  
 N L N V W Q T \* H L L T C I K R L G L M

12481 TAAGAAGAGTAAAGTTGTTCCGCTTTGAGACAATGCTTTTTAGCATGGTTCGTAAATT 12540  
 \* E E \* S C F R F A D N A F \* H G S \* I  
 K K S K V V S A L Q T M L F S M V R K L  
 I R R V K L F P L C R Q C F L A W F V N

12541 GGATAATCAGGCTTTAAATTCATCTGGATAATGCTGTTAAAGTTGTGTACCTTTGAG 12600  
 G \* S G F K F Y S G \* C C \* R L C T F E  
 D N Q A L N S I L D N A V K G C V P L S  
 W I I R L \* I L F W I M L L K V V Y L \*

12601 TGCTATTCAGCATTGGCTGCTAATACTTTAACTATAGTAATACCAGATAAACAGTTTT 12660  
 C Y S S I G C \* Y F N Y S N T R \* T S F  
 A I P A L A A N T L T I V I P D K Q V F  
 V L F Q H W L L I L \* L \* \* Y Q I N K F

12661 TGATAAAGTTGTTGATAATGTTTATGTTACATATGCTGGTAGTGTATGGCATATACAGAC 12720  
 \* \* S C \* \* C L C Y I C W \* C M A Y T D  
 D K V V D N V Y V T Y A G S V W H I Q T  
 L I K L L I M F M L H M L V V Y G I Y R

12721 TGTTCAAGATGCTGATGGTATTAATAAACAGTTAACTGATATTAGTGTGATTCTAATTG 12780  
 C S R C \* W Y \* \* T V N \* Y \* C \* F \* L  
 V Q D A D G I N K Q L T D I S V D S N W  
 L F K M L M V L I N S \* L I L V L I L I

12781 GCCTCTGTTATCATTCGGAACAGGTATAATGAAGTTGCTAATGCTGTTATGCAGAATAA 12840  
 A S C Y H C E Q V \* \* S C \* C C Y A E \*  
 P L V I I A N R Y N E V A N A V M Q N N  
 G L L L S L R T G I M K L L M L L C R I

12841 TGAGTTGATGCCTCATAAATTAAAATACAAGTTGTTAATAGTGGTTCTGATATGAATTG 12900  
 \* V D A S \* I K N T S C \* \* W F \* Y E L  
 E L M P H K L K I Q V V N S G S D M N C  
 M S \* C L I N \* K Y K L L I V V L I \* I

12901 TAATATTCCTACTCAATGTTATTATAAATAATGGTAGTAGGTTAGATACTTTATGCTGT 12960  
 \* Y S Y S M L L \* \* W \* \* W \* N S L C C  
 N I P T Q C Y Y N N G S S G R I V Y A V  
 V I F L L N V I I I M V V V V E \* F M L

FIG. 2 CONT.

26/201

12961 TCTTAGTGATGTTGATGGTCTTAAGTATACTAAGATAATGAAAGATGATGGAAATTGTGT 13020  
 S \* \* C \* W S \* V Y \* D N E R \* W K L C  
 L S D V D G L K Y T K I M K D D G N C V  
 F L V M L M V L S I L R \* \* K M M E I V

13021 TGTTTTAGAGCPTGATCCCTCCTTGTAAATTTTCTATACAAGATGTTAAGGGACTTAAAT 13080  
 C F R A \* S S L \* I F Y T R C \* G T \* N  
 V L E L D P P C K F S I Q D V K G L K I  
 L F \* S L I L L V N F L Y K M L R D L K

13081 TAAGTATCTTTATTTATTAAGGATGTAACACTTTAGCTAGAGGGTGGGTTGTGGTAC 13140  
 \* V S L F Y \* R M \* H F S \* R V G C W Y  
 K Y L Y F I K G C N T L A R G W V V G T  
 L S I F I L L K D V T L \* L E G G L L V

13141 TTTATCTTCAACAATTAGATTGCAGGCTGGTGTGCTACTGAGTATGCAGCTAATTCTTC 13200  
 F I F N N \* I A G W C C Y \* V C S \* F F  
 L S S T I R L Q A G V A T E Y A A N S S  
 L Y L Q Q L D C R L V L L L S M Q L I L

13201 TATACTTTCATTATGTGCATTTTCTGTAGATCCCTAAGAAAACCTATTTAGATTATATACA 13260  
 Y T F I M C I F C R S \* E N L F R L Y T  
 I L S L C A F S V D P K K T Y L D Y I Q  
 L Y F H Y V H F L \* I L R K L I \* I I Y

13261 ACRAAGGTGGTGTACCTATAATTAATTGTGTTAAAATGCTCTGTGATCATGCTGGTACTGG 13320  
 T R W C T Y N \* L C \* N A L \* S C W Y W  
 Q G G V P I I N C V K M L C D H A G T G  
 N K V V Y L \* L I V L K C S V I M L V L

13321 TATGGCCATTACTATTAAACCTGAGGCTACTATTAACCAAGATTCCTTATGGTGGTGCCTC 13380  
 Y G H Y Y \* T \* G Y Y \* P R F L W W C L  
 M A I T I K P E A T I N Q D S Y G G A S  
 V W P L L L N L R L L L T K I L M V V P

13381 AGTTTGTATTTATTGCCGTGCACGTGTAGAGCATCCAGATGTAGATGGTATATGTAATTT 13440  
 S L Y L L P C T C R A S R C R W Y M \* I  
 V C I Y C R A R V E H P D V D G I C K L  
 Q F V F I A V H V \* S I Q M \* M V Y V N

13441 ACGTGGTAAATTTGTACAAGTCCCTTTGGGTATAAAGATCCTATCTTTATGTGTTAAC 13500  
 T W \* I C T S P F G Y K R S Y S L C V N  
 R G K F V Q V P L G I K D P I L Y V L T  
 Y V V N L Y K S L W V \* K I L F F M C \*

FIG. 2 CONT.



27/201

13501 ACATGATGTTTGTCAAGTCTGTGGTTTTTGGAGAGATGGCAGTTGTTCTGTGTAGGTTTC 13560  
 T \* C L S S L W F L E R W Q L F L C R F  
 H D V C Q V C G F W R D G S C S C V G S  
 H M M F V K S V V F G E M A V V P V \* V

13561 AAGTGTGCGCTGTCAATCTAAAGATTTAAATTTTTTAAACGGGTTGCGGGTACTAGTGTG 13620  
 K C R C S I \* R F K F F K R V R G T S V  
 S V A V Q S K D L N F L N G F G V L V \*  
 Q V S L F N L K I \* I F \* T G S G Y \* C

13621 AATGCCCGGCTAGTACCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAGGGCATT 13680  
 N A R L V P C A S G L S T D V Q L R A F  
 M P G \* Y P V L V V Y L L M F N \* G H L  
 E C P A S T L C \* W F I Y \* C S I K G I

13681 GACATTTGTAATACCAATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGT 13740  
 D I C N T N R A G I G L Y Y K V N C C R  
 T F V I P I E L V \* V Y I I K \* I V A V  
 \* H L \* Y Q \* S W Y R F I L \* S E L L P

13741 TTTGAGCGTATAGATGACGACGGTAATAAATGGATAAGTTCTTTGTTGTCAAAGAAGT 13800  
 F Q R I D D D G N K L D K F F V V K R T  
 F S V \* M T T V I N W I S S L L S K E L  
 F S A Y R \* R R \* \* I G \* V L C C Q K N

13801 AATTTAGAAGTTTATAATAAAGAGAAAAGTATTATGAGTTGACTAAAAGTGTGGTGT 13860  
 N L E V Y N K E K T Y Y E L T K S C G V  
 I \* K F I I K R K L I M S \* L K V V V L  
 \* F R S L \* \* R E N L L \* V D \* K L W C

13861 GTGGCTGAACATGATTTCTTTACATTTGATATTGATGGTAGTCGGTGCCACATATAGTT 13920  
 V A E H D F F T F D I D G S R V P H I V  
 W L N M I S L H L I L M V V A C H I \* F  
 C G \* T \* F L Y I \* Y \* W \* S R A T Y S

13921 CGTAGGAATCTTCAAAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCAATTTTAT 13980  
 R R N L S K Y T M L D L C Y A L R H F D  
 V G I F Q S I L C \* I F A M H C V I L I  
 S \* E S F K V Y Y V R S L L C I A S F \*

13981 CGTAATGATTGTTCAATATTGTGTGAAATTTCTTTGTGAGTATGCTGATTGTRAAGAATCC 14040  
 R N D C S I L C E I L C E Y A D C K E S  
 V M I V Q Y C V K F F V S M L I V K N P  
 S \* \* L F N I V \* N S L \* V C \* L \* R I

FIG. 2 CONT.

28/201

14041 TACTTTTCTAAGAAAGATTGGGTATGATTTTGTGAAAATCCTGATATTATTAATATATAT 14100  
 Y F S K K D W Y D F V E N P D I I N I Y  
 T F L R K I G M I L L K I L I L L I Y I  
 L L F \* E R L V \* F C \* K S \* Y Y \* Y I

14101 AAAAAATTAGGCCCTATTTTTAATAGAGCTTTACTTAATACTGTCAATTTTGCAGACACC 14160  
 K K L G P I F N R A L L N T V I F A D T  
 K N \* A L F L I E L Y L I L S F L Q T P  
 \* K I R P Y F \* \* S F T \* Y C H F C R H

14161 TTAGTTGAAGTAGGTTTGTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAA 14220  
 L V E V G L V G V L T L D N Q D L Y G Q  
 \* L K \* V \* L V F \* L \* I T K I C M V N  
 L S \* S R F S W C F N F R \* P R F V W S

14221 TGGTATGATTTTGGTGATTTTATACAAACAGCCCCAGGGTTGGTGTGGCAGTTGCAGAT 14280  
 W Y D F G D F I Q T A P G F G V A V A D  
 G M I L V I L Y K Q P Q G L V W Q L Q I  
 M V \* F W \* F Y T N S P R V W C G S C R

14281 TCTTACTATTCTTATATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTA 14340  
 S Y Y S Y M M P M L T M C H V L D C E L  
 L T I L I \* C L C \* L C V M Y \* I V N Y  
 F L L F L Y D A Y V D Y V S C I R L \* I

14341 TTTGTTAATGATAGTTATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTACAAG 14400  
 F V N D S Y R Q F D L V Q Y D F T D Y K  
 L L M I V I D N S I L Y S M I L L I T S  
 I C \* \* \* L \* T I R S C T V \* F Y \* L Q

14401 TTAGAGTTGTTTAAATAAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTG 14460  
 L E L F N K Y F K Y W G M K Y H P N T V  
 \* S C L I S I L S I G V \* S I I L I L W  
 V R V V \* \* V F \* V L G Y E V S S \* Y C

14461 GATTGTGATAATGATAGGTGTATTATTCATTGTGCTAATTTTAAATACTATTAGTATG 14520  
 D C D N D R C I I H C A N F N I L F S M  
 I V I M I G V L F I V L I L I Y Y L V W  
 G L \* \* \* \* V Y Y S L C \* F \* Y T I \* Y

14521 GTTTTACCTAATACTTGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCG 14580  
 V L P N T C F G P L V R Q I F V D G V P  
 F Y L I L V L V P L L D K F L \* M V Y R  
 G F T \* Y L F W S P C \* T N F C R W C T

FIG. 2 CONT.

29/201

14581 TTTGTTGTTTCTATTGGTTACCAITACAAGAGTTAGGTGTAGTTATGAACTTAGATGTT 14640  
 F V V S I G Y H Y K E L G V V M N L D V  
 L L F L L V T I T K S \* V \* L \* T \* M L  
 V C C F Y W L P L Q R V R C S Y E L R C

14641 GACACACACCGTTATCGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCT 14700  
 D T H R Y R L S L K D L L L Y A A D P A  
 T H T V I V C L L K I Y F F M Q Q I L L  
 \* H T P L S F V S \* R F T S L C S R S C

14701 ATGCACGTTGCATCTGCTAGTGTCTGCTTGATTACGAACTTGTGTTTTAGGTAGCT 14760  
 M H V A S A S A L L D L R T C C F S V A  
 C T L H L L V L C L I Y E L V V L V \* L  
 Y A R C I C \* C S A \* F T N L L F \* C S

14761 GCCATTACAAGTGGTATAAAATTTCAAAGTGTAAACCAGGTAACCTTAACCAAGACTTT 14820  
 A I T S G I K F Q T V K P G N F N Q D F  
 P L Q V V \* N F K L \* N Q V T L T K T F  
 C H Y K W Y K I S N C K T R \* L \* P R L

14821 TACGAGTTTGTAAAAGTAAAGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACAT 14880  
 Y E F V K S K G L F K E G S T V D L K H  
 T S L L K V K A C L K R V V Q L I \* N I  
 L R V C \* K \* R L V \* R G \* Y S \* F E T

14881 TTTTCTTTACTCAAGATGGTAAATGCTGCAATTAAGTATTATAATTATTATAAGTATAAT 14940  
 F F F T Q D G N A A I T D Y N Y Y K Y N  
 F S L L K M V M L Q L L I I I I I S I I  
 F F L Y S R W \* C C N Y \* L \* L L \* V \*

14941 TTACCTACTATGGTTGATATTAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATAT 15000  
 L P T M V D I K Q L L F V L E V V Y K Y  
 Y L L W L I L S S Y C L Y \* K L F I N I  
 F T Y Y G \* Y \* A V I V C I R S C L \* I

15001 TTTGAAATTTATGATGGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGAT 15060  
 F E I Y D G G C I P A S Q V I V N N Y D  
 L K F M M V V V Y Q H H K L L L I I M I  
 F \* N L \* W W L Y T S I T S Y C \* \* L \*

15061 AAAAGTGTGGTTATCCATTTAATAAATTTGCTAAAGCCAGACTTTATTATGAGGCATTA 15120  
 K S A G Y P F N K F G K A R L Y Y E A L  
 K V L V I H L I N L V K P D F I M R H Y  
 \* K C W L S I \* \* I W \* S Q T L L \* G I

FIG. 2 CONT.

30/201

15121 TCATTTGAGGAACAGAATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTA 15180  
 S F E E Q N E I Y A Y T K R N V L P T L  
 H L R N R M K F M H I L N V M F C P P \*  
 I I \* G T E \* N L C I Y \* T \* C S A H L

15181 ACTCAAATGAATTTAAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGT 15240  
 T Q M N L K Y A I S A K N R A R T V A G  
 L K \* I \* N M L S V L R I E L A L \* Q V  
 N S N E F K I C Y Q C \* E \* S S H C S R

15241 GTTTCTATTCTTAGTACTATGACAGGCCGAATGTTCCATCAAAATGTTTGAAGAGTATA 15300  
 V S I L S T M T G R M F H Q K C L K S I  
 F L F L V L \* Q A E C S I K N V \* R V \*  
 C F Y S \* Y Y D R P N V P S K M F E E Y

15301 GCAGCTACCCGAGGTGTTCTGTTATAGGAACCACTAAATTTATGGTGGTGGGAC 15360  
 A A T R G V P V V I G T T K F Y G G W D  
 Q L P E V F L L L \* E P L N F M V V G T  
 S S Y P R C S C C Y R N H \* I L W W L G

15361 GATATGTTACGTCATCTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTAT 15420  
 D M L R H L I K D V D N P V L M G W D Y  
 I C Y V I L \* R M L T T L F L W V G I I  
 R Y V T S S Y K G C \* Q P C S Y G L G L

15421 CCTAAATGTGATCGTGCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTGGCC 15480  
 P K C D R A M P N I L R I V S S L V L A  
 L N V I V L C Q I F C V L L V V \* F W P  
 S \* M \* S C Y A K Y F A Y C \* \* F S F G

15481 CGCAAACATGAATTTTGTGTTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGT 15540  
 R K H E F C C S H G D R F Y R L A N E C  
 A N M N F V V H M V I D F I A L R M N V  
 P Q T \* I L L F T W \* \* I L S P C E \* M

15541 GCTCAAGTTTGTAGTGAATAGTTATGTGTGGCGGTTGCTATTATGTTAAGCCTGGTGGT 15600  
 A Q V L S E I V M C G G C Y Y V K P G G  
 L K F \* V K \* L C V A V A I M L S L V V  
 C S S F E \* N S Y V W R L L L C \* A W W

15601 ACTAGCAGTGGTGATGCAACTACTGCTTTTGCTAATTCGTTTTTAATATATGTCAGGCT 15660  
 T S S G D A T T A F A N S V F N I C Q A  
 L A V V M Q L L L L L I L F L I Y V R L  
 Y \* Q W \* C N Y C F C \* F C F \* Y M S G

FIG. 2 CONT.

31/201

15661 GTTACTGCTAATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGT 15720  
 V T A N V C S L M A C N G H K I E D L S  
 L L L M F V L L W P V M A I R L K I \* V  
 C Y C \* C L F S Y G L \* W P \* D \* R F K

15721 ATACGCAATTTACAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTAT 15780  
 I R N L Q K R L Y S N V Y R T D Y V D Y  
 Y A I Y K N A Y T L M F I V Q I M L I I  
 Y T Q F T K T L I L \* C L S Y R L C \* L

15781 ACATTTGTTAATGAGTATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGT 15840  
 T F V N E Y Y E F L C K H F S M M I L S  
 H L L M S I M N F Y V S I L V \* \* F \* V  
 Y I C \* \* V L \* I F M \* A F \* Y D D F E

15841 GATGATGGTGTGTCTGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATA 15900  
 D D G V V C Y N S D Y A S K G Y I A N I  
 M M V L S V I T L I M L V R V I \* L I \*  
 \* \* W C C L L \* L \* L C \* \* G L Y S \* Y

15901 AGTGTTTTCAACAAGTTTGTACTATCAGAATAATGCTTTTATGCTGAATCTAAATGT 15960  
 S V F Q Q V L Y Y Q N N V F M S E S K C  
 V F F N K F C T I R I M S L C L N L N V  
 K C F S T S F V L S E \* C L Y V \* I \* M

15961 TGGGTGAAAATGATATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTA 16020  
 W V E N D I T N G P H E F C S Q H T M L  
 G L K M I L L M V L M N F V P N I L C \*  
 L G \* K \* Y Y \* W S S \* I L F P T Y Y V

16021 GPTAAGATAGATGGTGATTATGTTTATTACCATATCCAGATCCTTCTAGAATTTTAGGA 16080  
 V K I D G D Y V Y L P Y P D P S R I L G  
 L R \* M V I M F I Y H I Q I L L E F \* E  
 S \* D R W \* L C L F T I S R S F \* N F R

16081 GCTGGTTGTTTGTGATGATTTATGAAGACTGACAGTGTCTTTTGATAGACGCGCTTT 16140  
 A G C F V D D L L K T D S V L L I E R F  
 L V V L L M I Y \* R L T V F F \* \* S A L  
 S W L F C \* \* F I E D \* Q C S F D R A L

16141 GTAAGTCTAGCTATAGATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAA 16200  
 V S L A I D A Y P L V H H E N E E Y Q K  
 \* V \* L \* M L T L \* Y I M K M K N T K K  
 C K S S Y R C L P F S T S \* K \* R I P K

FIG. 2 CONT.

32/201

16201 GTCTTTCGTGTATATTTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATC 16260  
V F R V Y L E Y I K K L Y N D L G T Q I  
S F V Y I \* N I \* K N C I M I L V L R S  
S L S C I F R I Y K K T V \* \* S W Y S D

16261 TTAGATAGTTATAGTGTATTTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCA 16320  
L D S Y S V I L S T C D G L K F T E E S  
\* I V I V L F \* V L V M V \* S L L K N H  
L R \* L \* C Y F K Y L \* W F K V Y \* R I

16321 TTTTACAAGAATATGTATTTAAAAAGTCCCGTGCAGAGTGTAGGTGCATGCCGTTGTT 16380  
F Y K N M Y L K S A V M Q S V G A C V V  
F T R I C I \* K V P \* C R V \* V H A L F  
I L Q E Y V F K K C R D A E C R C M R C

16381 TGTTCATCACAAACTTCTTTGCGTTGTGGCAGTTGTATACGTAAGCCTTTGTTATGTTGT 16440  
C S S Q T S L R C G S C I R K P L L C C  
V H H K L L C V V A V V Y V S L C Y V V  
L F I T N F F A L W Q L Y T \* A F V M L

16441 AAATGTTGTTATGACCATGTTATGGCAACTAATCATAAATATGTTTTGAGTGTCTCACCT 16500  
K C C Y D H V M A T N H K Y V L S V S P  
N V V M T M L W Q L I I N M F \* V S H L  
\* M L L \* P C Y G N \* S \* I C F E C L T

16501 TACGTTTGAATGCACCTAAGTGTGATGTGAGTGTGATGCACCAAAATATATTTGGGCGGT 16560  
Y V C N A P N C D V S D V T K L Y L G G  
T F V M H L T V M \* V M S P N Y I W A V  
L R L \* C T \* L \* C E \* C H Q I I F G R

16561 ATGTCTTACTATTGTGAAAACCATAAACCCTTATTCATTTAAGTTAGTTATGAAATGGT 16620  
M S Y Y C E N H K P H Y S F K L V M N G  
C L T I V K T I N P I I H L S \* L \* M V  
Y V L L L \* K P \* T P L F I \* V S Y E W

16621 ATGGTCTTTGGTTTGTATAAACAATCTTGCACGGGTTACCTTATATAGATGATTTTAAAT 16680  
M V F G L Y K Q S C T G S P Y I D D F N  
W S L V C I N N L A R V H L I \* M I L I  
Y G L W F V \* T I L H G F T L Y R \* F \*

16681 AAGATAGCTAGTTGTAATGGACAGAAGTTGATGATTATGTTCTGGCAAATGAGTGTATT 16740  
K I A S C K W T E V D D Y V L A N E C I  
R \* L V V N G Q K L M I M F W Q M S V L  
\* D S \* L \* M D R S \* \* L C S G K \* V Y

FIG. 2 CONT.

33/201

16741 GAACGTTTAAAGTTATTTGCTGCAGAACTCAAAAAGGCAACTGAAGAGGCTTTTAAACAA 16800  
 E R L K L F A A E T Q K A T E E A F K Q  
 N V \* S Y L L Q K L K R Q L K R L L N K  
 \* T F K V I C C R N S K G N \* R G F \* T

16801 AGCTATGCTTCTGCTACCATTCAAGAGATTGTTAGTGATAGAGAAGTTATTTTGTGTTGG 16860  
 S Y A S A T I Q E I V S D R E V I L C W  
 A M L L L P F K R L L V I E K L F C V G  
 K L C F C Y H S R D C \* \* \* R S Y F V L

16861 GAGACAGGTAAGTTAAACCACCACTTAATAAAAATTATGTTTTACAGGCTACCATTTT 16920  
 E T G K V K P P L N K N Y V F T G Y H F  
 R Q V K L N H H L I K I M F S Q A T I L  
 G D R \* S \* T T T \* \* K L C F H R L P F

16921 ACTAGTACTGGTAAGACAGTTTTAGGTGAGTATGTTTTGATAAAAGTGAATTAACAA 16980  
 T S T G K T V L G E Y V F D K S E L T N  
 L V L V R Q F \* V S M F L I K V N \* L T  
 Y \* Y W \* D S F R \* V C F \* \* K \* I N \*

16981 GGTGTGATTACCAGCGCTACAACACTTATAAACTTTCTATAGGTGATGTTTTGTTTTA 17040  
 G V Y Y R A T T T Y K L S I G D V F V L  
 V C I T A L Q L L I N F L \* V M F L F \*  
 R C V L P R Y N Y L \* T F Y R \* C F C F

17041 ACATCACATTCTGTAGCTAGTTTTAAGTGCACCTACACTTGTCCCACAAGAGAACTATGCT 17100  
 T S H S V A S L S A P T L V P Q E N Y A  
 H H I L \* L V \* V H L H L S H K R T M L  
 N I T F C S \* F K C T Y T C P T R E L C

17101 AGTATAAGATTTTCTAGTGTTTATAGTGTCCATTGGTGTTCAAAATAATGTTGCTAAT 17160  
 S I R F S S V Y S V P L V F Q N N V A N  
 V \* D F L V F I V F H W C F K I M L L I  
 \* Y K I F \* C L \* C S I G V S K \* C C \*

17161 TATCAGCACATTGGAATGAAACGTTATTGCACCTGTTCAAGTCCCCCTGGTACGGGAAAG 17220  
 Y Q H I G M K R Y C T V Q G P P G T G K  
 I S T L E \* N V I A L F K V P L V R E S  
 L S A H W N E T L L H C S R S P W Y G K

17221 TCTCATCTTGTATAGGTCTAGCTGTTTATTACTACACAGCACGGTGTAGTTTATACTGCT 17280  
 S H L A I G L A V Y Y Y T A R V V Y T A  
 L I L L \* V \* L F I T T Q H V \* F I L L  
 V S S C Y R S S C L L L H S T C S L Y C

FIG. 2 CONT.

34/201

17281 GCTAGTCATGCTGCTGTAGATGCATTGTGTGAAAAAGCTTATAAGTTTTTAAATATTAAC 17340  
 A S H A A V D A L C E K A Y K F L N I N  
 L V M L L \* M H C V K K L I S F \* I L T  
 C \* S C C C R C I V \* K S L \* V F K Y \*

17341 GATTGTACACGTATTATTCCTGCTAAAGTTCGTGTAGATTGTTATGATAAGTTTAAATTT 17400  
 D C T R I I P A K V R V D C Y D K F K I  
 I V H V L F L L K F V \* I V M I S L K L  
 R L Y T Y Y S C \* S S C R L L \* \* V \* N

17401 AATGATACCACTTGTAAAGTATGTTTTTACCACAATAAATGCATTACCAGAGTTGGTTACA 17460  
 N D T T C K Y V F T T I N A L P E L V T  
 M I P L V S M F L P Q \* M H Y Q S W L Q  
 \* \* Y H L \* V C F Y H N K C I T R V G Y

17461 GATATTGTTGTTGTTGATGAAGTTAGTATGCTTACTAATTATGAAATTGCTGTGTTATAAAT 17520  
 D I V V V D E V S M L T N Y E L S V I N  
 I L L L L M K L V C L L I M N C L L \* M  
 R Y C C C \* \* S \* Y A Y \* L \* I V C Y K

17521 GCTCGTATTAAGCTAAACATTATGTATATATTGGAGATCCTGCTCAATTACCTGCACCA 17580  
 A R I K A K H Y V Y I G D P A Q L P A P  
 L V L K L N I M Y I L E I L L N Y L H H  
 C S Y \* S \* T L C I Y W R S C S I T C T

17581 CGTGTGCTGTTGAGCAAGGTTCTTTAGAACCTAGGCACITCAATTCATTACTAAAATA 17640  
 R V L L S K G S L E P R H F N S I T K I  
 V C C \* A R V L \* N L G T S I L L L K \*  
 T C A V E Q G F F R T \* A L Q F Y Y \* N

17641 ATGTGTTGTTTAGGTCCTGATATCTTTTTGGGAAATGTTATAGGTGTCCTAAAGAAATT 17700  
 M C C L G P D I F L G N C Y R C P K E I  
 C V V \* V L I S F W E I V I G V L K K L  
 N V L F R S \* Y L F G K L L \* V S \* R N

17701 GTAGAACTGTTTCAGCATTGGTTTATGATAATAAACTCAAGGCTAAAAATGATAATAGT 17760  
 V E T V S A L V Y D N K L K A K N D N S  
 \* K L F Q H W F M I I N S R L K M I I V  
 C R N C F S I G L \* \* \* T Q G \* K \* \* \*

17761 TCATTATGTTTTAAAGTATATTTTTAAGGGACAGACAACACATGAGAGTTCAGTGCTGTA 17820  
 S L C F K V Y F K G Q T T H E S S S A V  
 H Y V L K Y I L R D R Q H M R V Q V L \*  
 F I M F \* S I F \* G T D N T \* E F K C C

FIG. 2 CONT.



35/201

17821 AATATTCAACAGATATATCTAATTAGTAAATTTTAAAGCTAATCCAGTTTGGGAATAGT 17880  
 N I Q Q I Y L I S K F L K A N P V W N S  
 I F N R Y I \* L V N F \* K L I Q F G I V  
 K Y S T D I S N \* \* I F K S \* S S L E \*

17881 GCTGTTTTATTAGTCCTTATAATAGTCAGAATTATGTTGCTAAGCGTGTTTTAGGTGTT 17940  
 A V F I S P Y N S Q N Y V A K R V L G V  
 L F L L V L I I V R I M L L S V F \* V F  
 C C F Y \* S L \* \* S E L C C \* A C F R C

17941 CAAACACAAACTGTAGATTCTGCTCAAGGTTCCGGAATATGATTATGTTATATATTCACAA 18000  
 Q T Q T V D S A Q G S E Y D Y V I Y S Q  
 K H K L \* I L L K V R N M I M L Y I H K  
 S N T N C R F C S R F G I \* L C Y I F T

18001 ACAGCAGAAACAGCCCATTCTGTTAATGTTAATCGATTATGTTGCCATAACTAGAGCC 18060  
 T A E T A H S V N V N R F N V A I T R A  
 Q Q K Q P I L L M L I D L M L P \* L E P  
 N S R N S P F C \* C \* S I \* C C H N \* S

18061 AAGAAGGGCAITTTTTGTGTTATGAGTAATATGCAATTATTTGAATCTCTTAATTTTATT 18120  
 K K G I F C V M S N M Q L F E S L N F I  
 R R A F F V L \* V I C N Y L N L L I L L  
 Q E G H F L C Y E \* Y A I I \* I S \* F Y

18121 ACTCTACCTTTAGATAAAATTCAAAATCAAACCTTACCTCGTTTGCATTGCACAACATAAT 18180  
 T L P L D K I Q N Q T L P R L H C T T N  
 L Y L \* I K F K I K L Y L V C I A Q L I  
 Y S T F R \* N S K S N F T S F A L H N \*

18181 CTTTTTAAAGATTGTAGTAAAAGTTGCTTAGGTTATCATCCAGCGCATGCCCCCTCATT 18240  
 L F K D C S K S C L G Y H P A H A P S F  
 F L K I V V K V A \* V I I Q R M P P H F  
 S F \* R L \* \* K L L R L S S S A C P L I

18241 TTAGCAGTTGATGATAAATATAAGGTTAATGAAAATTTGGCTGTRAATTTAAATATTTGT 18300  
 L A V D D K Y K V N E N L A V N L N I C  
 \* Q L M I N I R L M K I W L \* I \* I F V  
 F S S \* \* \* I \* G \* \* K F G C K F K Y L

18301 GAACCTGTTTTAACATATTCTCGTTAATATCTCTTATGGGTTTTAATTAGATTGACT 18360  
 E P V L T Y S R L I S L M G F K L D L T  
 N L F \* H I L V \* Y L L W V L N \* I \* L  
 \* T C F N I F S F N I S Y G F \* I R F D

FIG. 2 CONT.

36/201

18361 CTTGATGGTTATTTCTAAATTGTTTATTACTAAAGATGAAGCCATTAAACGTGTTAGAGGT 18420  
 L D G Y S K L F I T K D E A I K R V R G  
 L M V I L N C L L L K M K P L N V L E V  
 S \* W L F \* I V Y Y \* R \* S H \* T C \* R

18421 TGGGTTGGTTTTGATGTTGAGGGCGCTCATGCTACTCGCGAAAACATTGGAACAACTTT 18480  
 W V G F D V E G A H A T R E N I G T N F  
 G L V L M L R A L M L L A K T L E Q T F  
 L G W F \* C \* G R S C Y S R K H W N K L

18481 CCACTGCAAAATAGGTTTTTCAACTGGTGTGGATTTTGTAGTTGAGCTACTGGCTTATTT 18540  
 P L Q I G F S T G V D F V V E A T G L F  
 H C K \* V F Q L V W I L \* L K L L A Y L  
 S T A N R F F N W C G F C S \* S Y W L I

18541 GCTGAGAGAGATTGTTATACTTTTAAAAAACTGTAGCTAAAGCTCCTCCTGGTGAAAAA 18600  
 A E R D C Y T F K K T V A K A P P G E K  
 L R E I V I L L K K L \* L K L L L V K N  
 C \* E R L L Y F \* K N C S \* S S S W \* K

18601 TTTAAACATTTAATACCCCTTATGTCAAAGGTCAAAGTGGGATATTGTTAGAAATAGA 18660  
 F K H L I P L M S K G Q K W D I V R I R  
 L N I \* Y P L C Q K V K S G I L L E L E  
 I \* T F N T P Y V K R S K V G Y C \* N \*

18661 ATTGTTCAAATGTTATCTGATTATCTTTTAGACCTTCTGATAGTGTAGTATTATTACT 18720  
 I V Q M L S D Y L L D L S D S V V F I T  
 L F K C Y L I I F \* T F L I V \* Y L L L  
 N C S N V I \* L S F R P F \* \* C S I Y Y

18721 TGGTCTGCCAGTTTTGAACTTACTTGTTTAAGGTATTTTGCTAAATTAGGCAGAGAGCTT 18780  
 W S A S F E L T C L R Y F A K L G R E L  
 G L P V L N L L V \* G I L L N \* A E S L  
 L V C Q F \* T Y L F K V F C \* I R Q R A

18781 AATTGTAATGTGTCTTAATCGTGTACATGCTACAATCTAGAACTGTTATTATGGT 18840  
 N C N V C S N R A T C Y N S R T G Y Y G  
 I V M C V L I V L H A T I L E L V I M V  
 \* L \* C V F \* S C Y M L Q F \* N W L L W

18841 TGTGGCGCCATAGTTATACTTGTGATTATGTTATAATCCACTTATTGTAGATATACAA 18900  
 C W R H S Y T C D Y V Y N P L I V D I Q  
 V G A I V I L V I M C I I H L L \* I Y N  
 L L A P \* L Y L \* L C V \* S T Y C R Y T

FIG. 2 CONT.

37/201

18901 CAGTGGGGTTATACAGGTTCTTTAACTAGTAATCAGCATATAAATTTGTAATGTACATAAA 18960  
 Q W G Y T G S L T S N H D I I C N V H K  
 S G V I Q V L \* L V I T I \* F V M Y I K  
 T V G L Y R F F N \* \* S R Y N L \* C T \*

18961 GGTGCACATGTTGCCGTCAGCTGATGCAATTATGACTCGTTGTTAGCAATCTATGATTGT 19020  
 G A H V A S A D A I M T R C L A I Y D C  
 V H M L R Q L M Q L \* L V V \* Q S M I V  
 R C T C C V S \* C N Y D S L F S N L \* L

19021 TTTTGTAATCTGTTAATGGAATTTAGAGTATCCAATAATTTCTAATGAGGTCAGTATA 19080  
 F C K S V N W N L E Y P I I S N E V S I  
 F V N L L I G I \* S I Q \* F L M R S V \*  
 F L \* I C \* L E F R V S N N F \* \* G Q Y

19081 AATACATCTTGTAGGTTATTCAGCGTGTCTGCTTAAAGCTGCCATGCTATGTAATAGA 19140  
 N T S C R L L Q R V M L K A A M L C N R  
 I H L V G Y C S V S C L K L P C Y V I D  
 K Y I L \* V I A A C H A \* S C H A M \* \*

19141 TACAACCTATGTTATGACATAGGCAATCCTAAAGGTTTAGCTTGTGTCAAAGATTATGAA 19200  
 Y N L C Y D I G N P K G L A C V K D Y E  
 T T Y V M T \* A I L K V \* L V S K I M N  
 I Q L M L \* H R Q S \* R F S L C Q R L \*

19201 TTTAAATTTTATGATGCTTTTCCTGTAGCCAGTCTGTTAAACAGTTATTTTATGCTAT 19260  
 F K F Y D A F P V A K S V K Q L F Y V Y  
 L N F M M L F L \* P S L L N S Y F M S M  
 I \* I L \* C F S C S Q V C \* T V I L C L

19261 GATGTGCATAAAGATAATTTTAAAGATGGTTTATGTATGTTTGAATGTAATGTTGAT 19320  
 D V H K D N F K D G L C M F W N C N V D  
 M C I K I I L K M V Y V C F G I V M L I  
 \* C A \* R \* F \* R W F M Y V L E L \* C \*

19321 AAATATCCATCTAATCAATGTTTGTAGATTTGACACTCGAGTGTAAATAAATTAAC 19380  
 K Y P S N S I V C R F D T R V L N K L N  
 N I H L I Q L F V D L T L E C \* I N \* T  
 \* I S I \* F N C L \* I \* H S S V K \* I K

19381 CTTCCGGATGTAATGGTGGTAGTTTGTATGTTAATAAACATGCATCCATACTAATCCCT 19440  
 L P G C N G G S L Y V N K H A F H T N P  
 F L D V M V V V C M L I N M H S I L I L  
 P S W M \* W W \* F V C \* \* T C I P Y \* S

FIG. 2 CONT.

38/201

19441 TTTACTAGAACTGTTTTGAAAATCTTAAGCCTATGCCTTTTTTCTATTATTCAGATACG 19500  
 F T R T V F E N L K P M P F F Y Y S D F  
 L L E L F L K I L S L C L F S I I Q I R  
 F Y \* N C E \* K S \* A Y A F F L L F R Y

19501 CCTTGTTGTACGTAGATGGTTTGAATCTAAACAAGTTGATTACGTTCCTTTAAAGAAGC 19560  
 P C V Y V D G L E S K Q V D Y V P L R S  
 L V C T \* M V \* N L N K L I T F L \* E A  
 A L C V R R W F R I \* T S \* L R S F K K

19561 GCCACTTGATCACACGGTGTAAATCTAGGTGGAGCTGTTTGTTCAAAGCATGCTGAAGAA 19620  
 A T C I T R C N L G G A V C S K H A E E  
 P L V S H G V I \* V E L F V Q S M L K N  
 R H L Y H T V \* S R W S C L F K A C \* R

19621 TATTGTAACCTACCTTGAGTCTTATAATATAGTTACTACAGCAGGCTTTACTTTTTGGGTT 19680  
 Y C N Y L E S Y N I V T T A G F T F W V  
 I V T T L S L I I \* L L Q Q A L L F G F  
 I L \* L P \* V L \* Y S Y Y S R L Y F L G

19681 TATAAGAATTTTGATTTTTATAATTTATGGAACACTTTTACTACGTTACAGAGTTTAGAA 19740  
 Y K N F D F Y N L W N T F T T L Q S L E  
 I R I L I F I I Y G T L L L R Y R V \* K  
 L \* E F \* F L \* F M E H F Y Y V T E F R

19741 AACGTAATATATAACTTGGTTAATGTTGGTCATTATGATGGACGTACAGGTGAATTACCT 19800  
 N V I Y N L V N V G H Y D G R T G E L P  
 T \* Y I T W L M L V I M M D V Q V N Y L  
 K R N I \* L G \* C W S L \* W T Y R \* I T

19801 TGTGCTATTATGAATGACAAAGTTGTTGTTAAGATTAATAATGTAGATACTGTATTTTT 19860  
 C A I M N D K V V V K I N N V D T V I F  
 V L L \* M T K L L L R L I M \* I L L F L  
 L C Y Y E \* Q S C C \* D \* \* C R Y C Y F

19861 AAAAATAATACATCATTTCCCTACTAATATAGCTGTTGAATTGTTTACAAAACGTAGTATC 19920  
 K N N T S F P T N I A V E L F T K R S I  
 K I I H H F L L I \* L L N C L Q N V V S  
 \* K \* Y I I S Y \* Y S C \* I V Y K T \* Y

19921 CGGCACCACCTGAACTTAAGATTCTTAGAAATTTGAACATTGATATTTTGTGGAAGCAT 19980  
 R H H P E L K I L R N L N I D I C W K H  
 G T T L N L R F L E I \* T L I F V G S M  
 P A P P \* T \* D S \* K F E H \* Y L L E A

FIG. 2 CONT.

39/201

19981 GTCCTGTGGGATTATGTTAAAGATAGTTTGTGTTTGTAGTTCCACTTATGGTGTGTTGTAAA 20040  
 V L W D Y V K D S L F C S S T Y G V C K  
 S C G I M L K I V C F V V P L M V F V N  
 C P V G L C \* R \* F V L \* F H L W C L \*

20041 TACACAGATTTGAAGTTCATCGAAAATTTGAATATACTTTTGATGGTCGTGACACTGGC 20100  
 Y T D L K F I E N L N I L F D G R D T G  
 T Q I \* S S S K I \* I Y F L M V V T L A  
 I H R F E V H R K F E Y T F \* W S \* H W

20101 GCTTTAGAAGCTTTTAGAAAAGCAAGAATGGTGTGTTTTATTAGTACTGAAAAATTAAGT 20160  
 A L E A F R K A R N G V F I S T E K L S  
 L \* K L L E K Q E M V F L L V L K N \* V  
 R F R S F \* K S K K W C F Y \* Y \* K I K

20161 AGGTTATCAATGATTAAAGGTCGCAACGAGCTGATTTAAATGGTGTGATTGTGGATAAA 20220  
 R L S M I K G P Q R A D L N G V I V D K  
 G Y Q \* L K V R N E L I \* M V \* L W I K  
 \* V I N D \* R S A T S \* F K W C D C G \*

20221 GTTGAGAACTCAAAGTTGAGTTTTGGTTCGCTATGAGAAAAGATGGTGACGATGTTATC 20280  
 V G E L K V E F W F A M R K D G D D V I  
 L E N S K L S F G S L \* E K M V T M L S  
 S W R T Q S \* V L V R Y E K R W \* R C Y

20281 TTCAGCCGACAGACAGCCTATGCTCAAGCCATFACTGGAGCCCACAAGGTAATCTAGGT 20340  
 F S R T D S L C S S H Y W S P Q G N L G  
 S A E Q T A Y A Q A I T G A H K V I \* V  
 L Q P N R Q P M L K P L L E P T R \* S R

20341 GGTAATTGCGCGGTAATGTCATTGGTARTGATGCTTAACACGTTTTACTATCTTTACT 20400  
 G N C A G N V I G N D A L T R F T I F T  
 V I A R V M S L V M M L \* H V L L S L L  
 W \* L R G \* C H W \* \* C S N T F Y Y L Y

20401 CAGAGTCGTATPTGTCAAGTTTTGAACCTCGCTCAGATTTAGAACGGGATTTATTGAT 20460  
 Q S R V L S S F E P R S D L E R D F I D  
 R V V Y C Q V L N L A Q I \* N G I L L I  
 S E S C I V K F \* T S L R F R T G F Y \*

20461 ATGGATGATAATCTGTTTATTGCTAAATATGGTTTTAGAAGACTATGCATTTGATCATATA 20520  
 M D D N L F I A K Y G L E D Y A F D H I  
 W M I I C L L L N M V \* K T M H L I I \*  
 Y G \* \* S V Y C \* I W F R R L C I \* S Y

FIG. 2 CONT.

40/201

20521 GTTTATGGTAGTTTTAACCATAAAGTTATAGGAGGTTTGCATTTGCTTATAGGCTTATTT 20580  
V Y G S F N H K V I G G L H L L I G L F  
F M V V L T I K L \* E V C I C L \* A Y F  
S L W \* F \* P \* S Y R R F A F A Y R L I

20581 CGTAGGAAAAAAATCTAATTTGTTAATTCAGAGTTTTTACAGTATGATTCTAGTATT 20640  
R R K K K S N L L I Q E F L Q Y D S S I  
V G K K N L I C \* F K S F Y S M I L V F  
S \* E K K I \* F V N S R V F T V \* F \* Y

20641 CATTCATATTTTATTACTGATCAGGAGTGTGGTAGTAGTAAGAGTGTGTTGTACAGTTATT 20700  
H S Y F I T D Q E C G S S K S V C T V I  
I H I L L L I R S V V V V R V F V Q L L  
S F I F Y Y \* S G V W \* \* \* E C L Y S Y

20701 GATTTATTATTAGATGATTTTGTTCCTATTGTTAAGTCATTAATTTGAGTTCGTGTTAGT 20760  
D L L L D D E V S I V K S L N L S C V S  
I Y Y \* M I L F L L L S H \* I \* V V L V  
\* F I I R \* F C F Y C \* V I K F E L C \*

20761 AAAGTTGTTAATATTATGTTGATTTTAAAGGATTTTCATTTATGTTGGTGTAAATGAT 20820  
K V V N I N V D F K D F Q F M L W C N D  
K L L I L M L I L R I F N L C C G V M I  
\* S C \* Y \* C \* F \* G F S I Y V V V \* \*

20821 AATAAAATTTAGACTTTTTATCCATAAATGCAAGCCACTAATGATTGGAACCTGGCTAT 20880  
N K I M T F Y P K M Q A T N D W K P G Y  
I K L \* L F I L K C K P L M I G N L A I  
\* \* N Y D F L S \* N A S H \* \* L E T W L

20881 TCTATGCCTGTTTTGTATAAGTATTTGAATGTTCCATTAGAGAGAGTCTCTTTATGGAAT 20940  
S M P V L Y K Y L N V P L E R V S L W N  
L C L F C I S I \* M F H \* R E S L Y G I  
F Y A C F V \* V F E C S I R E S L F M E

20941 TATGGTAAACCTATTAATTTGCCTACAGGCTGATGATGAATGTTGCTAAGTACACTCAA 21000  
Y G K P I N L P T G C M M N V A K Y T Q  
M V N L L I C L Q A V \* \* M L L S T L N  
L W \* T Y \* F A Y R L Y D E C C \* V H S

21001 TTATGTCAGTATTTGAATACTACAACATTAGCTGTTCCCTGTTAATATGCGTGTGTTTACAT 21060  
L C Q Y L N T T T L A V P V N M R V L H  
Y V S I \* I L Q H \* L F L L I C V F Y I  
I M S V F E Y Y N I S C S C \* Y A C F T

FIG. 2 CONT.

41/201

21061 TTAGGTGCAGGCTCTGATAAGAAGTAGCTCCAGGTTCTGCTGTTTTAAGACAGTGGTTA 21120  
 L G A G S D K E V A P G S A V L R Q W L  
 \* V Q G L I K K \* L Q V L L F \* D S G Y  
 F R C R V \* \* R S S S R F C C F K T V V

21121 CCATCTGGTAGTATTCTTGTAGATAATGATTTAAACCCATTGTTAGCGATAGTTAGTT 21180  
 P S G S I L V D N D L N P F V S D S L V  
 H L V V F L \* I M I \* T H L L A I V \* L  
 T I W \* Y S C R \* \* F K P I C \* R \* F S

21181 ACTTATTTGGAGATTGTATGACTTTACCATTGATGTCATTGGGATTTGATAATATCT 21240  
 T Y F G D C M T L P F D C H W D L I I S  
 L I L E I V \* L Y H L I V I G I \* \* Y L  
 Y L F W R L Y D F T I \* L S L G F D N I

21241 GATATGTATGATCCTCTTACTAAAAATATTGGTGATTATAATGTGAGTAAGGATGGGTTT 21300  
 D M Y D P L T K N I G D Y N V S K D G F  
 I C M I L L L K I L V I I M \* V R M G F  
 \* Y V \* S S Y \* K Y W \* L \* C E \* G W V

21301 TTTACTTACATTGTCATTTAATTCGTGATAAATTATCTTTGGGTGGTAGTGTAGCTATA 21360  
 F T Y I C H L I R D K L S L G G S V A I  
 L L T F V I \* F V I N Y L W V V V \* L \*  
 F Y L H L S F N S \* \* I I F G W \* C S Y

21361 AAAATTACAGAGTTTCTTGAATGCTGATTTATATAAATTAATGAGTTGTTTTGCATTT 21420  
 K I T E F S W N A D L Y K L M S C F A F  
 K L Q S F L G M L I Y I N \* \* V V L H F  
 K N Y R V F L E C \* F I \* I N E L F C I

21421 TGGACAGTTTTTGTACTAATGTAATGCTTCTTCTAGTGAAGGTTTTTAATAGGTATA 21480  
 W T V F C T N V N A S S S E G F L I G I  
 G Q F F V L M \* M L L L V K G F \* \* V \*  
 L D S F L Y \* C K C F F \* \* R V F N R Y

21481 AATTACCTGGGTAATCTTCTTTGAAATAGATGGCAATGTTATGCATGCTAACTATTG 21540  
 N Y L G K S S F E I D G N V M H A N Y L  
 I T W V N L L L K \* M A M L C M L T I C  
 K L P G \* I F F \* N R W Q C Y A C \* L F

21541 TTTGGAGAAATAGTACAACATGGAATGGCGGTGCTTATAGTTTATTTGATATGACTAAA 21600  
 F W R N S T T W N G G A Y S L F D M T K  
 F G E I V Q H G M A V L I V Y L I \* L N  
 V L E K \* Y N M E W R C L \* F I \* Y D \*

FIG. 2 CONT.

42/201

21601 TTTTCTTTGAAATGGCTGGCACTGCTGTTGTTAATTTAAGACCAGATCAATTAATGAT 21660  
 F S L K L A G T A V V N L R P D Q L N D  
 F L \* N W L A L L L L I \* D Q I N \* M I  
 I F F E I G W H C C C \* F K T R S I K \*

21661 TTAGTTTATTCTCTTATTGAAAGAGGTAAATTTAGTTCGCGATACGCGTAAAGAGATT 21720  
 L V Y S L I E R G K L L V R D T R K E I  
 \* F I L L L K E V N Y \* F A I R V K R F  
 F S L F S Y \* K R \* I I S S R Y A \* R D

21721 TTTGTTGGTATAGTCTTGTAATACTTGTTAGATCTCATTAAATCTAAACTATGTTAAT 21780  
 F V G D S L V N T C \* I S L N L N Y V N  
 L L V I V L \* I L V R S H \* I \* T M L I  
 F C W \* \* S C K Y L L D L I K S K L C \*

21781 TATTTTTTTATTTTTTATTCTGTTATGGTTTTAATGAACCTCTTAATGTTGTCTCA 21840  
 Y F F I F L F L L W F \* \* T S \* C C V S  
 I F L F F Y F C Y G F N E P L N V V S H  
 L F F Y F F I S V M V L M N L L M L C L

21841 TTTAAACCATGACTGGTTTTTATTTGGTGATAGTCGTTCTGATTGTAACCATATTAATAA 21900  
 F K P \* L V F I W \* \* S F \* L \* P Y \* \*  
 L N H D W F L F G D S R S D C N H I N N  
 I \* T M T G F Y L V I V V L I V T I L I

21901 TTTAAAAATAAAAATTTGATTATTTGGATATTCACCCAGTTTGTGCAACAAATGGTAA 21960  
 F K N \* K F \* L F G Y S P \* F V Q Q W \*  
 L K I K N F D Y L D I H P S L C N N G K  
 I \* K L K I L I I W I F T L V C A T M V

21961 GATTTCATCTAGTGCCGGTATTCTATTTTTAAGAGTTTTCAITTCACCTCGATTTTATAA 22020  
 D F I \* C R \* F Y F \* E F S F H S I L \*  
 I S S S A G D S I F K S F H F T R F Y N  
 R F H L V P V I L F L R V F I S L D F I

22021 TTACACTGGCGAAGGTGATCAATTTATTTTTATGAGGGTGTAAATTTAATCCTTATCA 22080  
 L H W R R \* S N Y F L \* G C \* F \* S L S  
 Y T G E G D Q I I F Y E G V N F N P Y H  
 I T L A K V I K L F F M R V L I L I L I

22081 TAGATTTAAGTGTTCCTAATGGTAGTAATGATGTATGGCTTCTTAACAAGGTAAGATT 22140  
 \* I \* V F S \* W \* \* \* C M A S \* Q G K I  
 R F K C F P N G S N D V W L L N K V R F  
 I D L S V F L M V V M M Y G F L T R \* D

FIG. 2 CONT.



43/201

22141 TTATCGTGCCTTATATCTAATATGGCCTTTTTTCGTTATCTTACTTTTGGTGTATATCC 22200  
 L S C L I F \* Y G L F S L S Y F C \* Y S  
 Y R A L Y S N M A F F R Y L T F V D I P  
 F I V P Y I L I W P F F V I L L L L I F

22201 TTATAATGTTTCTCTTCTAAGTTAATCTTGTAAGTATTTTATCACTTAACAA 22260  
 L \* C F S F \* V \* F L \* K \* Y F I T \* Q  
 Y N V S L S K F N S C K S D I L S L N N  
 L I M F L F L S L I L V K V I F Y H L T

22261 TCCTATTTTATTAATTAATCTAAGGAAGTTATTTTACTTTATAGGTGTTCTCTTTA 22320  
 S Y F Y \* L F \* G S L F Y F I R L F S L  
 P I F I N Y S K E V Y F T L L G C S L Y  
 I L F L L I I L R K F I L L Y \* V V L F

22321 TTTAGTACCGCTTTGCCTTTTTAAATCTAAGTTAGTACGACTATTATAACATAGATAC 22380  
 F S T A L P F \* I \* L \* S V L L \* H R Y  
 L V P L C L F K S N F S Q Y Y Y N I D T  
 I \* Y R F A F L N L T L V S T I I T \* I

22381 TGGCTCTGTTTATGGTTTTCTAATGTTGTTTATCCGATTTAGACTGTATTTATATTC 22440  
 W L C L W F F \* C C L S \* F R L Y L Y F  
 G S V Y G F S N V V Y P D L D C I Y I S  
 L A L F M V F L M L F I L I \* T V F I F

22441 TCTTAAACCAGGTTCTTATAAAGTTTCCACCCTGCACCTTTTTTATCCTACCTACTAA 22500  
 S \* T R F L \* S F H H C T F F I L T Y \*  
 L K P G S Y K V S T T A P F L S L P T K  
 L L N Q V L I K F P P L H L F Y P Y L L

22501 AGCTCTCTGTTTTGATAAATCTAACAATTTGTACCTGTACAGGTTGTTGATTCTAGATG 22560  
 S S L F \* \* I \* T I C T C T G C \* F \* M  
 A L C F D K S K Q F V P V Q V V D S R W  
 K L S V L I N L N N L Y L Y R L L I L D

22561 GAACAACGAGCGTGCCTCAGATATTTCTTTATCTGTTGCATGTCAATTGCCATATTGTTA 22620  
 E Q R A C L R Y F F I C C M S I A I L L  
 N N E R A S D I S L S V A C Q L P Y C Y  
 G T T S V P Q I F L Y L L H V N C H I V

22621 TTTTCGCAATTTCTCTGCTAATTTATGTTGGCAAGTATGATATTAACCACGGTATAGTGG 22680  
 F S Q F F C \* L C W Q V \* Y \* P R \* \* W  
 F R N S S A N Y V G K Y D I N H G D S G  
 I F A I L L L I M L A S M I L T T V I V

FIG. 2 CONT.

44/201

22681 TTTTATTTCTAFTTTATCTGGTCTTTTATATAATGTTTCTTGTATTTCATATTATGGTGT 22740  
 F Y F Y F I W S F I \* C F L Y F I L W C  
 F I S I L S G L L Y N V S C I S Y Y G V  
 V L F L F Y L V F Y I M F L V F H I M V

22741 ATTTTATATGATAAATTTACATCCATTTGGCCCTATTATTCTTTTGGTAGGTGTCCCTAC 22800  
 I F I \* \* F Y I H L A L L F F W \* V S Y  
 F L Y D N F T S I W P Y Y S F G R C P T  
 Y F Y M I I L H P F G P I I L L V G V L

22801 ATCTTCTATTATTAACATCCAATTTGTGTTTATGATTTTTGGCCTATTATTTTACAAGG 22860  
 I F Y Y \* T S N L C L \* F F A Y Y F T R  
 S S I I K H P I C V Y D F L P I I L Q G  
 H L L L L N I Q F V F M I F C L L F Y K

22861 TATTTTATTAGTTTAGCTTACTTTTTGTTGTTTTTCTATTATTTTTGTTATATAACGA 22920  
 Y F I M F S F T F C C F S I I F V I \* R  
 I L L C L A L L F V V F L L F L L Y N D  
 V F Y Y V \* L Y F L L F F Y Y F C Y I T

22921 TAAATCTCATTAAATCTAAACATGTTATTAATTATTTTTATTTTGCCTACACATTAGCT 22980  
 \* I S L N L N M L L I I F I L P T T L A  
 K S H \* I \* T C Y \* L F L F C L Q H \* L  
 I N L I K S K H V I N Y F Y F A Y N I S

22981 GTTATAGGTGATTTTAAATGTTACTAATTTTGCTATTAATGATTTAACCACACAGTTCCT 23040  
 V I G D F N C T N F A I N D L N T T V P  
 L \* V I L I V L I L L L M I \* T P Q F L  
 C Y R \* F \* L Y \* F C Y \* \* F K H H S S

23041 CGCATAAGTGAGTATGTTGTGGATGTTTCTTATGGTTTGGGTACATATTATATACTTGAT 23100  
 R I S E Y V V D V S Y G L G T Y Y I L D  
 A \* V S M L W M F L M V W V H I I Y L I  
 S H K \* V C C G C F L W F G Y I L Y T \*

23101 CGTGTFTTTTAAATACTACTATATTATTTACTGCTTATTTCCCTAAATCTGGTGCCAAT 23160  
 R V Y L N T T I L F T G Y F P K S G A N  
 V F I \* I L L Y Y L L V I S L N L V P I  
 S C L F K Y Y Y I I Y W L F P \* I W C Q

23161 TTTAGGGATCTATCTTTAAAAGGTACTACATATTGAGTACTCTTTGGTATCAGAAACCC 23220  
 F R D L S L K G T T Y L S T L W Y Q K P  
 L G I Y L \* K V L H I \* V L F G I R N P  
 F \* G S I F K R Y Y I F E Y S L V S E T

FIG. 2 CONT.

45/201

23221 TTTTATCTGATTTAATAATGGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTT 23280  
 F L S D F N N G I F S R V K N T K L Y V  
 F Y L I L I M V F F L E L R I L S C M L  
 L F I \* F \* \* W Y F F \* S \* E Y \* V V C

23281 AATAAACTTTGTATACTGAGTTTACTACTATAGTTATAGGTAGTGTTTTATTAACAAC 23340  
 N K T L Y S E F S T I V I G S V F I N N  
 I K L C I V S L V L \* L \* V V F L L T T  
 \* \* N E V \* \* V \* Y Y S Y R \* C F Y \* Q

23341 TCTTACTATTGTTGTTCAACCTCATAATGGTGTTTTGGAGATTACAGCTTGTCATAC 23400  
 S Y T I V V Q P H N G V L E I T A C Q Y  
 L I L L L F N L I M V F W R L Q L V N T  
 L L Y Y C C S T S \* W C F G D Y S L S I

23401 ACTATGTGTGAGTATCCTCATACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCT 23460  
 T M C E Y P H T I C K S K G S S R N E S  
 L C V S I L I L F V N L K V V L V M N L  
 H Y V \* V S S Y Y L \* I \* R \* F S \* \* I

23461 TGGCATTGATAAATCTGAACCTTTGTTCTGTTCAAGAAAATTTTACTTATAATGTT 23520  
 W H F D K S E P L C L F K K N F T Y N V  
 G I L I N L N L C V C S R K I L L I M F  
 L A F \* \* I \* T F V S V Q E K F Y L \* C

23521 TCTACAGATTGGTTGATTTTCATTTTATCAAGACGTGGCACTTTTATGCTTATTAT 23580  
 S T D W L Y F H F Y Q E R G T F Y A Y Y  
 L Q I G C I F I F I K N V A L F M L I M  
 F Y R L V V F S F L S R T W H F L C L L

23581 GCTGATTCTGGCATGCCCTACTACTTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCT 23640  
 A D S G M P T T F L F S L Y L G T L L S  
 L I L A C L L L F Y L V C I L V L F Y L  
 C \* F W H A Y Y F F I \* F V S W Y S F I

23641 CATTATTATGTTTTGCCCTTTGACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACT 23700  
 H Y Y V L P L T C N A I S S N T D N E T  
 I I M F C L \* L V M L Y L L I L I M R L  
 S L L C F A F D L \* C Y I F \* Y \* \* \* D

23701 TTACAATATTGGGTCACACCTTTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGT 23760  
 L Q Y W V T P L S K R Q Y L L K F D N R  
 Y N I G S H L C L N A N I F L N L T T V  
 F T I L G H T F V \* T P I S S \* I \* Q P

FIG. 2 CONT.

46/201

23761 GGTGTTACTAATGCTGTTGATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAA 23820  
 G V I T N A V D C S S S F F S E I Q C K  
 V L L L M L L I V L V V S L A R F N V K  
 W C Y Y \* C C \* L F \* \* F L \* R D S M \*

23821 ACTAAATCTTTATTACCTAATACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCT 23880  
 T K S L L P N T G V Y D L S G F T V K P  
 L N L Y Y L I L V F M T Y L V L L L S L  
 N \* I F I T \* Y W C L \* L I W F Y C \* A

23881 GTTGCAACTGTACATCGTCGTATTCCTGATTACCTGATTGTGACATTGATAAATGGCCTT 23940  
 V A T V H R R I P D L P D C D I D K W L  
 L Q L Y I V V F L I Y L I V T L I N G L  
 C C N C T S S Y S \* F T \* L \* H \* \* M A

23941 AACAAATTTAATGTACCCTCACCTCTTAATTGGGAACGTAAAATTTTTCTAATGCAAC 24000  
 N N F N V P S P L N W E R K I F S N C N  
 T I L M Y P H L L I G N V K F F L I A T  
 \* Q F \* C T L T S \* L G T \* N F F \* L Q

24001 TTTAATTTGAGTACTTTGCTTCGTTTAGTTCATACTGATTCTTTTTCTTGTAATAATTTT 24060  
 F N L S T L L R L V H T D S F S C N N F  
 L I \* V L C F V \* F I L I L F L V I I L  
 L \* F E Y F A S F S S Y \* F F F L \* \* F

24061 GATGAATCTAAGATATATGGTAGTGTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATA 24120  
 D E S K I Y G S C F K S I V L D K F A I  
 M N L R Y M V V V L R V L F \* I N L P Y  
 \* \* I \* D I W \* L F \* E Y C F R \* I C H

24121 CCCAACTCCAGACGATCTGATTGCAGTTGGGCAGTTCTGGTTTTCTGCAATCTTCTAAT 24180  
 P N S R R S D L Q L G S S G F L Q S S N  
 P T P D D L I C S W A V L V F C N L L I  
 T Q L Q T I \* F A V G Q F W F S A I F \*

24181 TATAAAATGACACTACTTCTAGTTCCTGCAATTGTATTATAGTTGCCTGCAATTAAT 24240  
 Y K I D T T S S S C Q L Y Y S L P A I N  
 I K L T L L L V L V N C I I V C L Q L M  
 L \* N \* H Y F \* F L S I V L \* F A C N \*

24241 GTTACTATTAATAATTATAATCCTTCTTCTGGAATAGAAGGTATGGTTTTAATAATTTT 24300  
 V T I N N Y N P S S W N R R Y G F N N F  
 L L L I I I I L L L G I E G M V L I I L  
 C Y Y \* \* L \* S F F L E \* K V W F \* \* F

FIG. 2 CONT.

47/201

24301 AATTTGAGCTCTCATAGTGTGTTTACTCACGTTATGTTTTCTGTTAATAAATACTTTT 24360  
 N L S S H S V V Y S R Y C F S V N N T F  
 I \* A L I V L F T H V I V F L L I I L F  
 \* F E L S \* C C L L T L L F F C \* \* Y F

24361 TGTCCTTGTGCTAAACCTTCTTTTGCTTCAAGTTGCAAGAGTCATAAACCCCTTCTGCT 24420  
 C P C A K P S F A S S C K S H K P P S A  
 V L V L N L L L L Q V A R V I N H L L L  
 L S L C \* T F F C F K L Q E S \* T T F C

24421 TCCTGTCCTATTGGTACTAATTATCGTTCCTTGTGAGAGTACTACTGTACTCGACCACACT 24480  
 S C P I G T N Y R S C E S T T V L D H T  
 P V L L V L I I V L V R V L L Y S T T L  
 F L S Y W Y \* L S F L \* E Y Y C T R P H

24481 GACTGGTGTAGGTGTTCTTGTTTACCTGATCCCTATAACTGCTTATGACCCTAGGTCTTGT 24540  
 D W C R C S C L P D P I T A Y D P R S C  
 T G V G V L V Y L I L \* L L M T L G L V  
 \* L V \* V F L F T \* S Y N C L \* P \* V L

24541 TCTCAAAAAAGTCTCTGGTGGTGGTGAACATTGTGCAGGGTTCGGTGTGTGATGAA 24600  
 S Q K K S L V G V G E H C A G F G V D E  
 L K K S L W L V L V N I V Q G S V L M K  
 F S K K V S G W C W \* T L C R V R C \* \*

24601 GAAAAGTGTGGTGTATGGATGGATCAATATAATGTTTCTTGTCTTGTAGTACTGATGCC 24660  
 E K C G V L D G S Y N V S C L C S T D A  
 K S V V Y W M D H I M F L V F V V L M P  
 R K V W C I G W I I \* C F L S L \* Y \* C

24661 TTCTAGGTTGGTCTTATGACACTTCCGTCAGTAAACAACCGTTGTAATATTTTTTCTAAT 24720  
 F L G W S Y D T C V S N N R C N I F S N  
 F \* V G L M T L A S V T T V V I F F L I  
 L S R L V L \* H L R Q \* Q P L \* Y F F \*

24721 TTTATTTTAAATGGTATCAATAGTGGTACCCTTGTCTAATGATTTATTCAGCCTAAT 24780  
 F I L N G I N S G T T C S N D L L Q P N  
 L F \* M V S I V V P L V L M I Y C S L I  
 F Y F K W Y Q \* W Y H L F \* \* F I A A \*

24781 ACTGAAGTTTTACTGATGTTTGTGTTGATTACGACCTTTATGGTATTACAGGACAGGT 24840  
 T E V F T D V C V D Y D L Y G I T G Q G  
 L K F L L M F V L I T T F M V L Q D K V  
 Y \* S F Y \* C L C \* L R P L W Y Y R T R

FIG. 2 CONT.

48/201

24841 ATTTTAAAGAAGTTTCTGCTGTTTATAAATAGTTGGCAAATCTTTTGTATGATTCT 24900  
 I F K E V S A V Y Y N S W Q N L L Y D S  
 F L K K F L L F I I I V G K I F C M I L  
 Y F \* R S F C C L L \* \* L A K S F V \* F

24901 AATGGCAACATTATGGTTTAAAGATTTTGTACTAATAAAACATATAATATTTCCCT 24960  
 N G N I I G F K D F V T N K T Y N I F P  
 M A T L L V L K I L L L I K H I I F S L  
 \* W Q H Y W F \* R F C Y \* \* N I \* Y F P

24961 TGTATGTCAGGAAGAGTTTCTGCTGCTTTTCATCAAATGCTTCCTCTTTGGCTTACTT 25020  
 C Y A G R V S A A F H Q N A S S L A L L  
 V M Q E E F L L L F I K M L P L W L Y F  
 L L C R K S F C C F S S K C F L F G F T

25021 TATCGTAATTTAAATGTAGCTATGTTTGAATAATATTTCTTTAACTACTCAGCCATAT 25080  
 Y R N L K C S Y V L N N I S L T T Q P Y  
 I V I \* N V A M F \* I I F L \* L L S H I  
 L S \* F K M \* L C F E \* Y F F N Y S A I

25081 TTTGATAGTTATCTTGGTTGCGTTTTTAATGCTGATAATTTAACTGATTATCTGTTTCT 25140  
 F D S Y L G C V F N A D N L T D Y S V S  
 L I V I L V A F L M L I I \* L I I L F L  
 F \* \* L S W L R F \* C \* \* F N \* L F C F

25141 TCTTGTGCTCTTCGCATGGGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCTTCTTCC 25200  
 S C A L R M G S G F C V D Y N S P S S S  
 L V L F A W V V V F V L I I T H L L L P  
 F L C S S H G \* W F L C \* L \* L T F F F

25201 TCTTCGCGTCGTAACGTAGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCC 25260  
 S S R R K R R S I S A S Y R F V T F E P  
 L R V V N V E V F L L L I V L L L L N P  
 L F A S \* T \* K Y E C F L S F C Y F \* T

25261 TTTAATGTCAGTTTTGTTAATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAA 25320  
 F N V S F V N D S I E S V G G L Y E I K  
 L M S V L L M T V L S L W V V F M R S K  
 L \* C Q F C \* \* Q Y \* V C G W S L \* D Q

25321 ATTCCCACTAACTTACTATAGTTGGTCAAGAGGAATTTATCAAACATAATTCCTCAAA 25380  
 I P T N F T I V G Q E E F I Q T N S P K  
 F P L T L L \* L V K R N L F K L I L L K  
 N S H \* L Y Y S W S R G I Y S N \* F S \*

FIG. 2 CONT.

49/201

25381 GTTACTATTGATTGTTCTTTTATTGTCGTCTTAATTATGCAGCTTGCCATGACTTATTG 25440  
 V T I D C S L F V C S N Y A A C H D L L  
 L L L I V L Y L S V L I M Q L A M T Y C  
 S Y Y \* L F F I C L F \* L C S L P \* L I

25441 TCAGAGTATGGCACTTTTTGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTA 25500  
 S E Y G T F C D N I N S I L D E V N G L  
 Q S M A L F V I I L I V F \* M K L M V Y  
 V R V W H F L \* \* Y \* \* Y F R \* S \* W F

25501 CTTGATACTACTCAATTGCATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCC 25560  
 L D T T Q L H V A D T L M Q G V T L S S  
 L I L L N C M \* L I L L C K V S H L A P  
 T \* Y Y S I A C S \* Y S Y A R C H T \* L

25561 AATCTTAATACTAATTTGCATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGA 25620  
 N L N T N L H F D V D N I N F K S L V G  
 I L I L I C I L M L I I L I L N P \* L D  
 Q S \* Y \* F A F \* C \* \* Y \* F \* I P S W

25621 TGTTTAGGTCACACTGCGGTTCTTCTCTCGTCTTTTTTTGAAGATTATTGTTGAC 25680  
 C L G P H C G S S S R S F F E D L L F D  
 V \* V H T A V L L L V L F L K I Y C L T  
 M F R S T L R F F F S F F F \* R F I V \*

25681 AAAGTTAACTTTCAGATGTTGGTTTGTGTTGAAGCTTATAACAATTGTACTGGTGGTAGT 25740  
 K V K L S D V G F V E A Y N N C T G G S  
 K L N F Q M L V L L K L I T I V L V V V  
 Q S \* T F R C W F C \* S L \* Q L Y W W \*

25741 GAAATTAGAGATCTTCTTTGTGTACAATCCTTTAATGCTATTAAAGTTTTCCTCCTATT 25800  
 E I R D L L C V Q S F N G I K V L P P I  
 K L E I F F V Y N P L M V L K F C L L F  
 \* N \* R S S L C T I L \* W Y \* S F A S Y

25801 TTGTCTGAATCTCAAATTTCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCA 25860  
 L S E S Q I S G Y T T A A T V A A M F P  
 C L N L K F L V T P Q P L L L L L C F H  
 F V \* I S N F W L H H S R Y C C C Y V S

25861 CCATGGTCAGCAGCAGCTGGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGT 25920  
 P W S A A A G I P F S L N V Q Y R I N G  
 H G Q Q Q L A Y H F L L M Y N I E L M V  
 T M V S S S W H T I F S \* C T I \* N \* W

FIG. 2 CONT.

50/201

25921 TTGGGTGTTACTATGGATGTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTTAAT 25980  
 L G V T M D V L N K N Q K L I A T A F N  
 W V L L W M F L I K I K S \* \* L L L L I  
 F G C Y Y G C S \* \* K S K V D S Y C F \*

25981 AATGCTCTTCTTTCTATTTCAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATA 26040  
 N A L L S I Q N G F S A T N S A L A K I  
 M L F F L F R M V L V L P T L H L L K Y  
 \* C S S F Y S E W F \* C Y Q L C T C \* N

26041 CAAAGTGTGTTAATTCTAATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAAT 26100  
 Q S V V N S N A Q A L N S L L Q Q L F N  
 K V L L I L M L K H L I V C Y S N Y L I  
 T K C C \* F \* C S S T \* \* F V T A I I \*

26101 AAATTTGGTGCAATTAGTTCCTTCTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAG 26160  
 K F G A I S S S L Q E I L S R L D A L E  
 N L V Q L V L L Y K K F Y L V S M L \* R  
 \* I W C N \* F F F T R N F I S S R C F R

26161 GCTCAGGTTTCAGATTGATAGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTC 26220  
 A Q V Q I D R L I N G R L T A L N A Y V  
 L R F R L I G L L M V V \* L L \* M L M S  
 G S G S D \* \* A Y \* W S F N C F K C L C

26221 TCTCAACAGCTTAGTGATATTTCTCTTGTAATAATTTGGTGCTGCTTTAGCTATGGAGAAG 26280  
 S Q Q L S D I S L V K F G A A L A M E K  
 L N S L V I F L L \* N L V L L \* L W R R  
 L S T A \* \* Y F S C K I W C C F S Y G E

26281 GTTAATGAGTGTGTTAAAAGTCAATCTCCTCGTATTAATTTTGGTGGTAAATGGTAATCAT 26340  
 V N E C V K S Q S P R I N F C G N G N H  
 L M S V L K V N L L V L I F V V M V I I  
 G \* \* V C \* K S I S S Y \* F L W \* W \* S

26341 ATTTTGCATTAGTTCAAAATGCTCCTTATGGTTTGTGTTTATGCATTTAGTTATAAA 26400  
 I L S L V Q N A P Y G L L F M H F S Y K  
 F C H \* F K M L L M V C C L C I L V I N  
 Y F V I S S K C S L W F V V Y A F \* L \*

26401 CCTATTTCTTTTAAAACGTTTTAGTAAGTCCTGGTTTGTGTATATCAGGTGATGTAGGT 26460  
 P I S F K T V L V S P G L C I S G D V G  
 L F L L K L F \* \* V L V C V Y Q V M \* V  
 T Y F F \* N C F S K S W F V Y I R \* C R

FIG. 2 CONT.



51/201

26461 ATTGCACCTAAACAAGGGTATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGT 26520  
 I A P K Q G Y F I K H N D H W M F T G S  
 L H L N K G I L L N I M I I G C S L V V  
 Y C T \* T R V F Y \* T \* \* S L D V H W \*

26521 TCTTACTATTATCCTGAACCAATTTTCAGATAAAAATGTTGTTTTATGAATACTTGTCT 26580  
 S Y Y Y P E P I S D K N V V F M N T C S  
 L T I I L N Q F Q I K M L F L \* I L V L  
 F L L L S \* T N F R \* K C C F Y E Y L F

26581 GPTAATTTACTAAAGCGCCTCTTGTATTGGAATCATTCTGTACCAAAAATTGCTGAT 26640  
 V N F T K A P L V Y L N H S V P K L S D  
 L I L L K R L L F I \* I I L Y Q N C L I  
 C \* F Y \* S A S C L F E S F C T K I V \*

26641 TTTGAATCTGAGTTATCTCATTGGTTTAAAAATCAACATCCATTGCGCCTAATTGACT 26700  
 F E S E L S H W F K N Q T S I A P N L T  
 L N L S Y L I G L K I K H P L R L I \* L  
 F \* I \* V I S L V \* K S N I H C A \* F D

26701 TTAAATCTTCATACTATTAATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATT 26760  
 L N L H T I N A T F L D L Y Y E M N L I  
 \* I F I L L M L L F \* I C I M R \* I L F  
 F K S S Y Y \* C Y F F R F V L \* D E S Y

26761 CAAGAGTCTATTAAGTCTTTGAATAATAGTTATCAATCTTAAAGATATAGGTACATAT 26820  
 Q E S I K S L N N S Y I N L K D I G T Y  
 K S L L S L \* I I V I S I L K I \* V H M  
 S R V Y \* V F E \* \* L Y Q S \* R Y R Y I

26821 GAAATGTATGTAATAATGGCCTTGATGTTGGCTACTAATTTCTTTTCATTATAATA 26880  
 E M Y V K W P W Y V W L L I S F S F I I  
 K C M \* N G L G M F G Y \* F L F H L \* Y  
 \* N V C K M A L V C L A T N F F F I Y N

26881 TTCCTTGATGCTCTTTTTATATGTTGTTGACTGGTTGTTGTTCTGCATGTTTGTAGT 26940  
 F L V L L F F I C C C T G C G S A C F S  
 S L Y C S F L Y V V V L V V V L H V L V  
 I P C I A L F Y M L L Y W L W F C M F \*

26941 AAATGTCATAATTGTTGTGATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCT 27000  
 K C H N C C D E Y G G H H D F V I K T S  
 N V I I V V M S M V V I M I L L S K H L  
 \* M S \* L L \* \* V W W S S \* F C Y Q N I

FIG. 2 CONT.

52/201

27001 CATGATGATTAGAATCTCTTGTGAGATCTCATTAAATCTAAACTTTATTTATGGACGTTT 27060  
H D D \* N L L S D L I K S K L Y L W T F  
M M I R I S C Q I S L N L N F I Y G R L  
S \* \* L E S L V R S H \* I \* T L F M D V

27061 GGAGACCTAGCTACACACATTCTCTTGTATTAGAGAATTTGGTGTACAAACCTTGAAG 27120  
G D L A T H I L L L L E N L V L Q T L K  
E T \* L H T F S C Y \* R I W C Y K P \* R  
W R P S Y T H S L V I R E F G V T N L E

27121 ATTTGTGTCTAAAGTATAAATACTGTCAACCTATGTGTGTTACTGTATTGTACCTTTAA 27180  
I C V \* S I I T V N L L L V T V L Y L \*  
F V S K V \* L L S T Y C W L L Y C T F K  
D L C L K Y N Y C Q P I V G Y C I V P L

27181 ATGTTTGGTGTGCAAGTTTGGCAAATTTGCTTCTCACTTTACATTAGGTAGTCACGATA 27240  
M F G V A S L A N L L L T L H Y V V T I  
C L V S Q V W Q I C F S L Y I T \* S R Y  
N V W C R K F G K F A S H F T L R S H D

27241 TTTCCCATAGTAATAATTTTGGTGTGTAAGTACTTTTACTACTTATGGTAATACTGTTT 27300  
F P I V I I L V L \* L V L L L M V I L F  
F P \* \* \* F W C C N \* F Y Y L W \* Y C F  
I S H S N N F G V V T S F T T Y G N T V

27301 CTGAGGCTGTGTCTAGATTAGTTGAATCAGCTTCTGAATTTATGTTTGGCGTGCAGAGG 27360  
L R L C L D \* L N Q L L N L L F G V Q R  
\* G C V \* I S \* I S F \* I Y C L A C R G  
S E A V S R L V E S A S E F I V W R A E

27361 CACTTAATAAGTATGGTTGATTTATTTTCAATGATACTGCTTGGTACATAGGACAGATT 27420  
H L I S M V D L F F N D T A W Y I G Q I  
T \* \* V W L I Y F S M I L L G T \* D R F  
A L N K Y G \* F I F Q \* Y C L V H R T D

27421 TTAGTTTGTAGTTTATTTTGTCTTATTTCTTTAATCTTTGTTGTTGCTTTTGTAGCACT 27480  
L V L V L F C L I S L I F V V A F L A T  
\* F \* F Y F V L F L \* S L L L L F \* Q L  
F S F S F I L S Y F F N L C C C F F S N

27481 ATTAAGCTTTGTATGCAACTTTTGTGGTTTTTGTAAATTTCTTTATTTTACCTTCGGCT 27540  
I K L C M Q L C G F C N F F I I S P S A  
L S F V C N F V V F V I S L L F H L R L  
Y \* A L Y A T L W F L \* F L Y Y F T F G

FIG. 2 CONT.

53/201

27541 TACGTTTATAAAAAGAGGTTATGCAGTTGTATAAGTCTTATAGTGAACAAGTTATACCACCC 27600  
 Y V Y K R G M Q L Y K S Y S E Q V I P P  
 T F I K E V C S C I S L I V N K L Y H P  
 L R L \* K R Y A V V \* V L \* \* T S Y T T

27601 ACTTCAGATTATTTAATCTAAATCTAAACATTATGAATAAATCTTTCTTCTCAATTTA 27660  
 F S D Y L I \* I \* T L \* I N L F F L N L  
 L Q I I \* S K S K H Y E \* I F S S S I Y  
 H F R L F N L N L N I M N K S F L P Q F

27661 CTTCTGATCAAGCTGTTACATTCCTAAAAGAATGGAATTTCTCTTTGGGTGTAATACTAC 27720  
 L L I K L L H S \* K N G I S L W V \* Y Y  
 F \* S S C Y I L K R M E F L F G C N T T  
 T S D Q A V T F L K E W N F S L G V I L

27721 TTTTATTACTATCATATTGCAGTTCGGTTATACGAGCCGTAGTATGTTTCTTATCTTA 27780  
 F L L L S Y C S S V I R A V V C L F I L  
 F Y Y Y H I A V R L Y E P \* Y V C L S Y  
 L F I T I I L Q F G Y T S R S M F V Y L

27781 TCAAGATGATTATTCCTTTGGCTTATGTGGCCATGACTATCACCTTGACTATATTTAATT 27840  
 S R \* L F F G L C G H \* L S P \* L Y L I  
 Q D D Y S L A Y V A I D Y H L D Y I \* L  
 I K M I I L W L M W P L T I T L T I F N

27841 GTTTTATGCTTTGAATAATGCTTTTCTTGCAATTTCTATAGTGTACTATATTTCTA 27900  
 V F M L \* I M L F L H F L \* C L L L F L  
 F L C F E \* C F S C I F Y S V Y Y Y F Y  
 C F Y A L N N A F L A F S I V F T I I S

27901 TTGTTATATGGATTCTTTATTTTGTAAATAGTATTCGGCTTTTATTAGAACTGGCAGTT 27960  
 L L Y G F F I L L I V F G F L L E L A V  
 C Y M D S L F C \* \* Y S A F Y \* N W Q L  
 I V I W I L Y F V N S I R L F I R T G S

27961 GGTGGAGTTTAAATCCAGAGACCAATAAATCTTATGTGTATTGATATGAAGGCAAGATGT 28020  
 G G V L I Q R P I I L C V L I \* K A R C  
 V E F \* S R D Q \* S Y V Y \* Y E R Q D V  
 W W S F N P E T N N L M C I D M K G K M

28021 TTGTTAGGCCAGTTATTGAGGACTATCACACATTAAGTCTACTGTTATTCGTGGTCATC 28080  
 L L G Q L L R T I T H \* L L L L F V V I  
 C \* A S Y \* G L S H I N C Y C Y S W S S  
 F V R P V I E D Y H T L T A T V I R G H

FIG. 2 CONT.

54/201

28081 TTTATATACAGGGTGTCAAACCTGGCACTGGTTATACTCTTTCAGATTGGCCCGTATATG 28140  
 F I Y R V S N L A L V I L F Q I C P Y M  
 L Y T G C Q T W H W L Y S F R F A R I C  
 L Y I Q G V K L G T G Y T L S D L P V Y

28141 TTACTGTAGCTAAGGTGCAAGTACTTTGCTACCTATAAACGTGCCTTTTGTAGATAAGTTAG 28200  
 L L \* L R C K Y F V P I N V P F \* I S \*  
 Y C S \* G A S T L Y L \* T C L F R \* V R  
 V T V A K V Q V L C T Y K R A F L D K L

28201 ATGTTAATAGTGGTTTTGCTGTTTTGTTAAGTCTAAAGTTGGTAACTATCGTTTACCGT 28260  
 M L I V V L L F L L S L K L V T I V Y R  
 C \* \* W F C C F C \* V \* S W \* L S F T V  
 D V N S G F A V F V K S K V G N Y R L P

28261 CTAGTAAACCTAGTGGTATGGATACTGCCTTGTTAAGAGCTTAAATCTAAACTATTAGGA 28320  
 L V N L V V W I L P C \* E L K S K L L G  
 \* \* T \* W Y G Y C L V K S L N L N Y \* D  
 S S K P S G M D T A L L R A \* I \* T I R

28321 TGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCRGGAA 28380  
 C L I L P V I M L E V E A P L E I V Q E  
 V L Y S R S L C W K \* K L L W K S F R N  
 M S Y T P G H Y A G S R S S S G N R S G

28381 TCCTCAAGAAACTTCTTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGAG 28440  
 S S R K L L G L T N L S E I T K P L I E  
 P Q E N F L G \* P I \* A K L P N L \* \* R  
 I L K K T S W A D Q S E R N Y Q T F N R

28441 GCAGAAAACCCAACCTAAATTCACTGTGTCTACTCAACCACAAGGAAATACTATCCCAC 28500  
 A E K P N L N S L C L L N H K E I L S H  
 Q K N P T \* I H C V Y S T T R K Y Y P T  
 G R K T Q P K F T V S T Q P Q G N T I P

28501 ATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCAG 28560  
 I I P G S P G S L N F K K V E T L N F Q  
 L F L V L R D H S I S K R \* R L \* I F R  
 H Y S W F S G I T Q F Q K G R D F K F S

28561 ATGTC AAGGAGTCCCATGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGGT 28620  
 M V K E F P L L S E Y P L L K Q K D I G  
 W S R S S H C F R S T P F \* S K R I L V  
 D G Q G V P I A F G V P P S E A K G Y W

FIG. 2 CONT.

55/201

28621 ATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCGA 28680  
 I D T A G V L L K Q L M V N K S S C Y R  
 \* T Q P A F F \* N S \* W S T K A V V T E  
 Y R H S R R S F K T A D G Q Q K Q L L P

28681 GATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCCC 28740  
 D G I S T I S V P A H M P M H P M V N P  
 M V F L L S R Y R P I C Q C I L W \* I P  
 R W Y F Y Y L G T G P Y A N A S Y G E S

28741 TCGAAGGGGTCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTTT 28800  
 S K G S S G L L I T K L T L L L P P M F  
 R R G L L G C \* S P S \* H F Y S L R C F  
 L E G V F W V A N H Q A D T S T P S D V

28801 CGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATTT 28860  
 R Q G I L L L K K L S L L G F R L V R F  
 V K G S Y Y S R S Y P Y \* V S A W Y D F  
 S S R D P T T Q E A I P T R F P P G T I

28861 TGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAAGTCGACCAGGTT 28920  
 C L K A I M L K A Q E G L L L I V D Q V  
 A S R L L C \* R L R K V C F \* \* S T R F  
 L P Q G Y Y V E G S G R S A S N S R P G

28921 CACGTTCTCAATCAGCTGGACCCAATAATCGTTCATTAAGTAGAAGTAATTCTAATTTTA 28980  
 H V L N H V D P I I V H \* V E V I L I L  
 T F S I T W T Q \* S F I K \* K \* F \* F \*  
 S R S Q S R G P N N R S L S R S N S N F

28981 GACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATCGCTAATCTTGTTTTAG 29040  
 D I Q I L \* \* N L I W L M R S L I L F \*  
 T F R F Y S K T \* Y G \* \* D R \* S C F S  
 R H S D S I V K P D M A D E I A N L V L

29041 CCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAATCA 29100  
 P S L V K I L N L S K S L S K M P R K S  
 Q A W \* R F \* T S A S H \* A K C Q G N Q  
 A K L G K D S K P Q Q V T K Q N A K E I

29101 GGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTTTC 29160  
 G I K F \* Q N L A K S E L L I N I V M F  
 A \* N F N K T S P K A N S \* \* T L \* C S  
 R H K I L T K P R Q K R T P N K H C N V

FIG. 2 CONT.

56/201

29161 AACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAGC 29220  
 N S V L V K E D L L K I L V M L K C \* S  
 T V F W \* K R T F S K F W \* C \* N V K A  
 Q Q C F G K R G P S Q N F G N A E M L K

29221 TTGGFACTAATGATCCTCAGTTTCTATTCTTGCGAGAATTAGCTCCTACACCAGGTGCTT 29280  
 L V L M I L S F L F L Q N \* L L H Q V L  
 W Y \* \* S S V S Y S C R I S S Y T R C F  
 L G T N D P Q F P I L A E L A P T P G A

29281 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTTA 29340  
 F S L V L N \* T W L K E I P R L T H L L  
 F L W F \* I R L G \* K R F R G \* L T C \*  
 F F F G S K L D L V K R D S E A D S P V

29341 AAGATGTTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGCT 29400  
 K M F L N F I I L V L L G L I V L Y Q A  
 R C F \* T S L F W F Y \* V \* \* Y F T R L  
 K D V F E L H Y S G S I R F D S T L P G

29401 TTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATTCTAATCAGA 29460  
 L R Q L \* K F L K R I \* M L T L I L I R  
 \* D N Y E S S \* R E F K C L R \* F \* S E  
 F E T I M K V L E E N L N A Y V N S N Q

29461 ACACTGATTCTGATTCTGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTAC 29520  
 T L I L I R \* V L N L S V K E V L N N Y  
 H \* F \* F V E F \* T S A \* K R C \* T I T  
 N T D S D S L S S K P Q R K R G V K Q L

29521 CAGAACAGTTTGAATCTCTTAATTTAAGTCTGCTACTCAGCACATTTCAAATGATTTTA 29580  
 Q N S L T L L I \* V L V L S T F Q M I L  
 R T V \* L S \* F K C W Y S A H F K \* F Y  
 P E Q F D S L N L S A G T Q H I S N D F

29581 CTCCTGAGGATCATAGTTTACTTGTACTCTTGTATGATCCTTATGTAGAAGACTCTGTG 29640  
 L L R I I V Y L L L M I L M \* K T L L  
 S \* G S \* F T C Y S \* \* S L C R R L C C  
 T P E D H S L L A T L D D P Y V E D S V

29641 CTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTCGCTATTATTCCGGAAT 29700  
 L N E N E S \* F D T R W \* P L A I I R N  
 L M R M N P N S T L G G N P S L L F G I  
 A \* \* E \* I L I R H \* V V T P R Y Y S E

FIG. 2 CONT.

57/201

29701 AGGACACTCTCTATCAGAATGAATTCTTGCCTGTAATAACAGATAGAGTAGGTTGTTACAG 29760  
 R T L S I R M N S C C N N R \* S R L L Q  
 G H S L S E \* I L A V I T D R V G C Y R  
 \* D T L Y Q N E F L L \* \* Q I E \* V V T

29761 ACTATATATTAATTAGTAGAAATTTTATATTTAGACATTTGATTGTTAGAGTAGTTATAA 29820  
 T I Y \* L V E I L Y L D I \* L L E \* L \*  
 L Y I N \* \* K F Y I \* T F D C \* S S Y K  
 D Y I L I S R N F I F R H L I V R V V I

29821 GGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTATCAATTGTAGTGTTTAATATATA 29880  
 G L A V V \* T P P G R A I N C S V \* Y I  
 V \* L \* Y K R L R E E L S I V V F N I Y  
 R F S C S I N A S G K S Y Q L \* C L I Y

29881 TATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTACAAAAAAAAAAAAA 29940  
 Y \* Y M I E I N Y S L L E E L Q K K K K  
 I S I \* L K L I I A F W R N Y K K K K K  
 I L V Y D \* N \* L \* P F G G I T K K K K

29941 AA 29942

K

FIG. 2 CONT.

58/201

1 CTTATTCTCGCTTAACGCAGGCATGGCAGATAGTCGAATGCTAGAGAACAGTCTAGAGTA 60  
 Y S R I A D T G D I L K R D R T L D \*  
 I L A F Q T R V T \* \* S V I E Q \* I E  
 F L L S N R G Y R R D A \* S R K D S R M

61 ATTTAGATTTGAAAAATTTGTTCTAAGGGACAATAGGTACGAACACTCAGACCAAATTAG 120  
 \* I \* V K \* V L N G T I W A Q S H P K I  
 N F R F K K F L I G Q \* G H K H T H N L  
 L D L S K L C S E R N D M S T L T T \* D

121 TATTAGAACATAAAAATGAAAGGTGTGAAAAGTAGAGAGACGGTCACTGCACAACCAACAG 180  
 M I K Y K V K W V K \* R E A L S T N T T  
 \* L R T N \* K G C K E D R Q W H R T P Q  
 Y D Q I K S E V S K M E R G T V H Q N D

181 GAGTCGCAGGGAGGGTATCCAGCGTTACTAATTTTGGTTCGTTATGCCAGAGCCGAAGTT 240  
 R L T G G M P R L S \* F W C I R D R S \*  
 G \* R G E W L D C H N F G A F V T E A E  
 E A D R G Y T A I I L V L L Y P R P K L

241 CACCCGCGGTCTTAAAGCAACCGACGAAGGCCTACGTGCGCTCCTCAACCGATCAGGATA 300  
 T P A L I E N A A E P H L P P T P \* D \*  
 L P R W F K T P Q K R I C R L L Q S T R  
 H A G S N R Q S S G S A A S S N A L G I

301 CTTCACTACTCCCAACCAATACGGGGAGATGACCAAGTTCGCTACCTTTCACAACCTAA 360  
 S T L H P H T I G R \* Q D L S P F H Q I  
 H L \* I L T P \* A G R S T L R H F T N S  
 F D S S P P N H G E V P \* A I S L T P N

361 GCAAATACTATTAGTACACTTCTATCTAACAGCGACGTAAGAACCCTGTTCTTACCGTACA 420  
 R K H Y D H S S L N D S C E Q V L I A H  
 E N I I I M H L Y I T A A N K S L F P M  
 T \* S L \* T F I S Q R Q M R P C S H C T

421 CGTCAGTTAGAAATAGGCACTATAAAAACAAGTACTTCTAGATGTACAACATCTTCAAGA 480  
 A T L D \* G H Y K Q E H L D V H Q L L E  
 H L \* I K D T I N K N M F I \* M N Y F N  
 C D F R I R S I K T \* S S R C T T S T R

481 TTGATTTTGTCCGCATTTCCAGGCCATGCCGTTAAAATTAATTTAGTGGAACGTATCGAA 540  
 L \* F L R L T R Y P L K L \* I V K A Y S  
 \* S F C G Y L G T R C N \* N F \* R Q M A  
 V L V A T F D P V A I K I L D G K C L K

FIG. 3



59/201

541 CCCACCCAAAAGGATTTCCCATACAATACCCGAAACAAGGCAAGTATGTTCTGATTTGCAAT 600  
 P H N E \* L T H \* P S T G N M C S \* V N  
 Q T T K R F P I N H A Q E T \* V L S F T  
 P P K G L P Y T I P K N R E Y L V L R \*

601 ACAACATGTAGTAGAAAGATACTGATGTAGATGATGATTAACCCTTCTAAAAACCC 660  
 H Q V D D K \* S \* M \* \* \* N Q H L N K P  
 I N Y M M K R H S C R S S I K T F I K Q  
 T T C \* R E I V V D V V L K P S S K K P

661 AACCTAACATGGAACCAAAATACGGTAGAATACAAGTGTTTACCAAAGTTAAGACATC 720  
 N S Q V K Q N \* A M K H E C I T E I R Y  
 T P N Y R K T K H W R I N V F P K L E T  
 Q I T G K P K I G D \* T \* L H N \* N Q L

721 CAACATATAACTTCTCTCACTAAATTATTAAGTTTAAAAATTTAACTACTAATACTAAA 780  
 T T Y Q L S H N L L K L N \* I Q H N H N  
 P Q I N F L T I \* Y N \* I K F K I I I I  
 N Y I S S L S K I I E F K L N S S \* S K

781 ATCACATCTTCTACGAATACGACTCCAAGTACGACTCGGATTTCCATTATAAGTGTTT 840  
 \* H L L H K H Q P E H Q A \* L Y I N V F  
 K T Y F I S I S L N M S L R F T F I \* L  
 L T S S A \* A S T \* A S G L P L Y E C F

841 TCGAATACGAAATGAATCTGTATAGCACCATAATTGGGCATGAAAAACATCTGGTCAT 900  
 L K H K V \* V I D H Y \* V R V K Q L G T  
 F S I S \* K S L I T T N F G Y K K Y V L  
 A \* A K S L C Y R P I L G T S K T S W Y

901 ACCAACACTGATAAGACCATTTAATCGTCTAACAGAAGTTCGAATACCAGTAATAAGAAA 960  
 H N H S N Q Y I L L N D E L K H D N N K  
 I T T V I R T E \* C I T K L S I T M I R  
 P Q S \* E P L N A S Q R \* A \* P \* \* E K

961 CGTTCATACTCTGTTTTTCGTCAGACATACCGAACGGTTAACACTGAACTATAACATCA 1020  
 A L Y S V F A T Q I A Q W N H S Q Y Q L  
 Q L I H S L L L R Y P K G I T V K I N Y  
 C S I L C F C D T H S A L Q S K S I T T

1021 CCGAACCGTACATCAAGCACTAAGTGCTAAACAATACGCGGACGTCTGATATCGATGATA 1080  
 P K A H L E H N V I Q \* A G A S \* L \* \*  
 H S P M Y N T I \* S K N H A Q L S Y S S  
 A Q C T T R S E R N T I R R C V I A V I

FIG. 3 CONT'D

60/201

1081 AACACCATAATTTATACAACGTTGGATGTCTTCTACATCATCTACCTCTACATCAATA 1140  
 K H Y \* I H Q V V \* L L H L L H L H L \*  
 N T T N F I N C L R C F I Y Y I S I Y N  
 Q P I L Y T A C G V S S T T S P S T T I

1141 TGCCTTGGACATGTAATAATAGACGACTACGTTATCAAAATTCGAAGGATCAAACTA 1200  
 V H V Q V N I I Q Q H L L K L A E \* N S  
 Y T F R Y M \* \* R S I C Y N \* L K R T Q  
 R S G T C K N D A S A I T K F S G L K I

1201 CTTTCAATACTGAGTATACCTACTAAAAAGATAATTTAGATATATATTACAACATAAACAC 1260  
 S L \* S E Y P H N K \* \* I \* I Y H Q N T  
 H F N H S M H I I K R N F R Y I I N I Q  
 F T I V \* I S S K E I L D I Y L T S K H

1261 ACTAACACCAAAACAATACGTCATACCAATACATCTAACAAAATTACTATTAACACTAAA 1320  
 H N H N Q \* A T H N H L N N \* H Y N H N  
 T I T T K N H L I T I Y I T K I I I T I  
 S Q P K T I C Y P \* T S Q K L S L Q S K

1321 AATACCAACCCAAAGTCCATTATACTACCTACCAAAAAGAACAGGTAACACAACATGTCA 1380  
 K H N P K L Y Y S P H N K K D M T N Y L  
 K I T P N \* T I H H I T K R T W Q T T C  
 \* P Q T E P L I I S P K E Q G N H Q V T

1381 AATACTGAGATCGCTTCAATTTTCGGGTTAGTAGACCACAATAAGGACTTTTAGGACACAA 1440  
 K H S \* R L \* L G I M Q H \* E Q F D Q T  
 N I V R A F N F G L \* R T N N R F I R H  
 \* S E L S T L A W D D P T I G S F G T N

1441 TAAATGATTAATCATGACTATGACAATGGTACTAAGAAAATTAACATACCAATAAGACA 1500  
 I \* \* Y Y Q Y Q \* G H N K \* N T H N N Q  
 \* K S I T S I S N V M I R K I Q I T I R  
 N V L L V S V T L W S E K L K Y P \* E T

1501 GTGTGGTAAACCAAGAACATATATAACCAGCGGCGCAGGACCTAACACCTAAGGATATTA 1560  
 \* V M Q N K Y I N T A A D Q I T S E \* L  
 D C W K T R T Y I P R R T R S Q P N R Y  
 V G N P E Q I Y Q D G R G P N H I G I I

1561 ATTTAGAAGTCAGTTCAGAATACTACTAAACCAATAAGTCCACATCATCCAACATTTAG 1620  
 \* I K L \* T K H H N P K N L H L L N Y I  
 N F R \* D L R I I I Q N I \* T Y Y T T F  
 L D E T L D \* S S K T \* E P T T P Q L D

FIG. 3 CONT'D

61/201

1621 ATAACAATTTCTTTGACGAGAATAATGAGTACGTGAAATGAATCTAATACAAGTTACATT 1680  
 \* Q \* L F Q E \* \* E H V K S L N H E I Y  
 R N N F F S S K N S M C K V \* I I N L T  
 I T L S V A R I V \* A S \* K S \* T \* H L

1681 CACACCATTAGAACTGTTTTAGTATAAGAACCAGCAATTATTAAGAACCACATCCGTGTA 1740  
 T H Y D Q V F D Y E Q R \* Y N K T Y A V  
 L T T I K F L I M N K A N I I R P T P L  
 H P L R S C F \* I R P T L L E Q H L C S

1741 CAACGAATTATCTCCACTAATATTATACGAAGATTTTTTATAACTGAACAAACAATTCGC 1800  
 T A \* Y L H N Y Y A E L F Y Q S T Q \* A  
 Q Q K I S T I I I H K \* F I N V Q K N L  
 N S L L P S \* L I S R F F I S K N T L R

1801 AGCACGACTAAAACGAACGTTCAAACGTCAAACACCTCTACCAAACATGGAAAAATGA 1860  
 D H Q N Q K C T Q L K H L H N Q V K K V  
 T T S I K S A L K C N T S I T K Y R K \*  
 R A S K A Q L N A T Q P S P K T G K K S

1861 TCTACCAAATTAAGGGGCATCAATAATAGATTAAGTCTCACCATAAAAAGAAATGTAGAAA 1920  
 L H N L E G Y N N D L E S H Y K R \* M K  
 \* I T \* N G T T I I \* N L T T N E K C R  
 S P K I G R L \* \* R I \* L P I K K V D K

1921 CTACAGAGTTAAAAGTGTTC'TTCAAAGACTATACCAAATTTTACACATAAAAACAAATA 1980  
 S T E I K V L L K Q Y T N L F T Y K T \*  
 Q H R L K \* L F N R I H T \* F H T N Q K  
 I D \* N E C S T E S I H K F I H I K N I

1981 CCTGTCTCAAAGTCAACGATGTAATAATATATCTCGTAATACAATATCCAACCAATGAGT 2040  
 F C L K L Q \* M K Y L A N H \* Y T P \* E  
 H V S N \* N S C K I Y L M I N I P Q N S  
 S L T E T A V N \* I S C \* T L L N T V \*

2041 TAAATTCAATAACCCATGATGTGAACAATTTATTTTACCAATTAACCAAATTTATGGTACAA 2100  
 I \* T I P Y \* V Q \* Y F P \* N T \* Y W T  
 L K L \* Q T S C K N I F H N I P K I G H  
 N L N N P V V S T L L I T L Q N L V M N

2101 TCTACGATCACGTGGACGATGTCCGACCGAAGAAATGGTTAATAACTTACCAGAAAAACA 2160  
 L H \* H V Q \* L S A E K G I I S H D K Q  
 \* I S T C R S C A P K K V L \* Q I T K K  
 S A L A G A V P Q S R \* W N N F P R K T

FIG. 3 CONT'D

62/201

2161 TCATAGAGTTCGGTTGAAATTAACAACGAAATATGGACTAATACGATTTTAAATCA 2220  
 L I E L W S \* N Q Q K L V Q N H \* F K L  
 Y Y R L G V K I K N S \* Y R I I S F N \*  
 T D \* A L K L K T A K I G S \* A L I K T

2221 ATTATTTAAATGTGAAAAAATCAATAATAATCTCACACAATGTCAACTACAAAATTT 2280  
 \* Y I K C K K \* T I I L T H \* L Q H K L  
 N I F K V S K K L \* \* \* L T N C N I N \*  
 L L N \* V K K L N N N S H T V T S T K F

2281 TCTATACGGACAAGAATTTTGATAATTACCAAATCAAACATAACATCCGTTATTCAAAT 2340  
 L Y A Q E \* F \* \* H N L K Y Q L C Y T K  
 F I H R N K F S N I T \* N T N Y A I L K  
 S I G T R L V I L P K T Q I T P L L N \*

2341 ATTGCAATCATGTCCCAATTAAGGACCAAAACAAAATGGTACATTACGTGTCCTTGTGT 2400  
 Y R \* Y L T L E Q N Q K V M Y H V P V V  
 I V N T C P \* N R T K N \* W T I C L F L  
 L T L V P N I G P K T K G H L A C S C C

2401 TTAATAAAAAAACTCCGCAACGCTTAGACAATATCATCTTCTACTACAATAACTCTT 2460  
 F K N K Q L R Q L I Q \* L L L H H \* Q S  
 L N I K K F A N C F R N Y Y F I I N N L  
 I \* K K S P T A S D T I T S S S T I S F

2461 ACAGTTTAGAAGAAATAGTAGAATACTCATAACAGTTGGTGGATTTAGACATCTTTTFTA 2520  
 H \* I K K I M K H T N D V V \* I Q L F F  
 I D F R R \* \* R I L I T L W R F R Y F F  
 T L D E K D D \* S Y Q \* G G L D T S F I

2521 AACATAATATCTATTATACATGTACCCATTACACCACTATTTAAAAAGGGATAACAGTA 2580  
 K Y \* L Y Y T C P Y T H H Y I K G \* Q \*  
 N T N Y I I H V H T L T T I F K E R N D  
 Q I I S L I Y M P L H P S L N K G I T M

2581 CTTACTATTTTATAAACAGAAAATCTAGTCCGAACCGCAAAAGGTACACGTCCATCTTT 2640  
 S H Y F Y K D K L D P K A N E M H L Y F  
 H I I F I N T K \* I L S P T K W T C T S  
 F S L F I Q R K S \* A Q R K G H A P L F

2641 TCAATTAATAATGCTCTTTGGACAACARTACCTCTAAGGCAGAACTACTGTCAATTC 2700  
 L \* N \* R S V Q Q \* P S E T K S S L \* P  
 F N I K V L F R N N H L N R R Q H C N L  
 T L K L S F G T T I S I G D K I V T L T

FIG. 3 CONT'D

63/201

2701 ATACAACTAAATCTAAGATGAAAACACTACTATAAAATCCATTTCAAACAAGTCTTAAACT 2760  
 \* T Q N L N \* K Q H Y K L Y L K N L I Q  
 N H K I \* I R S K I I N \* T F N T \* F K  
 I N S K S E V K S S I K P L T Q E S N S

2761 TCATCTTTCCCAATGACATCTACTAAAACAACGACAACAACACTACGATATCTCTT 2820  
 L L F P H \* Q L H N Q Q Q Q K H H \* L S  
 F Y F L T N S Y I I K N S N N T I S Y L  
 T S F P T V T S S K T A T T Q S A I S F

2821 ACGAAATTTGAGAACATTTCTCGTAGGTCACCAACCAATAGTTCAAGCAGTAAAAATTT 2880  
 H K L S K Y L A D L P Q N D L E H M K L  
 I S \* V R T F L M W H N T I L N T C K \*  
 A K F E Q L S C G T T P \* \* T R A N K F

2881 ATTTGAATTACTCTTACAACAAA'AAATAAACTACTCCGACCACTACTTCGTTACCGGAG 2940  
 Y V \* H S H Q K N I Q H P Q H H L L P R  
 I F K I L I N N I \* K I L S T I F C H G  
 L S L S F T T \* K N S S A P S S A I A E

2941 AGCATACATAACATGAAAACGATAACTCCTACAACCTCTGCAATAGTCATCACTTCGACA 3000  
 E Y T N Y K Q \* Q P H Q L R \* \* Y H L Q  
 R T H I T S K S N L I N F V N D T T F S  
 R I Y Q V K A I S S T S S T I L L S A T

3001 GCTTCTATGATAACTACCACAGCAACTTCTGTGATAATTACTGCTACTTCTACAACAATG 3060  
 R L Y \* Q H H R Q L C \* \* H R H L H Q \*  
 D F I S N I T D N F V S N I V I F I N N  
 S S V I S P T T S S V I L S S S S T T V

3061 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3120  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3121 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3180  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3181 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3240  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

FIG. 3 CONT'D

64/201

3241 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3300  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3301 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3360  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3361 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3420  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3421 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3480  
 Q H C H R H L H Q \* Q H C Y R H L S Q \*  
 S T V I V I F I N N S T V I V I F L N N  
 P S L S S S S T T V P S L L S S S I T V

3481 ACCACTGTTACTACTGGTTTACAACAATGACCACTACTACATCTACTATAACTTTTCATA 3540  
 Q H C H H G F Q Q \* Q H H H L H Y Q F Y  
 S T V I I V L N N N S T I I Y I I N F T  
 P S L S S W I T T V P S S T S S I S L I

3541 AATACTGAAACTATGAATATTTGAGAAAATCAAAAATTACTACAGATATTACTACGAAA 3600  
 K H S Q Y K Y L E K L K \* H H R Y H H K  
 N I V K I S I F S K \* N K I I D I I I S  
 \* S K S V \* L A R K T K L S T \* L S A K

3601 CAAACAATCAATACCAAGATCACAACCTTTGTCTTTGTATAAAAATTTCAATACCAAAATAC 3660  
 T Q \* N H N \* H Q F L F M N \* L \* H N I  
 Q K N T I T R T N F C F C I K F N I T \*  
 N T L \* P E L T S V S V Y K L T L P K H

3661 CAGTGGATGATAATGTGTATGATTAACAACCAACGCAAGACACAATGAACATTACGTCTT 3720  
 T V \* \* \* V Y \* N N T A N Q T V Q L A S  
 P \* R S N C M S I T P Q T R H \* K Y H L  
 D G V I V C V L Q Q N R E T N S T I C F

3721 TAATGGAAAATTCAAATTCCTAAATCGATAACTTTTATACACCAATAGAAATATTCACCC 3780  
 I V K \* T \* P N L \* Q F Y T T I K Y P P  
 F \* R K L K L I \* S N F I H P \* R I L H  
 N G K L N L S K A I S F I H N D \* L T P

FIG. 3 CONT'D

65/201

3781 AATATTAGTTTCAAAACAATAAATGACTGGTGATAAGGATTTTCGATAACAAAACGG 3840  
 N Y D F N Q Q N N V S W \* E \* L \* Q K A  
 T I I L T K N I I \* Q G S N R F S N N Q  
 \* L \* L K T S \* K S V V I G L A I T K G

3841 AGTTCCACCAAAACATCGACTAAAACGAATAACCAAAAATTTGGTCAAATAATAATTCG 3900  
 E L H N Q L Q N Q K N T K L G T Q Y \* H  
 R L T T K Y S I K S I P K \* V L K I N I  
 \* P P K T A S K A \* Q N K F W N S I L A

3901 CATACGATTAACCACAACAAATTTACACCAAAAAGAAAATAAATTTACCAAACTACG 3960  
 T H \* N T N N L I H N K K Q N L H N P H  
 R I S I P T T \* F T T K R K I \* I T Q I  
 Y A L Q H Q K F H P K E K S K F P K S A

3961 AAACAAAAAATACCTCTATAACACAGAGTACAAACATTCACACCTGTATTATACTGAGA 4020  
 K T K K H L Y Q T E H K Y T H V Y Y S E  
 S Q K K I S I N H R M N T L T S M I H S  
 K N K \* P S I T D \* T Q L H P C L I V R

4021 TTATCGTCGCCTGAATGGAACATGTAATGTAAAAAGTAATAAACTACTGTAAAAACCG 4080  
 L L L P S V K Y M V N K M I Q H C N K H  
 \* Y C R V \* R T C \* M K \* \* K I V I K T  
 I A A S K G Q V N C K E N N S S L K Q A

4081 AAAAACTGGGGATTTTTTAAAAATAACGACGTACACGACACCTACATTTGCAAAACAGT 4140  
 K K C G \* F F K \* Q Q M H Q P H L R K D  
 S K A G R F F N K N S C T S H I Y V N T  
 K Q V G L F I K I A A H A T S T F T Q \*

4141 AAGACATCGACAATATCCACTACTTGTATTATCTACCATTCAAACAATGATTTAAATCACC 4200  
 N Q L Q \* L H H V F L H Y T Q \* \* I \* H  
 M R Y S N Y T I F L Y I T L K N S F K T  
 E T A T I P S S C I S P L N T V L N L P

4201 ACTAFTTAAACTAAAATATCATCCAATACCTTACAGTAAATCATAACAGAAAACAA 4260  
 H Y I Q N \* L L N H E T M \* Y T K K Q T  
 T I F K I K Y Y T I S H \* K T H R R K L  
 S L N S K I T P \* P I D N L I D E K S N

4261 TGGAGTTAACATACCAAAACACATATTGTGGATTACATACAAAACAATTTCCACTATAATA 4320  
 V E I T H N T Y L V \* H I N Q \* L H Y \*  
 \* R L Q I T Q T Y C R I Y T K N F T I N  
 G \* N Y P K H I V G L T H K T L P S I I

FIG. 3 CONT'D

66/201

4321 TTTACAACGATCTGAACAATTTGACTACAATAACAATTAGGACGATTACCCGTATACGA 4380  
 L H Q \* V Q \* L Q H \* Q \* D Q \* H A Y A  
 Y I N S S K N F S I N N N I R S I P M H  
 F T A L S T L A S T I T L G A L P C I S

4381 GGTACCACCACCTCAACGTTTTTCGATATCGACATCGACGTCCATTTTTTAAAAGATTCT 4440  
 G H H H L Q L L \* L Q L Q L Y F I K \* L  
 E M T T S N C F S Y S Y S C T F F K R F  
 W P P P T A F A I A T A A P L F N E L S

4441 TTGACGACGATACCAATTTAGATTTCCACAACGGTTCATCCTCTAACCAATACAAAGATG 4500  
 F Q Q \* P \* I \* L H K G L L L N N H K \*  
 F S S S H N F R F T N A L Y S I T I N R  
 V A A I T L D L P T Q W T P S Q \* T E V

4501 GCCACCATTTAATACATTTTGTTAAGAAATATAACATCCGGGACTACGATCTGTTCTACC 4560  
 R H Y I I Y F L E \* Y Q L G Q H \* V L H  
 G T T F \* T F C N K I N Y A R I S S L I  
 P P L N H L V I R L I T P G S A L C S P

4561 TTCTGTAGAAATACAAAACAATCGTGCACGAATATTCGTAGAATTATTAATACTAACAAC 4620  
 F V I K H K T L V H K Y A D \* Y N H N N  
 S S L R I N Q \* C T S I L M K I I I I T  
 L C D \* T K N A R A \* L C R L L \* S Q Q

4621 AAACAGATGAGAGTATAGCCGACCATATAAATCACAGGACGACTACACAGTAATTGART 4680  
 N T \* E \* I P Q Y I \* H E Q Q H T M L K  
 T Q R S E Y R S T Y K T N R S I H \* \* S  
 K D V R M D A P I N L T G A S T D N V \*

4681 GGAAGATCCACAACAACACTATTTGTTCAATAGGAACAATCATTATTATTCTTCTAAAAC 4740  
 G E L H Q Q Y V L \* G Q \* Y Y Y L L N Q  
 V K \* T N N I F L N D K N T I I F F I K  
 R R P T T S L C T I R T L L L L S S K S

4741 ATAATAAGTTTTTACAGTTTAAATGAAGTCAACAACCATGATTTGTAACCGACAATCTAA 4800  
 Y \* E F I D F \* K L Q Q Y \* L M P Q \* I  
 I N N L F T L N S \* N N T S F C Q S N S  
 I I \* F H \* I V E T T P V L A N A T L N

4801 TTGACGATTACATCCGGCACAATAATTTAAACTCTGTCTACGTATGTTGAAAAAACTC 4860  
 L Q \* H L G H \* \* I Q S L H M C V K K S  
 \* S S I Y A T N N F K L C I C V F K K Q  
 V A L T P R T I L N S V S A Y L S K K L

FIG. 3 CONT'D



67/201

4861 ACCACTACTAACAACAAACAAAGTTTAAGAAGACAATATGTTCTTCAAATAACGAAGCAGT 4920  
 H H H N N Q K L N K Q \* V L L K I A E D  
 T T I I T K N \* I R R N Y L F N \* Q K T  
 P S S Q K T E F E E T I C S T K N S R \*

4921 ACTATATGTTAACTTATTACTGCAAGCACTAATAAACACAGATTCTACTGATCAGAAGG 4980  
 H Y V I S Y H R E H N N T T \* S S \* D E  
 M I Y L Q I I V N T I I Q Q R L H S T K  
 S I C N F L S T R S \* K N D L I V L R G

4981 ATTTCTAACCGCAGAATAGTTATTTAACTACAATAATTGCCACAATTTTGACAATTCAT 5040  
 \* L N A D \* \* Y I Q H \* \* R H \* F Q \* T  
 R F I P T K D I F K I N N V T N F S N L  
 L S Q R R I L L N S T I L P T L V T L Y

5041 AAAACTCACAGGATTAAGATAAATATATACATCAGTCCCATTCTGAAACCAATACATAC 5100  
 N Q T D \* N \* K Y I Y D P Y L S Q N H I  
 I K L T R I R N I Y T T L T F V K T I Y  
 K S H G L E I \* I H L \* P L S K P \* T H

5101 ACTACCAAGAAAAATATTTTCGTTGACAATTAGTTCAAACACAAAATAATCGATTCTTCTA 5160  
 H H N K K Y L L Q \* D L K H K I L \* S S  
 T I T R K I F C S N I L N T N \* \* S L L  
 S P E K \* L A V T L \* T Q T K N A L F I

5161 TCTACAAAACGAATGACATCTACCACAATTAATAATTTAGATAAAGAGAATGACATCCACT 5220  
 L H K A \* Q L H H \* N \* I \* K E \* Q L H  
 Y I N Q K S Y I T N I K F R N R K S Y T  
 S T K S V T S P T L K L D I E R V T P S

5221 TCAAAAACCATTTTATGAACCATTACAAAAGACACTACCGTAACTACAATGATTCATTT 5280  
 L K Q Y F V Q Y H K R H H C Q H \* \* T L  
 F N K T F Y K T I N E T I A N I N S L \*  
 T K P L I S P L T K Q S P M S T V L N F

5281 CACATCACTAAAAATACGGCTATTTTAAAAATATAGTCATACTTTTAAACAGAAATCGACT 5340  
 T Y H N K H R Y F K I D T H . F N T K L Q  
 L T T I K I G I F N \* I L I F I Q R \* S  
 H L S K \* A S L I K Y \* Y S F K D K A S

5341 ATAAAGACGACATGTTTCAAGTAAACCCAAACTAGTCGTTGTTAACGAACGAATAATATT 5400  
 Y K Q Q V F N M Q T Q D A V I A Q K N Y  
 I N R S Y L T \* K P K I L L L Q K S I I  
 I E A T C L E N P N S \* C C N S A \* \* L

FIG. 3 CONT'D

68/201

5401 AAAAAATGTGCATACATTTACCAGACATCAACAATTGCCAGGTAAGAAAAAGAAAACITGT 5460  
 N K L L I Y I T Q L Q \* R D M K K K Q V  
 I K \* C Y T F P R Y N N V T W K K R K F  
 K K V T H L H D T T T L P G N K E K S C

5461 CAGAGTATTATTAACAATACACTTACATCGAACAGAATACAACGTCGTATAATTAGAATT 5520  
 T E Y Y N N H S H L K D \* T A A Y \* D \*  
 L R M I I T I H I Y S T K H Q L M N I K  
 D \* L L Q \* T F T A Q R I N C C I L R L

5521 TAAATTTATTTACCGTCACCGTCCTTCGTACCATACTTAAAGCACGACCGTCTGGTGTATC 5580  
 I \* Y I A T A P L M T H I E H Q C V V Y  
 F K I F P L P L F C P I F K T S A S W M  
 N L L H C H C S A H Y S N R A P L G C L

5581 CAATCAAGGAGAACAAAATCGATTTCCAGTAAAATTTAAACTACTTGGTAGTCTACGATG 5640  
 T L Q E Q K L \* L D N \* I Q H V M L H \*  
 P \* N S K N \* S F T M K F K I F W \* I S  
 N T A R T K A L P \* K L N S S G D S A V

5641 ACTAAAATAAGCACAAACAAACTTTGTTTCGACTAAATAGTCCACGTTAAACACTTAATCT 5700  
 Q N \* E H Q K S V L Q N I L H L K H I L  
 S I K N T N N Q F L S I \* \* T C N T F \*  
 S K I R T T K F C A S K D P A I Q S N S

5701 TGAATAAACACTAACACCATAATTTGTTCTTTCAGCACAACCACAACACTACGACAATACGT 5760  
 V \* K H N H Y \* V L F D H Q H Q H Q \* A  
 F K N T I T T N F L F T T N T N I S N H  
 S I Q S Q P I L C S L R T P T S A T I C

5761 AAAACCATGTAATCGTTTCTGACTAGAAAAATTACCAATATTCTAACCGACATTAACACG 5820  
 N Q Y M L L S Q D K \* H N Y S Q S Y N H  
 M K T C \* C L S I K K I T I L N A T I T  
 K P V N A F V S R K L P \* L I P Q L Q A

5821 TCCATCTTAACAGGTAACATGATTTAACTTACATGGTAAAAACTAAACAAGATTATGAGG 5880  
 L Y F Q G N Y \* I S H V M K S K N \* Y E  
 C T S N D M T S F Q I Y W K Q N T R I S  
 P L I T W Q V L N F T G N K I Q E L V G

5881 AGACTCATTCCTAAATGGACTACTACAACAACGTCGATTGTACAAAATACCCACATCCACA 5940  
 E S Y P N V Q H H Q Q L \* C T \* P H L H  
 R Q T L I \* R I I N N C S V H K H T Y T  
 R L L S K G S S T T A A L M N I P T P T

FIG. 3 CONT'D

69/201

5941 TCCGGTAATATGTGTAAACTTTACACCAAGTGGAAATGGTTGTAAATACTACGAACATCACA 6000  
 L G N Y V N S I H N V K G V N H H K Y H  
 Y A M I C M Q F T T \* R V L M I I S T T  
 P W \* V C K F H P E G \* W C \* S A Q L T

6001 ATTTTTTATATGTCCACAATCACCACAAAATTGACTGACGAACATAGAATTTTAAATTG 6060  
 \* F I Y L H \* H N N L Q S S T D \* F N L  
 N F F I C T N T T T \* S V A Q I K F I \*  
 L F Y V P T L P Q K V S Q K Y R L F K V

6061 GGTCTGAAAATGTAGATACAACCTGATTAATAAAAAACCTACTACAACCTTACCAACGAAT 6120  
 G S K \* M \* T S \* N N K P H H Q F P Q K  
 G L S K C R H Q S I I K Q I I N F H N S  
 W V K V D I N V L \* K K S S T S I T A \*

6121 ATTGGGACTAGAAAAGTGTATAATAACACTATTACCATTACATAATATGTTTTGGATAATA 6180  
 Y G Q D K V I N N H Y H Y T N Y L V \* \*  
 I V R I K \* L I I T I I T L I I C F R N  
 L G S R E C Y \* Q S L P L Y \* V F G I I

6181 TTCCGAGTCAAATTTGGTAAACGATTTCAACTGCCACAAATATGATTGAAATTCAATCA 6240  
 L P E T \* V M Q \* L Q R H K Y \* S \* T L  
 Y L S L K F W K S F N V T N I S V K L \*  
 F A \* N L G N A L T S P T \* V L K L N T

6241 ACCTGTACTATAAACACGAGTTAACTTACTATTCAATCCAAAATTACATCTAAACGGCAA 6300  
 Q V H Y K H E I S H Y T L N \* H L N A T  
 N S M I N T S L Q I I L \* T K I Y I Q R  
 P C S I Q A \* N F S L N P K L T S K G N

6301 ACAACTCATGTTTCATTGTCAGACCGGACATCGATGACCACTACAACAAAACCGTAGACT 6360  
 Q Q T C L L L R A Q L \* Q H H Q K P M Q  
 K N L V F Y C D P R Y S S T I N N Q C R  
 T S Y L T V T Q G T A V P S T T K A D S

6361 ACTAAATATACACTTTGCAATAAAAATTCCTACACTTTGAAAACCATTCGGACAATAAAC 6420  
 H N I H S V N N \* L I H F K Q Y A Q \* K  
 I I \* I H F T I K F S T F S K T L R N N  
 S K Y T F R \* K L P H S V K P L G T C Q

6421 CAAAACAGTACTACTTCGTAGTAACTTAAGAGAATGAATAAAAATTTATTGGATCAAATTT 6480  
 T K D H H L M M S N E \* K N \* Y V \* N \*  
 P K T M I F C \* Q I R K S I K I F R T K  
 N Q \* S S A D N F E R V \* K L L G L K L

FIG. 3 CONT'D

70/201

6481 TAGACTTTTATCTATATACAAAAACAGACAACCTAAGACATAGACTCCTCAGTGTTCATT 6540  
 I Q F Y L Y H K T Q Q N Q I Q P T V L Y  
 F R F I S I T N Q R N I R Y R L L \* L T  
 D S F L Y L T K D T S E T D S S D C P L

6541 ACACCAATGAAGACAATACCTTAGCGTCTAATCATGATTTCTCCAATTC AATTTCCACA 6600  
 H P \* K Q \* P I A S \* Y \* L P \* T L P H  
 I H N S R N H F R L N T S F L N L \* L T  
 T T V E T I S D C I L V L S T L N F P T

6601 ATCTTTCTGACAATTTTATCTTCTACGATAATAACAATTACTACTTTTATCAAGATAATT 6660  
 \* F S Q \* F L L H \* \* Q \* H H F Y N \* \*  
 N S L S N F Y F I S N N N I I F I T R N  
 L F V T L I S S A I I T L S S F L E I L

6661 CCAACAATTTTCAAATAGAAATCAACTACAACCCCTATACATAAACTGTCCAACACTAAT 6720  
 P Q \* F N I K L Q H K P Y T N S L N H N  
 L N N F T \* R \* N I N P I H I Q C T T I  
 T T L L K D K T S T Q S I Y K V P Q S \*

6721 ACAACAAACCCAACGATTACTTAACAGTGGGATCAATTTAGTGGTGTGCAATCCCCTAT 6780  
 H Q K P Q \* H I T V G L \* I V L L \* P I  
 I N N P N S I F Q \* A \* N F \* W C N P F  
 T T Q T A L S N D R R T L D G V T L S Y

6781 ATATGCTATACCATAAATTTGGATAATGATATGGATATCTAAACAATACAAATCTCTACT 6840  
 Y V I H Y \* V \* \* \* V \* L N T I N L L H  
 I Y S I T N F R N S Y R Y I Q \* T \* S I  
 I R Y P I L G I V I G I S K N H K L S S

6841 ATTAGTTTGAGAAAATCAAGGATTTTAAAAATTCGTTCTCGATATCTTAAAAATACCAA 6900  
 Y D F E K L E \* F K \* L L L \* L I K H N  
 I I L S K \* N R F N K F C S S Y F K I T  
 L \* V R K T G L I K L A L A I S N \* P K

6901 AAACCTCACCAACAAATAAATACAAAAATCAAATAATGTA AAAATGTTTACTATTTTGGTA 6960  
 K S T T T \* K H K \* N I V N \* L H Y F W  
 K Q L P Q K N I N K T \* \* M K C I I F G  
 K F H N N I \* T K L K N C K V F S L V M

6961 AAAAAATATGATGTCTTTATCGAAGATTC AATGAAAATTAACAAAACAAACCGAGAATT 7020  
 K K Y \* L F L K \* T \* K \* N T K N P E \*  
 N K I S C F Y S R L K S K I Q K T Q S K  
 K \* V V S I A E L N V K L K N Q K A R L

FIG. 3 CONT'D

71/201

7021 TTTACGAAAAGTCTGTAAATCTACCTCATATAAATATTTTCCAAAAGAACAACATCGGTG 7080  
 F H K E S M \* I S Y I \* L L N E Q Q L W  
 F I S K L C K S P T Y K Y F T K K N Y G  
 F A K \* V N L H L I N I F P K R T T A V

7081 ACACAAAACAAAACCAATTTAAAAACATATATTTACAATAAAAACTACTGAAAATAGA 7140  
 Q T K T K T \* N K T Y L H \* K \* H S K D  
 S H K Q K P K I K Q I Y I N N K T V K I  
 T N K N Q N L K K Y I F T I K L S K \* R

7141 AGGATTATAATCACAAAAGGATAAAAACACCCCTTCTTAACAATACACCTATTTCCGATG 7200  
 E \* Y \* H K E \* K Q P F F Q \* T S L P \*  
 K R I N T N K R N K H S S N N H P Y L S  
 G L I L T K G I K T P L I T I H I F A V

7201 AAAACCAACCAATGTTAAACACTAAAAATAAGATTCAATCCACATCCAAAATGTTTCAGT 7260  
 K Q N P \* L K H N K N \* T L H L N \* L D  
 S K T Q N C N T I K I R L \* T Y T K C T  
 K P K T V I Q S K \* E L N P T P K V L \*

7261 AAAACATTACCATCAAAATATACACTTAACACAGTAAGACCAAAACCTATACAACTATG 7320  
 N K Y H Y N \* I H I T D N Q N Q Y T P Y  
 M K T I T T K Y T F Q T M R T K I H Q I  
 K Q L P L K I H S N H \* E P K S I N S V

7321 TATACGTCGATATCTAAAACAAGTCATACTTCATCTATCTGCACAAAATAAACTAACACA 7380  
 M H L \* L N Q E T H L L Y V H K I Q N H  
 C I C S Y I K N L I F Y I S T N \* K I I  
 Y A A I S K T \* Y S T S L R T K N S \* T

7381 ATCAAATCAGTTTAATTAACAACCTTGAGCAATAACCAATAAGTAATATGFGTCATACCAA 7440  
 \* N L \* I L Q Q V R \* Q N N M I C L I T  
 N T \* D F \* N N F E N N T I \* \* V C Y P  
 L K T L N I T S S T I P \* E N Y V T H N

7441 AATAGGTAATAAAAACAGAATAACCAATGTTAATAAATGATGTACCAACGGACTAAACAA 7500  
 K D M I K D \* Q N V I I \* \* M T A Q N T  
 K I W \* K T K N T \* L \* K S C P Q R I Q  
 \* G N N Q R I P K C N N V V H N G S K N

7501 ATACAATCTTTGATACGTAACCAACTAATCTAAATAACATAAACATCGATTAACAAATGG 7560  
 \* T L F \* A N T S \* I \* Q I Q L \* Y T V  
 K H \* F S H M F Q N S K N Y K Y S I H \*  
 I N S V I C Q N I L N I T N T A L I N G

FIG. 3 CONT'D

72/201

7561 ACGAAAACAGAACCAACGCCAAAATATATCAACAATGACGATACATATTTTCATCAACCAA 7620  
 Q K Q R T A T K Y L Q \* Q \* T Y L L Q N  
 R S K D Q Q P K I Y N N S S H I F Y N T  
 A K T K N R N \* I T T V A I Y L T T P K

7621 ATAATCCGTATAACAGATACCAACATTATTTTCGACCAACAATAAAAACAATATTTGCTTT 7680  
 \* \* A Y Q R H N Y Y L Q N N I K N Y V F  
 K N P M N D I T T I F S T T \* K T I F S  
 I L C I T \* P Q L L A P Q K N Q \* L R F

7681 AACATCACAAGCACAATTCACATCATGATAACAACCACCACATTAAGCAATAATACTATA 7740  
 N Y H E H \* T Y Y \* Q Q H H L E N N H Y  
 I T T N T N L T T S N N T T Y N T I I I  
 Q L T R T L H L V I T P P T I R \* \* S I

7741 ATGACGATTACCACCATGACCAAAAACACAATTTGTAGTTACCTTAACAAAATTAACGGT 7800  
 \* Q \* H H Y Q N K H \* V D I S N N \* N G  
 N S S I T T S T K T N F M L P I T K I A  
 V A L P P V P K Q T L C \* H F Q K L Q W

7801 AAGAAAATTTGGTCCATTGTGAAAATATTGACATCTTCGACGATATCTTCAAAGATTTCT 7860  
 N K \* V L Y C K \* L Q L L Q \* L V K \* L  
 M R K F W T V S K Y S Y F S S Y F K R F  
 E K L G P L V K I V T S A A I S S E L S

7861 CGAATTTGCTGGACATTTAGGTTGACTACGAAGTGAATACATCAATGACTATAAATTCGT 7920  
 A \* V V Q L D L Q H K V N H L \* Q Y \* A  
 L K F S R Y I W S I S \* M I Y N S I N L  
 S L R G T F G V S A E C \* T T V S I L C

7921 TCAACCAACATACTACGCAAAACAAGATACTATCTCTACCTGTCGCACAAATGCTACTACA 7980  
 L Q N Y S A N T R H Y L H V A H K R H H  
 L N T T H H T Q E I I S I S L T N V I I  
 T P Q I I R K N \* S L S P C R T \* S S T

7981 ACTACGATCAAATAAACATCTATAATTTATTAGACAATGTAAGATTTCAATTTCAACRAAG 8040  
 Q H \* N I Q L Y \* Y D T V N \* L \* L Q E  
 N I S T \* K Y I N I I Q \* M R F N F N N  
 S A L K N T S I L L R N C E L T L T T G

8041 ATTAAAGATACATCAACATCATCTCTCACTACGACTATCTCGATTAAGAAAGACTTACGACA 8100  
 \* N T H L Q L L S H H Q Y L \* N E S H Q  
 R I Q I Y N Y Y L T I S I S S I K Q I S  
 L K Y T T T T S I S A S L A L K R F A T

FIG. 3 CONT'D

73/201

8101 ACACAAAATACGTGTTAGTAAACATATCCGGATATAATGAACATCTGTTTTCAATTAATG 8160  
 Q T . K H V I M T Y A \* I V Q L C F T L \*  
 N H K I C L \* Q I P R Y \* K Y V F L \* N  
 T N \* A C D N Y L G I N S T S L F N I V

8161 ATGTTCGAACATTACCATAGAGACATTGGGTCTGATACAAACTACAAATACAACTATGAAA 8220  
 \* L K Y H Y R Q L G S \* T Q H K H Q Y K  
 S C S T I T D R Y G L S H K I N I N I S  
 V A Q L P I E T V W V I N S T \* T S V K

8221 ATACAGAGTAAACTACAACATCTTTCTCAAATTTATAAACAATTGTAACGAGTACG 8280  
 \* T E N Q H Q Y F S N \* Y N Q \* C Q E H  
 K H R M K I N I S L T K I I K N V N S M  
 I D \* K S T S L F L K L L K T L M A \* A

8281 AAGAGAATCTCTCCCACAGTTAATCTTTTCCAAATCTATGAAAACACCCCTACACATGC 8340  
 K E \* L P H A I L F P K L Y K Q P I H V  
 S R K S L T H L \* F L N \* I S K H S T Y  
 E R L S P T C N S F T K S V K T P H T R

8341 ATTTACAACAAGGTAAGTAACTAAGTCTACAACCTTTGTTCTAAATAATGATTTAGATACTATAG 8400  
 Y I N N W Q N L H Q F L I \* \* \* I \* S I  
 T F T T G N I \* I N F C S K N S F R H Y  
 L H Q E M S E S T S V L N I V L D I I D

8401 ACGTCATCGACGACCAACCTTAAATGACTACTTTTAATATTGTTAAACCATGGATGTAT 8460  
 Q L L Q Q N P I \* Q H F N Y C N P V \* M  
 R C Y S S T Q F K S I F I I V I Q Y R C  
 A T A A P K S N V S S F \* L L K T G V Y

8461 AAATTTCTCACTATTATAACATCGACGACTAAATCCACAAGAATATGTCTTACCACGATT 8520  
 N L S H Y Y Q L Q Q N L H E \* V S H H \*  
 I \* L T I I N Y S S I \* T N K Y L I T S  
 K F L S L I T A A S K P T R I C F P A L

8521 CGTACATGTCCATTACAACGATTCCGTGATTATAAAGAACATATACCAAATAACTACG 8580  
 A H V P Y H Q \* P L \* Y K K Y I T \* Q H  
 L M Y L T I N S L C S I N R T Y P K N I  
 C T C P L T A L A A L I E Q I H N I S A

8581 AAAATTAGTTGAATGACGACTAAATGTCGTATTTAATTTTTCGTACACAATTTTGACC 8640  
 K \* D V \* Q Q N V A Y I L F L M H \* F Q  
 S K I L K S S I \* L M F \* F F C T N F S  
 K L \* S V A S K C C L N F F A H T L V P

FIG. 3 CONT'D

74/201

8641 GAACTTCAATTTTAACTGAAAATTATTCGTTCTCCGTTCCACAGGGATAAGAATGTTGTGG 8700  
 S S T L I S K \* Y A L P L H G \* E \* L V  
 A Q L \* F Q S K I L L L C T D R N K C C  
 K F N F N V K L L C S A L T G I R V V G

8701 GAAAAGTGAATTTCCCTCCACAACATAACTCATTAACAATATATATAATAAAAAACAATC 8760  
 R K V \* L L H Q I S Y N T I Y I I K Q \*  
 G K \* K F S T N Y Q T I Q \* I Y \* K K N  
 K E S L P P T T N L L K N Y I N N K T L

8761 AAATTAGACAAAATATAATAACACCCGAAATAACGGATGTATATCACAATATTCAGACT 8820  
 N L R N \* I I T P K I A \* M Y H K Y T Q  
 T \* D T K Y \* Q P S \* Q R C I T N I L R  
 K I Q K I N N H A K N G V Y L T \* L D S

8821 ATAAGTAAACGGACGAATACGATCAAATTTCAATAACTATTACCAACAACAATCTCTATA 8880  
 Y E N A Q K H \* N \* L \* Q Y H H Q \* L Y  
 I N M Q R S I S T K F N N I I T N N S I  
 I \* K G A \* A L K L T I S L P T T L S I

8881 AAGTCAATFACTAAATACAAAACGATTATTTAAAAGGTTAAACTAGTTACCATACTCAG 8940  
 K L \* H N I N Q \* Y I K G I Q D I T H T  
 N \* N I I \* T K S I F K E L K I L P I L  
 E T L S K H K A L L N K W N S \* H Y S D

8941 GTGAAAACCCAGACAAATGATAGTATTAAGATACCTAACGGGATAACATCACCGTCAATA 9000  
 W K Q T Q K S D Y N \* P N G \* Q L P L \*  
 G S K P R N V I M I R H I A R N Y H C N  
 V K P D T \* \* \* L E I S Q G I T T A T I

9001 CCTACTTCTATAGCCAAGATGATACAAATTACAAGGATGATTTCAAAACTCTGTACCGAA 9060  
 P H L Y R N \* \* T \* H E \* \* L K S V H S  
 H I F I D T R S H K I N R S F N Q S M A  
 S S S I P E V I N L T G V L T K L C P K

9061 AGTACAAAATGTAAAAAATGAATACGTAAACGATCACTATCACAAGTCACGATATGTGG 9120  
 E H K V N K L K H M Q \* H Y H E T S Y V  
 K M N \* M K \* S I C K S T I T N L A I C  
 \* T K C K K V \* A N A L S L T \* H \* V G

9121 TGTATAAGTCTAAAGAATATTACTAAAAATACGATCACCAACACAAAATAGTAGAAACAC 9180  
 V Y E S K K Y H N K H \* H N H K I M K T  
 W M N L N R I I I K I S T T T N \* \* R Q  
 C I \* I E \* L S K \* A L P Q T K D D K H

FIG. 3 CONT'D



75/201

9181 ATGATACAAATTTTCTCCACTACCATGTGGTGTAGGAATAACAATAAGTCTACCAACAATA 9240  
 Y \* T \* F L H H Y V V D K N N N L H H \*  
 T S H K F S T I T C W M R I T I \* I T N  
 V I N L L P S P V G C G \* Q \* E S P T I

9241 CTTCTTACGAAGAAACATATGTAGAAACCAAGGTGTATGTGCAATATCGGAACGATTAAG 9300  
 S S H K K T Y M K P E V Y V N Y G Q \* N  
 H L I S R Q I C R Q N W M C T I A K S I  
 F F A E K Y V D K T G C V R \* L R A L E

9301 ATTACCAAAATATTCTAAAGGACTACAATAATCACTTCCATAACATGCATAACATTCTTG 9360  
 \* H N \* L I E Q H \* \* H L Y Q V Y Q L F  
 R I T K Y S K R I N N T F T N Y T N Y S  
 L P K I L N G S T I L S P I T R I T L V

9361 CGOGAGATACTGAATAACATCTCACCCACGTACACTTATGCGGCTTCTCCCATATACAAA 9420  
 A S \* S K N Y L P H M H I R R L P Y I N  
 R A R H S I T S H T C T F V G F L T Y T  
 R E I V \* Q L T P A H S Y A S S P I H K

9421 ATTAAATATCAAGGACCCAAAACCTATTACTAATAATATCTTCATACGGACCTTGAAA 9480  
 \* N \* Y N R P K S Y H N N Y F Y A Q F K  
 K I K I T G P N Q I I I I I S T H R S S  
 L K L L E Q T K F L S \* \* L L I G P V K

9481 AACACCATCTCTAGAAAACTAAACAAAATAGTTAAAAATCATCAATTAAGCAGGATA 9540  
 K H Y L D K Q N T K D I K \* Y N L E D \*  
 K T T S I K K I Q K I L K K T T \* N T R  
 Q P L S R K S K N \* \* N K L L K I R G I

9541 TCTAAAGAAAAGAGAATGACGATCAAGATAAAAACCTCGATATAACCGATATCAACAACA 9600  
 L N R K E \* Q \* N \* K Q L \* I P \* L Q Q  
 Y I E K R K S S T R N K S S Y Q S Y N N  
 S K K E R V A L E I K P A I N A I T T T

9601 GAACCAAAAAATAATAAATTTTGAATTCGCACGAAAACCTCTAATATGATCACACA 9660  
 R P K K N N L L V \* A H K Q L N Y \* H Q  
 D Q N K I I \* Y F K L T S K S I I S T N  
 K T K \* \* K I F S L R A K P S \* V L T T

9661 TCAATATTTACAACAACAACCACATAATTAAGAATACGAAAAACAAAAGTTCAAT 9720  
 L \* L H Q Q K T Y \* N E \* A K Q K E L K  
 Y N Y I N N N P T N I K K H K K N K L N  
 T I F T T T Q H I L K R I S K T K \* T \*

FIG. 3 CONT'D

76/201

9721 AGGATAAACACGTTACACAAATACGAACAAAAATAAAAAATACATTGTAACATAAAAGGAAG 9780  
 D \* K H M H K H K N K N K H L M T N E K  
 I R N T C T N I S T K I K I Y C Q I K R  
 G I Q A H T \* A Q K \* K \* T V N Y K G E

9781 ACTTTAATCACATTAATACGTTAAACGTTACCTAACAAATACATACCACGATATTACGGAAA 9840  
 Q F \* H L \* A N A I S Q \* T H H \* L A K  
 R F N T Y N H M Q L P N N H I T S Y H R  
 S I L T I I C K C H I T I Y P A I I G K

9841 AACCAAAACACAGTGTATACATCGATACCAATAACGTTTGGTACAAAATACCAATAAAAG 9900  
 K T K H \* M H L \* P \* Q L G H K I T I K  
 K P K T D C I Y S H N N C V M N \* P \* K  
 Q N Q T V Y T A I T I A F W T K H N N E

9901 TATAACATCCTTTTAAACCACAATTACATACATCACTATCATGTAACTTCTTTGTAGAGA 9960  
 M N Y S F Q H \* H I Y H Y Y M Q L F M E  
 \* I T P F N T N I Y T T I T C K F F C R  
 Y Q L F I P T L T H L S L V N S S V D R

9961 ATGATGAAAATACTAATGATTTCTAAGAATAACATCTAATTTCTTAAGACAAAGACTACA 10020  
 \* \* K \* S \* \* L N K N Y I L S N Q K Q H  
 K S S K H N S F I R I T S \* L I R N R I  
 V V K I I V L S E \* Q L N F F E T E S T

10021 ACGGATGTTATCTATAAACTCAAACATATTTATTCATAGCAATGATATCACCATTTTACCT 10080  
 Q R C Y I N S N T Y Y T D N S Y H Y F P  
 N G V I S I Q T Q I I L I T V I T T F H  
 A \* L L Y K L K Y L L Y R \* \* L P L I S

10081 ATGACGACGGATATCTCTTCGCCGCACAAGAGTCAATCGATTTCGATACCTTTGTAAATT 10140  
 Y Q Q R Y L L P T N E T L \* L \* P F M \*  
 I S S G I S F R R T R L \* S F S H F C K  
 V A A \* L S A A H E \* N A L A I S V N L

10141 AGTGTTATTACCATTACTACAGAATATGGTTGGAGGATGTCGTFAGACAAAGATGTAGAAA 10200  
 D C Y H Y H H R I G V E \* L M Q K \* M K  
 I V I I T I I D \* V L R R C C R N R C R  
 \* L L P L S T K Y W G G V A D T E V D K

10201 AAACGTTAGTCCATAACATTTCTACCATAGAGGATGCAGTTTTTAACTTGGAACATAACA 10260  
 K A I L Y Q L S P I E \* T L F Q V K Y Q  
 K Q L \* T N Y L H Y R R R \* F N F R T N  
 K C D P I T F I T D G V D F I S G Q I T

FIG. 3 CONT'D

77/201

10261 ATCACAATGAATACCATCATACTGAAACTTACCAAATACCAATCTACTGTTTCAAATAAC 10320  
 \* H \* K H Y Y S K S H N I T L H C L K N  
 N T N S I T T H S Q I T \* P \* I V F N I  
 L T V \* P L I V K F P K H N S S L T \* Q

10321 AGGAGCAGTACAATATACAAGTAGGAGATTATACTTGCTTGGACTAATAAGACGGAATAA 10380  
 D E D H \* I N M R \* Y S R V Q N N Q R I  
 T R T M N Y T \* G R I H V F R I I R G \*  
 G R \* T I H E D E L I F S G S \* E A K N

10381 CACATCTCAATGAGATCCACTAAAATGATATTACAGACCAGCCTACTCAAATTGTCAACA 10440  
 T Y L \* E L H N \* \* L T Q D S S N L L Q  
 Q T S N S \* T I K S Y H R T P H T \* C N  
 H L T V R P S K V I I D P R I L K V T T

10441 CAGAATGGTCTACGTCCCGACAGTTGAACAAAATGTCAGAGAAATGTTTGTAGGAATGTG 10500  
 T K G S A P S D V Q K S L R K V F D K C  
 H R V L H L A T L K N Q C D R \* L I R V  
 D \* W I C P Q \* S T K V T E K C F G \* V

10501 AGTTTTATATGAAAACCATTACAATTTGGACCACTTTGAAAATGACAAAATCGACGCAT 10560  
 E L I Y K Q Y H \* V Q H F K \* Q K L Q T  
 S W F I S K T I N F R T F S K S N \* S R  
 G F Y V K P L T L G P S V K V T K A A Y

10561 ATTACCGGCTGGTGTCCCGTAAAGTACAATGATACGCATCATCAATATGATAATTTCC 10620  
 Y H G V V L P M E H \* \* A Y Y N Y \* \* L  
 I I A S W L P C K M N S H T T T I S N F  
 L P R G C P A N \* T V I R L L \* V I L P

10621 AAGAAAAACACACCCAGTACACCTAGACAACCAATACATAATTTGCCACTAT'CACAAT' 10680  
 N K K T H T M H I Q Q N H I L L H Y H \*  
 T R K Q T P \* T S R N T I Y \* C T I T N  
 E K K H P D H P D T P \* T N V P S L T L

10681 CAAACATATATACGTAGTTAATCTCGAGTCATGACCAACAGTGTGACCGTGACTAAAATG 10740  
 T Q I Y A D I L A \* Y Q N D C Q C Q N \*  
 L K Y I H M L \* L E T S T T V S A S I K  
 N T Y I C \* N S S L V P Q \* V P V S K V

10741 ACCATFAAAAATACCAGGTATATCTCTACGAGTTCAACATGTCAACGGTCAATTCCTGAT 10800  
 Q Y N K H D M Y L H E L Q V T A L \* P S  
 S T I K I T W I S I S L N Y L Q W N L V  
 P L K \* P G Y L S A \* T T C N G T L S \*

FIG. 3 CONT'D

78/201

10801 GCAGGTCTGACAATTACAATAACGAACCGAGATACGTGATATGAATTATTAACACGAAC 10860  
 R G S Q \* H \* Q K A R H L \* V \* Y N H K  
 V D L S N I N N S P E I C S Y K I I T S  
 T W V T L T I A Q S \* A A I S L L Q A Q

10861 CAAACATGTTTTACTACAAACAAGATGACTTCTAAAATTACAAACCCGATACCGTTTACC 10920  
 T Q V F H H K N \* Q L N \* H K P \* P L H  
 P K Y L I I N T R S F I K I N P S H C I  
 N T C F S T Q E V S S K L T Q A I A F P

10921 AAAATCGGTTCAATTTTCGTCTAGAACAGAATCTACGAAACCGAAGTTACTGTCCACAAAG 10980  
 N \* G L L L L D Q R L H K P K L S L H K  
 T K A L Y F C I K D \* I S Q S \* H C T N  
 K L W T F A S R T K S A K A E I V P T E

10981 ATAACCTTGAAATAACCGACGATAATTCGCAGATATATACCCATAAGTTCCAGCAGTTTA 11040  
 \* Q F K I P Q \* \* A D I Y P I E L D D F  
 R N F S \* Q S S N L T \* I H S K L T T L  
 I S V K N A A I L R R Y I P N \* P R \* I

11041 TGATCCTTCAACATGAAAACCTTACTTAACCGTGGAGACTGCAAATAGTTGTTAACCG 11100  
 V L F N Y K Q L H I P V K Q R K D V I P  
 Y \* S T T S K F I F Q C R R V N I L L Q  
 S P L Q V K S S S N A G E S T \* \* C N A

11101 ACCACAATTTAACGTTAGATTTTGTGTTTTCTAAATAATTTCTTTGTTAAATAACCTAAAA 11160  
 Q H \* I A I \* F L F I \* \* L F L K N S K  
 S T N F Q L R F C F S K N F F C N I P N  
 P T L N C D L V F L N I L S V I \* Q I K

11161 CTATAGATGTA AAAACAATCAACATATTAAGACGTAAACAATTTACCTGATATAAATA 11220  
 S I \* M K T \* N Y L K Q M Q \* I S \* I \*  
 Q Y R C K Q K T T Y N R C K N F P S Y K  
 I D V N K N L Q I I E A N T L H V I N I

11221 CATATAATTATGTGTATACTAACCACAATGTAATACACATGAAACAAAACAATCAAATA 11280  
 T Y \* Y V Y S Q H \* M I H V K N Q \* N \*  
 H I N I C M H N T N C \* T Y K T K N T K  
 Y I L V C I I P T V N H T S Q K T L K I

11281 CTACAATGATCAATTTGTATTCGTAAAAATAAACTGATACATATATTAAGGACATGAGAC 11340  
 S T V L \* V Y A N K N S \* T Y L E Q V R  
 H H \* \* N F M L M K I Q S H I Y N R Y E  
 I N S T L C L C K \* K V I Y I I G T S Q

FIG. 3 CONT'D

79/201

11341 ATGGAACAAAATACATTTAATAAATCAACAAATATTCCTTCCAAAATCTCCAAAATGAAT 11400  
 Y R T K H L N N L Q K Y P L N \* L N \* K  
 T G Q K I Y I I \* N N I L F T K S T K S  
 V K N \* T F \* K T T \* L S P K L P K V \*

11401 ACAGACCGAGAGTATAAAACAAGGACGACACTTAAAATGAATACAAATACTTCATAAAAT 11460  
 H R A R M N Q E Q Q S N \* K H K H L I K  
 I D P E \* I K N R S H I K S I N I F Y K  
 T Q S E Y K T G A T F K V \* T \* S T N \*

11461 ACCAACATAAAAATACACAAAAACGATAAAAATATTGATACGTATCATAATTAGTACTGTA 11520  
 H N Y K I H K Q \* K \* L \* A Y Y \* D H C  
 I T T N \* T N K S N K Y S H M T N I M V  
 P Q I K H T K A I K I V I C L I L \* S M

11521 AAAAAGAAACTACAAAAACCAACCATCTTATCAATGAAATTAAGATACACCATAAAACC 11580  
 K K K S T K P Q Y F L \* K L K \* T T N Q  
 N K R Q H K Q N T S Y N S \* N R H P I K  
 K E K I N K T P L I T V K I E I H Y K P

11581 CAGCTTAAATCTTCTCCTACAAAACAATAAATAATGTCGGAAAAATCCATGAATATGTAC 11640  
 T S N L L P H K T I \* \* L R K L Y K Y M  
 P R I \* F L I N Q \* K N C G K \* T S I C  
 D F K S S S T K N N I V A K K P V \* V H

11641 CTGGTGATAAAAACAGTAATCGATATCGTTTTTAAACAACGATTAACCAACAGACAATTATA 11700  
 S W \* K T M L \* L L F Q Q \* N T T Q \* Y  
 P G S N Q \* \* S Y C F N N S I P Q R N I  
 V V I K D N A I A F I T A L Q N D T L I

11701 TAAAATAAAATGTCTACATGGAATATAATTTAACTAAGAGAACTCAATGAATAAATATCC 11760  
 I K N \* L H V K Y \* I S E R S N S I \* L  
 Y K I K C I Y R I N F Q N E Q T V \* K Y  
 N \* K V S T G \* I L N I R K L \* K N I P

11761 CATATAAAATAGAACAATAACCCCTAAAAAGAGAGAAAATTTGTACAAAAATCTTACGG 11820  
 T Y K I K N N P I K R E K L C H K \* F A  
 P I N \* R T I P S K E R K \* V T N K S H  
 Y I K D Q \* Q P N K E R K F L T K L I G

11821 ATACCCACAAAATATTAATATTTTAAAGACAAGTTCCTAACGCAATATACTTACGATTACC 11880  
 \* P H K Y N Y F K Q E L I A N Y S H \* H  
 R H T N I I I F N R N L F Q T I H I S I  
 I P T \* L \* L I E T \* S N R \* I F A L P

FIG. 3 CONT'D

80/201

11881 GAATGCAGGTGGAGCATTATCAAACCTCCGATAAAAACAATTTAAATTTTGACGAACCTTA 11940  
 S V D V E Y Y N Q P \* K T L N L V A Q F  
 A \* T W R T I T K L S N Q \* I \* F Q K S  
 K R G G R L L K S A I K N F K F S S P I

11941 TCCACCGCAOAGTCAATAACTTCAGAGGGTTTAAAGTTAGTTTAACTGACTACACTTAC 12000  
 L H R A L \* Q L R G F E I L I S Q H S I  
 Y T A H W N N F D G L N L \* F Q S I H F  
 P P T G T I S T E W I \* D F N V S T F H

12001 ACGATTACAACAAAACAATTTAACAAATGTCGTAACGTACAACGAAGATTAAGATTCAA 12060  
 H \* H Q K T L N N V A N A H Q K \* N \* T  
 T S I N N Q \* I T \* L M Q M N S R I R L  
 A L T T K N F Q K C C K C T A E L E L N

12061 CACCGTCATAACATCACAAAATGTATTACTTTATGATAGATGAAGTCTAAACTCACATCG 12120  
 T A T N Y H K V Y H F V I \* K L N S H L  
 Q P L I T T N \* M I F Y \* R S \* I Q T Y  
 H C Y Q L T K C L S I S D V E S K L T A

12121 AAAACTATTGGAACGAGTTAATAACTAACAAAATAAGCGGTTAGGACGACGTCAACTATG 12180  
 K Q Y A Q E I I S Q K I R W D Q Q L Q Y  
 S K I L K S L \* Q N N \* E G I R S C N I  
 K S L S A \* N N I T K N A L G A A T S V

12181 ATTACACAGAACGTTTCATATCTACTTCAATCGCTACTAATACAAGTTCTATCATGGCAAAA 12240  
 \* T D Q L Y L H L \* R H N H E L Y Y R K  
 S L T K C T Y I F N A I I I N L I T G N  
 L H R A L I S S T L S S \* T \* S L V T K

12241 CGTCCGAAACGTTTCACTCAAACATTTATACCGATCAAAACAACCTTATACTTCAGCGTTT 12300  
 A P K A F H T Q L Y P \* N Q Q I H L R L  
 Q L S Q L T L K Y I H S T K N F I F D C  
 C A K C L S N T F I A L K T S Y S T A F

12301 CTTTTTAAACCGACTACGATTTTTATCACCAAGACAATTAGTTGTTGTCTATTTTGTCAA 12360  
 S F N P Q H \* F Y H N Q \* D V V S L V T  
 L F I Q S I S F I T T R N I L L L Y F L  
 F F K A S A L F L F E T L \* C C I F C N

12361 TCTTTTTCGTACATTATATCGATTTCAGACACATACTTGCACATATTCGACATCGAGCGTT 12420  
 L F L M Y Y L \* T Q T H V H Y L Q L E C  
 \* F F C T I Y S L R H I F T I F S Y S A  
 S F A H L I A L D T Y S R S L A T A R L

FIG. 3 CONT'D

81/201

12421 TGAACCTGCAATACCGTCTGGATCGTGAATGATGTACATATTTCTCCGAGCCTAATTA 12480  
V Q V Y P L G L V \* \* C T Y L P E S \* H  
F K F T H C V \* C K S V H I F L S P N I  
S S R I A S R A S V L M Y L S A R I L S

12481 ATTCTTCTCATTTCACAAAGGCGAAACGTCTGTACGAAAAATCGTACCAAGCATTAA 12540  
Y S S Y L Q K R K A S L A K \* C P E Y I  
I L L T F N N G S Q L C H K K A H N T F  
L F L L T T E A K C V I S K L M T R L N

12541 CCTATTAGTCCGAAATTTAAGATAAGACCTATTACGACAATTTCCAACACATGGAAACTC 12600  
P Y D P K L N \* E P Y H Q \* L N H V K S  
Q I I L S \* I R N Q I I S N E T T Y R Q  
S L \* A K F E I R S L A T L P Q T G K L

12601 ACGATAAGGTCGTAACCGACGATTATGAAATTGATATCATTATGGTCTATTTGTTCAAAA 12660  
H \* E L M P Q \* Y K L \* L L V L Y V L K  
T S N W C Q S S I S \* S Y Y Y W I F L N  
A I G A N A A L V K V I T I G S L C T K

12661 ACTATTTCAACAACCTATTACAAATACAATGTATACGACCATCACATACCGTATATGCTG 12720  
Q Y L Q Q Y H K H \* M H Q Y H I A Y V S  
K I F N N I I N I N C I S T T Y P M Y L  
S L T T S L T \* T V Y A P L T H C I C V

12721 ACAAGTTCTACGACTACCATAATTATTTGTCAATTGACTATAATCACAACCTAAGATTAAC 12780  
Q E L H Q H Y \* Y V T L Q Y \* H Q N \* N  
S N L I S I T N I F L \* S I N T N I R I  
T \* S A S P I L L C N V S I L T S E L Q

12781 CGGAGAACAATAGTAACGCTTGTCCATATTACTTCAACGATTACGACAATACGTCTTATT 12840  
A E Q \* \* Q S C T Y H L Q \* H Q \* A S Y  
P R K N D N R V P I I F N S I S N H L I  
G R T I M A F L Y L S T A L A T I C F L

12841 ACTCAACTACGGAGTATTTAATTTTATGTTCAACAATTATCACCAGACTATACTTAAC 12900  
H T S A E Y I L F V L Q \* Y H N Q Y S N  
I L Q H R M F \* F Y L N N I T T R I H I  
S N I G \* L N F I C T T L L P E S I F Q

12901 AITATAAGGATGAGTTACAATAATATTATTACCATCATCACCATCTATCAAATACGACA 12960  
Y Y E \* E I N N Y Y H Y · Y H Y F L K H Q  
T I N R S L T I I I I T T T T S Y N I S  
L I G V \* H \* \* L L P L L P L I T \* A T

FIG. 3 CONT'D

82/201

12961 AGAATCACTACAACCTACCAGAATTCATATGATTCTATTACTTTCTACTACCTTTAACACA 13020  
 E \* H H Q H D \* T Y \* S L S L H H F N H  
 N K T I N I T K L I S L Y H F I I S I T  
 R L S T S P R L Y V L I I F S S P F Q T

13021 ACAAAAATCTCGAACTAGGAGGAACATTTAAAAGATATGTTCTACAATTCCTGAAATTTTA 13080  
 Q K L A Q D E K Y I K \* V L H \* P V \* F  
 N N \* L K I R R T F K R Y L I N L S K F  
 T K S S S G G Q L N E I C S T L P S L I

13081 ATTCATAGAAAATAAAATAATTTCTACATTTGTGAAATCGATCTCCACCCAACAACCATG 13140  
 \* T D K N \* \* L I Y C K L \* L T P Q Q Y  
 N L I K I K N F S T V S \* S S P P N N T  
 L Y R \* K I L P H L V K A L P H T T P V

13141 AAATAGAAGTTGTTAATCTAACGTCGACCACAACGATGACTCATACGTCGATTAAGAAG 13200  
 K I K L L \* I A P Q H Q \* Q T H L \* N K  
 S \* R \* C N S Q L S T N S S L I C S I R  
 K D E V I L N C A P T A V S Y A A L E E

13201 ATATGAAAGTAATACACGTAAGACATCTAGGATTTCTTTTGAATAAAATCTAATATATGT 13260  
 \* V K M I H M K Q L D \* S F K N L N Y V  
 R Y K \* \* T C K R Y I R L F S I \* I I Y  
 I S E N H A N E T S G L F V \* K S \* I C

13261 TGTTCACCACATGGATATTAATTAACACAATTTTACGAGACACTAGTACGACCATGACC 13320  
 V L H H V \* L \* N H \* F A R H D H Q Y Q  
 L L T T Y R Y N I T N F H E T I M S T S  
 C P P T G I I L Q T L I S Q S \* A P V P

13321 ATACCGGTAATGATAAATTTGGACTCCGATGATAATGGTTCTAAGAATACCACCACGGAG 13380  
 Y P W \* \* \* V Q P \* \* \* G L N K H H H R  
 T H G N S N F R L S S N V L I R I T T G  
 I A M V I L G S A V I L W S E \* P P A E

13381 TCAAACATAAATAACGGCACGTGCACATCTCGTAGGTCTACATCTACCATATACATTTAA 13440  
 L K Y K N G H V H L A D L H L H Y I Y I  
 \* N P N I A T C T Y L M W I Y I T Y T F  
 T Q I \* Q R A R T S C G S T S P I H L N

13441 TGCACCATTTAAACATGTTTCAGGGAAACCCATATTTTCTAGGATAAGAATACACAATG 13500  
 V H Y I Q V L G K P Y L L D \* E K H T L  
 \* T T F K Y L D R Q T Y F I R N K I H \*  
 R P L N T C T G K P I F S G I R \* T N V

FIG. 3 CONT'D



83/201

13501 TGSTACTACAAACAGTTTCAGACACCAAAAACCTCTCTACCGTCAACAAGGACACATCCAAG 13560  
 V H H K D L R H N K S L H C N N R H L N  
 C M I N T L D T T K P S I A T T G T Y T  
 C S T Q \* T Q P K Q L S P L Q E Q T P E

13561 TTCACAGCGACAAGTTAGATTTCTAAATTTAAAAAATTTGCCAAGCCCCATGATCACAC 13620  
 L H R Q E I \* L N L N K L R T R P V L T  
 \* T D S N L R F I \* I K \* V P E P Y \* H  
 L T A T \* D L S K F K K F P N P T S T H

13621 TTACGGGCCGATCATGGGACACGATCACCAATAGATGACTACAAGTTAATTCCCGTAAA 13680  
 F A R S T G Q A L P K D V S T \* N L A N  
 S H G A L V R H \* H N I \* Q H E I L P M  
 I G P \* Y G T S T T \* R S I N L \* P C K

13681 CTGTAACATTATGGTTATCTCGACCATATCCAATATAATATTTCACTTAACAACGGCA 13740  
 S M Q L V L L A P I P K Y \* L T F Q Q R  
 Q C K Y Y W Y L Q Y L N I N Y L S N N G  
 V N T I G I S S T Y T \* I I F H I T A T

13741 AAAGTCGCATATCTACTGCTGCCATTATTTAACCTATTCAGAAAACAACAGTTTCTTGA 13800  
 K \* R I S S S P L L N S L N K T T L L V  
 N E A Y L H R R Y Y I P Y T R Q Q \* F F  
 K L T Y I V V T I F Q I L E K N D F S S

13801 TTAAATCTTCAAATATTATTTCTCTTTTGAATAATACTCAACTGATTTTCAACACCACAA 13860  
 L K S T \* L L S F V \* \* S N V L L Q P T  
 \* N L L K Y Y L S F K N H T S \* F N H H  
 I \* F N I I F L F S I I L Q S F T T T N

13861 CACCGACTTGTAATAAGAAATGTAAACTATAACTACCATCAGCGCACGGTGTATATCAA 13920  
 T A S C S K K V N S I S P L R T G C I T  
 Q P Q V H N R \* M Q Y Q H Y D R A V Y L  
 H S F M I E K C K I N I T T A H W M Y N

13921 GCATCCTTAGAAAGTTTCATAATGATACAATCTAGAAACGATACGTAACGCAGTAAACTA 13980  
 R L F R E F Y V I N S R Q \* A N R \* K S  
 E Y S D K L T Y \* T L D K S H M A D N Q  
 T P I K \* L I S H \* I K A I C Q T M K I

13981 GCATTACTAACAAAGTTATAACACACTTTAAGAAACACTCATACGACTAACATTTCTTAGG 14040  
 R L S Q E I N H S I R Q S Y A S Q L S D  
 D Y H N N L I T H F E K H T H Q N Y L I  
 T I I T \* Y Q T F N K T L I S I T F F G

FIG. 3 CONT'D

84/201

14041 ATGAAAAGATTCTTTCTAACCATACTAAAACAACCTTTTAGGACTATAATAATTATATATA 14100  
 \* K E L F S Q Y S K T S F G S I I L I Y  
 R S K \* S L N T H N Q Q F D Q Y \* \* Y I  
 V K R L F I P I I K N F I R I N N I Y I

14101 TTTTTAATCCGGGATAAAAATTATCTCGAAATGAATTATGACAGTAAAAACGTCTGTGG 14160  
 L F N P G I K L L A K S L V T M K A S V  
 Y F I L G \* K \* Y L K V \* Y Q \* K Q L C  
 F F \* A R N K I S S \* K I S D N K C V G

14161 AATCAACTTCATCCAAATCAACCACAAAATTGAAATCTATTGGTTCTAAACATACCAGTT 14220  
 K T S T P K T P T K V K S L W S K Y P \*  
 R L Q L L N L Q H K L K L Y G L N T H D  
 \* N F Y T \* N T N \* S \* I V L I Q I T L

14221 ACCATACTAAACCACTAAAATATGTTTGTGGGGTCCCAAACCACCGTCAACGTCTA 14280  
 H Y S K P S K I C V A G P N P T A T A S  
 I T H N Q H N \* V F L G L T Q H P L Q L  
 P I I K T I K Y L C G W P K T H C N C I

14281 AGAATGATAAGAATATACTACGGATACAACCTGATACACAGTACATAAATCTAACACTTAAT 14340  
 E \* \* E \* I I G I N V I H \* T N S Q S N  
 N K S N K Y S A \* T S \* T D H I L N H I  
 R V I R I H H R H Q S H T M Y \* I T F \*

14341 AAACAATTACTATCAATATCTGTTAAGCTAGAACATGTCATACTAAAATGACTAATGTTC 14400  
 N T L S L \* L C N S R T C Y S K V S \* L  
 I Q \* H Y N Y V I R D Q V T H N \* Q N C  
 K N I I T I S L E I K Y L I I K S I V L

14401 AATCTCAACAAATTTATTCATAAAATTCATAACCCCACTTCATAGTAGGATTATGACAC 14460  
 N S N N L L Y K L Y Q P I F Y \* G L V T  
 T L T T \* Y T N \* T N P Y S T D D \* Y Q  
 \* L Q K I L I K L I P T H L I M R I S H

14461 CTAACACTATFACTATCCACATAATAAGTAACACGATTAAAATTATATGATAAATCATAC 14520  
 S Q S L S L H I I \* Q A L K L I S N L I  
 P N H Y H Y T Y \* E N H \* N \* Y V I \* Y  
 I T I I I P T N N M T S I K I Y \* K T H

14521 CAAANTGGATTATGAACAAAACCAGGGGAACAATCTGTTTAAAAACATCTACCACATGGC 14580  
 T K G L V Q K P G R T L C I K T S P T G  
 P K V \* Y K N Q D G Q \* V F K Q L H H V  
 N \* R I S T K T G K N S L N K Y I T Y R

FIG. 3 CONT'D

85/201

14581 AAACAACAAAGATAACCAATGGTAATGTTTCTCAATCCACATCAATACTTGAATCTACAA 14640  
 N T T E I P \* W \* L S N P T T I F K S T  
 T Q Q K \* Q N G N C L T L H L \* S S L H  
 K N N R N T V M V F L \* T Y N H V \* I N

14641 CTGTGTGTGGCAATAGCAAACAGAGAATTTCTAAATGAAGAAATACGTGCTTAGGACGA 14700  
 S V C R \* R K D R L S K S R \* A A S G A  
 Q C V G N D N T E \* L N V E K H L L D Q  
 V C V T I T Q R K F I \* K K I C C I R S

14701 TACGTGCAACGTAGACGATCACGAGACGAACTAAATGCTTGAACAACAAAATCACATCGA 14760  
 I C T A D A L A R S S K R V Q Q K L T A  
 \* A R Q M Q \* H E A Q N V F K N N \* H L  
 H V N C R S T S Q K I \* S S T T K T Y S

14761 CGGTAATGTTACCATATTTTAAAGTTTGACATTTTGGTCCATTGAAAATGGTTCTGAAA 14820  
 A M V L F I F N \* V T F G P L K L W S K  
 Q W \* L H Y L I E F Q L V L Y S \* G L S  
 G N C T T Y F K L S Y F W T V K V L V K

14821 ATGCTCAAACAATTTTCATTTCCGAACAATTTCTCCCATCATGTCAACTAAACTTTGTA 14880  
 \* S N T L L L P K N L S P L V T S K F C  
 K R T Q \* F Y L S T \* L P Y Y L Q N S V  
 V L K N F T F A Q K F L T T C N I Q F M

14881 AAAAAAGAAATGAGTTCTACCATTACGACGTTAATGACTAATATTAATAATATTCATATTA 14940  
 K K K V \* S P L A A I V S \* L \* \* L Y L  
 N K R \* E L H Y H Q L \* Q N Y N N Y T Y  
 K E K S L I T I S C N S I I I I I I L I I

14941 AATGGATGATACCAACTATAATTCGTCAATAACAAACATAATCTTCAACAATATTTATA 15000  
 K G V I T S I L C N N N T N S T T \* L Y  
 N V \* \* P Q Y \* A T I T Q I L L Q K Y I  
 \* R S H N I N L L \* Q K Y \* F N N I F I

15001 AAACHTTAATACTACCACCAACATATGGTCGTAGTGTCAATAACAATTATTAATACTA 15060  
 K S I \* S P P Q I G A D C T I T L L \* S  
 N Q F K H H H N Y V L M V L \* Q \* Y N H  
 K F N I I T T T Y W C \* L N N N I I I I

15061 TTTTCACGACCAATAGSTAATTA'TTTAAACCATTTCGGPCTGAAATAATACTCCGTAAT 15120  
 L L A P \* G N L L N P L A L S \* \* S A N  
 Y F H Q N D M \* Y I Q Y L W V K N H P M  
 F T S T I W K I F K T F G S K I I L C \*

FIG. 3 CONT'D

86/201

15121 AGTAAACTCCTTGTCTTACTTTTAAATACGTATATGATTGCAATTACAAGACGGGTGGAAAT 15180  
 D N S S C F S I \* A Y V L R L T R G V K  
 I M Q P V S H F K H M Y \* V Y H E A W R  
 \* K L F L I F N I C I S F T I N Q G G \*

15181 TGAGTTTACTTAAATTTTATACGATAGTCACGATTCTTATCTCGAGCGTGACATCGTCCA 15240  
 V \* I F K F Y A I L A L F L A R V T A P  
 L E F S N L I H \* \* H \* S Y L E C Q L L  
 S L H I \* F I S D T S L I S S A S Y C T

15241 CAAAGATAAGAATCATGATACTGTCGGCTTACAAGGTAGTTTTTACAAACTTCTCATAT 15300  
 T E I R L V I V P R I N W \* F H K F L I  
 H K \* E \* Y \* S L G F T G D F I N S S Y  
 N R N K T S H C A S H E M L F T Q L T Y

15301 CGTCGATGGGCTCCACAAGGACAACAATATCCTTGGTGATTTTAAATACCACCAACCCTG 15360  
 A A V R P T G T T I P V V L N \* P P Q S  
 L L \* G L H E Q Q \* L F W \* I K H H N P  
 C S G S T N R N N Y S G S F K I T T P V

15361 CTATACAATGCAGTAGAATATTTCTTACAACCTGTTGGGACAAGAATACCCAACCCTAATA 15420  
 S I N R \* R I F S T S L G T R I P Q S \*  
 R Y T V D D \* L P H Q C G Q E \* P N P N  
 I H \* T M K Y L I N V V R N K H T P I I

15421 GGATTTACACTAGCACGATACGGTTTATAAAAACGCATAACAATCATCAAATCAAACCCG 15480  
 G L H S R A I G F I K R I T L L K T K A  
 D \* I H D H \* A L Y K A Y Q \* Y N L K P  
 R F T I T S H W I N Q T N N T T \* N Q G

15481 GCGTTTGTACTTAAAACAACAAGTGTACCACTATCTAAAATAGCGGAACGCTTACTTACA 15540  
 R L C S N Q Q E C P S L N \* R R A F S H  
 G C V H I K N N V H H Y I K D G Q S H I  
 A F M F K T T \* M T I S K I A K R I F T

15541 CGAGTTCAAAACTCACTTTATCAATACACACCGCCAACGATAATACAATTCGGACCACCA 15600  
 A \* T K L S I T I H P P Q \* \* T L G P P  
 H E L K S H F L \* T H R N S N H \* A Q H  
 S L N Q T F Y N H T A T A I I N L R T T

15601 TGATCGTCACCACACTACGTTGATGACGAAAACGATTAAAGACAAAAATTATATACAGTCCGA 15660  
 V L L P S A V V A K A L E T K L I H \* A  
 Y \* C H H H L \* Q K Q \* N Q K \* Y I D P  
 S A T T I C S S S K S I R N K I Y T L S

FIG. 3 CONT'D

87/201

15661 CAATGACGATTACAAACAAGAGAATACCGGACATTACCGGTATTCTAACTTCTAAATTC 15720  
T V A L T Q E R I A Q L P W L I S S K L  
Q \* Q \* H K N E \* P R Y H G Y S Q L N L  
N S S I N T R K H G T I A M, L N F I \* T

15721 TATGCGTTAAATGTTTTGCGAATATGAGATTACAAATAGCATGTCTAATACAAC TAATA 15780  
I R L K C F R K Y E L T \* R V S \* T S \*  
Y V C N V E V S I S \* H K D Y L N H Q N  
Y A I \* L F A \* V R I N I T C I I N I I

15781 TGTAACAAT TACTCATAATACTTAAAAATACATTCGTAATAATCATACTACTAAAAC TCA 15840  
V N T L S Y \* S N K H L C K L I I I K L  
Y M Q \* H T N H I K I Y A N \* Y S S K S  
C K N I L I I F K \* T L M K T H H N Q T

15841 C TACTACCACAACAGACAATATGAGACTAATACGATCATCCCAATATATCGATTATAT 15900  
S S P T T Q \* L E S \* A L L P \* I A L I  
H H H H Q R N Y S Q N H \* Y P N Y L \* Y  
I I T N D T I V R I I S T L T I Y S I Y

15901 TCACAAAAGTTGTTCAAACATGATAGTCTTATTACAGAAATACAGACTTAGATT TACA 15960  
L T K \* C T K Y \* \* F L T K I D S D L H  
L H K E V L K T S D S Y H R \* T Q I \* I  
T N K L L N Q V I L I I D K H R F R F T

15961 ACCCAACTTTTACTATAATGATTACCAGGAGTACTTAAAACAAGGGTTGTATGATA CAAT 16020  
Q T S F S I V L P G \* S N Q E W C V I N  
N P Q F H Y \* \* H D E H I K N G V Y \* T  
P N F I I N S I T R M F K T G L M S H \*

16021 CAATTCTATCTACCCTAATAACAATAAATGGTATAGGTCTAGGAAGATCTTAAAAT CCT 16080  
T L I S P S \* T \* K G Y G S G E L I K P  
L \* S L H H N H K N V M D L D K \* F K L  
N L Y I T I I N I \* W I W I R R S N \* S

16081 CGACCAACAAAACAACTACTAAATAACTTCTGACTGTCACAAGAAAAC TATCTCGCGAAA 16140  
A P Q K T S S K N F V S L T R K I S R K  
L Q N N Q Q H N I S S Q C H E K S L A S  
S T T K N I I \* Q L S V T N K Q Y L A K

16141 CATTTCAGATCGATATCTACGAATGGGAAATCATGTAGTACTTTTACTTCTTATGGT TTTT 16200  
T L R A I S A \* G K T C \* S F S S Y W F  
Q L D L \* L H K G K L V D H F H L I G F  
Y T \* S Y I S V R \* Y M M F I F F V L F

FIG. 3 CONT'D

88/201

16201 CAGAAAGCACATATAAATCTTATATATTTTTTTTGACATATTACTAGAACCATGAGTCTAG 16260  
 T K R T Y K S Y I F F S Y L S R P V \* I  
 L R E H I N L I Y L F V T Y H D Q Y E S  
 D K T Y I \* F I Y F F Q I I I K T S L D

16261 AATCTATCAATATCACATAAAATTCATGAACACTACCAAATTCAAATGACTTCTTAGT 16320  
 K S L \* L T I K L V Q S P K F N V S S D  
 R L Y N Y H \* K L Y K H H N L T \* Q L I  
 \* I T I T N N \* T S T I T \* L K S F F \*

16321 AAAATGTTCTTATACATAAAATTTTTACGGGCACTACGTCTCACATCCACGTACGCAACAA 16380  
 N \* L F I Y K F L A T I C L T P A H T T  
 M K C S Y T N L F H R S A S H L H M R Q  
 K V L I H I \* F T G H H L T Y T C A N N

16381 ACAAGTAGTGTTGAAGAAACGCAACACCGTCAACATATGCATTGGGAAACAATACAACA 16440  
 Q E D C V E K R Q P L Q I R L G K N H Q  
 K N M V F K K A N H C N Y V Y A K T I N  
 T \* \* L S R Q T T A T T Y T L R Q \* T T

16441 TTTACAACAA'ACTGGTACAATACCGTTGATTAGTATTTATACAAA'ACTCACAGAGTGGAA 16500  
 L H Q \* S W T I A V L \* L Y T K L T E G  
 Y I N N H G H \* P L \* D Y I H K S H R V  
 F T T I V M N H C S I M F I N Q T D \* R

16501 ATGCAAAACAT'ACGTGGATTGACACTACACTCACTACAGTGGTT'AAATATAAACCCGCCA 16560  
 \* T Q L A G L Q S T L S T V L N Y K P P  
 K R K Y H V \* S H H S H H \* W I I N P R  
 V N T I C R V T I H T I D G F \* I Q A T

16561 TACAGAATGATAACACTTTTGGTATTTGGGGTARTAAAGTAAATCAATCAATACTTACCA 16620  
 I D \* \* Q S F W L G W \* E N L N T I F P  
 Y T K S N H F G Y V G N N M \* T L \* S H  
 H R V I T F V M F G M I \* K L \* N H I T

16621 TACCAGAAACCAAACATATTTGTTAGAACGTGCCCAAGTGGAAATATATCTACTAAAATTA 16680  
 I T K P K Y L C D Q V P E G \* I S S K L  
 Y P R Q N T Y V I K C P N V K Y L H N \*  
 H D K T Q I F L R A R T \* R I Y I I K I

16681 TTCTATCGATCAACATTTACCTGTCTTCAACTACTAATACAAGACCGTTTACTCACATAA 16740  
 L I A L Q L H V S T S S \* T R A F S H I  
 Y S L \* N Y I S L L Q H N H E P L H T Y  
 L Y S T T F P C F N I I I N Q C I L T N

FIG. 3 CONT'D

89/201

16741 CTGTGCAAAATTTCAATAAACGACGTCCTTGAGTTTTCCGTTGACTTCTCCGAAAATTTGTT 16800  
 S R K F N N A A S V \* F A V S S A K L C  
 Q V N L T I Q Q L F E F P L Q L P K \* V  
 F T \* L \* K S C F S L L C S F L S K F L

16801 TCGATACGAAGACGATGGTAAGTTCTCTAACAATCACTATCTCTTCAATAAAACACAACC 16860  
 L \* A E A V M \* S I T L S L S T I K H Q  
 F S H K Q \* W E L S Q \* H Y L L \* K T N  
 A I S R S G N L L N N T I S F N N Q T P

16861 CTCTGTCCATTTCAATTTGGTGGTGAATTATTTTTAATACAAAAGTGTCCGATGGTAAAA 16920  
 S V P L T L G G S L L F \* T K V P \* W K  
 P S L Y L \* V V V \* Y F N H K \* L S G N  
 L C T F N F W W K I F I I N E C A V M K

16921 TGATCATGACCATTCTGTCAAAATCCACTCATACAAAACACTATTTTCACTTAATTTGATTG 16980  
 V L V P L V T K P S Y T K S L L S N V L  
 \* \* Y Q Y S L K L H T H K Q Y F H I L \*  
 S T S T L C N \* T L I N K I F T F \* S V

16981 CCACACATAATGGCGCGATGTTGATGAATATTTGAAAGATATCCACTACAAAACAAAAT 17040  
 P T Y \* R A V V V \* L S E I P S T K T K  
 R H T N G R \* L \* K Y V K \* L H H K Q K  
 T H I V A S C S S I F K R Y T I N K N \*

17041 TGTAGTGTAAAGACATCGATCAAATTCACGTGGATGTGAACAGGGTGTCTCTTGATACGA 17100  
 V D C E T A L K L A G V S T G C S F \* A  
 L M V N Q L \* N L H V \* V Q G V L S S H  
 C \* M R Y S T \* T C R C K D W L L V I S

17101 TCATATPCTAAAAGATCACAAATATCACAGGTAACCACAAAAGTTTTATTACAACGATTA 17160  
 L I L N E L T \* L T G N T N \* F L T A L  
 \* Y L I K \* H K Y H E M P T E F Y H Q \*  
 T Y S K R T N I T N W Q H K L I I N S I

17161 ATAGTCGTGTAACCTTACTTTGCAATAACGTGACAAGTCCAGGGGGACCATGCCCTTTC 17220  
 \* \* C M P I F R \* Q V T \* P G G P V P F  
 N D A C Q F S V N N C Q E L D G Q Y P F  
 I L V N S H F T I A S N L T G R T R S L

17221 AGAGTAGAACGATATCCAGATCGACAATAATGATGTGTGTCGCACATCAAATATGACGA 17280  
 D \* R A I P R A T \* \* \* V A R T T \* V A  
 T E D Q \* L D L Q K N S C L V H L K Y Q  
 R M K S Y T \* S N I V V C C T Y N I S S

FIG. 3 CONT'D

90/201

17281 CGATCAGTACGACGACATCTACGTAACACACTTTTCGAATATTCAAAAATTTATAATTG 17340  
 A L \* A A T S A N H S F A \* L N K F I L  
 Q \* D H Q Q L H M T H F L K Y T K L Y \*  
 S T M S S Y I C Q T F F S I L K \* I N V

17341 CTAACATGTGCATAATAAGGACGATTTCAAGCACATCTAACAACTACTATTCAAATTTTAA 17400  
 S Q V R I I G A L T R T S Q \* S L N L I  
 R N Y V Y \* E Q \* L E H L N N H Y T \* F  
 I T C T N N R S F N T Y I T I I L K F N

17401 TTACTATGGTGAACATTCATACAAAATGGTGTATTACGTAATGGTCTCAACCAATGT 17460  
 L S V V Q L Y T K V V I F A N G S N T V  
 \* H Y W K Y T H K \* W L L H M V L T P \*  
 I I G S T L I N K G C Y I C \* W L Q N C

17461 CTATAACAACAACAACACTTCAATCATACGAATGATTAATACTTAACAGACAATATTTA 17520  
 S I T T T S S T L I S V L \* S N D T I F  
 L Y Q Q Q Q H L \* Y A \* \* N H I T Q \* L  
 I N N N N I F N T H K S I I F Q R N Y I

17521 CGAGCATAATTTTCGATTTGTAATACATAATAACCTCTAGGACGAGTTAATGGACGTGGT 17580  
 A R I L A L C \* T Y I P S G A \* N G A G  
 H E Y \* L \* V N H I Y Q L D Q E I V Q V  
 S T N F S F M I Y I N S I R S L \* R C W

17581 GCACACGACAACCTCGTTCCCAAGAAATCTTGGATCCGTGAAGTTAAGATAATGATTTTAT 17640  
 R T S N L L P E K S G L C K L E I V L I  
 V H A T S C P N K L V \* A S \* N \* \* \* F  
 T H Q Q A L T R \* F R P V E I R N S F Y

17641 TACACAACAAATCCAGGACTATAGAAAACCCTTTAACAATATCCACAGGATTTCTTTAA 17700  
 I H Q K P G S I K K P F Q \* L H G L S I  
 L T N N L D Q Y R K P F N N Y T D \* L F  
 H T T \* T R I D K Q S I T I P T R E F N

17701 CAICTTTTGACAAAGTCGTAACCAAACTACTATTATTGAGTTCCGATTTTACTATTATCA 17760  
 T S V T E A N T \* S L L S L A L F S L L  
 Q L F Q K L M P K H Y Y V \* P \* F H Y Y  
 Y F S N \* C Q N I I I F E L S F I I I T

17761 AGTAATACAAAATTCATATAAAATCCCTGTCTGTGTGTACTCTCAAGTTCACGACAT 17820  
 E N H K L T Y K L P C V V C S L E L A T  
 N M I N \* L I N \* P V S L V H S N L H Q  
 \* \* T K E Y I K L S L C C M L T \* T S Y

FIG. 3 CONT'D



91/201

17821 TTATAAGTTGTCTATATAGATTAATCATTTAAAAATTTTCGATTAGGTCAAACCTTATCA 17880  
 F I \* C I Y R I L L N K F A L G T Q F L  
 L Y E V S I D L \* Y I K L L \* D L K S Y  
 I N L L Y I \* N T F K \* F S I W N P I T

17881 CGACAAAAATAATCAGGAATATTATCAGTCTTAATACAACGATTTCGCACAAAATCCACAA 17940  
 A T K I L G \* L L \* F \* T A L R T K P T  
 H Q K \* \* D K Y Y D S N H Q \* A H K L H  
 S N K N T R I I T L I I N S L T N \* T N

17941 GTTTGTGTTTGACATCTAAGACGAGTCCAAGCCTTATACTAATAACAATATATAAGTGT 18000  
 \* V C V T S E A \* P E S Y S \* T I Y E C  
 E F V F Q L N Q E L N P I H N H \* I N V  
 L C L S Y I R S L T R F I I I N Y I \* L

18001 TGTGCTCTTTGTCGGGTAGACAATTACAATTAGCTAAATTACAACGGTATTGATCTCGG 18060  
 V A S V A W E T L T L R N L T A M V L A  
 F L L F L G N Q \* H \* D I \* H Q W L \* L  
 C C F C G M R N I N I S K I N G Y S S G

18061 TTCTTCCCGTAAAAAACACAATACTCATTTATACGTTAATAAACTTAGAGAATTAAAAATA 18120  
 L F P M K Q T I L L I C N N S D R L K I  
 W S P C K K H \* S Y Y A I I Q I E \* N \*  
 L L A N K T N H T I H L \* K F R K I K N

18121 TGAGATGGAATCTATTTAAGTTTTAGTTTGAAATGGAGCAAACGTAACGTGTTGATTA 18180  
 V R G K S L I \* F \* V K G R K C Q V V L  
 \* E V K L Y F E F D F K V E N A N C L \*  
 S \* R \* I F N L I L S \* R T Q M A C S I

18181 GAAAAATTTCTAACATCATTTTCAACGAATCCAATAGTAGGTTCGCGTACGGGGGAGTAAA 18240  
 R K L S Q L L L Q K P \* \* G A C A G E N  
 D K \* L N Y Y F N S L N D D L A H G R M  
 K K F I T T F T A \* T I M W R M G G \* K

18241 AATCGTCAACTACTATTTATATTTCCAATTACTTTTAAACCGACATTTAAATTTATAAACA 18300  
 K A T S S L Y L T L S F K A T F K F I Q  
 K L L Q H Y I Y P \* H F N P Q L N L Y K  
 \* C N I I F I L N I F I Q S Y I \* I N T

18301 CTTGGACAAAATTTGATAAGAGCAAATTATAGAGAATACCCAAAATTTAATCTAAACTGA 18360  
 S G T K V Y E R K I D R I P K L N S K V  
 H V Q K L M N E N L I E \* P N \* I L N S  
 F R N \* C I R T \* Y R K H T K F \* I Q S

FIG. 3 CONT'D

92/201

18361 GAACTACCAATAAGATTTAACAAATAATGATTTCTACTTCGGTAATTTGCACAATCTCCA 18420  
R S P \* E L N N I V L S S A M L R T L P  
E Q H N N \* I T \* \* \* L H L W \* V H \* L  
K I T I R F Q K N S F I F G N F T N S T

18421 ACCCAACCAAACTACAACCTCCCGGAGTACGATGAGCGCTTTTGTAACTTGTGTTGAAA 18480  
Q T P K S T S P A \* A V R S F M P V F K  
N P Q N Q H Q P R E H \* E R F C Q F L S  
P N T K I N L A S M S S A F V N S C V K

18481 GGTGACGTTTATCCAAAAAGTTGACCACACCTAAAACATCAACTTCGATGACCGAATAAA 18540  
G S C I P K E V P T S K T T S A V P K N  
E V A F L N K L Q H P N Q L Q L \* Q S I  
W Q L Y T K \* S T H I K Y N F S S A \* K

18541 CGACTCTCTACAATATGAAAATTTTTTGACATCGATTCGAGGAGGACCACTTTTT 18600  
A S L S Q \* V K L E V T A L A G G P S F  
Q Q S L N N Y K \* F F Q L \* L E E Q H F  
S L S I T I S K F F S Y S F S R R T F F

18601 AAATTTGTAATATATGGGGAATACAGTTTCCAGTTTCCACCCTATAACAATCTTAATCT 18660  
N L C K I G R I D F P \* F H S I T L I L  
I \* V N L V G \* T L L D F T P Y Q \* F \*  
K F M \* Y G K H \* F T L L P I N N S N S

18661 TAACAAGTTTACAATAGACTAATAGAAAATCTGGAAAGACTATCACATCATAAATAATGA 18720  
I T \* I N D S \* R K S R E S L T T N I V  
F Q E F T I Q N D K L G K Q Y H L I \* \*  
N N L H \* R I I K \* V K R I T Y Y K N S

18721 ACCGACGGTCAAACCTTGAATGAACAAATCCATAAAACGATTTAATCCGTCTCTCGAA 18780  
Q D A L K S S V Q K L Y K A L N P L S S  
K T Q W N Q V \* K N L T N Q \* I L C L A  
P R G T K F K S T \* P I K S F \* A S L K

18781 TTAACATTACACACAAGATTAGCAGGTGTACGATGTTAAGATCTTGACCAATAATACCA 18840  
L Q L T H E L R A V H \* L E L V P \* \* P  
\* N Y H T N \* D H \* M S C N \* F Q N N H  
I T I H T R I T S C A V I R S S T I I T

18841 ACAACCGGGTATCAATATGAACACTAATACACATAATAGGTGAATAACATCTATATGTT 18900  
Q Q R W L \* V Q S \* T Y L G S I T S I C  
N N A G Y N Y K H N H T Y D V \* Q L Y V  
T P A M T I S T I I H I I W K N Y I Y L

FIG. 3 CONT'D

93/201

18901 GTCACCCCAATATGTCCAAGAAATTGATCATTAGTGCTATATTAAACATTACATGTATTT 18960  
 C H P \* V P E K V L L \* S I I Q L T C L  
 V T P N Y L N K L \* Y D R Y L K Y H V Y  
 L P T I C T R \* S T I V I Y N T I Y M F

18961 CCACGTGTACAACGCAGTCGACTACGTTAATACTGAGCAACAAATCGTTAGATACTAACA 19020  
 P A C T A D A S A I I V R Q K A I \* S Q  
 L H V H Q T L Q H L \* S E N N L L R H N  
 T C M N R \* S I C N H S T T \* C D I I T

19021 AAAACATTTAGACAATTAACCTTAAATCTCATAGGTTATTAAGATTACTCCAGTCATAT 19080  
 K Q L D T L Q F K S Y G I I E L S T L I  
 N K Y I Q \* N S N L T D L L K \* H P \* Y  
 K T F R N I P I \* L I W Y N R I L D T Y

19081 TTATGTAGAACATCCAATAACGTCGCACAGTACGAATTCGACGGTACGATACATTATCT 19140  
 F V D Q L N N C R T M S L A A M S H L L  
 L Y M K Y T I A A H \* A \* L Q W A I Y Y  
 I C R T P \* Q L T D H K F S G H \* T I S

19141 ATGTTGAATACAATACTGTATCCGTTAGGATTTCCAATCGAACACAGTTTCTAATACTT 19200  
 Y L K H \* S M P L G L P K A Q T L S \* S  
 I C S I N H C L C D \* L N L K H \* L N H  
 V V \* T I V Y A I R F T \* S T D F I I F

19201 AAATTTAAAATACTACGAAAAGGACATCGGTTCAGACAATTTGTCAATAAAATACAGATA 19260  
 N L N \* S A K G T A L D T L C N N \* T . \*  
 I \* I K H H K E Q L W T Q \* V T I K H R  
 K F K I I S K R Y G L R N F L \* K I D I

19261 CTACAGTATTTCTATTAATAATTTCTACCAAATACATACAAAACCTTAACATTACAACATA 19320  
 S T C L S L K L S P K H I N Q F Q L T S  
 H H A Y L Y N \* L H N I Y T K S N Y H Q  
 I H M F I I K F I T \* T H K P I T I N I

19321 TTTATAGGTAGATTAAGTTAACAAACATCTAAACTGTGAGCTCACATTTATTTAATTTG 19380  
 L Y G D L E I T Q L N S V R T N F L N F  
 Y I D M \* N L Q K Y I Q C E L T L Y I L  
 F I W R I \* N N T S K V S S H \* I F \* V

19381 GAAGGACCTACATTACCACCATCAAACATACAATTTATTTGTACGTAAGGTATGATTAGGA 19440  
 R G P H L P P L K Y T L L C A N W V L G  
 G E Q I Y H H Y N T H \* Y V H M G Y \* D  
 K R S T I T T T Q I N I F M C E M S I R

FIG. 3 CONT'D

94/201

19441 AAATGATCTTGACAAAACTTTTAGAATTCGGATACGGAAAAAGATAATAAGTCTATGC 19500  
 K V L V T K S F R L G I G K K \* \* E S V  
 K \* \* F Q K Q F D \* A \* A K K R N N L Y  
 K S S S N K F I K L R H R K E I I \* I R

19501 GGAACACACATGCATCTACCAATCTTAGATTGTTCAACTAATGCAAGGAAATTCCTCG 19560  
 G Q T Y T S P K S D L C T S \* T G K L L  
 A K H T R L H N L I \* V L Q N R E K L F  
 R T H V Y I T \* F R F L N I V N R \* S A

19561 CGGTGAACATAGTGTGCCACATTAGATCCACCTCGACAAACAAGTTTCGTACGACTTCTT 19620  
 A V Q I V R H L R P P A T Q E F C A S S  
 R W K Y \* V T Y D L H L Q K N L A H Q L  
 G S T D C P T I \* T S S N T \* L M S F F

19621 ATAACATTGATGGAACCTCAGAATATTATATCAATGATGTCGTCGAAATGAAAAACCCAA 19680  
 Y Q L \* R S D \* L I T V V A P K V K Q T  
 I N Y S G Q T K Y Y L \* \* L L S \* K K P  
 I T V V K L R I I Y N S C C A K S K P N

19681 ATATTCTTAAAACTAAAAATATTAATACCTTGTGAAAATGATGCAATGTCTCAAATCTT 19740  
 \* L F K S K \* L K H F V K V V N C L K S  
 K Y S N Q N K Y N I S C K \* \* T V S N L  
 I L I K I K I I \* P V S K S R \* L T \* F

19741 TTGCATTATATATGAACCAATTACAACCAGTAATACTACCTGCATGTCCACTTAATGGA 19800  
 F T I Y L K T L T P \* \* S P R V P S N G  
 F R L I Y S P \* H Q D N H H V Y L H I V  
 V Y Y I V Q N I N T M I I S T C T F \* R

19801 ACACGATAAATACTTACTGTTTCAACAACAATTCTAATTATTACATCTATGACAATAAAAA 19860  
 Q A I I F S L T T T L I L L T S V T I K  
 K H \* \* S H C L Q Q \* S \* Y H L Y Q \* K  
 T S N H I V F N N N L N I I Y I S N N K

19861 TTTTATTATGTAGTAAAGGATGATTATATCGACAACCTTAACAAATGTTTTCATCATAG 19920  
 L F L V D N G V L I A T S N N V F R L I  
 \* F Y Y M M E \* \* Y L Q Q I T \* L V Y Y  
 F I I C \* K R S I Y S N F Q K C F T T D

19921 GCCGTGGTGGGACTTGAATTCTAAGAATCTTTAAACTTGTAACCTATAAACACCTTCGTA 19980  
 R C W G S S L I R L F K F M S I Q Q F C  
 G A G G Q V \* S E \* F N S C Q Y K N S A  
 P V V R F K L N K S I Q V N I N T P L M

FIG. 3 CONT'D

95/201

19981 CAGGACACCCCTAATACAATTTCTATCAAACAAAACATCAAGGTGAATACCACAAACATTT 20040  
 T R H S \* T L S L K N Q L E V \* P T Q L  
 H G T P N H \* L Y N T K Y N W K H H K Y  
 D Q P I I N F I T Q K T T G S I T N T F

20041 ATGTGTCTAAACTTCAAGTAGCTTTTAACTTATATGAAAACTACCAGCACTGTGACCG 20100  
 Y V S K F N M S F K F I S K S P R S V P  
 I C L N S T \* R F N S Y V K Q H D H C Q  
 V C I Q L E D F I Q I Y K K I T T V S A

20101 CGAAATCTTCGAAAATCTTTTCGTTCTTTACCACAAAATAATCATGACTTTTTTAATCA 20160  
 A K S A K L F A L F P T K I L V S F N L  
 R K L L K \* F L L F H H K \* \* Y Q F I L  
 S \* F S K S F C S I T N K N T S F F \* T

20161 TCCAATAGTTACTAATTTCCAGGCGTTGCTCGACTAAATTTACCACACTAACACCTATTT 20220  
 L N D I I L P G C R A S K F P T I T S L  
 Y T I L S \* L D A V L Q N L H H S Q P Y  
 P \* \* H N F T R L S S I \* I T H N H I F

20221 CAACCTCTTGAGTTTCAACTCAAACCAAGCGATACTCTTTTCTACCCTGCTACAATAG 20280  
 T P S S L T S N Q N A I L F S P S S T I  
 L Q L V \* L Q T K T R \* S F L H H R H \*  
 N S F E F N L K P E S H S F I T V I N D

20281 AAGTCGGCTTGTCTGTCGGATACGAGTTCGGTAATGACCTCGGGTGTTCATTAGATCCA 20340  
 K L R V S L R H E L W \* Q L G C P L R P  
 R \* G F L C G I S L G N S S G V L Y D L  
 E A S C V A \* A \* A M V P A W L T I \* T

20341 CCATTAACGCGCCCATTACAGTAACCATTTACTACGAGATTGTGCAAAATGATAGAAATGA 20400  
 P L Q A P L T M P L S A R V R K V I K V  
 H Y N R P Y H \* Q Y H H E L V N \* \* R \*  
 T I A R T I D N T I I S \* C T K S D K S

20401 GTCTCAGCACATAACAGTTCAAACCTTGGAGCGAGTCTAAATCTTGCCCTAAAATAACTA 20460  
 \* L R T N D L K S G R E S K S R S K I S  
 E S D H I T L N Q V E S L N L V P N \* Q  
 L T T Y Q \* T K F R A \* I \* F P I K N I

20461 TACCTACTATTAGACAAATAACGATTTATACCAATCTTCTGATACGTAACCTAGTATAT 20520  
 I S S L R N I A L Y P K S S \* A N S \* I  
 Y P H Y D T \* Q \* I H N L L S H M Q D Y  
 H I I I Q K N S F I T \* F V I C K I M Y

FIG. 3 CONT'D

96/201

20521 CAAATACCATCAAAATGGTATTTCAATATCCTCCAAACGTAAACGAATATCCGAATAAA 20580  
 T \* P L K L W L T I P P K C K S I P K N  
 L K H Y N \* G Y L \* L L N A N A \* L S I  
 N I T T K V M F N Y S T Q M Q K Y A \* K

20581 GCATCCTTTTTTTTAGATTAAACAATTAAGTCTCAAAAATGTCATACTAAGATCATAA 20640  
 R L F F F D L K N I \* S N K C Y S E L I  
 E Y S F F I \* N T L E L T K V T H N \* Y  
 T P F F F R I Q \* N L L K \* L I I R T N

20641 GTAAGTATAAAAATAAGACTAGTCTCACACCATCATCATTCTCACAACATGTCAATAA 20700  
 \* E Y K I V S \* S H P L L L L T Q V T I  
 E N M N \* \* Q D P T H Y Y Y S H K Y L \*  
 M \* I K N S I L L T T T T L T N T C N N

20701 CTAAATAATAATCTACTAAAACAAGATAACAATTCAGTAATTTAAACTCAACACAATCA 20760  
 S K N N S S K T E I T L D N F K L Q T L  
 Q N I I L H N Q K \* Q \* T M L N S N H \*  
 I \* \* \* I I K N R N N L \* \* I Q T T N T

20761 TTTCAACAAATTATAATTACAACATAAAATTCCTAAAAGTTAAATACAACACCACATTA 20820  
 L T T L I L T S K L S K \* N I N H H L S  
 Y L Q \* Y \* H Q N \* P N E I \* T T T Y H  
 F N N I N I N I K L I K L K H Q P T I I

20821 TTATTTAATAACTGAAAAATAGGATTTTACGTTCCGGTGATTACTAACCTTTGGACCGATA 20880  
 L L I I V K \* G L I C A V L S Q F G P \*  
 Y Y F \* S K K D \* F A L W \* H N S V Q S  
 I F N H S K I R F H L G S I I P F R A I

20881 AGATACGGACAAAACATATTCATAAACTTACAAGGTAATCTCTCAGAGAAAATACCTTA 20940  
 E I G T K Y L Y K F T G N S L T E K H F  
 N \* A Q K T Y T N S H E M L S L R K I S  
 R H R N Q I L I Q I N W \* L S D R \* P I

20941 ATACCATTTGGATAATTAACCGGATGTCGACATACTACTTACAACGATTCATGTGAGTT 21000  
 \* P L G I L K G V P Q I I F T A L Y V \*  
 N H Y V \* \* N A \* L S Y S S H Q \* T C E  
 I T F R N I Q R C A T H H I N S L V S L

21001 AATACAGTCATAAACTTATGATGTTGTAATCGACAAGGACAATTATACGCACAAAATGTA 21060  
 N H \* Y K F V V V N A T G T L I R T K C  
 I I D T N S Y \* L M L Q E Q \* Y A H K V  
 \* T L I Q I S C C \* S N R N I H T N \* M

FIG. 3 CONT'D

97/201

21061 AATCCACGTCGCCAGACTATTTCTTCATCGAGGTCCAAGACGACAAAATTCTGTACCAAT 21120  
 K P A P D S L S T A G P E A T K L C H N  
 N L H L T Q Y L L L E L N Q Q K L V T T  
 \* T C P R I F F Y S W T R S N \* S L P \*

21121 GGTAGACCATCATAAGAACATCTATTAATAAATTTGGGTAAACAATCGCTATCAAATCAA 21180  
 G D P L I R T S L S K F G N T L S L K T  
 V M Q Y Y E Q L Y H N L G M Q \* R Y N L  
 W R T T N K Y I I I \* V W K N A I T \* N

21181 TGAATAAAACCTCTAACATACTGAAATGGTAAACTAACAGTAACCCTAAACTATTATAGA 21240  
 V \* K P S Q I V K G N S Q \* Q S K I I D  
 \* K N Q L N Y S K V M Q N D N P N S L I  
 S I K S I T H S \* W K I T M P I Q Y Y R

21241 CTATACATACTAGGAGATGATTTTTATAACCACTAATATTACACTCATTCCTACCCAAA 21300  
 S I Y S G R V L F I P S \* L T L L S P N  
 Q Y T H D E \* \* F Y Q H N Y H S Y P H T  
 I H I I R K S F I N T I I I H T L I P K

21301 AAATGAATGTAAACAGTAAATTAAGCACTATTTAATAGAAACCCACCATCACATCGATAT 21360  
 K V \* M Q \* K I R S L N D K P P L T A I  
 K \* K C K D N L E H Y I I K P H Y H L \*  
 K S V N T M \* N T I F \* R Q T T T Y S Y

21361 TTTTAATGTCTCAAAGAACCTTACGACTAAATATATTTAATTAATCAACAAAACGTAAA 21420  
 F I V S N E Q F A S K Y L N I L Q K A N  
 L F \* L T K K S H Q N I Y I L S N N Q M  
 F N C L K R P I S I \* I F \* H T T K C K

21421 ACCTGTCAAAAAACATGATTACATTTACGAAGAAGATCACTTCCCAAAAATTATCCATAT 21480  
 Q V T K Q V L T F A E E L S P N K I P I  
 K S L K K Y \* H L H K K \* H L T K L L Y  
 P C N K T S I Y I S R R T F P K \* Y T Y

21481 TTAATGGACCCATTTAGAAGAAAACCTTTATCTACCGTTACAATACGTACGATTGATAAAC 21540  
 F \* R P L D E K S I S P L T I C A L \* K  
 L N G P Y I K K Q F L H C H \* A H \* S N  
 I V Q T F R R K F Y I A I N H M S V I Q

21541 AAAACCTCTTTATCATGTTGTACCTTACCGCCACGAATATCAAATAAACTATACTGATTT 21600  
 N Q L F L V V H F P P A \* L K N S I V L  
 T K S F Y Y L M S H R H K Y N I Q Y S \*  
 K P S I T C C P I A T S I T \* K I H S F

FIG. 3 CONT'D

98/201

21601 AAAAGAAACTTTAACCGACCGTGACGACAACAATTAATTCTGGTCTAGTTAAATTTACTA 21660  
 N E K F N A P V A T T L K L G S \* N F S  
 I K K S I P Q C Q Q Q \* N L V L D I L H  
 K R Q F Q S A S S N N I \* S W I L \* I I

21661 AATCAAATAAGAGAATAACTTTCTCCATTTAATAATCAAGCGCTATGCGCATTTCCTAA 21720  
 K T \* E R I S L P L N N T R S V R L S I  
 N L K N E \* Q F L Y I I L E R Y A Y L S  
 \* N I R K N F S T F \* \* N A I R T F L N

21721 AAACAACCACTATCAGAACATTTATGAACAATCTAGAGTAATTTAGATTTGATACAATTA 21780  
 K T P S L R T F V Q \* I E N F R F \* T L  
 K Q Q H Y D Q L Y K N S R M L D L S H \*  
 K N T I T K Y I S T L D \* \* I \* V I N I

21781 ATAAAAAAATAAAAAAATAAGACAATACCAAAATTACTTGGAGAATTACAACACAGAGT 21840  
 \* K K I K K N R N H N \* H V E \* H Q T E  
 N N K \* K K I E T I T K I F R K I N H R  
 I K K N K \* K Q \* P K L S G R L T T D \*

21841 AAATTTGGTACTGACCAAAAAATAAACCACTATCAGCAAGACTAACATTGGTATAATATT 21900  
 N L G H S T K I Q H Y D N Q N Y G Y \* Y  
 M \* V M V P K \* K T I T T R I T V M N I  
 K F W S Q N K N P S L R E S Q L W I L L

21901 AAATTTTAAATTTTAAACTAATAAACCTATAAGTGGGATCAAACACGTTGTTACCATT 21960  
 N L F \* F N Q N N P Y E G \* N T C C H Y  
 I \* F N F I K I I Q I N V R T Q A V I T  
 K F I L F K S \* K S I \* G L K H L L P L

21961 CTAAAGTAGATCACGGCCACTAAGATAAAAAATCTCAAAGTAAAGTGAGCTAAAATATT 22020  
 S K M \* H R H N \* K \* S N E N \* E I K Y  
 L N \* R T G T I R N K L T K M E S S K I  
 I E D L A P S E I K L L K \* K V R N \* L

22021 AATGTGACCGCTTCCACTAGTTTAATAAAAAATACTCCACAATTAAAATTAGGAATAGT 22080  
 N C Q R L H D F \* K K H P H \* N \* D K D  
 I V S A F T I L N N K I L T N I K I R I  
 \* V P S P S \* I I K \* S P T L K L G \* \*

22081 ATCTAAATTCACAAAAGGATTACCATCATTACTACATACCGAAGAATTGTTCCATTCTAA 22140  
 Y I \* T N E \* H Y Y H H I A E \* C P L I  
 M S K L T K R I T T I I Y P K K V L Y S  
 L N L H K G L P L L S T H S R L L T L N

FIG. 3 CONT'D



99/201

22141 AATAGCACGGAATATAAGATTATACCGGAAAAAAGCAATAGAATGAAAACAACATATAAGG 22200  
 K D H R I N \* Y P R K E N D \* K Q Q Y E  
 K I T G \* I R I H G K K T I K S K N I N  
 \* R A K Y E L I A K K R \* R V K T S I G

22201 AATATTACAAAGAGAAAGATTCAAATTAAGAACATTTTCACTATAAAAATAGTGAATTGTT 22260  
 K Y H K E K \* T \* N K Y F H Y K I V \* C  
 R I I N R K R L K I R T F T I N \* \* K V  
 \* L T E R E L N L E Q L L S I K D S L L

22261 AGGATAAAAAATAATTAATAAGATTCTTCAAATAAAATGAAAATAATCCAACAAGAGAAAT 22320  
 D \* K \* \* N N \* P L K N \* K I L N N E K  
 I R N K N I I R L F N I K S \* \* T T R K  
 G I K I L \* E L S T \* K V K N P Q E R \*

22321 AAATCATGGCGAAACGGAAAAATTTAGATTGAAATCAGTCATGATAATATTGTATCTATG 22380  
 N L V A K G K \* I \* S \* D T S N Y C L Y  
 I \* Y R K A K K F R V K T L V I I V Y I  
 K T G S Q R K L D L K L \* Y \* \* L M S V

22381 ACCGAGACAAATACCAAAAAGATTACAACAAATAGGACTAAATCTGACATAAATATAAAG 22440  
 Q S Q K H N K \* H Q K D Q N L S Y K Y K  
 S A R N I T K R I N N I R I \* V T N I N  
 P E T \* P K E L T T \* G S K S Q I \* I E

22441 AGAATTTGGTCCAAGAATATTTCAAAGGTGGTGACGTGGAAAAAATAGGAATGGATGATT 22500  
 E \* V L N K Y L K W W Q V K K I R V \* \*  
 R K F W T R I F N G G S C R K \* G \* R S  
 R L G P E \* L T E V V A G K K D K G V L

22501 TCGAGAGACAAAACATTTTAGATTGTAAACATGGACATGTCCAACAACATAAGATCTAC 22560  
 L E R N Q Y I \* V I Q V Q V P Q Q N \* I  
 F S E T K I F R F L K Y R Y L N N I R S  
 A R Q K S L D L C N T G T C T T S E L H

22561 CTTGTTGCTCGCACGGAGTCTATAAAGAAATAGACAACGTACAGTTAACGGTATAACAAT 22620  
 S C R A H R L Y K K I Q Q M D I A M N N  
 P V V L T G \* I N R \* R N C T E Q W I T  
 F L S R A E S I E K D T A H \* N G Y Q \*

22621 AAAAGCGTTAAGAAGACGATTAATACAACCGTTCATACTATAATTGGTGCCACTATCACC 22680  
 N E C N K Q \* N H Q C T H Y \* G R H Y H  
 I K A I R R S I I N A L I I N V V T I T  
 K R L E E A L \* T P L Y S I L W P S L P

FIG. 3 CONT'D

100/201

22681 AAAATAAAGATAAAATAGACCAGAAAATATATTTACAAGAACATAAAGTATAATACCACA 22740  
 N \* K \* K I Q D K I Y H K K Y K M N H H  
 T K N R N \* R T K \* I I N R T N \* I I T  
 K I E I K D P R K Y L T E Q I E Y \* P T

22741 TAAAAATATACTATTAAATGTAGGTAAACCGGGATAATAAGAAAACCATCCACAGGATG 22800  
 I K I H Y N \* M W K A R N N K Q Y T D \*  
 Y K \* I I I K C G N P G I I R K T P T R  
 N K Y S L K V D M Q G \* \* E K P L H G V

22801 TAGAAGATAATAATTTGTAGGTAAACACAAATACTAAAAACGGATAATAAAATGTTCC 22860  
 M K \* \* \* V D L K H K H N K A \* \* K V L  
 C R R N N F M W N T N I I K Q R N N \* L  
 D E I I L C G I Q T \* S K K G I I K C P

22861 ATAAAAATAACAAATCGAAATGAAAAACAACAAAAAGATAATAAAAAACAATATATTGCT 22920  
 Y K I I N L K V K Q Q K E I I K T I Y R  
 T N \* \* T \* S \* K K N N K \* \* K Q \* I V  
 I K N H K A K S K T T K R N N K N Y L S

22921 ATTTAGAGTAATTTAGATTTGTACAATAATTAATAAAAAATAAACGGATGTTGTAATCGA 22980  
 Y I E N F R F M N N I I K I K G V V N A  
 I F R M L D L C T I L \* K \* K A \* L M L  
 L D \* \* I \* V H \* \* N N K N Q R C C \* S

22981 CAATATCCACTAAAATTAACATGATTAACGATAATTACTAAATTTGTGGTGTCAAGGA 23040  
 T I P S K L Q V L K A I L S K F V V T G  
 Q \* L H N \* N Y \* N Q \* \* H N L C W L E  
 N Y T I K I T S I K S N I I \* V G C N R

23041 GCGTATTCACCTCATAACAACCTACAAGAATACCAAACCCATGTATAATATATGAACTA 23100  
 R M L S Y T T S T E \* P K P V Y \* I S S  
 E C L H T H Q P H K K H N P Y M N Y V Q  
 A Y T L I N H I N R I T Q T C I I Y K I

23101 GCACAAATAAATTTATGATGATATAATAAATGACCAATAAAGGATTTAGACCACGGTTA 23160  
 R T \* K F V V I N N V P \* K G L D P A L  
 D H K N L Y \* \* I I \* Q N N G \* I Q H W  
 T N I \* I S S Y \* K S T I E R F R T G I

23161 AAATCCCTAGATAGAAAATTTCCATGATGTATAAACTCATGAGAAACCATAGTCTTTGGG 23220  
 K L S R D K F P V V Y K L V R Q Y \* F G  
 N \* P D I K L L Y \* M N S Y E K T D S V  
 K P I \* R \* F T S C I Q T S K P I L F G

FIG. 3 CONT'D

101/201

23221 AAAAATAGACTAAAATTTATTACCATAAAAAAGATCTCAATCTTATGATTCAACATACAA 23280  
 K K D S K L L P I K E L T L F V L N Y T  
 R K I Q N \* Y H Y K K \* L \* S Y \* T T H  
 K \* R I K I I T N K R S N L I S L Q I N

23281 TTATTTTGAAACATATCACTCAAATCATGATATCAATATCCATCACAAAAATAATTGTTG 23340  
 L L V K Y L S N L V I T I P L T K I L L  
 \* Y F K T Y H T \* Y \* L \* L Y H K \* \* C  
 I F S Q I T L K T S Y N Y T T N K N V V

23341 AGAATATGATAACAACAAGTTGGAGTATTACCACAAAACCTCTAATGTCGAACAGTTATG 23400  
 E \* V I T T \* G \* L P T K S I V A Q \* Y  
 S K Y \* Q Q E V E Y H H K P S \* L K D I  
 R I S N N N L R M I T N Q L N C S T L V

23401 TGATACACTCATAGGAGTATGATAAACATTTAGATTTCCATCAAGAGCATTACTTAGA 23460  
 V I H S Y G \* V I Q L D L P L E R L S D  
 C \* T H T D E Y \* K Y I \* L Y N E Y H I  
 S H T L I R M S N T F R F T T R T I F R

23461 ACCGTAAAACATTTAGACTTGGAAACACAGACAAGTTCTTTTAAAATGAATATTACAA 23520  
 Q C K S L D S G K H R N L F F K V \* L T  
 K A N Q Y I Q V K T D T \* S F N \* K Y H  
 P M K I F R F R Q T Q E L F I K S I I N

23521 AGATGTCTAACCAACATAAAAAGTAAAATAGTTCTTGCACCGTGAAAAATACGAATAATA 23580  
 E V S Q N Y K \* K \* \* S R P V K \* A \* \*  
 K \* L N T T N E N K D L V H C K K H K N  
 R C I P Q I K M K I L F T A S K I S I I

23581 CGACTAAGACCGTACGGATGATGAAAAATAAATCAAACATAGAACCATGAGAAAAATAGA 23640  
 A S E P M G V V K K N L K Y R P V R K D  
 H Q N Q C A \* \* K K I \* N T D Q Y E K I  
 S I R A H R S S K \* K T Q I K T S K \* R

23641 GTAATAATACAAAACGGAAACTGAACATTACGATATAGAAGATTATGACTATTACTCTGA 23700  
 \* \* \* T K G K V Q L A I D E L V S L S V  
 E N N H K A K S K Y H \* I K \* Y Q Y H S  
 M I I N Q R Q S T I S Y R R I S I I L S

23701 AATGTTATAACCCAGTGTGGAAACAGATTGCGGTTATAGAAGAATTTAAACTGTTGGCA 23760  
 K C Y Q T V G K D L R W Y R R L N S L R  
 K V I N P \* V K T \* V G I D E \* I Q C G  
 \* L I P D C R Q R F A L I K K F K V V T

FIG. 3 CONT'D

102/201

23761 CCACAATAATGATTACGACAACCTAACAAGATCATCAAAGAAATCGCTCTAAGTTACATTT 23820  
 P T I V L A T S Q E L L K K L S I \* H L  
 H H \* \* \* H Q Q N N \* Y N R \* R S E I Y  
 T N N S I S N I T R T T E K A L N L T F

23821 TGATTTAGAAATAATGGATTATGACCACAAATACTGAATAGACCAAAATGACAATTCGGGA 23880  
 V L D K N G L V P T \* S K D P K V T L G  
 F \* I K I V \* Y Q H K H S I Q N \* Q \* A  
 S F R \* \* R I S T N I V \* R T K S N L R

23881 CAACGTTGACATGTAGCAGCATAAGGACTAAATGGACTAACACTGTAACCTATTTACCGAA 23940  
 T A V T C R R I G S K G S Q S M S L H S  
 Q Q L Q V D D Y E Q N V Q N H C Q Y I A  
 N C S Y M T T N R I \* R I T V N I F P K

23941 TTGTTAAAATTACATGGGAGTGGAGAATTAACCCCTTGCATTTTAAAAAAGATTAACGTTG 24000  
 L L K L T G E G R L Q S R L I K E L Q L  
 \* C N \* H V R V E \* N P V Y F K K \* N C  
 V I K I Y G \* R K I P F T F N K R I A V

24001 AAATTAACCTCATGAAACGAAGCAATCAAGTATGACTAAGAAAAAGAACATTTATTAATA 24060  
 K L K L V K S R K T \* V S E K E Q L L K  
 S \* N S Y K A E N L E Y Q N K K K Y Y N  
 K I Q T S Q K T \* N M S I R K R T I I K

24061 CTAAGTAGATCTATATACCATCAACAAAATTCATACAAAATCTATTTAAACGGTAT 24120  
 S S D L I Y P L Q K L L I T K S L N A M  
 Q H I \* S I H Y N N \* S Y Q K L Y I Q W  
 I F R L Y I T T T K L T N N \* I F K G Y

24121 GGGTTGAGGTCTGCTAGACTAAACGTCACCCGTCAGACCAAAAGACGTTAGAAGATTA 24180  
 G L E L R D S K C N P L E P K R C D E L  
 V W S W V I Q N A T P C N Q N E A I K \*  
 G V G S S R I Q L Q A T R T K Q L R R I

24181 ATATTTAACTGTGATGAAGATCAAGAACAGTTAACATAATATCAAACGGACGTTAATTA 24240  
 \* L I S V V E L E Q \* N Y \* L K G A I L  
 N Y F Q C \* K \* N K D I T N Y N A Q L \*  
 I F N V S S R T R T L Q I I T Q R C N I

24241 CAATGATAATTATTAATATTAGGAAGAAGAACCCTTATCTCCATACCAAAATTTATTAATA 24300  
 T V I L L \* L G E E Q F L L Y P K L L K  
 H \* \* \* Y N Y D K K K S Y F T H N \* Y N  
 N S N I I I R R R P I S P I T K I I K

FIG. 3 CONT'D

103/201

24301 TTAAACTCGAGAGTATCACAAATGAGTGCATAACAAAAAGACAATTATTATGAAAA 24360  
 L K L E \* L T T \* E R \* Q K E T L L V K  
 \* N S S E Y H Q K S V N N N K Q \* Y Y K  
 I Q A R M T N N V \* T I T K R N I I S K

24361 ACAGGAACAGGATTTGGAAGAAAACGAGTTCACGTTCTCAGTATTTGGTGAAGACGA 24420  
 Q G Q A L G E K A E L Q L L \* L G G E A  
 K D K H \* V K K Q K L N C S D Y V V K Q  
 T R T S F R R K S \* T A L T M F W R R S

24421 AGGACAGGATAACCATGATTAATAGCAAGAACAACCTCTCATGATGACATGAGCTGGTGTGA 24480  
 E Q G I P V L \* R E Q S L V V T S S W V  
 K R D \* Q Y \* N D N K H S Y \* Q V R G C  
 G T R N T S I I T R T L T S S Y E V V S

24481 CTGACCACATCCACAAGAACAATGGACTAGGATATTGACGAATACTGGGATCCAGAACA 24540  
 S Q H L H E Q K G S G I V A \* S G L D Q  
 Q S T Y T N K N V Q D \* L Q K H G \* T K  
 V P T P T R T \* R I R Y S S I V R P R T

24541 AGAGTTTTTTTCAGAGACCAACCACAACCACTTGTAACACGTCCCAAGCCACAACACTTT 24600  
 E \* F F D R T P T P S C Q A P N P T S S  
 N E F F T E P Q H Q H V N H L T R H Q H  
 R L F L R Q N T N T F M T C P E T N I F

24601 CTTTTCACACCACATAACCTACCTAGTATATTACAAAGAACAGAAACATCATGACTACGG 24660  
 S F H P T N S P D Y L T E Q R Q L V S A  
 L F T H H I P H I M Y H K K D K Y Y Q H  
 F L T T Y Q I S \* I I N R T K T T S I G

24661 AAAGATCCAACCAGAATACTGTGAACGCAGTCATTGTTGGCAACATATAAAAAAGATTA 24720  
 K R P Q D \* S V Q T L L L R Q L I K E L  
 R E L N T K H C K R \* Y C G N Y Y K K \*  
 K \* T P R I V S A D T V V T T I N K R I

24721 AAAFAAAATTTACCATAGTTATCACCATGGTGAACAAGATTACTAAATAACGTCGGGATTA 24780  
 K I K F P I L L P V V Q E L S K N C G L  
 N \* K L H Y \* Y H Y W K N \* H N I A A \*  
 K N \* I T D I T T G S T R I I \* Q L R I

24781 TGACTTCAAAAATGACTACAAACACAACCTAATGCTGGAAATACCATAATGTCCTGTCCA 24840  
 V S T K V S T Q T S \* S R \* P I V P C P  
 Y Q L K \* Q H K H Q N R G K H Y \* L V L  
 S F N K S I N T N I V V K I T N C S L T

FIG. 3 CONT'D

104/201

24841 TAAAAATTTCTTCAAAGACGACAAATAATATTATCAACCGTTTTAGAAAAACATACTAAGA 24900  
 I K L S T E A T \* \* L L Q C F R K Y S E  
 Y K \* L L K Q Q K N Y Y N A F D K T H N  
 N K F F N R S N I I I T P L I K Q I I R

24901 TTACCGTTGTAATAACCAAATTTCTAAAACAATGATATTTTGTATATATATAAAAGGGA 24960  
 L P L M I P K L S K T V L L V Y L I K G  
 \* H C C \* Q N \* L N Q \* \* Y F M Y Y K G  
 I A V N N T K F I K N S I F C I I N E R

24961 ACAATACGTCCTTCTCAAAGACGACAAAAGTAGTTTACGAAGGAGAAACCGAAATGAA 25020  
 Q \* A P L T E A A K \* \* F A E E K A K S  
 K N H L F L K Q Q K E D F H K R K P K V  
 T I C S S N R S S K M L I S G R Q S \* K

25021 ATAGCATTAAATTTTACATCGATACAAAACCTTATTATAAAGAAATGATGAGTCGGTATA 25080  
 \* R L K F H L \* T K F L I E K V V \* G Y  
 K D Y N L I Y S H K S Y Y K K L \* E A M  
 I T I \* F T A I N Q I I N R \* S S L W I

25081 AAATATCAATAGAACCAACGCAAAAATTACGACTATTAATGACTAATAAGACAAAGA 25140  
 K S L \* R P Q T K L A S L K V S \* E T E  
 N Q Y N D Q N R K \* H Q Y N L Q N N Q K  
 K I T I K T A N K I S I I \* S I I R N R

25141 AGAACACGAGAAGCGTACCCATCACCAAAAACACAATAATATTGAGTGAAGAAGAAGG 25200  
 E Q A R R M P L P K Q T S \* L E G E E E  
 K K H E E C P Y H N K H Q N Y S V K K K  
 R T S K A H T T T K T N I I V \* R R R G

25201 AGAAGCGCAGCATTGTCATCTTCATAAAGACGAAGAAATAGCAAAAACAATGAAAACCTGGG 25260  
 E E R R L R L L I E A E \* R K T V K S G  
 R K A D Y V Y F Y K Q K K D N Q \* K Q V  
 R R T T F T S T N R S R I T K N S K F G

25261 AAATTACAGTCAAAAACAATTACTGTCACTCACTCAGACACCCACCAGAAATACTCTAGTTT 25320  
 K L T L K T L S L I S D T P P R \* S I L  
 R \* H \* N Q \* H C Y Q T Q P H D K H S \*  
 K I D T K N I V T N L R H T T K I L D F

25321 TAAGGGTGATTGAAATGATATCAACCGTTCTCCTTAAATAAGTTTGATTAAGAGGATTT 25380  
 I G V L K V I T P \* S S N I \* V L E G L  
 F E W \* S \* \* L Q D L P I \* E F \* N E \*  
 N G S V K S Y N T L L F K N L S I R R F

FIG. 3 CONT'D

105/201

25381 CAATGATAACTAACAAGAAATAAACAGACAAGATTAAATACGTGGAACGGTACTGAATAAC 25440  
 T V I S Q E K N T Q E L \* A A Q W S K N  
 L \* \* Q N N K I Q R N \* N H L K G H S I  
 N S N I T R \* K D T R I I C S A M V \* Q

25441 AGTCTCATACCGTGAAAAACACTATTATAATTATCATAAAATCTACTTCAATTACCAAAT 25500  
 D S Y P V K Q S L I L L I K S S T L P K  
 T L T H C K K H Y Y \* Y Y K L H L \* H N  
 \* L I A S K T I I N I T N \* I F N I T \*

25501 GAACTATGATGAGTTAACGTACATCGACTATGAGAATACGTTCCACAGTGTGAATCGAGG 25560  
 S S V V \* N C T A S V R I C P T V S L E  
 V Q Y \* E I A H L Q Y E \* A L H \* V \* S  
 K I S S L Q M Y S I S K H L T D C K A G

25561 TTAGAATTATGATTAACGTAAAACACTACAACATTTATAAATAAAATTTAGGGATCAACCT 25620  
 L R L V L K C K S T S L I L K L D R T P  
 W D \* Y \* N A N Q H Q Y Y \* N \* I G L Q  
 I K I S I Q M K I N I I N I K F G \* N S

25621 ACAAATCCAGGTGTGACGCCAAGAAGAAGAGCAAGAAAAAACTTCTAAATAACAAACTG 25680  
 H K P G C Q P E E E R E K K S S K N N S  
 I N L D V S R N K K E N K K Q L N I T Q  
 T \* T W V A T R R R T R K K F I \* Q K V

25681 TTTCAATTTGAAAGTCTACAACCAAAACAACCTTCGAATATTGTTAACATGACCACCATCA 25740  
 L T L S E S T P K T S A \* L L Q V P P L  
 C L \* V K L H Q N Q Q L K Y C N Y Q H Y  
 F N F K \* I N T K N F S I V I T S T T T

25741 CTTTAATCTCTAGAAGAAACACATGTTAGGAAATTACCATAAATTCAAAACGGAGGATAA 25800  
 S I L S R R Q T C D K L P I L T K G G I  
 H F \* L D E K H V I R \* H Y \* L K A E \*  
 F N S I K K T Y L G K I T N F N Q R R N

25801 AACAGACTTAGAGTTTAAAGACCAATGTGGTGTGCGGATGACAACGACGATACAAAGGT 25860  
 K D S D \* I E P \* V V A A V T A A I N G  
 K T Q I E F K Q N C W L R \* Q Q Q \* T E  
 Q R F R L N R T V G C G S S N S S H K W

25861 GGTACCAGTCGTCGACCGTATGGTAAAAGAGAATTACATGTTATATCTTAATTACCA 25920  
 G H D A A A P M G N E R L T C Y L I L P  
 V M T L L L Q C V M K E \* H V I Y F \* H  
 W P \* C C S A Y W K R K I Y L I S N I T

FIG. 3 CONT'D

106/201

25921 AACCCACAATGATACCTACAAGAATTATTTTTAGT'TTCAACTATCGATGACGAAAATTA 25980  
 K P T V I S T R L L F \* F N I A V A K L  
 N P H \* \* P H E \* Y F D E F T S L \* Q K \*  
 Q T N S H I N K I F I L L Q Y S S S K I

25981 TTACGAGAAGAAAAGATAAGTCTTACCAAAATCAGGATGGTTGAGACGTGAACGATTTTAT 26040  
 L A R R E I \* F P K L A V L E A S A L I  
 Y H E E K \* E S H N \* H \* W S Q V Q \* F  
 I S K K R N L I T K T S G V R C K S F Y

26041 GTTTCACAACAATTAAGATTACGAGTTCGTGAATTATCAAAACAATGTCGTTAATAAATTA 26100  
 C L T T L E L A \* A S L L K N C C N N L  
 V F H Q \* N \* H E L V \* Y N T V A I I \*  
 L T N N I R I S L C K I T Q \* L L \* K I

26101 TTTAAACCACGTTAATCAAGAAGAAATGTTCTTTAAAATAGAGCAGAGCTACGAAATCTC 26160  
 L N P A I L E E K C S I K D R R S A K S  
 Y I Q H L \* N K K V L F K I E D R H K L  
 F K T C N T R R \* L F N \* R T E I S \* L

26161 CGAGTCCAAGTCTAACTATCCGAATAATTACCAGCAAATGACGAAATTTACGAATACAG 26220  
 A \* T \* I S L S I L P R K V A K F A \* T  
 P E P E S Q Y A \* \* H D N L Q K L H K H  
 S L N L N I P K N I T T \* S S \* I S I D

26221 AGAGTTGTGGAATCAC'TATAAAGAGAACATTTTAAACCACGACGAAATCGATACCTCTTC 26280  
 E \* C S L S I E R T F N P A A K A I S F  
 R E V A \* H Y K E Q L I Q H Q K L \* P S  
 R L L K T I N R K Y F K T S S \* S H L L

26281 CAATTACTCACACAATTTTCAGTTAGAGGAGCATAATTA AAAACACCATTACCATAGTA 26340  
 T L S H T L L \* D G R I L K Q P L F L \*  
 P \* H T H \* F D I E E Y \* N K H Y H Y D  
 N I L T N F T L R R T N I K T T I T I M

26341 TAAAACAGTAATCAAGTTTTACGAGGAATACCAAACAACAATACGTAAAAATCAATATTT 26400  
 I K D N T \* F A G \* P K N N I C K L \* L  
 Y K T M L E F H E K H N T T \* A N \* N Y  
 N Q \* \* N L I S R I T Q Q K H M K T I F

26401 GGATAAAGAAAAATTTTGACAAAATCATTCAGGACCAACACATATAGTCCACTACATCCA 26460  
 G I E K L V T K T L G P K H I D P S T P  
 V \* K K \* F Q K L L D Q N T Y I L H H L  
 R N R K F S N \* Y T R T Q T Y \* T I Y T

FIG. 3 CONT'D



107/201

26461 TAACGTGGATTGTGCCATAAAATAATTTGTATTACTAGTAACCTACAAGTGACCATCA 26520  
 I A G L C P Y K I L C L S \* Q I N V P L  
 Y Q V \* V L T N \* \* V Y H D N S T \* Q Y  
 N C R F L P I K N F M I I M P H E S T T

26521 AGAATGATAANTAGGACTTGGTTAAAGTCTATTTTTACAACAAAATACTTATGAACAAGA 26580  
 E \* \* \* G S G I E S L F T T K I F V Q E  
 N K S N D Q V L K L Y F H Q K \* S Y K N  
 R V I I R F W N \* I F I N N K H I S T R

26581 CAATTAAAATGATTCGCGGAGAACAAATAAACTTAGTAAGACATGGTTTTAACAGACTA 26640  
 T L K V L A G R T \* K F \* E T G F N D S  
 Q \* N \* \* L A E Q K N S D N Q V L I T Q  
 N I K S F R R K N I Q I M R Y W F Q R I

26641 AAACTTAGACTCAATAGAGTAACCAAATTTTTAGTTGTAGGTAACGCGGATTAACACTGA 26700  
 K S D S N D \* Q N L F \* V D M A G L K V  
 N Q I Q T I E N T \* F D F M W Q A \* N S  
 K F R L \* R M P K F I L C G N R R I Q S

26701 AATTTAGAAGTATGATAATTACGATGAAAAAATCTAACATAATACCTACTTAGAATAA 26760  
 K F R \* V I L A V K K S K Y \* S I F R I  
 K L D E Y \* \* H \* K K L N T N H S S D \*  
 \* I K M S N I S S K \* I Q I I L H I K N

26761 GTTCTCAGATAAATCAGAACTTATTATCAATATAGTTAGAATTTCTATATCCATGTATA 26820  
 \* S D I L D K F L L \* I L R L S I P V Y  
 E L T \* \* T K S Y Y N Y \* D \* L Y L Y M  
 L L R N L R Q I I T I D I K F I Y T C I

26821 CTTTACATACATTTTACCGGAACCATACAACCGATGATTAAGAAAAAGTAAATATTTAT 26880  
 S I Y T F H G Q Y T Q S S I E K E N I I  
 H F T H L I A K T H K A V L K K K M \* L  
 F H I Y F P R P I N P \* \* N R K \* K Y Y

26881 AAGGAACATAACGAGAAAAAATATACAACAACATGACCAACACCAAGACGTACAAAATCA 26940  
 N R T N S K K I H Q Q V P Q P E A H K L  
 I G Q I A R K \* I N N Y Q N H N Q M N \*  
 E K Y Q E K K Y T T T S T T T R C T K T

26941 TTTACAGTATTAACAACACTACTCATACCACCAGTAGTACTAAAACAATAGTTTGTAGA 27000  
 L H \* L Q Q S S Y P P \* \* S K T I L V D  
 Y I D Y N N H H T H H D D H N Q \* \* F M  
 F T M I T T I L I T T M M I K N D F C R

FIG. 3 CONT'D

108/201

27001 GTACTACTAATCTTAGAGAACAGTCTAGAGTAATTTAGATTTGAAATAAATACCTGCAAA 27060  
 \* S S \* F R K D S R M L D L S \* K H V N  
 E H H N S D R T L D \* \* I \* V K N I S T  
 M I I L I E Q \* I E N F R F K I \* P R K

27061 CCTCTGGATCGATGTGTGTAAGAGAACAATAATCTCTTAAACCACAATGTTTGGAACTTC 27120  
 P S R A V C M R K N N S F K T N C V K F  
 Q L G L \* V C E R T I L S N P T V F R S  
 S V \* S C V N E Q \* \* L I Q H \* L G Q L

27121 TAAACACAGATTTTCATATTAATGACAGTTGGATAACAACCAATGACATAACATGGAAATT 27180  
 I Q T \* L I I V T L R N N T V T N Y R \*  
 S K H R F Y L \* Q \* G I T P \* Q I T G K  
 N T D L T Y N S D V \* Q Q N S Y Q V K L

27181 TACAAACCACAGCGTTCAAACCGTTTAAACGAAGAGTGAATGTAATGCATCAGTGCAT 27240  
 I N P T A L K A F K S R V K C \* T T V I  
 F T Q H R L N P L N A E \* K V N R L \* S  
 H K T D C T Q C I Q K E S \* M V Y D R Y

27241 AAAGGGTATCATTATTAACCAACAACATGATCAAATGATGAATACCATTTATGACAAA 27300  
 N G M T I I K T N Y S T K S S I T I S N  
 I E W L L L K P T T V L K V V \* P L V T  
 K G Y Y Y N Q H Q L \* N \* \* K H Y Y Q K

27301 GACTCCGACACAGATCTAATCAACTTAGTCGAAGACTTAAATAACAAAACCGCACGTC?CC 27360  
 R L S H R S \* N F \* S R F K N N P T C L  
 E S A T D L N T S D A E S N I T Q R A S  
 Q P Q T \* I L Q I L K Q I \* Q K A H L P

27361 GTGAATTATTTCATACCAACTAAATAAAAAGTTACTATGACGAACCATGTATCCTGTCTAA 27420  
 C K I L I T S K N K L S V A Q Y M P C I  
 A S L L Y P Q N I K \* H Y Q K T C L V S  
 V \* Y T H N I \* K E I I S S P V Y S L N

27421 AATCAAATCAAATAAAACAGAATAAAGAAATTAGAAACAACAACGAAAAAATCGTTGA 27480  
 K T K T K N Q R I E K I K T T A K K A V  
 K L K L K I K D \* K K L R Q Q Q K K L L  
 \* N \* N \* K T K N R \* D K N N S K \* C S

27481 TAATTCGAAACATACGTTGAAACACCAAAAACATTAAGAAATAATAAAGTGGAAAGCCGA 27540  
 I L S Q I C S Q P K Q L K K I I E G E A  
 \* \* A K Y A V K H N K Y N R \* \* K V K P  
 N L K T H L K T T K T I E K N N \* R R S

FIG. 3 CONT'D

109/201

27541 ATGCCAATATTTTCTCCATACGTCAACATATTCAGAATATCACTTGTTC AATATGGTGGG 27600  
 \* T \* L L P I C N Y L D \* L S C T I G G  
 K R K Y F L Y A T T Y T K Y H V L \* V V  
 V N I F S T H L Q I L R I T F L N Y W G

27601 TGAAGTCTAATAAATTAGATTTAGATTTGTAATACTTATTTAGAAAAGAAGGAGTTAAAT 27660  
 V E S \* K I \* I \* V N H I F R K K R L K  
 W K L N N L R F R F M I F L D K R G \* N  
 S \* I I \* D L D L C \* S Y I K E E E I \*

27661 GAAGACTAGTTCGACAATGTAAGAATTTCTTACCTTAAAGAGAAACCCACATTATGATG 27720  
 S R I L S N C E \* F F P I E R Q T Y Y \*  
 V E S \* A T V N K F S H F K E K P T I S  
 K Q D L Q \* M R L L I S N R K P H L V V

27721 AAAAATAATGATAGTATAACGTCAAGCCAATATGCTCGGCATCATACAAACAAATAGAAT 27780  
 K K N S D Y Q L E T I R A T T H K N I K  
 S K I V I M N C N P \* V L R L I N T \* R  
 K \* \* \* \* I A T R N Y S G Y Y T Q K D \*

27781 AGTTCTACTAATAAGAAACCGAATACACCGGTAACGATAGTGGAACGATATAAATTA 27840  
 D L H N N K P K H P W Q S D G Q S Y K I  
 I L I I I R Q S I H G N V I V K V I N L  
 \* S S \* E K A \* T A M S \* \* R S \* I \* N

27841 CAAAATACGAACTTATTACGAAAAGAACGTAAAAGATATCACAATGATAATAAAGAT 27900  
 T K I S Q I I S K K C K R Y H K S N N R  
 Q K \* A K F L A K R A N E I T N V I I E  
 N K H K S Y H K E Q M K \* L T \* \* \* K \*

27901 AACAAATACCTAAGAAATAAAACAATTATCATAAGCCGAAAAATAATCTTGACCGTCAA 27960  
 N N Y P N K I K N I T N P K K N S S A T  
 I T I H I R \* K T L L I R S K I L V P L  
 Q \* I S E K N Q \* Y Y E A K \* \* F Q C N

27961 CCACCTCAAATAGGTCTCTGGTATTATTAGAATACACATAACTATACTTCCGGTTCTACA 28020  
 P P T K I W L G I I K H T N I H F A L H  
 Q H L K L G S V L L R I H I S I F P L I  
 T S N \* D L S W Y D \* T Y Q Y S L C S T

28021 AACAAATCCGGTCAATAACTCCTGATAGTGTGTAATTGACGATGACAATAAGCACCAGTAG 28080  
 K N P W N N L V I V C \* S S S N N T T M  
 N T L G T I S S \* \* V N V A V T I R P \*  
 Q \* A L \* Q P S D C M L Q \* Q \* E H D D

FIG. 3 CONT'D

110/201

28081 AAATATATGTCCACAGTTTGAACCGTGACCAATATGAGAAAAGTCTAAACGGGCATATAC 28140  
 K I Y L T D F K A S T I S K \* I Q G Y I  
 R \* I C P T L S P V P \* V R E S K G T Y  
 K Y V P H \* V Q C Q N Y E K L N A R I H

28141 AATGACATCGATTCCACGTTTCATGAAACATGGATATTTGCACGGAAAAATCTATTCAATC 28200  
 N S Y S L H L Y K T G I F T G K \* I L \*  
 T V T A L T C T S Q V \* L R A K K S L N  
 \* Q L \* P A L V K Y R Y V H R K L Y T L

28201 TACAATTATCACCAAACGACAAAACAATTGAGATTTCAACCATTGATAGCAAATGGCA 28260  
 I N I T T K S N K N L R F N T V I T \* R  
 S T L L P K A T K T L D L T P L \* R K G  
 H \* Y H N Q Q K Q \* T \* L Q Y S D N V T

28261 GATCATTGGATCACCATACCTATGACGGAACAATTCGAAATTTAGATTTGATAATCCT 28320  
 R T F R T T H I S G Q \* S S L D L S N P  
 D L L G L P I S V A K N L A \* I \* V I L  
 \* Y V \* H Y P Y Q R T L L K F R F \* \* S

28321 ACAGAATATGAGGGCCAGTAATACGACCTTCATCTTCGAGGAGACCTTTAGCAAGTCCTT 28380  
 H R I S G T M I S S T S A G R S I T \* S  
 I D \* V G P \* \* A P L L L E E P F R E P  
 T K Y E R D N H Q F Y F S R Q F D N L F

28381 AGGAGTTCTTTTGAAGAACCAGACTGGTTAGACTCGCTTTAATGGTTTGGAAATATATCTC 28440  
 D E L F S R P S V L R L S I V L G K I S  
 I R L F V E Q A S W D S R F \* W V K L L  
 G \* S F K K P Q G I Q A F N G F R \* Y L

28441 CGTCTTTTGGGTTGGATTTAAGTGACACAGATGAGTTGGTGTTCCTTTATGATAGGGTG 28500  
 A S F G L R F E S H R S L W L S I S D W  
 P L F V W G L N V T D V \* G C P F V I G  
 C F F G V \* I \* Q T \* E V V L F Y \* G V

28501 TAATAAGGACCAAGAGGCCCTAGTGAGTTAAAGTTTTCCATCTCTGAAATTTAAAAGTC 28560  
 M I G P E G P D S L K L F T S V K F K \*  
 C \* E Q N E P I V \* N \* F P L S K L N E  
 N N R T R R S \* E I E F L Y L S \* I K L

28561 TACCAGTTCTCAAGGTAACGAAAGCCTCAATGGGGGAAGACTTCGTTTTCTATAACCA 28620  
 I T L S N G N S E S Y G R R F C F S I P  
 S P \* P T G M A K P T G G E S A F P Y Q  
 H D L L E W Q K R L V G K Q L L L I N T

FIG. 3 CONT'D

111/201

28621 TATCTGTGTCGGCCGCAAGAAAATTTGTGCGACTACCGTTGTTTTCGTCAACAATGGCT 28680  
 I S V A P T R K F C S I T L L L L Q \* R  
 Y L C L R R E K L V A S P \* C F C N N G  
 Y V C G A N K \* F L Q H D V F A T T V S

28681 CTACCATAAAGATGATAGAGCCATGGCCGGGTATACGGTTACGTAGGATACCACTTAGGG 28740  
 S P I E V I E T G A W I G I C G I T F G  
 L H Y K \* \* R P V P G Y A L A D \* P S D  
 I T N R S D R Y R G M H W H M R H H I G

28741 AGCTTCCCCAGAAGACCCAACGATTAGTGGTTCGACTGTGAAGATGAGGGAGGCTACAAA 28800  
 E F P D E P N S I V L S V S R S G G I N  
 R S P T K Q T A L \* W A S V E V G E S T  
 R L P R R P Q \* D G L Q C K \* E R R H K

28801 GCAGTTCCTTAGGATGATGAGTTCTTCGATAGGGATGATCCAAAGCGGACCATGCTAAA 28860  
 R \* P I R S S L F S D R S P K R R T R N  
 E D L S G V V \* S A I G V L N G G P V I  
 T L P D \* \* E L L \* G \* \* T E A Q Y S K

28861 ACGGAGTCCGATAATAACAACCTCCGAGTCCTTCAGACGAAGATTATCAGCTGGTCCAA 28920  
 Q R L A I I N F A \* S P R S R I T S W T  
 K G \* P \* \* T S P E P L D A E L L R G P  
 A E L S N H Q L S L F T Q K \* Y D V L N

28921 GTGCAAGAGTTAGTGCACCTGGGTATTATAGCAAGTAATTCATCTTCATTAAGATTAAAAAT 28980  
 \* T R L \* T S G I I T \* \* T S T I R I K  
 E R E \* D R P G L L R E N L L L L E L K  
 V N E I V H V W Y D N M L Y F Y N \* N \*

28981 CTGTAAAGCTAAGATATCATTTTGGACTATACCGACTACTCTAGCGATTAGAACAAAATC 29040  
 S M \* I R Y Y F R I H S I L D S I K N \*  
 L C E S E I T F G S I A S S I A L R T K  
 V N L N \* L L V Q Y P Q H S R \* D Q K L

29041 GGTTCGAACCATTTCTAAGATTTGGAGTCGTTTCAGTGATTGTTTACGGTTCCTTTAGT 29100  
 G L K T F I R F R L L D S L L I G L F D  
 A L S P L S E L G \* C T V L C F A L S I  
 W A Q Y L N \* V E A L \* \* A F H W P E \*

29101 CCGTATTTTAAAATGTTTTGGAGCGGTTTTTCGCTTGAGGATTATTTGTAACATTACAAG 29160  
 P M F N \* C F R A L L S S R I F M T I N  
 L C L I K V F G R W F R V G L L C Q L T  
 A Y F K L L V E G F A F E \* Y V N Y H E

FIG. 3 CONT'D

112/201

29161 TTGTCACAAAACCATTTTCTCCTGGAAGAGTTTTAAAACCATACGACTTTACAATTTTCG 29220  
 L L T K T F S S R R L I K T I S F H \* L  
 \* C H K P L L P G E \* F K P L A S I N F  
 V T N Q Y F L V K E F N Q Y H Q F T L A

29221 AACCATGATTACTAGGAGTCAAAGGATAAGAACGCTTTAATCGAGGATGTGGTCCACGAA 29280  
 K T S I I R L K R N K C F \* S R C W T S  
 S P V L S G \* N G I R A S N A G V G P A  
 Q Y \* H D E T E \* E Q L I L E \* V L H K

29281 AAAAGAAACCAAGATTTAATCTGAACCAATTTTCTCTAAGGCTCCGACTGAGTGGACAAT 29340  
 K E K T R F \* V Q N F S I G L S V \* R N  
 K K K F E L N S K T L L S E S A S E G T  
 K R Q N \* I L S P \* F L N R P Q S V Q \*

29341 TTCTACAAAACCTGAAGTAATAAGACCAAGATAATCCAAACTATCATGAAATGGTCCGA 29400  
 F I N K F K M I R T R N P K I T S \* W A  
 L S T K S S \* \* E P E I L N S L V K G P  
 L H K Q V E N N Q N \* \* T Q Y Y K V L S

29401 AACTCTGTTAATACTTTCAAGAACCTTCTCTTAAATTTACGAATGCAATTAAGATTAGTCT 29460  
 K L C N H F N K F L I \* I S V N I R I L  
 K S V I I F T R S S F K F A \* T L E L \*  
 Q S L \* S L E Q L S N L H K R \* N \* D S

29461 TGTGACTAAGACTAAGCAACTCAAGATTTGGAGTCGCATTTTCTCCACAATTTGTTAATG 29520  
 V S I R I R Q T R F R L T F S T N F L \*  
 F V S E S E N L E L G \* R L L P T L C N  
 C Q N Q N T S N \* V E A Y F L H \* V I V

29521 GTCTTGTCAAACCTGAGAGAATTAATTCACGACCATGAGTCGTGTAAGTTTACTAAAAT 29580  
 W F L K V R K I \* T S T S L V N \* I I K  
 G S C N S E R L K L A P V \* C M E F S K  
 L V T Q S E \* N L H Q Y E A C K L H N \*

29581 GAGGACTCCTAGTATCAAATGAACGATGAGAACTACTAGGAATACATCTTCTGAGACAAC 29640  
 S R L I M T \* K S S K I I R I Y F V R N  
 V G S S \* L K S A V R S S G \* T S S E T  
 E Q P D Y N V Q \* E Q H D K H L L S Q Q

29641 GAATTAATCTTACTTACTTAGGATTAAGCTGTGATCCACCATTTGGGGAGCGATAATAAGCCTTA 29700  
 S L S F S D \* N S V L H Y G R A I I R F  
 A \* H S H I R I R C \* T T V G R \* \* E S  
 K I L I F G L E V S P P L G E S N N P I

FIG. 3 CONT'D

113/201

29701 TCCTGTGAGAGATAGTCTTACTTAAGAACGACATTATTGTCTATCTCATCCAACAATGTC 29760  
 L V S E I L I F E Q Q L L L Y L L N N C  
 Y S V R \* \* F S N K S Y Y C I S Y T T V  
 P C E R D S H I R A T I V S L T P Q \* L

29761 TGATATATAATTAATCACTCTTAAAATATAAAATCTGTAAACTAACAATCTCATCAATATT 29820  
 V I Y \* N T S I K Y K S M Q N N S Y N Y  
 S \* I N I L L E K I N L C K I T L T T I  
 S Y I L \* Y F N \* I \* V N S Q \* L L \* L

29821 CCAAATCGACATCATATTTGCGGAGGCCCTTCTCGATAGTTAACATCACAAATATATAT 29880  
 P K A T T Y V G G P L A I L Q L T \* Y I  
 L N L Q L I F A E P F L \* \* N Y H K I Y  
 T \* S Y Y L R R R S S S D I T T N L I Y

29881 ATAATCATATACTAACTTTAATTAATATCGGAAAACCTCCTTAATGTTTTTTTTTTTTTT 29940  
 Y \* Y I I S I L \* L R K S S N C F F F F  
 I N T Y S Q F \* N Y G K P P I V F F F F F  
 I L I H N F N I I A K Q L F \* L F F F F

29941 TT 29942  
 F  
 F

FIG. 3 CONT'D

114/201




FIG. 4



115/201




FIG. 5A

116/201




FIG. 5B

117/201




FIG. 6

118/201





FIG. 7

119/201



**FIG. 8**

## 120/201

1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGAGATCTCAT 60  
 E \* E R I A S V P S I S L R S L V R S H  
 N K S E L R P Y R L S A Y D L L S D L I  
 I R A N C V R T V Y Q L T I S C Q I S L

61 TAAATCTAAACTTTTAAACAAGATCCCTGTTATCCATGCTTGTGAGTGTGGTTAATC 120  
 \* I \* T F \* T R F P V I H A C E C G L I  
 K S K L F K Q D S L L S M L V S V V \* S  
 N L N F L N K I P C Y P C L \* V W F N H

121 ATAATCTTGTATTTTACTTTCCACACTTTTCATCTCTGCCAGTGACGTGTTGGTTGTC 180  
 I I L Y F T F H T F H L S A S D V L V V  
 \* S C I L L S T L F I S L P V T C W L S  
 N L V F Y F P H F S S L C Q \* R V G C P

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAACCAGCAAATACGGTCTCGGCTTCAA 240  
 L S V P P I G R N D \* N Q Q I R S R L Q  
 S A S L P \* V A M I K T S K Y G L G F K  
 Q R P S H R S Q \* L K P A N T V S A S S

241 GTGGGCGCCAGAATTTTCGTTGGCTGCTTCCGGATGCAGCGGAGGAGTTGGCTAGTCCTAT 300  
 V G A R I S L A A S G C S G G V G \* S Y  
 W A P E F R W L L P D A A E E L A S P M  
 G R Q N F V G C F R M Q R R S W L V L \*

301 GAAGTCAGATGAGGGTGGGTTATGCCCTCTACTGGTCAAGCGATGGAAAGTGTGGATT 360  
 E V R \* G W V M P L Y W S S D G K C W I  
 K S D E G G L C P S T G Q A M E S V G F  
 S Q M R V G Y A P L L V K R W K V L D L

361 TGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420  
 C L \* \* S C E D R L S L H S W T R M A C  
 V Y D N H V K I D C R C I L G Q E W H V  
 F M I I M \* R \* I V A A F L D K N G M C

421 GCAGTCAAATCTTATCCGTGATATTTTGTTCATGAAGATCTACATGTTGTAGAAGTTCT 480  
 A V K S Y P \* Y F C S \* R S T C C R S S  
 Q S N L I R D I F V H E D L H V V E V L  
 S Q I L S V I F L F M K I Y M L \* K F \*

481 AACTAAAACAGCCGTAAAGTCCGGTACGGCAATTTTAAATTAATCACCTTTGCATAGCTT 540  
 N \* N S R K V R Y G N F N \* I T F A \* L  
 T K T A V K S G T A I L I K S P L H S L  
 L K Q P \* S P V R Q F \* L N H L C I A W

FIG. 9

121/201

541 GGGTGGTTTTCCCTAAAGGGTATGTTATGGGCTTGTTCGGTTCATACAAGACTAAACGTTA 600  
 G W F S \* R V C Y G L V P F I Q . D \* T L  
 G G F P K G Y V M G L F R S Y K T K R Y  
 V V F L K G M L W A C S V H T R L N V M

601 TGGTTGACATCATCTTTCTATGACTACATCTACTACTAATTTTGGTGAAGATTTTTTGGG 660  
 C C T S S F Y D Y I Y Y \* F W \* R F F G  
 V V H H L S M T T S T T N F G E D F L G  
 L Y I I F L \* L H L L L I L V K I F W V

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTACAAAATGGTTTCAATTCTGTAG 720  
 L D C T F W F Y A I L C S Q M V S I L \*  
 W I V P F G F M P S Y V H K W F Q F C R  
 G L Y L L V L C H L M F T N G F N S V G

721 GTTGTATATTGAAGAGAGTGATTTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780  
 V V Y \* R E \* F N N F K F \* I \* \* L \* F  
 L Y I E E S D L I I S N F K F D D Y D F  
 C I L K R V I \* \* F Q I L N L M I M I L

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAAATATTCACAAA 840  
 \* C R R C L C \* G S C \* A \* R \* I F T K  
 S V E D A Y A E V H A E P K G K Y S Q K  
 V \* K M L M L R F M L S L K V N I H K K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAAACCCGTACTCTTTGTAGACCAGTA 900  
 S L C F T \* T I S W Y \* T R T L C R P V  
 A Y A L L R Q Y R G I K P V L F V D Q Y  
 L M L Y L D N I V V L N P Y S L \* T S M

901 TGGTTGTGACTATTCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATCTTT 960  
 W L \* L F W \* I S R L S S S L W S L F F  
 G C D Y S G K L A D C L Q A Y G H Y S L  
 V V T I L V N \* Q I V F K L M V I I L C

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGCGACTTTGATATTGTAGT 1020  
 A R Y E T K A V C M A C Q L R L \* Y C S  
 Q D M R Q K Q S V W L A N C D F D I V V  
 K I \* D K S S L Y G L P I A T L I L \* W

1021 GGCTTGGCATGTAGTTGCTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080  
 G L A C S S \* F T I C Y A P A D Y S Y Y  
 A W H V V R D S R F V M R L Q T I A T I  
 L G M \* F V I H D L L C A C R L \* L L F

FIG. 9 CONT.

122/201

1081 TTGTGGTATTAAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGCTGTAGTTAT 1140  
 L W Y \* I C C T T Y R R C S R W S C S Y  
 C G I K Y V A Q P T E D V V D G A V V I  
 V V L N M L H N L Q K M \* \* M E L \* L Y

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTTAAAGCTTCCTAGTTTGAT 1200  
 T \* T C T F I I C \* C N S F K A S \* F D  
 R E P V H L L S A D A I V L K L P S L M  
 V N L Y I Y Y L L M Q \* F \* S F L V \* \*

1201 GAAAGTTATGACTCATATGGATGATTTTCTATTAATCTATATACAATGTTGATTTGTG 1260  
 E S Y D S Y G \* F F Y \* I Y I Q C \* F V  
 K V M T H M D D F S I K S I Y N V D L C  
 K L \* L I W M I F L L N L Y T M L I C V

1261 TGATTGTGGTTTTGTTATGCAGTATGGTTATGTAGATTGTTTTAATGATAATTGTGATTT 1320  
 \* L W F C Y A V W L C R L F \* \* \* L \* F  
 D C G F V M Q Y G Y V D C F N D N C D F  
 I V V L L C S M V M \* I V L M I I V I F

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTTCTGTCCATTGTGTTGTACAGT 1380  
 L W L G F R \* Y D G W F F L S I V L Y S  
 Y G W V S G N M M D G F S C P L C C T V  
 M V G F Q V I \* W M V F L V H C V V Q F

1381 TTATGACTCTAGTGAAGTTAAAGCCCAATCATCTGGTGTATTTCCTGAGAATCCTGTGTT 1440  
 L \* L \* \* S \* S P I I W C Y S \* E S C V  
 Y D S S E V K A Q S S G V I P E N P V L  
 M T L V K L K P N H L V L F L R I L C Y

1441 ATTTACTAATAGTACTGATACTGTTAACCCCTGATTCTTTTAATTTGTATGGTTATTTCTGT 1500  
 I Y \* \* Y \* Y C \* P \* F F \* F V W L F C  
 F T N S T D T V N P D S F N L Y G Y S V  
 L L I V L I L L T L I L L I C M V I L L

1501 TACACCATTGGTTCTTGTATATATTGGTCACCGCTCCTGGATTGTGGATTCCCTATCAT 1560  
 Y T I W F L Y I L V T A S W I V D S Y H  
 T P F G S C I Y W S P R P G L W I P I I  
 H H L V L V Y I G H R V L D C G F L S L

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTCAGGTGTAGTAGGTTGTAATC 1620  
 \* I F S Q V L \* \* F G L F R C S R L \* I  
 K S S V K S Y D D L V Y S G V V G C K S  
 N L Q S S L M M I W F I Q V \* \* V V N L

FIG. 9 CONT.



123/201

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACTTACTTAGATTATGTTCAATGTAA 1680  
 Y C \* R N C S Y Y S C T L L R L C S M \*  
 I V K E T A L I T H A L Y L D Y V Q C K  
 L L K K L L L L L M H F T \* I M F N V S

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGTGTAAATAATTCTTGGTGTAGGCAACT 1740  
 V W \* S \* T K S Y S W C \* \* F L V \* A T  
 C G N L E Q N H I L G V N N S W C R Q L  
 V V I L N K I I F L V L I I L G V G N C

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTTTAAAAAATATTGACTTGTGTTGTTAAGCG 1800  
 V A \* \* R \* L \* Y A F K K Y \* L V C \* A  
 L L N R G D Y N M L L K N I D L F V K R  
 C L I E V I I I C F \* K I L T C L L S V

1801 TCGTGCTGATTTTGCTTGCAAGTTTGCAGTTTGTGGAGATGGTTTGTACCTTTTTTACT 1860  
 S C \* F C L Q V C S L W R W F C T F F T  
 R A D F A C K F A V C G D G F V P F L L  
 V L I L L A S L Q F V E M V L Y L F Y \*

1861 AGATGGTTTAAATCCCCGTAGTTATTATCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920  
 R W F N S P \* L L S N S E W Y F L Y I F  
 D G L I P R S Y Y L I Q S G I F F T S L  
 M V \* F P V V I I \* F R V V F S L H L \*

1921 GATGCTCAATTTTACACAAGAAGTTTCTGATATGTGTTTAAAAATGTGTATTTTGTGTTAT 1980  
 D V S I F T R S F \* Y V F K N V Y F V Y  
 M S Q F S Q E V S D M C L K M C I L F M  
 C L N F H K K F L I C V \* K C V F C L W

1981 GGACAGAGTTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040  
 G Q S F S C Y I L Y R A L C \* \* V G Y S  
 D R V S V A T F Y I E H Y V N R L V T Q  
 T E F Q L L H F I \* S I M L I G W L L N

2041 ATTTAAGTTATTGGGTACTACACTTGTAAATAAAATGGTTAATTGGTTAATACCATGTT 2100  
 I \* V I G Y Y T C \* \* N G \* L V \* Y H V  
 F K L L G T T L V N K M V N W F N T M L  
 L S Y W V L H L L I K W L I G L I P C \*

2101 AGATGCTAGTGCACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTTGT 2160  
 R C \* C T C Y R L A S L P I I E W S F C  
 D A S A P A T G W L L Y Q L L N G L F V  
 M L V H L L Q A G F F T N Y \* M V F L \*

FIG. 9 CONT.

124/201

2161 AGTATCTCAAGCCAACTTTAATTTTGGTTGCTTTAATACCTGATTATGCTAAAATTTTAGT 2220  
 S I S S Q L \* F C C F N T \* L C \* N F S  
 V S Q A N F N F V A L I P D Y A K I L V  
 Y L K P T L I L L L \* Y L I M L K F \* L

2221 TAATAAATTTTACACTTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTTAAA 2280  
 \* \* I L H F F \* V I I R V C Y S \* C F K  
 N K F Y T F F K L L L E C V T V D V L K  
 I N F T L F L S Y Y \* S V L Q L M F \* K

2281 AGATATGCCTGTCTTAAAACCTATTAATGGTTTAGTTTGTATTGTAGGCAATAAGTTTTA 2340  
 R Y A C S \* N Y \* W F S L Y C R Q \* V L  
 D M P V L K T I N G L V C I V G N K F Y  
 I C L F L K L L M V \* F V L \* A I S F I

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTTGTTTTACCATGTAATGCACAGGAACAACA 2400  
 \* R \* Y R V N S W F C F T M \* C T G T T  
 N V S T G L I P G F V L P C N A Q E Q Q  
 T L V Q G \* F L V L F Y H V M H R N N K

2401 AATTTATTTTTTTGAAGGCGTTCAGAACTCTGTTATAGTAGAAGATGATGTTATTGAGAA 2460  
 N L F F \* R R C R I C Y S R R \* C Y \* E  
 I Y F F E G V A E S V I V E D D V I E N  
 F I F L K A L Q N L L \* \* K M M L L R M

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAAT 2520  
 C Q I F F I I L \* V L S T T \* I C R K N  
 V K S S L S S Y E Y C Q P P K S V E K I  
 S N L L Y H L M S I V N H L N L \* K K F

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTTCCCTATTGTCAT 2580  
 L Y Y R \* Y V H G \* V W \* \* I F P Y C H  
 C I I D N M Y M G K C G D K F F P I V M  
 V L \* I I C T W V S V V I N F S L L S \*

2581 GAATGATAAAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTTCCATGTGCAGGTAGAAA 2640  
 E \* \* K Y L S F R S G L A F S M C R \* K  
 N D K N I C L L D Q A W R F P C A G R K  
 M I K I F V F \* I R L G V F H V Q V E K

2641 AGTTAATTTTAAACGAGAAACCTGTTGTTATGGAGATTCCGTCCTTTGATGACAGTTAAGGT 2700  
 S \* F \* R E T C C Y G D S V F D D S \* G  
 V N F N E K P V V M E I P S L M T V K V  
 L I L T R N L L L W R F R L \* \* Q L R L

FIG. 9 CONT.

125/201

2701 TATGTTTGATTTAGATTCTACTTTTGATGATATTTTAGGTAAAGTTTGTTCAGAATTTGA 2760  
 Y V \* F R F Y F \* \* Y F R \* S L F R I \*  
 M F D L D S T F D D I L G K V C S E F E  
 C L I \* I L L L M I F \* V K F V Q N L K

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTGCTGTTGTTTGTGATGCTATAGAGAA 2820  
 S R K G C Y C R \* F C R C C L \* C Y R E  
 V E K G V T V D D F V A V V C D A I E N  
 \* K R V L L \* M I L S L L F V M L \* R M

2821 TGCTTTAAACTCTTGTAAGATCATCCAGTGGTTGTTATCAAGTTCGTGCATTTTAA 2880  
 C F K L L \* R S S S G W L S S S C I F K  
 A L N S C K D H P V V G Y Q V R A F L N  
 L \* T L V K I I Q W L V I K F V H F \* I

2881 TAACTTAATGAGAACGTTGTTATTTATTTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940  
 \* T \* \* E R C L F I \* \* G W \* \* S N G L  
 K L N E N V V Y L F D E A G D E A M A S  
 N L M R T L F I Y L M R L V M K Q W P L

2941 TCGTATGTATTGTACTTTTGTCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000  
 S Y V L Y F C Y \* G C \* R R Y Q \* \* S C  
 R M Y C T F A I E D V E D V I S S E A V  
 V C I V L L L L R M L K T L S V V K L L

3001 TGAAGATACTATPGATGGTGTGCTGAAGACACTATTAATGATGATGAAGATGTTGTTAC 3060  
 \* R Y Y \* W C R \* R H Y \* \* \* \* R C C Y  
 E D T I D G V V E D T I N D D E D V V T  
 K I L L M V S L K T L L M M M K M L L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120  
 W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
 G D N D D E D V V T G D N D D E D V V T  
 V T M T M K M L L L V T M T M K M L L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180  
 W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
 G D N D D E D V V T G D N D D E D V V T  
 V T M T M K M L L L V T M T M K M L L L

3181 TGGTGATAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240  
 W \* \* \* R \* R C C Y W \* Q \* R \* R C C Y  
 G D N D D E D V V T G D N D D E D V V T  
 V I M T M K M L L L V T M T M K M L L L

FIG. 9 CONT.

126/201

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3361 TGGTGACAATGACGATGAAGAGATTGTTACTGGTGACAATGATGACCAAATTGTTGTTAC 3420  
W \* Q \* R \* R D C Y W \* Q \* \* P N C C Y  
G D N D D E E I V T G D N D D Q I V V T  
V T M T M K R L L L V T M M T K L L L L

3421 TGGTGATGATGTAGATGATATTGAAAGTGTCTATGATTTTGATACTTATAAAGCTCTTTT 3480  
W \* \* C R \* Y \* K C L \* F \* Y L \* S S F  
G D D V D D I E S V Y D F D T Y K A L L  
V M M \* M I L K V S M I L I L I K L F \*

3481 AGTTTTTAATGATGTCTATAATGATGCTTTGTTTGTAGTTATGGTTCTAGTGTGAAAC 3540  
S F \* \* C L \* \* C F V C \* L W F \* C \* N  
V F N D V Y N D A L F V S Y G S S V E T  
F L M M S I M M L C L L V M V L V L K Q

3541 AGAAACATATTTTAAAGTTAATGGTTTATGGTCACCTACTATTACACATACTAACTGTTG 3600  
R N I F \* S \* W F M V T Y Y Y T Y \* L L  
E T Y F K V N G L W S P T I T H T N C W  
K H I L K L M V Y G H L L L H I L T V G

3601 GTTGC GTTCTGTGTTACTTGTAAATGCAGAAATTACCTTTTAAAGTTAAGGATTTAGCTAT 3660  
V A F C V T C N A E I T F \* V \* G F S Y  
L R S V L L V M Q K L P F K F K D L A I  
C V L C Y L \* C R N Y L L S L R I \* L L

3661 TGAAAATATGTGGTTATCTTATAAGGTGGGTTATAATCAAAGTTTTGTTGATTATTTACT 3720  
\* K Y V V I L \* G G L \* S K F C \* L F T  
E N M W L S Y K V G Y N Q S F V D Y L L  
K I C G Y L I R W V I I K V L L I I Y \*

3721 GACCACTATTCCCTAAAGCTATTGTTTTGCCTCAAGGTGGTTATGTAGCTGACTTTGCTTA 3780  
D H Y S \* S Y C F A S R W L C S \* L C L  
T T I P K A I V L P Q G G Y V A D F A Y  
P L F L K L L F C L K V V M \* L T L L I

FIG. 9 CONT.

127/201

3781 TTGGTTTTTAAACCAGTTTGATATTAATGCGTATGCTAATTGGTGTGTTTTAAATGTGG 3840  
 L V F K P V \* Y \* C V C \* L V L F K M W  
 W F L N Q F D I N A Y A N W C C L K C G  
 G F \* T S L I L M R M L I G V V \* N V V

3841 TTTTCTTTTGATTAAATGGTTGGATGCTGTGTTTTTTATGGAGATATTGTGCTCA 3900  
 F F F \* F K W F G C C V F L W R Y C V S  
 F S F D L N G L D A V F F Y G D I V S H  
 F L L I \* M V W M L C F F M E I L C L M

3901 TGTTTGTAAAGTGTGGACATAATATGACTCTAATAGCAGCGGACTTACCTTGACATTACA 3960  
 C L \* V W T \* Y D S N S S G L T L Y I T  
 V C K C G H N M T L I A A D L P C T L H  
 F V S V D I I \* L \* \* Q R T Y L V H Y I

3961 TTTTTCATTATTTGATGACAAATTTTGTGCTTTTTCACCCCTAAAAAATTTTATTGC 4020  
 F F I I \* \* Q F L C F L H P \* K N F Y C  
 F S L F D D N F C A F C T P K K I F I A  
 F H Y L M T I F V L F A P L K K F L L L

4021 TGCAATGTGCTGTGGATGTAACGTTTGTCAATCTGTAGCTGTTATAGGTGATGAACAAAT 4080  
 C M C C G C K R L S F C S C Y R \* \* T N  
 A C A V D V N V C H S V A V I G D E Q I  
 H V L W M \* T F V I L \* L L \* V M N K \*

4081 AGATGGTAAGTTTGTACTAAATTTAGTGGTGATAAATTTGATTTTATAGTAGGTTATGG 4140  
 R W \* V C Y \* I \* W \* \* I \* F Y S R L W  
 D G K F V T K F S G D K F D F I V G Y G  
 M V S L L L N L V V I N L I L \* \* V M E

4141 AATGTCATTTAGTATGCTCTCTTTTGTAGTTAGCTCAATTGTATGGTTTGTGATAACACC 4200  
 N V I \* Y V F F \* V S S I V W F V Y N T  
 M S F S M S S F E L A Q L Y G L C I T P  
 C H L V C L L L S \* L N C M V C V \* H L

4201 TAATGTATGTTTTGTTAAAGGTGATATTATAAATGTTGCTAGACTTGTAAAGCTGATGT 4260  
 \* C M F C \* R \* Y Y K C C \* T C \* S \* C  
 N V C F V K G D I I N V A R L V K A D V  
 M Y V L L K V I L \* M L L D L L K L M L

4261 TATTGTTAACCCCTGCTAATGGGCATATGCTCCATGGTGGTGGAGTTGCAAAAGCTATAGC 4320  
 Y C \* P C \* W A Y A P W W W S C K S Y S  
 I V N P A N G H M L H G G G V A K A I A  
 L L T L L M G I C S M V V E L Q K L \* L

FIG. 9 CONT.

128/201

4321 TGTAGCTGCAGGTAAAAAATTTTCTAAAGAACTGCTGCTATGGTTAAATCTAAAGGTGT 4380  
 C S C R \* K I F \* R N C C Y G \* I \* R C  
 V A A G K K F S K E T A A M V K S K G V  
 \* L Q V K N F L K K L L L W L N L K V F

4381 TTGCCAAGTAGGAGATTGTTATGTTTCTACCGGTGGTAAATTATGTAACAATTCTTAA 4440  
 L P S R R L L C F Y R W \* I M \* N N S \*  
 C Q V G D C Y V S T G G K L C K T I L N  
 A K \* E I V M F L P V V N Y V K Q F L I

4441 TATTGTAGGTCCTGATGCTAGACAAGATGGAAGACAATCTTATGTTTTGTAGCACGTGC 4500  
 Y C R S \* C \* T R W K T I L C F V S T C  
 I V G P D A R Q D G R Q S Y V L L A R A  
 L \* V L M L D K M E D N L M F C \* H V L

4501 TTATAAGCATCTAATAATTATGATTGTTGTTTGTCTACTCTCATATCGGCTGGTATATT 4560  
 L \* A S \* \* L \* L L F V Y S H I G W Y I  
 Y K H L N N Y D C C L S T L I S A G I F  
 I S I L I I M I V V C L L S Y R L V Y L

4561 TAGTGTTCCTGCTGATGTGTCATTAACCTTACCTTCTAGGTGTTGTTGATAAACAAGTTAT 4620  
 \* C S C \* C V I N L P S R C C \* \* T S Y  
 S V P A D V S L T Y L L G V V D K Q V I  
 V F L L M C H \* L T F \* V L L I N K L S

4621 CCTTGTTAGTAATAATAAAGAAGATTTTGATATTATTCAAAAATGTCAAATTACTTCAGT 4680  
 P C \* \* \* \* R R F \* Y Y S K M S N Y F S  
 L V S N N K E D F D I I Q K C Q I T S V  
 L L V I I K K I L I L F K N V K L L Q L

4681 TGTGGTACTAAAGCATTGGCTGTTAGATTAACCTGCTAATGTAGGCCGTGTTATTAATT 4740  
 C W Y \* S I G C \* I N C \* C R P C Y \* I  
 V G T K A L A V R L T A N V G R V I K F  
 L V L K H W L L D \* L L M \* A V L L N L

4741 TGAGACAGATGCATACAACTTTTCTTGAGTGGTGATGATTGTTTTGTTCAAATCTTC 4800  
 \* D R C I Q T F L E W \* \* L F C F K F F  
 E T D A Y K L F L S G D D C F V S N S S  
 R Q M H T N F S \* V V M I V L F Q I L L

4801 TGTATACAAGAAGTTTTATTGCTTCGTCATGATATACAATTGAATAATGACGTTTCGTGA 4860  
 C Y T R S F I A S S \* Y T I E \* \* R S \*  
 V I Q E V L L L R H D I Q L N N D V R D  
 L Y K K F Y C F V M I Y N \* I M T F V I

FIG. 9 CONT.

129/201

4861 TTATTTGTGTCTAAGATGACTAGTCTTCCCAAAGATTGGCGTCTTATCAATAAATTTGA 4920  
 L F V V \* D D \* S S Q R L A S Y Q \* I \*  
 Y L L S K M T S L P K D W R L I N K F D  
 I C C L R \* L V F P K I G V L S I N L M

4921 TGTTATTAACGGTGTFAAACTGTTAAGTACTTTGAGTGTCTTAATTCATTTATATATG 4980  
 C Y \* R C \* N C \* V L \* V S \* F Y L Y M  
 V I N G V K T V K Y F E C P N S I Y I C  
 L L T V L K L L S T L S V L I L F I Y V

4981 TAGTCAGGGTAAAGACTTTGGTTATGTATGTGATGGTCTTTTTATAAAGCAACTGTTAA 5040  
 \* S G \* R L W L C M \* W F F L \* S N C \*  
 S Q G K D F G Y V C D G S F Y K A T V N  
 V R V K T L V M Y V M V L F I K Q L L I

5041 TCAAGTTTGTGTGTATTAGCTAAGAAGATAGATGTTTTGCTTACTGTAGATGGTGTAA 5100  
 S S L C V I S \* E D R C F A Y C R W C \*  
 Q V C V L L A K K I D V L L T V D G V N  
 K F V C Y \* L R R \* M F C L L \* M V L I

5101 TTTTAAATCTATTTCTTACTGTAGGTGAAGTTTTGGTAAAATACTTGGTAATGTTTT 5160  
 F \* I Y F S Y C R \* S F W \* N T W \* C F  
 F K S I S L T V G E V F G K I L G N V F  
 L N L F L L L \* V K F L V K Y L V M F S

5161 CTGTGATGGCATTGATGTTACTAAGTTAAAGTGTAGTGATTTTTATGCCGATAAAATTTT 5220  
 L \* W H \* C Y \* V K V \* \* F L C R \* N F  
 C D G I D V T K L K C S D F Y A D K I L  
 V M A L M L L S \* S V V I F M P I K F Y

5221 ATATCAGTATGAAAATTTGTCTTTAGCTGATATTTCTGCTGTACAAAGTTCATTTGGGTT 5280  
 I S V \* K F V F S \* Y F C C T K F I W V  
 Y Q Y E N L S L A D I S A V Q S S F G F  
 I S M K I C L \* L I F L L Y K V H L G L

5281 TGATCAGCAACAATTGCTTGCTTACTATAATTTTTTAACAGTATGTAATGGTCTGTAGT 5340  
 \* S A T I A C L L \* F F N S M \* M V C S  
 D Q Q Q L L A Y Y N F L T V C K W S V V  
 I S N N C L L T I I F \* Q Y V N G L \* L

5341 TGTTAACGGTCCATTTTTTTCTTTTGAACAGTCTCATAATAATTGTTATGTGAATGTAGC 5400  
 C \* R S I F F F \* T V S \* \* L L C E C S  
 V N G P F F S F E Q S H N N C Y V N V A  
 L T V H F F L L N S L I I I V M \* M \* L

FIG. 9 CONT.

130/201

5401 TTGCTTATGTTGCAGCATATTAATCTTAAATTTAATAAATGGCAGTGGCAGGAAGCATG 5460  
 L S Y V A A Y \* S \* I \* \* M A V A G S M  
 C L M L Q H I N L K F N K W Q W Q E A W  
 V L C C S I L I L N L I N G S G R K H G

5461 GTATGAATTTGCTGCTGGCAGACCACATAGGTTAGTTGCTCTTGTGTTTGTAGCTAAAGGTCA 5520  
 V \* I S C W Q T T \* V S C S C F S \* R S  
 Y E F R A G R P H R L V A L V L A K G H  
 M N F V L A D H I G \* L L L F \* L K V I

5521 TTTTAAATTTGATGAACCATCAGATGCTACTGATTTTATTCGTTGTTTGTGAAACAAGC 5580  
 F \* I \* \* T I R C Y \* F Y S C C F E T S  
 F K F D E P S D A T D F I R V V L K Q A  
 L N L M N H Q M L L I L F V L F \* N K L

5581 TGATTATCAGGTGCAATTTGTGAATTAGAACTTATTTGTGATTGTGGTATTAACAAGA 5640  
 \* F I R C N L \* I R T Y L \* L W Y \* T R  
 D L S G A I C E L E L I C D C G I K Q E  
 I Y Q V Q F V N \* N L F V I V V L N K K

5641 AAGTCGTGTTGGTGTGATGCTGTTATGCATTTTGGTACATTAGCAAAGACTGATCTTTT 5700  
 K S C W C \* C C Y A F W Y I S K D \* S F  
 S R V G V D A V M H F G T L A K T D L F  
 V V L V L M L L C I L V H \* Q R L I F L

5701 TAATGGTTATAAGATTGGCTGTAATTGTGCAGGTAGAATTGTCCATTGTACTAAATGAA 5760  
 \* W L \* D W L \* L C R \* N C P L Y \* I E  
 N G Y K I G C N C A G R I V H C T K L N  
 M V I R L A V I V Q V E L S I V L N \* M

5761 TGTACCATTTTGTGATTGTTCTAATACTCCTCTGAGTAAGGATTTACCTGATGATGTTGT 5820  
 C T I F D L F \* Y S S E \* G F T \* \* C C  
 V P F L I C S N T P L S K D L P D D V V  
 Y H F \* F V L I L L \* V R I Y L M M L L

5821 TGCAGCTAACATGTTTATGGGTGTAGGTGTAGGCCATTATACACATTTGAAATGTGGTTC 5880  
 C S \* H V Y G C R C R P L Y T F E M W F  
 A A N M F M G V G V G H Y T H L K C G S  
 Q L T C L W V \* V \* A I I H I \* N V V H

5881 ACCTTACCAACATTATGATGCTTGTAGTGTTAAAAAATATACAGGTGTTAGTGGTTGTTT 5940  
 T L P T L \* C L \* C \* K I Y R C \* W L F  
 P Y Q H Y D A C S V K K Y T G V S G C L  
 L T N I M M L V V L K N I Q V L V V V \*

FIG. 9 CONT.



131/201

5941 AACTGACTGCTTGTATCTTAAAAATTTAACCCAGACTTTTACATCTATGTTGACTAATTA 6000  
 N \* L L V S \* K F N P D F Y I Y V D \* L  
 T D C L Y L K N L T Q T F T S M L T N Y  
 L T A C I L K I \* P R L L H L C \* L I I

6001 TTTTTGGATGATGTTGAAATGGTTGCTTATAACCCTGATCTTTCACAATATTATTGTGA 6060  
 F F G \* C \* N G C L \* P \* S F T I L L \*  
 F L D D V E M V A Y N P D L S Q Y Y C D  
 F W M M L K W L L I T L I F H N I I V I

6061 TAATGGTAAGTATTATACAAAACCTATTATAAAGGCTCAGTTTAAACCATTGCTAAAGT 6120  
 \* W \* V L Y K T Y Y K G S V \* T I C \* S  
 N G K Y Y T K P I I K A Q F K P F A K V  
 M V S I I Q N L L \* R L S L N H L L K L

6121 TGACGGTGTTTATACTAACTTTAAGTTAGTTGGACATGATATTTGTGCTCAATTGAATGA 6180  
 \* R C L Y \* L \* V S W T \* Y L C S I E \*  
 D G V Y T N F K L V G H D I C A Q L N D  
 T V F I L T L S \* L D M I F V L N \* M I

6181 TAAGTTAGGTTTTAATGTAGATTTGCCGTTTGTGAGTACAAAGTAACAGTCTGGCCTGT 6240  
 \* V R F \* C R F A V C \* V Q S N S L A C  
 K L G F N V D L P F V E Y K V T V W P V  
 S \* V L M \* I C R L L S T K \* Q S G L \*

6241 AGCTACTGGTGATGTTGTTTTGGCATCTGATGATTTATATGTTAAACGTTATTTTAAAGG 6300  
 S Y W \* C C F G I \* \* F I C \* T L F \* R  
 A T G D V V L A S D D L Y V K R Y F K G  
 L L V M L F W H L M I Y M L N V I L K D

6301 ATGTGAAACTTTTGGTAAGCCTGTTATTTGGCTTTGTCATGATGAAGCATCATTGAATTC 6360  
 M \* N F W \* A C Y L A L S \* \* S I I E F  
 C E T F G K P V I W L C H D E A S L N S  
 V K L L V S L L F G F V M M K H H \* I L

6361 TCTTACTTATTTTAAATAAACCTAGTTTTAAATCTGAAAATAGATATAGTGTTTTGTCTGT 6420  
 S Y L F \* \* T \* F \* I \* K \* I \* C F V C  
 L T Y F N K P S F K S E N R Y S V L S V  
 L L I L I N L V L N L K I D I V F C L L

6421 TGATTCTGTATCTGAGGAGTCACAAGGTAATGTGGTTACTTCTGTTATGGAATCGCAGAT 6480  
 \* F C I \* G V T R \* C G Y F C Y G I A D  
 D S V S E E S Q G N V V T S V M E S Q I  
 I L Y L R S H K V M W L L L L W N R R L

FIG. 9 CONT.

132/201

6481 TAGTACTAAAGAGGTTAAGTTAAAGGGTGTAGAAAGACTGTAAAAATAGAAGATGCTAT 6540  
 \* Y \* R G \* V K G C \* K D C \* N R R C Y  
 S T K E V K L K G V R K T V K I E D A I  
 V L K R L S \* R V L E R L L K \* K M L L

6541 TATTGTTAATGATGAAAAATAGTTCTATTAAAGGTTGTAAAAGTTTATCTTTAGTTGATGT 6600  
 Y C \* \* \* K \* F Y \* G C \* K F I F S \* C  
 I V N D E N S S I K V V K S L S L V D V  
 L L M M K I V L L R L L K V Y L \* L M F

6601 TTGGGATAIGTATTTGACAGGTTGTGATTATGTTGTTGGGTTGCTAATGAATTGTCACG 6660  
 L G Y V F D R L \* L C C L G C \* \* I V T  
 W D M Y L T G C D Y V V W V A N E L S R  
 G I C I \* Q V V I M L F G L L M N C H A

6661 CCTAGTTAAATCACCAACAGTTAGGGAATATATACGATATGGTATTAACCTATTACTAT 6720  
 P S \* I T N S \* G I Y T I W Y \* T Y Y Y  
 L V K S P T V R E Y I R Y G I K P I T I  
 \* L N H Q Q L G N I Y D M V L N L L L Y

6721 ACCTATAGATTTGTTATGTTTAAGAGATGATAATCAAACCTCTTTAGTTCCTAAAATTTT 6780  
 T Y R F V M F K R \* \* S N S F S S \* N F  
 P I D L L C L R D D N Q T L L V P K I F  
 L \* I C Y V \* E M I I K L F \* F L K F L

6781 TAAAGCAAGAGCTATAGAATTTTATGTTTTTTGAAGTGGTTGTTTATTTATGTTTTTAG 6840  
 \* S K S Y R I L W F F E V V V Y L C F \*  
 K A R A I E F Y G F L K W L F I Y V F S  
 K Q E L \* N F M V F \* S G C L F M F L V

6841 TTTATTACATTTTACAAATGATAAAACCATTTTTTATACTACAGAAATAGCTTCTAAGTT 6900  
 F I T F Y K \* \* N H F L Y Y R N S F \* V  
 L L H F T N D K T I F Y T T E I A S K F  
 Y Y I L Q M I K P F F I L Q K \* L L S L

6901 TACTTTTAATTTGTTTTGTTGGCTCTTAAAAATGCTTTTCAGACATTTAGATGGAGTAT 6960  
 Y F \* F V L F G S \* K C F S D I \* M E Y  
 T F N L F C L A L K N A F Q T F R W S I  
 L L I C F V W L L K M L F R H L D G V Y

6961 ATTTATAAAAGGTTTTCTGTTGTAGCCACTGTGTTTTGTTTTGGTTTAATTTTTTGTA 7020  
 I Y K R F S C C S H C V F V L V \* F F V  
 F I K G F L V V A T V F L F W F N F L Y  
 L \* K V F L L \* P L C F C F G L I F C I

FIG. 9 CONT.

## 133/201

7021 TATAAATGTTATTTTGTAGTGATTTTATCTTCCTAATATTAGTGTTTTTCCTATTTTTGT 7080  
 Y K C Y F \* \* F L S S \* Y \* C F S Y F C  
 I N V I F S D F Y L P N I S V F P I F V  
 \* M L F L V I F I F L I L V F F L F L W

7081 GGAAGAATTGTTATGTGGATAAAGGCTACTTTTGGTTTGGTTACAATTTGTGATTTTTA 7140  
 G K N C Y V D K G Y F W F G Y N L \* F L  
 G R I V M W I K A T F G L V T I C D F Y  
 E E L L C G \* R L L L V W L Q F V I F I

7141 TTCTAAGTTAGGTGTAGGTTTTACAAGTCATTTTTGTAATGGTAGTTTTATATGTGAATT 7200  
 F \* V R C R F Y K S F L \* W \* F Y M \* I  
 S K L G V G F T S H F C N G S F I C E L  
 L S \* V \* V L Q V I F V M V V L Y V N C

7201 GTGTTATTCTGGTTTTGATATGTTGGATACATATGCAGCTATAGATTTTTGTTTCAGTATGA 7260  
 V L F W F \* Y V G Y I C S Y R F C S V \*  
 C Y S G F D M L D T Y A A I D F V Q Y E  
 V I L V L I C W I H M Q L \* I L F S M K

7261 AGTAGATAGACGTGTTTTATTTGATTATGTTAGTTTGTAGTCAAATTAATTGTTGAACCTCGT 7320  
 S R \* T C F I \* L C \* F S Q I N C \* T R  
 V D R R V L F D Y V S L V K L I V E L V  
 \* I D V F Y L I M L V \* S N \* L L N S L

7321 TATTGGTTATTCATTATATACAGTATGGTTTTATCCATTATTTGTCTTATTGGTTTACA 7380  
 Y W L F I I Y S M V L S I I L S Y W F T  
 I G Y S L Y T V W F Y P L F C L I G L Q  
 L V I H Y I Q Y G F I H Y F V L L V Y N

7381 ATTATTTACTACATGGTTGCCTGATTTGTTTTATGTTAGAAACTATGCATTGGTTGATTAG 7440  
 I I Y Y M V A \* F V Y V R N Y A L V D \*  
 L F T T W L P D L F M L E T M H W L I R  
 Y L L H G C L I C L C \* K L C I G \* L D

7441 ATTTATTGTATTTGTAGCTAATATGTTACCTGCTTTTGTCTTGTGCGGTTTTATATAGT 7500  
 I Y C I C S \* Y V T C F C L V A V L Y S  
 F I V F V A N M L P A F V L L R F Y I V  
 L L Y L \* L I C Y L L L S C C G F I \* L

7501 TGTTACTGCTATGTATAAAGTAGTTGGTTTTATTAGGCATATTGTTTATGGTTGTAATAA 7560  
 C Y C Y V \* S S W F Y \* A Y C L W L \* \*  
 V T A M Y K V V G F I R H I V Y G C N K  
 L L L C I K \* L V L L G I L F M V V I K

FIG. 9 CONT.

134/201

7561 AGCTGGTTGTTTGTGGTTATAAACGAAATTGTAGTGTTCGTGTTAAGTGTAGTACTAT 7620  
 S W L F V L L \* T K L \* C S C \* V \* Y Y  
 A G C L F C Y K R N C S V R V K C S T I  
 L V V C F V I N E I V V F V L S V V L L

7621 TGTTGGTGGTGAATTCGTTATTATGATATTACTGCTAATGGTGGTACTGGTTTTGTGT 7680  
 C W W C N S L L \* Y Y C \* W W Y W F L C  
 V G G V I R Y Y D I T A N G G T G F C V  
 L V V \* F V I M I L L L M V V L V F V L

7681 TAAACATCAATGGAATTGTTTTAATTGCCATTCTTTTAAACCAGGTAACACTTTTATAAC 7740  
 \* T S M E L F \* L P F F \* T R \* H F Y N  
 K H Q W N C F N C H S F K P G N T F I T  
 N I N G I V L I A I L L N Q V T L L \* L

7741 TGTAGAAGCTGCTATAGAACTTCTAAAGAGCTTAAACGACCTGTAAACCCAACTGATGC 7800  
 C R S C Y R T F \* R A \* T T C K P N \* C  
 V E A A I E L S K E L K R P V N P T D A  
 \* K L L \* N F L K S L N D L \* T Q L M L

7801 TTCACATTATGTAGTTACTGATATTAAGCAAGTTGGTTGTATGATGCGTTTGTCTATGA 7860  
 F T L C S Y \* Y \* A S W L Y D A F V L \*  
 S H Y V V T D I K Q V G C M M R L F Y D  
 H I M \* L L I L S K L V V \* C V C S M I

7861 TAGAGATGGACAGCGTGTTTACGATGATGTTGATGCTAGTTTATTTGTAGATATTAATAA 7920  
 \* R W T A C L R \* C \* C \* F I C R Y \* \*  
 R D G Q R V Y D D V D A S L F V D I N N  
 E M D S V F T M M L M L V Y L \* I L I I

7921 TCTGTTACATTCTAAAGTCAAAGTTGTTCCCTAATTTGTATGTAGTTGTAGTAGAGAGTGA 7980  
 S V T F \* S Q S C S \* F V C S C S R E \*  
 L L H S K V K V V P N L Y V V V V E S D  
 C Y I L K S K L F L I C M \* L \* \* R V M

7981 TGCTGATAGAGCTAATTTCTGAATGCTGTTGTGTTTTATGCACAATCATTGTATAGGCC 8040  
 C \* \* S \* F S E C C C V L C T I I V \* A  
 A D R A N F L N A V V F Y A Q S L Y R P  
 L I E L I F \* M L L C F M H N H C I G L

8041 TATATTACTTGTAGACAAAAAGTTAATTACTACAGCTTGTAAATGGTATCTCTGTAACCCA 8100  
 Y I T C R Q K V N Y Y S L \* W Y L C N P  
 I L L V D K K L I T T A C N G I S V T Q  
 Y Y L \* T K S \* L L Q L V M V S L \* P R

FIG. 9 CONT.

135/201

8101 GACTATGTTTGATGTTTATGTTGATACTTTTATGTCTCATTTTGATGTTGATAGAAAGAG 8160  
 D Y V \* C L C \* Y F Y V S F \* C \* \* K E  
 T M F D V Y V D T F M S H F D V D R K S  
 L C L M F M L I L L C L I L M L I E R V

8161 TTTTAATAATTTTGTTAACATTGCTCATGCTTCTCTTAGAGAGGGTGTGCAATTAGAAAA 8220  
 F \* \* F C \* H C S C F S \* R G C A I R K  
 F N N F V N I A H A S L R E G V Q L E K  
 L I I L L T L L M L L L E R V C N \* K R

8221 GGTTTTAGATACTTTTGTGGGATGTGTACGTAAATGTTGTTCCATTGATTCAGATGTTGA 8280  
 G F R Y F C G M C T \* M L F H \* F R C \*  
 V L D T F V G C V R K C C S I D S D V E  
 F \* I L L W D V Y V N V V P L I Q M L K

8281 AACAAAGATTATTACTAAATCTATGATATCTGCAGTAGCTGCTGGTTTGAATTACTGA 8340  
 N K I Y Y \* I Y D I C S S C W F G I Y \*  
 T R F I T K S M I S A V A A G L E F T D  
 Q D L L L N L \* Y L Q \* L L V W N L L M

8341 TGAAAATTATAACAATTTGGTACCTACATATTTAAAGAGTGATAATATTGTAGCTGCAGA 8400  
 \* K L \* Q F G T Y I F K E \* \* Y C S C R  
 E N Y N N L V P T Y L K S D N I V A A D  
 K I I T I W Y L H I \* R V I I L \* L Q I

8401 TTTAGGTGTTCTTATACAGAATGGTGCTAAGCATGTACAGGGTAATGTTGCTAAGGCAGC 8460  
 F R C S Y T E W C \* A C T G \* C C \* G S  
 L G V L I Q N G A K H V Q G N V A K A A  
 \* V F L Y R M V L S M Y R V M L L R Q L

8461 TAATATTTCTTGTATATGGTTTATTGACACTTTTAATCAACTTACTGCTGATTACAGCA 8520  
 \* Y F L Y M V Y \* H F \* S T Y C \* F T A  
 N I S C I W F I D T F N Q L T A D L Q H  
 I F L V Y G L L T L L I N L L L I Y S I

8521 TAAATTAATAAAGCATGTGTAAACTGGCTTGAAGTAAATGACTTTTAATAAGCA 8580  
 \* I K K S M C \* N W L E V K I D F \* \* A  
 K L K K A C V K T G L K L K L T F N K Q  
 N \* K K H V L K L A \* S \* N \* L L I S K

8581 AGAGGCAAGTGTTCCCTATTCTTACAACGCCCTTTTCACTTAAAGGAGGTGTTGATTGAG 8640  
 R G K C S Y S Y N A L F T \* R R C C I E  
 E A S V P I L T T P F S L K G G V V L S  
 R Q V F L F L Q R P F H L K E V L Y \* V

FIG. 9 CONT.

136/201

8641 TAATTTGTTATATATATATTATTTTTTATTAGTTTAACTGTTTTATATTATTGTGGGCTTT 8700  
 \* F V I Y I I F Y \* F N L F Y I I V G F  
 N L L Y I L F F I S L I C F I L L W A L  
 I C Y I Y Y F L L V \* S V L Y Y C G L Y

8701 ACTGCCTACATATAGTGTTTATAAGTCTGATATTCATTTGCCTGCTTATGCTAGTTTTAA 8760  
 T A Y I \* C L \* V \* Y S F A C L C \* F \*  
 L P T Y S V Y K S D I H L P A Y A S F K  
 C L H I V F I S L I F I C L L M L V L K

8761 AGTTATTGATAATGGTGTGTTAGAGATATTCAGTTAATGATTATGTTTTGCTAATAA 8820  
 S Y \* \* W C C \* R Y F S \* \* F M F C \* \*  
 V I D N G V V R D I S V N D L C F A N K  
 L L I M V L L E I F Q L M I Y V L L I N

8821 ATTTTTCCAATTTGATCAATGGTATGAGTCCACTTTTGGGTCTTTTTACTATCATAATTC 8880  
 I F P I \* S M V \* V H F W V F L L S \* F  
 F F Q F D Q W Y E S T F G S F Y Y H N S  
 F S N L I N G M S P L L G L F T I I I L

8881 TATGGATTGCCCTATTGTTGTGGCAGTTATGGATGAAGATATTGGTCTACTATGTTTTAA 8940  
 Y G L P Y C C G S Y G \* R Y W F Y Y V \*  
 M D C P I V V A V M D E D I G S T M F N  
 W I A L L L W Q L W M K I L V L L C L M

8941 TGTTCTACTAAAGTTTTGAGACATGGCTTTCATGTTTTACATTTTCTAACTTATGCATT 9000  
 C S Y \* S F E T W L S C F T F S N L C I  
 V P T K V L R H G F H V L H F L T Y A F  
 F L L K F \* D M A F M F Y I F \* L M H L

9001 TGCTAGTGATAGTGTTCAGTGCTATACACCACATATTCAGATTTCTTATAATGATTTTTA 9060  
 C \* \* \* C S V L Y T T Y S D F L \* \* F L  
 A S D S V Q C Y T P H I Q I S Y N D F Y  
 L V I V F S A I H H I F R F L I M I F M

9061 TGCTAGTGGTTGTGTTTTATCATCTTTGTGTAATGTTTAAAAGAGGTGATGGTACACC 9120  
 C \* W L C F I I F V Y Y V \* K R \* W Y T  
 A S G C V L S S L C T M F K R G D G T P  
 L V V V F Y H L C V L C L K E V M V H H

9121 ACATCCTTATTGTTATTCAGATGGTGTATGAAGAATGCTTCTTTGTATACATCTTTGGT 9180  
 T S L L L F R W C Y E E C F F V Y I F G  
 H P Y C Y S D G V M K N A S L Y T S L V  
 I L I V I Q M V L \* R M L L C I H L W F

FIG. 9 CONT.

137/201

9181 TCCACATACACGTTATAGCCTTGCTAATTCTAATGGTTTTATAAGATTCCTGATGTTAT 9240  
 S T Y T L \* P C \* F \* W F Y K I S \* C Y  
 P H T R Y S L A N S N G F I R F P D V I  
 H I H V I A L L I L M V L \* D F L M L L

9241 TAGTGAAGGTATTGTACGTATTGTAAGAACGCGCTCTATGACTTATTGTAGAGTGGGTGC 9300  
 \* \* R Y C T Y C K N A L Y D L L \* S G C  
 S E G I V R I V R T R S M T Y C R V G A  
 V K V L Y V L \* E R A L \* L I V E W V H

9301 ATGTGAATATGCCGAAGAGGGTATATGTTTTAATTTAATAGTTCCTGGGTTTTGAATAA 9360  
 M \* I C R R G Y M F \* F \* \* F L G F E \*  
 C E Y A E E G I C F N F N S S W V L N N  
 V N M P K R V Y V L I L I V P G F \* I M

9361 TGATTATTATAGAAGTATGCCTGGAACTTTTTGTGGTAGAGATCTTTTGTATTGTTTTA 9420  
 \* L L \* K Y A W N F L W \* R S F \* F V L  
 D Y Y R S M P G T F C G R D L F D L F Y  
 I I I E V C L E L F V V E I F L I C F I

9421 TCAATTTTTAGTAGTTAATTCGCTATAGATTTCTTTCTTACTGCTAGTCTAT 9480  
 S I F \* \* F N S S Y R F L F S Y C \* F Y  
 Q F F S S L I R P I D F F S L T A S S I  
 N F L V V \* F V L \* I S F L L L L V L F

9481 TTTTGGAGCTATATTGGCTATAGTCGTTGCTGGTTTTTTATTATTTAATAAAACTTAA 9540  
 F W S Y I G Y S R C L G F L L F N K T \*  
 F G A I L A I V V V L V F Y Y L I K L K  
 L E L Y W L \* S L S W F F I I \* \* N L S

9541 GCGTGCCTTTGGAGATTATACTAGTGTGTAGTTATAAATGTTATTGTTGGTGTATTAA 9600  
 A C F W R L Y \* C C S Y K C Y C L V Y \*  
 R A F G D Y T S V V V I N V I V W C I N  
 V L L E I I L V L \* L \* M L L F G V L I

9601 TTTTCTTATGCTTTTTGTTTTCAAGTTTATCCTATTTGTGCATGTGTCTATGCTTGTTT 9660  
 F S Y A F C F S S L S Y L C M C L C L F  
 F L M L F V F Q V Y P I C A C V Y A C F  
 F L C F L F F K F I L F V H V S M L V F

9661 TTATTTTTATGTAACATTGTATTTTCCTTCTGAAATTAGTGTAAATTATGCATTGCAATG 9720  
 L F L C N I V F S F \* N \* C N Y A F A M  
 Y F Y V T L Y F P S E I S V I M H L Q W  
 I F M \* H C I F L L K L V \* L C I C N G

FIG. 9 CONT.

138/201

9781 TATTGCAAACCATGTTTTATGGTTATTTTCATATTGTAGGAAAATTGGTGTTAATGTATG 9840  
 Y C K P C F M V I F I L \* E N W C \* C M  
 I A N H V L W L F S Y C R K I G V N V C  
 L Q T M F Y G Y F H I V G K L V L M Y V

9841 TAATGATAGTACATTTGAAGAAACATCTCTACTACTTTTATGATTACTAAAGATTCTTA 9900  
 \* \* \* Y I \* R N I S Y Y F Y D Y \* R F L  
 N D S T F E E T S L T T F M I T K D S Y  
 M I V H L K K H L L L L L \* L L K I L I

9901 TTGTAGATTAAAGAATTCTGTTTCTGATGTTGCTTACAATAGATATTTGAGTTGTATAA 9960  
 L \* I K E F C F \* C C L Q \* I F E F V \*  
 C R L K N S V S D V A Y N R Y L S L Y N  
 V D \* R I L F L M L L T I D I \* V C I I

9961 TAAGTATCGTTACTATAGTGGTAAAATGGATACTGCTGCCTATAGAGAAGCGCGTGTTC 10020  
 \* V S L L \* W \* N G Y C C L \* R S G V F  
 K Y R Y Y S G K M D T A A Y R E A A C S  
 S I V T I V V K W I L L P I E K R R V L

10021 TCAGTTAGCTAAAGCTATGGAAACATTTAATCACAATAATGGTAATGATGCTTATACCA 10080  
 S V S \* S Y G N I \* S Q \* W \* \* C L I P  
 Q L A K A M E T F N H N N G N D V L Y Q  
 S \* L K L W K H L I T I M V M M S Y T N

10081 ACCTCCTACAGCATCTGTTTCTACATCTTTTTGCAATCAGGTATTGTAAAGATGGTATC 10140  
 T S Y S I C F Y I F F A I R Y C K D G I  
 P P T A S V S T S F L Q S G I V K M V S  
 L L Q H L F L H L F C N Q V L \* R W Y L

10141 TCCTACGTCAAAAATTGAACCTTGTATTGTTAGTGTACTTATGGTAGTATGACTTTGAA 10200  
 S Y V K N \* T L Y C \* C Y L W \* Y D F E  
 P T S K I E P C I V S V T Y G S M T L N  
 L R Q K L N L V L L V L L M V V \* L \* M

10201 TGGTTTATGGTTAGATGACAAAAGTTTATTGTCCTCGTCATGTTATATGTTTATCCTCTAA 10260  
 W F M V R \* Q S L L S S S C Y M F I L \*  
 G L W L D D K V Y C P R H V I C L S S N  
 V Y G \* M T K F I V L V M L Y V Y P L I

10261 TATGAATGAACCTGATTATTCTGCCTTATTATGTAGAGTTACTCTAGGTGATTTTACTAT 10320  
 Y E \* T \* L F C L I M \* S Y S R \* F Y Y  
 M N E P D Y S A L L C R V T L G D F T I  
 \* M N L I I L P Y Y V E L L \* V I L L \*

FIG. 9 CONT.



139/201

9721 GATTGTTATGTATGGTGCTATAATGCCTTTTGGTTTTGTGTACACATATGTAGCTATGGT 9780  
 D C Y V W C Y N A F L V L C H I C S Y G  
 I V M Y G A I M P F W F C V T Y V A M V  
 L L C M V L \* C L F G F V S H M \* L W L

10321 AATGTCTGGGCGGATGAGTTTAAACAGTTGTGTCTTACCAGATGCAGGGCTGTCAACTTGT 10380  
 N V W A D E F N S C V L P D A G L S T C  
 M S G R M S L T V V S Y Q M Q G C Q L V  
 C L G G \* V \* Q L C L T R C R A V N L F

10381 TTTGACAGTCTCTTTACAAAATCCTTACACTCCAAAATATACTTTTGGTGTGTAAACC 10440  
 F D S L F T K S L H S K I Y F W C C \* T  
 L T V S L Q N P Y T P K Y T F G V V K P  
 \* Q S L Y K I L T L Q N I L L V L L N L

10441 TGGTAAACTTTTACTGTTTTAGCTGCGTATAATGGCCGACCACAAGGGGCATTTTCATGT 10500  
 W \* N F Y C F S C V \* W P T T R G I S C  
 G E T F T V L A A Y N G R P Q G A F H V  
 V K L L L F \* L R I M A D H K G H F M L

10501 TACTATGCGTAGTAGTTATACTATTAAGGTTCTTTTTTGTGTGGGTCAATGTGGATCTGT 10560  
 Y Y A \* \* L Y Y \* R F F F V W V M W I C  
 T M R S S Y T I K G S F L C G S C G S V  
 L C V V V I L L K V L F C V G H V D L L

10561 TGGTTATGTATTAACAGGTGATAGTGTAAAGTTTGTATATATGCATCAATTAGAGCTCAG 10620  
 W L C I N R \* \* C \* V C I Y A S I R A Q  
 G Y V L T G D S V K F V Y M H Q L E L S  
 V M Y \* Q V I V L S L Y I C I N \* S S V

10621 TACTGGTTGTACACTGGCACTGATTTTACTGGTAATTTTTATGGTCCATATAGAGATGC 10680  
 Y W L S H W H \* F Y W \* F L W S I \* R C  
 T G C H T G T D F T G N F Y G P Y R D A  
 L V V T L A L I L L V I F M V H I E M L

10681 TCAAGTTGTACAGTTGCCAGTTAAGGACTACGTCCAAACTGTTAATGTTATTGCTTGGCT 10740  
 S S C T V A S \* G L R P N C \* C Y C L A  
 Q V V Q L P V K D Y V Q T V N V I A W L  
 K L Y S C Q L R T T S K L L M L L L G S

10741 CTATGCAGCTATACTTAATAATTGTGCTTGGTTTGTACAAAATGATGTTTGTCTATTGA 10800  
 L C S Y T \* \* L C L V C T K \* C L F Y \*  
 Y A A I L N N C A W F V Q N D V C S I E  
 M Q L Y L I I V L G L Y K M M F V L L K

FIG. 9 CONT.

## 140/201

10801 AGATTTTAATGTTTGGGCTATGACAAATGGTTTTAGCCAAGTAAAAGCAGATCTTGTTTT 10860  
R F \* C L G Y D K W F \* P S K S R S C F  
D F N V W A M T N G F S Q V K A D L V L  
I L M F G L \* Q M V L A K \* K Q I L F \*

10861 AGATGCTTTGGCTTCAATGACAGGTGTTTCTATTGAACTTTATTGGCTGCTATTAAGCG 10920  
R C F G F N D R C F Y \* N F I G C Y \* A  
D A L A S M T G V S I E T L L A A I K R  
M L W L Q \* Q V F L L K L Y W L L L S V

10921 TCTATATATGGGATTTCAAGGTCGTCAAATACTAGGAAGTTGTACTTTTGAAGATGAATT 10980  
S I Y G I S R S S N T R K L Y F \* R \* I  
L Y M G F Q G R Q I L G S C T F E D E L  
Y I W D F K V V K Y \* E V V L L K M N W

10981 GGCACCTTCTGACGTTTATCAACAATTGGCTGGTGTAAATTGCAATCTAAAACAAAAG 11040  
G T F \* R L S T I G W C \* I A I \* N K K  
A P S D V Y Q Q L A G V K L Q S K T K R  
H L L T F I N N W L V L N C N L K Q K D

11041 ATTTATTAAGAAACAATTTATTGGATTTTGATATCTACATTTTGTTTAGTTGTATAAT 11100  
I Y \* R N N L L D F D I Y I F V \* L Y N  
F I K E T I Y W I L I S T F L F S C I I  
L L K K Q F I G F \* Y L H F C L V V \* F

11101 TTCTGCATTTGTTAAATGGACTATATTTATGTATATTAATACACATATGATTGGTGTAC 11160  
F C I C \* M D Y I Y V Y \* Y T Y D W C Y  
S A F V K W T I F M Y I N T H M I G V T  
L H L L N G L Y L C I L I H I \* L V L H

11161 ATTATGTGTACTTTGTTTGTAGTTTATGATGTTACTAGTTAAACATAAGCATTTTTA 11220  
I M C T L F C \* F Y D V T S \* T \* A F L  
L C V L C F V S F M M L L V K H K H F Y  
Y V Y F V L L V L \* C Y \* L N I S I F I

11221 TTTGACTATGTATATAATTCCTGTACTCTGTACCTGTTTTATGTAATTTATTAGTTGT 11280  
F D Y V Y N S C T L Y L V L C K L F S C  
L T M Y I I P V L C T L F Y V N Y L V V  
\* L C I \* F L Y S V P C F M \* I I \* L S

11281 CTATAAGGAAGGTTTTAGAGGTCTTACTTATGTCTGGCTCTCATATTTTGTTCCTGCTGT 11340  
L \* G R F \* R S Y L C L A L I F C S C C  
Y K E G F R G L T Y V W L S Y F V P A V  
I R K V L E V L L M S G S H I L F L L \*

FIG. 9 CONT.

## 141/201

11341 GAATTTTACTTATGTTTATGAAGTATTTTATGGTTGTATTTTATGTGTTTTGCTATTTT 11400  
 E F Y L C L \* S I L W L Y F M C F C Y F  
 N F T Y V Y E V F Y G C I L C V F A I F  
 I L L M F M K Y F M V V F Y V F L L F L

11401 TATAACTATGCATAGTATTAATCATGACATTTTTCTTTGATGTTTTTGGTTGGTAGAAT 11460  
 Y N Y A \* Y \* S \* H F F F D V F G W \* N  
 I T M H S I N H D I F S L M F L V G R I  
 \* L C I V L I M T F F L \* C F W L V E \*

11461 AGTTACTTTAATTTCTATGTGGTATTTTGGGTCGAATTTAGAAGAGGATGTTTTGTTATT 11520  
 S Y F N F Y V V F W V E F R R G C F V I  
 V T L I S M W Y F G S N L E E D V L L F  
 L L \* F L C G I L G R I \* K R M F C Y L

11521 TATTACAGCCTTTTTAGGTACTIONTATACATGGACCACTATTTTGTGATTAGCTATAGCAA 11580  
 Y Y S L F R Y L Y M D H Y F V I S Y S K  
 I T A F L G T Y T W T T I L S L A I A K  
 L Q P F \* V L I H G P L F C H \* L \* Q K

11581 AATTGTTGCTAATTGGTTGTCTGTTAATATATTTTATTTTACAGATGTACCTTATATTAA 11640  
 N C C \* L V V C \* Y I L F Y R C T L Y \*  
 I V A N W L S V N I F Y F T D V P Y I K  
 L L L I G C L L I Y F I L Q M Y L I L N

11641 ATTGATTCTTTGAGTTACTTATTTATAGGGTATATTTTATCTTGTATTGGGGATTTTT 11700  
 I D S F E L L I Y R V Y F I L L L G I F  
 L I L L S Y L F I G Y I L S C Y W G F F  
 \* F F \* V T Y L \* G I F Y L V I G D F S

11701 CTCTCTTTTAAACAGTGTTTTTAGAAATGCCTATGGGTGTTTATAATTATAAAATTTCTGT 11760  
 L S F K Q C F \* N A Y G C L \* L \* N F C  
 S L L N S V F R M P M G V Y N Y K I S V  
 L F \* T V F L E C L W V F I I I K F L F

11761 TCAAGAATGCGTTATATGAATGCTAATGGCTTACGTCCACCCGTAATAGTTTTGAGGC 11820  
 S R I A L Y E C \* W L T S T P \* \* F \* G  
 Q E L R Y M N A N G L R P P R N S F E A  
 K N C V I \* M L M A Y V H P V I V L R L

11821 TATTTTGTAAATTTAAACTGCTTGAATAGGTGGCGTGCCAGTTATTGAAGTTTCTCA 11880  
 Y F V K F K T A W N R W R A S Y \* S F S  
 I L L N L K L L G I G G V P V I E V S Q  
 F C \* I \* N C L E \* V A C Q L L K F L K

FIG. 9 CONT.

## 142/201

11881 AATTCAATCAAAATTGACTGATGTGAAATGTGCTAATGTTGTTTTGTTAAATTGTTTACA 11940  
 N S I K I D \* C E M C \* C C F V K L F T  
 I Q S K L T D V K C A N V V L L N C L Q  
 F N Q N \* L M \* N V L M L F C \* I V Y S

11941 GCATTTGCATGTTGCTTCTAATCTAGGTTGTTGGCAGTATTGTAGTATTTTACATAATGA 12000  
 A F A C C F \* F \* V V A V L \* Y F T \* \*  
 H L H V A S N S R L W Q Y C S I L H N E  
 I C M L L L I L G C G S I V V F Y I M K

12001 AATACTATCTACTTCAGATTTAAGTGTAGCTTTTGATAAGCTTGCTCAATTATTGATTGT 12060  
 N T I Y F R F K C S F \* \* A C S I I D C  
 I L S T S D L S V A F D K L A Q L L I V  
 Y Y L L Q I \* V \* L L I S L L N Y \* L F

12061 TTTATTGCGCAATCCTGCTGCGAGTTGATACTAAGTGTCTTGCAAGTATAGATGAAGTTAG 12120  
 F I R Q S C C S \* Y \* V S C K Y R \* S \*  
 L F A N P A A V D T K C L A S I D E V S  
 Y S P I L L Q L I L S V L Q V \* M K L A

12121 CGATGATTATGTTCAAGATAGTACTGTTTTGCAGGCTTTGCAAAGTGAGTTTGTAAATAT 12180  
 R \* L C S R \* Y C F A G F A K \* V C K Y  
 D D Y V Q D S T V L Q A L Q S E F V N M  
 M I M F K I V L F C R L C K V S L \* I W

12181 GGCTAGTTTTGTTGAATATGAAGTCGCAAAGAAAATTGGCTGATGCTAAAAATAGTGG 12240  
 G \* F C \* I \* S R K E K F G \* C \* K \* W  
 A S F V E Y E V A K K N L A D A K N S G  
 L V L L N M K S Q R K I W L M L K I V V

12241 TTCTGTTAATCAACAACAGATAAAACAGTTAGAAAAGGCATGTAATATAGCTAAGTCTGT 12300  
 F C \* S T T D K T V R K G M \* Y S \* V C  
 S V N Q Q Q I K Q L E K A C N I A K S V  
 L L I N N R \* N S \* K R H V I \* L S L C

12301 GTATGAACGCGATAAAGCTGTAGCTCGCAAACCTGGAACGTATGGCAGACCTAGCACTTAC 12360  
 V \* T R \* S C S S Q T G T Y G R P S T Y  
 Y E R D K A V A R K L E R M A D L A L T  
 M N A I K L \* L A N W N V W Q T \* H L L

12361 TAACATGTATAAAGAGGCTCGGATTAATGATAAGAAGAGTAAAGTTGTTTCCGCTTTGCA 12420  
 \* H V \* R G S D \* \* \* E E \* S C F R F A  
 N M Y K E A R I N D K K S K V V S A L Q  
 T C I K R L G L M I R R V K L F P L C R

FIG. 9 CONT.

## 143/201

12421 GACAATGCTTTTTAGCATGGTTCGTAAATTCGATAATCAGGCTTTAAATTCTATTCTGGA 12480  
 D N A F \* H G S \* I G \* S G F K F Y S G  
 T M L F S M V R K L D N Q A L N S I L D  
 Q C F L A W F V N W I I R L \* I L F W I

12481 TAATGCTGTTAAAGGTTGTGTACCTTTGAATGCTATTCAGCGCTGGCTGCTAATACTTT 12540  
 \* C C \* R L C T F E C Y S S A G C \* Y F  
 N A V K G C V P L N A I P A L A A N T L  
 M L L K V V Y L \* M L F Q R W L L I L \*

12541 AACTATAATAATACCAGATAAACAAGTTTTGATAAAGTTGTTGATAATGTTTATGTTGC 12600  
 N Y N N T R \* T S F \* \* S C \* \* C L C C  
 T I I I P D K Q V F D K V V D N V Y V A  
 L \* \* Y Q I N K F L I K L L I M F M L H

12601 ATATGCTGGTAGTGTATGGCATATACAGACTGTTCAAGATGCTGATGGTATTAATAAACA 12660  
 I C W \* C M A Y T D C S R C \* W Y \* \* T  
 Y A G S V W H I Q T V Q D A D G I N K Q  
 M L V V Y G I Y R L F K M L M V L I N S

12661 GTTAACTGATATTAGTGTGATTCTAATTGGCCTCTTGTTATTATTGCTAACAGGTATAA 12720  
 V N \* Y \* C \* F \* L A S C Y Y C \* Q V \*  
 L T D I S V D S N W P L V I I A N R Y N  
 \* L I L V L I L I G L L L L L L L T G I M

12721 TGAAGTTGCTAATGCTGTTATGCAGAATAATGAGTTGATGCCTCATAAATTAATAAACA 12780  
 \* S C \* C C Y A E \* \* V D A S \* I K N T  
 E V A N A V M Q N N E L M P H K L K I Q  
 K L L M L L C R I M S \* C L I N \* K Y K

12781 AGTTGTTAATAGTGGTCTGATATGAATTGTAACATTCCTACTCAATGTTATTATAATAA 12840  
 S C \* \* W F \* Y E L \* H S Y S M L L \* \*  
 V V N S G S D M N C N I P T Q C Y Y N N  
 L L I V V L I \* I V T F L L N V I I I M

12841 TGGTAGTAGTGGTAGAATAGTTTATGCTGTTCTTAGTGATGTTGATGGTCTTAAGTATAC 12900  
 W \* \* W \* N S L C C S \* \* C \* W S \* V Y  
 G S S G R I V Y A V L S D V D G L K Y T  
 V V V V E \* F M L F L V M L M V L S I L

12901 TAAGATAATAAAAGATGATGGAATTGTGTGTTTTAGAGCTTGATCCTCCTTGTAATT 12960  
 \* D N K R \* W K L C C F R A \* S S L \* I  
 K I I K D D G N C V V L E L D P P C K F  
 R \* \* K M M E I V L F \* S L I L L V N F

FIG. 9 CONT.

## 144/201

12961 TTCTATACAAGATGTTAAGGGACTTAAAATAAGTATCTTTATTTTATTAAAGGATGTAA 13020  
 F Y T R C \* G T \* N \* V S L F Y \* R M \*  
 S I Q D V K G L K I K Y L Y F I K G C N  
 L Y K M L R D L K L S I F I L L K D V T

13021 CACTTTAGCTAGAGGGTGGGTTGTTGGTACTTTATCTCAACAATTAGATTGCAGGCTGG 13080  
 H F S \* R V G C W Y F I F N N \* I A G W  
 T L A R G W V V G T L S S T I R L Q A G  
 L \* L E G G L L V L Y L Q Q L D C R L V

13081 TGTTGCTACTGAGTATGCAGCTAATTCCTTCTATACTTTCATTATGTGCATTTTCTGTAGA 13140  
 C C Y \* V C S \* F F Y T F I M C I F C R  
 V A T E Y A A N S S I L S L C A F S V D  
 L L L S M Q L I L L Y F H Y V H F L \* I

13141 TCCTAAGAAAACCTTATTTAGATTATATAACAAGGTGGTGTACCTATAATTAATTGTGT 13200  
 S \* E N L F R L Y T T R W C T Y N \* L C  
 P K K T Y L D Y I Q Q G G V P I I N C V  
 L R K L I \* I I Y N K V V Y L \* L I V L

13201 TAAAATGCTCTGTGATCATGCTGGTACTGGTATGGCTATTACTATTAAACCTGAGGCTAC 13260  
 \* N A L \* S C W Y W Y G Y Y Y \* T \* G Y  
 K M L C D H A G T G M A I T I K P E A T  
 K C S V I M L V L V W L L L L N L R L L

13261 TATTAATCAAGATTCTTATGGTGGTGCCTCAGTTTGTATTTACTGCCGTGCACGTGTAGA 13320  
 Y \* S R F L W W C L S L Y L L P C T C R  
 I N Q D S Y G G A S V C I Y C R A R V E  
 L I K I L M V V P Q F V F T A V H V \* S

13321 GCATCCAGATGTAGATGTTTGTGTAATACTGGTAAATTTGTACAAGTCCCTTTGGG 13380  
 A S R C R W F V \* I T W \* I C T S P F G  
 H P D V D G L C K L R G K F V Q V P L G  
 I Q M \* M V C V N Y V V N L Y K S L W V

13381 TATAAAAGATCCTATTCTCTATGTGTTAACACATGATGTTTGTCAAGTTTGTGGATTTTG 13440  
 Y K R S Y S L C V N T \* C L S S L W I L  
 I K D P I L Y V L T H D V C Q V C G F W  
 \* K I L F S M C \* H M M F V K F V D F G

13441 GAGAGATGGCAGTTGTTCCCTGTGTAGTTTCAGGTGTCGCTGTTCAATCTAAAGATTTAAA 13500  
 E R W Q L F L C R F R C R C S I \* R F K  
 R D G S C S C V G S G V A V Q S K D L N  
 E M A V V P V \* V Q V S L F N L K I \* I

FIG. 9 CONT.

## 145/201

13501 TTTTTTAAACGGGTTCGGGGTACTAGTGTGAATGCCCGTCTAGTACCCTGTGCTAGTGGT 13560  
 F F K R V R G T S V N A R L V P C A S G  
 F L N G F G V L V \* M P V \* Y P V L V V  
 F \* T G S G Y \* C E C P S S T L C \* W F

13561 TTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACTAATAGAGCTGGTATA 13620  
 L S T D V Q L R A F D I C N T N R A G I  
 Y L L M F N \* G H L I F V I L I E L V \*  
 I Y \* C S I K G I \* Y L \* Y \* \* S W Y R

13621 GGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGATGACGACGGTAATAAA 13680  
 G L Y Y K V N C C R F Q R I D D D G N K  
 V Y I I K \* I V A V F S V \* M T T V I N  
 F I L \* S E L L P F S A Y R \* R R \* \* I

13681 TTGGATAAGTTCTTTGTTGTTAAAAGAACTAATCTAGAAGTTTATAATAAGAGAAACT 13740  
 L D K F F V V K R T N L E V Y N K E K T  
 W I S S L L L K E L I \* K F I I K R K L  
 G \* V L C C \* K N \* S R S L \* \* R E N L

13741 TATTATGAGTTGACTAAAAGTTGTGGTGTGGCTGAACATGATTTCTTTACATTTGAT 13800  
 Y Y E L T K S C G V V A E H D F F T F D  
 I M S \* L K V V V L W L N M I S L H L I  
 L \* V D \* K L W C C G \* T \* F L Y I \* Y

13801 ATTGATGGTAGTCGTGTGCCACATATAGTTTCGTAAGAACCCTCTCAAAGTATACTATGTTA 13860  
 I D G S R V P H I V R K N L S K Y T M L  
 L M V V V C H I \* F V R T S Q S I L C \*  
 \* W \* S C A T Y S S \* E P L K V Y Y V R

13861 GATCTTTGCTATGCATTGCGCCATTTTGATTGTAATGATTGTTTCAGTATTGTGTGAAATT 13920  
 D L C Y A L R H F D C N D C S V L C E I  
 I F A M H C A I L I V M I V Q Y C V K F  
 S L L C I A P F \* L \* \* L F S I V \* N S

13921 CTTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAAGATTGGTATGATTTT 13980  
 L C E Y A D C K E S Y F S K K D W Y D F  
 F V S M L I V K N P T F L R K I G M I L  
 L \* V C \* L \* R I L L F \* E R L V \* F C

13981 GTTGAAAATCCTGATATTATTAATATTTATAAAAAATTAGGCCCTATTTTAAATAGAGCT 14040  
 V E N P D I I N I Y K K L G P I F N R A  
 L K I L I L L I F I K N \* A L F L I E L  
 \* K S \* Y Y \* Y L \* K I R P Y F \* \* S F

FIG. 9 CONT.

146/201

14041 TTA C T T A A T A C T G T C A G T T T T G C A G A T A C T T T A G T A A A A G T A G G T T T A G T T G G T G T T T T A 14100  
 L L N T V S F A D T L V K V G L V G V L  
 Y L I L S V L Q I L \* \* K \* V \* L V F \*  
 T \* Y C Q F C R Y F S K S R F S W C F N

14101 A C T T T A G A T A A T C A A G A C T T G T A T G G T C A A T G G T A T G A T T T T G G T G A T T T T A T A C A A A C A 14160  
 T L D N Q D L Y G Q W Y D F G D F I Q T  
 L \* I I K T C M V N G M I L V I L Y K Q  
 F R \* S R L V W S M V \* F W \* F Y T N S

14161 G C T C C A G G T T T T G G T G T G G C A G T T G C A G A T T C T T A C T A T T C T T A T A T G A T G C C T A T G T T G 14220  
 A P G F G V A V A D S Y Y S Y M M P M L  
 L Q V L V W Q L Q I L T I L I \* C L C \*  
 S R F W C G S C R F L L F L Y D A Y V D

14221 A C T A T G T G T C A T G T A T T A G A T T G T G A A T T A T T T G T T A A T G A T A G T T A T A G A C A A T T C G A T 14280  
 T M C H V L D C E L F V N D S Y R Q F D  
 L C V M Y \* I V N Y L L M I V I D N S I  
 Y V S C I R L \* I I C \* \* \* L \* T I R S

14281 C T T G T A C A G T A T G A T T T T A C T G A T T A T A A G T T A G A A T T G T T T A A T A A G T A T T T T A A G T A T 14340  
 L V Q Y D F T D Y K L E L F N K Y F K Y  
 L Y S M I L L I I S \* N C L I S I L S I  
 C T V \* F Y \* L \* V R I V \* \* V F \* V L

14341 T G G G G T A T G A A G T A T C A T C C T A A T A C T G T G G A T T G T G A T A A T G A T A G G T G T A T T A T T C A T 14400  
 W G M K Y H P N T V D C D N D R C I I H  
 G V \* S I I L I L W I V I M I G V L F I  
 G Y E V S S \* Y C G L \* \* \* \* V Y Y S L

14401 T G T G C T A A T T T T A A T A T A T T A T T T T A G T A T G G T C T T A C C T A A T A C T T G T T T T G G T C C T C T T 14460  
 C A N F N I L F S M V L P N T C F G P L  
 V L I L I Y Y L V W S Y L I L V L V L L  
 C \* F \* Y I I \* Y G L T \* Y L F W S S C

14461 G T T A G A C A A A T T T T T G T A G A T G G T G T T C C G T T T G T T G T T T C A A T T G G T T A C C A T T A T A A A 14520  
 V R Q I F V D G V P F V V S I G Y H Y K  
 L D K F L \* M V F R L L F Q L V T I I K  
 \* T N F C R W C S V C C F N W L P L \* R

14521 G A G T T A G G T G T A G T T A T G A A C T T G G A T G T T G A T A C A C A C C G C T A T C G T T T G T C T C T T A A A 14580  
 E L G V V M N L D V D T H R Y R L S L K  
 S \* V \* L \* T W M L I H T A I V C L L K  
 V R C S Y E L G C \* Y T P L S F V S \* R

FIG. 9 CONT.



147/201

14581 GACTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCTGCTAGTGCTCTGCTT 14640  
 D L L L Y A A D P A M H V A S A S A L L  
 T Y F F M Q Q I L L C M L H L L V L C L  
 L T S L C S R S C Y A C C I C \* C S A \*

14641 GATTTACGAAGTGTGTTTGTAGTGTAGCTGCCATTACAAGTGGTATAAAGTTTCAAAGT 14700  
 D L R T C C F S V A A I T S G I K F Q T  
 I Y E L V V L V \* L P L Q V V \* S F K L  
 F T N L L F \* C S C H Y K W Y K V S N C

14701 GTTAAACCAGGTAATTTTAAACCAAGATTTTATGAGTTTGTCAAAAGTAAAGGCTTGTTF 14760  
 V K P G N F N Q D F Y E F V K S K G L F  
 L N Q V I L T K I F M S L S K V K A C L  
 \* T R \* F \* P R F L \* V C Q K \* R L V \*

14761 AAAGAGGGTAGTACAGTTGATTGAAACACTTTTTCTTTACTCAAGATGGTAATGCTGCA 14820  
 K E G S T V D L K H F F F T Q D G N A A  
 K R V V Q L I \* N T F S L L K M V M L Q  
 R G \* Y S \* F E T L F L Y S R W \* C C N

14821 ATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTTGATATTAAGCAGTTA 14880  
 I T D Y N Y Y K Y N L P T M V D I K Q L  
 L L I I I I I S I I Y L L W L I L S S Y  
 Y \* L \* L L \* V \* F T Y Y G \* Y \* A V I

14881 TTGTTTGTATTAGAAGTTGTTTATAAGTATTTTGAATTTATGATGGTGGTTGTATACCA 14940  
 L F V L E V V Y K Y F E I Y D G G C I P  
 C L Y \* K L F I S I L K F M M V V V Y Q  
 V C I R S C L \* V F \* N L \* W W L Y T S

14941 GCATCACAAGTTATTGTTAATAATTATGACAAAAGTCTGGTTATCCATTTAATAAATTT 15000  
 A S Q V I V N N Y D K S A G Y P F N K F  
 H H K L L L I I M T K V L V I H L I N L  
 I T S Y C \* \* L \* Q K C W L S I \* \* I W

15001 GGTAAGCTAGACTTTATTATGAGGCATTATCATTTGAGGAGCAGAATGAAATTTATGCA 15060  
 G K A R L Y Y E A L S F E E Q N E I Y A  
 V K L D F I M R H Y H L R S R M K F M H  
 \* S \* T L L \* G I I I \* G A E \* N L C I

15061 TATACTAAACGTAATGTGTTGCCCACTTTAACTCAAATGAATTTAAAATATGCTATTAGT 15120  
 Y T K R N V L P T L T Q M N L K Y A I S  
 I L N V M C C P L \* L K \* I \* N M L L V  
 Y \* T \* C V A H F N S N E F K I C Y \* C

FIG. 9 CONT.

148/201

15121 GCTAAGAATAGAGCTCGTACTGTTGCAGGTGTTTCCATTCTTAGTACTATGACAGGTCGA 15180  
 A K N R A R T V A G V S I L S T M T G R  
 . L R I E L V L L Q V F P F L V L \* Q V E  
 \* E \* S S Y C C R C F H S \* Y Y D R S N

15181 ATGTTTCATCAAAAATGTTTGAAGAGTATAGCAGCTACTCGTGGTGTTCCCTGTTGTTATA 15240  
 M F H Q K C L K S I A A T R G V P V V I  
 C F I K N V \* R V \* Q L L V V F L L L \*  
 V S S K M F E E Y S S Y S W C S C C Y R

15241 GGAACTACTAAATTTTATGGTGGCTGGGATGATATGTTACGCCATCTTATAAAGGATGTT 15300  
 G T T K F Y G G W D D M L R H L I K D V  
 E L L N F M V A G M I C Y A I L \* R M L  
 N Y \* I L W W L G \* Y V T P S Y K G C \*

15301 GACAACCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGTGCCATGCCAAATATT 15360  
 D N P V L M G W D Y P K C D R A M P N I  
 T T L F L W V G I I L N V I V P C Q I F  
 Q P C S Y G L G L S \* M \* S C H A K Y F

15361 TTGCGTATTGTTAGTAGTTTAGTTTTGGCTCGTAAACATGAATTTTGTGTTTCACATGGT 15420  
 L R I V S S L V L A R K H E F C C S H G  
 C V L L V V \* F W L V N M N F V V H M V  
 A Y C \* \* F S F G S \* T \* I L L F T W \*

15421 GATAGATTCTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGTGAATAGTTATGTGT 15480  
 D R F Y R L A N E C A Q V L S E I V M C  
 I D S I A L R M N V L K F \* V K \* L C V  
 \* I L S P C E \* M C S S F E \* N S Y V W

15481 GGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGATGCAACCACTGCTTTT 15540  
 G G C Y Y V K P G G T S S G D A T T A F  
 A V A I M L S L V V L A V V M Q P L L L  
 R L L L C \* A W W Y \* Q W \* C N H C F C

15541 GCTAACTCTGTTTTTAATATATGTCAAGCTGTTACTGCTAATGTTTGTCTCTTATGGCT 15600  
 A N S V F N I C Q A V T A N V C S L M A  
 L T L F L I Y V K L L L L M F V L L W L  
 \* L C F \* Y M S S C Y C \* C L F S Y G L

15601 TGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAAAAACGCTTATACTCT 15660  
 C N G H K I E D L S I R N L Q K R L Y S  
 V M A I R L K I \* V Y A I Y K N A Y T L  
 \* W P \* D \* R F K Y T Q F T K T L I L \*

FIG. 9 CONT.

## 149/201

15661 AATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAGTATTATGAATTTTTA 15720  
 N V Y R T D Y V D Y T F V N E Y Y E F L  
 M F I V Q I M L I I H L L M S I M N F Y  
 C L S Y R L C \* L Y I C \* \* V L \* I F M

15721 TGTAAGCATTITTAGTATGATGATTTTGAGTGATGATGGTGTGTTGTTTATAACTCTGAT 15780  
 C K H F S M M I L S D D G V V C Y N S D  
 V S I L V \* \* F \* V M M V L F V I T L I  
 \* A F \* Y D D F E \* \* W C C L L \* L \* L

15781 TATGCTAGTAAGGGTTATATAGCCAATATAAGTGTTTTCAACAAGTTTTGTACTATCAG 15840  
 Y A S K G Y I A N I S V F Q Q V L Y Y Q  
 M L V R V I \* P I \* V F F N K F C T I R  
 C \* \* G L Y S Q Y K C F S T S F V L S E

15841 AATAACGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGATATTACTAATGGTCCT 15900  
 N N V F M S E S K C W V E N D I T N G P  
 I T F L C L N L N V G L K M I L L M V L  
 \* R F Y V \* I \* M L G \* K \* Y Y \* W S S

15901 CATGAATTCTGTTCCACAACATACTATGTTGGTTAAGATAGATGGTGACTATGTTTATCTA 15960  
 H E F C S Q H T M L V K I D G D Y V Y L  
 M N S V H N I L C W L R \* M V T M F I Y  
 \* I L F T T Y Y V G \* D R W \* L C L S T

15961 CCCTATCCAGACCCTTCTAGAATTTTAGGAGCTGGTTGTTTTGTTGATGATTTATGAAG 16020  
 P Y P D P S R I L G A G C F V D D L L K  
 P I Q T L L E F \* E L V V L L M I Y \* R  
 L S R P F \* N F R S W L F C \* \* F I E D

16021 ACTGACAGTGTCTTTTTGATAGAGCGCTTTGTAAGTCTAGCTATAGATGCTTACCCTTTA 16080  
 T D S V L L I E R F V S L A I D A Y P L  
 L T V F F \* \* S A L \* V \* L \* M L T L \*  
 \* Q C S F D R A L C K S S Y R C L P F S

16081 GTACACCATGAAAATGAAGAATACCAAAAAGTTTTTCGTGTATATTTAGAATATATAAAA 16140  
 V H H E N E E Y Q K V F R V Y L E Y I K  
 Y T M K M K N T K K F F V Y I \* N I \* K  
 T P \* K \* R I P K S F S C I F R I Y K K

16141 AAACATATAATGATCTTGGAATCAGATCTTAGATAGTTATAGTGTATTTTAAAGTACT 16200  
 K L Y N D L G N Q I L D S Y S V I L S T  
 N Y I M I L V I R S \* I V I V L F \* V L  
 T I \* \* S W \* S D L R \* L \* C Y F K Y L

FIG. 9 CONT.

## 150/201

16201 TGTGATGGTTTAAAGTTCACCTGATGAATCATTTTATAAGAATATGTATTTAAAAAGTGCC 16260  
 C D G L K F T D E S F Y K N M Y L K S A  
 V M V \* S S L M N H F I R I C I \* K V P  
 \* W F K V H \* \* I I L \* E Y V F K K C R

16261 GTGATGCAGAGTGTAGGTGCATGTGTTGTTTTCATCACAGACGCTTTGCGTTGTGGC 16320  
 V M Q S V G A C V V C S S Q T S L R C G  
 \* C R V \* V H V L F V H H R R L C V V A  
 D A E C R C M C C L F I T D V F A L W Q

16321 AGTTGTATACGGAAGCCTTTGTTGTGTTGTAATGTTGCTATGATCATGTTATGGCAACC 16380  
 S C I R K P L L C C K C C Y D H V M A T  
 V V Y G S L C C V V N V A M I M L W Q P  
 L Y T E A F V V L \* M L L \* S C Y G N Q

16381 AATCATAAATATGTTTTGAGTGTTCACCTTATGTGTGTAATGCACCTAACTGTGATGTG 16440  
 N H K Y V L S V S P Y V C N A P N C D V  
 I I N M F \* V F H L M C V M H L T V M \*  
 S \* I C F E C F T L C V \* C T \* L \* C E

16441 AGTGATGCACCAAATTATATTTGGGTGGTATGTCTTATTATTGTGAAAACCATAAACCT 16500  
 S D V T K L Y L G G M S Y Y C E N H K P  
 V M S P N Y I W V V C L I I V K T I N L  
 \* C H Q I I F G W Y V L L L \* K P \* T S

16501 CATTATTCATTTAAGTTAGTTATGAATGGTATGGTCTTTGGTTTGTATAACAATCTTGT 16560  
 H Y S F K L V M N G M V F G L Y K Q S C  
 I I H L S \* L \* M V W S L V C I N N L V  
 L F I \* V S Y E W Y G L W F V \* T I L Y

16561 ACAGTTCACCTTATATAGATGATTTTAAATAAGATAGCTAGTTGTAATGGACAGAAGTT 16620  
 T G S P Y I D D F N K I A S C K W T E V  
 Q V H L I \* M I L I R \* L V V N G Q K L  
 R F T L Y R \* F \* \* D S \* L \* M D R S \*

16621 GATGATTATGTTCTGGCAAATGAGTGTATTGAACGTTTAAAGTTATTTGCTGCAGAAACT 16680  
 D D Y V L A N E C I E R L K L F A A E T  
 M I M F W Q M S V L N V \* S Y L L Q K L  
 \* L C S G K \* V Y \* T F K V I C C R N S

16681 CAAAAGGCAACTGAAGAAGCTTTTAAACAAAGCTATGCTTCTGCTACTATTCAAGAGATT 16740  
 Q K A T E E A F K Q S Y A S A T I Q E I  
 K R Q L K K L L N K A M L L L L F K R L  
 K G N \* R S F \* T K L C F C Y Y S R D C

FIG. 9 CONT.

## 151/201

16741 GTTAGTGATAGAGAAATTATTTTGTGTTGGGAGACAGGTAAAGTTAAACCACCACTTAAT 16800  
V S D R E I I L C W E T G K V K P P L N  
L V I E K L F C V G R Q V K L N H H L I  
\* \* \* R N Y F V L G D R \* S \* T T T \* \*

16801 AAAAATTATGTTTTCACTGGCTATCATTTTACTAGTACTGGTAAGACAGTTTTAGGTGAG 16860  
K N Y V F T G Y H F T S T G K T V L G E  
K I M F S L A I I L L V L V R Q F \* V S  
K L C F H W L S F Y \* Y W \* D S F R \* V

16861 TATGTTTTGATAAAAGTGAATTAACATAATGGTGTATTATATCGCGCTACAACACTTAC 16920  
Y V F D K S E L T N G V Y Y R A T T T Y  
M F L I K V N \* L M V F I I A L Q L L T  
C F \* \* K \* I N \* W C L L S R Y N Y L Q

16921 AAACCTTCTATAGGTGATGTTTTGTCTTAACATCACATTCTGTAGCTAATCTAAGTGCA 16980  
K L S I G D V F V L T S H S V A N L S A  
N F L \* V M F L S \* H H I L \* L I \* V H  
T F Y R \* C F C L N I T F C S \* S K C T

16981 CCTACACTTGTTCCACAAGAGAAGTATGCTAGTATAAGATTTTCTAGTGTATTATAGCGTT 17040  
P T L V P Q E N Y A S I R F S S V Y S V  
L H L F H K R T M L V \* D F L V F I A F  
Y T C S T R E L C \* Y K I F \* C L \* R S

17041 CCTTGCTGTTTCAAACATAATGTTGCTAACTATCAGCACATTGGAATGAAACGTTATTGC 17100  
P L L F Q T N V A N Y Q H I G M K R Y C  
L C C F K L M L L T I S T L E \* N V I A  
F A V S N \* C C \* L S A H W N E T L L H

17101 ACTGTGCAAGGTCCTCCTGGTACGGGCAAGTCTCACCTTGCTATAGGTTAGCTGTTTAT 17160  
T V Q G P P G T G K S H L A I G L A V Y  
L C K V L L V R A S L T L L \* V \* L F I  
C A R S S W Y G Q V S P C Y R F S C L L

17161 TACTATACAGCACGTGTAGTTTATACTGCTGCTAGTCATGCTGCTGTAGATGCATTGTGT 17220  
Y Y T A R V V Y T A A S H A A V D A L C  
F I Q H V \* F I L L L V M L L \* M H C V  
L Y S T C S L Y C C \* S C C C R C I V \*

17221 GAAAAAGCTTATAAGTTTTTAAATATTAATGACTGTACACGCATTATACCTGCTAAAGTT 17280  
E K A Y K F L N I N D C T R I I P A K V  
K K L I S F \* I L M T V H A L Y L L K F  
K S L \* V F K Y \* \* L Y T H Y T C \* S S

FIG. 9 CONT.

152/201

17281 CGTGTAGATTGTTATGATAAGTTTAAATTAATGATACTACTTGTAAAGTATGTTTTTACT 17340  
R V D C Y D K F K I N D T T C K Y V F T  
V \* I V M I S L K L M I L L V S M F L L  
C R L L \* \* V \* N \* \* Y Y L \* V C F Y Y

17341 ACAATAAATGCATTACCAGAGTTAGTCACAGATATTGTTGTTGTTGATGAAGTTAGTATG 17400  
T I N A L P E L V T D I V V V D E V S M  
Q \* M H Y Q S \* S Q I L L L L M K L V C  
N K C I T R V S H R Y C C C \* \* S \* Y A

17401 CTTACTAATTATGAATTGTCTGTTATAAATGCTCGTGTAAAGCTAAACATTATGTATAT 17460  
L T N Y E L S V I N A R V K A K H Y V Y  
L L I M N C L L \* M L V L K L N I M Y I  
Y \* L \* I V C Y K C S C \* S \* T L C I Y

17461 ATTGGAGATCCTGCTCAGTTACCTGCACCACGTGTGCTATTGAGTAAGGGTTCTTTAGAA 17520  
I G D P A Q L P A P R V L L S K G S L E  
L E I L L S Y L H H V C Y \* V R V L \* N  
W R S C S V T C T T C A I E \* G F F R T

17521 CCTAGGCATTTTAATTCCTACTAAAATAATGTGCTGTTTAGGTCCTGATATTTTTTTTG 17580  
P R H F N S I T K I M C C L G P D I F L  
L G I L I L L L K \* C A V \* V L I F F W  
\* A F \* F Y Y \* N N V L F R S \* Y F F G

17581 GGAAATGTTATAGATGTCCTAAAGAAATGTAGAAACTGTTTCAGCATTGGTTTATGAT 17640  
G N C Y R C P K E I V E T V S A L V Y D  
E I V I D V L K K L \* K L F Q H W F M I  
K L L \* M S \* R N C R N C F S I G L \* \*

17641 AATAAACTTAAGGCTAAGAATGATAATAGTTCATTATGCTTTAAAGTATATTTTAAGGGA 17700  
N K L K A K N D N S S L C F K V Y F K G  
I N L R L R M I I V H Y A L K Y I L R D  
\* T \* G \* E \* \* \* F I M L \* S I F \* G T

17701 CAGACAACACATGAGAGTTCAAGTGCTGTAAATATTCAACAAATATATTTAATTAGTAAA 17760  
Q T T H E S S S A V N I Q Q I Y L I S K  
R Q H M R V Q V L \* I F N K Y I \* L V N  
D N T \* E F K C C K Y S T N I F N \* \* I

17761 TTTTGAAGCTAATCCAGTTTGAATAGTGCTGTTTTTATTAGTCCTTATAATAGTCAG 17820  
F L K A N P V W N S A V F I S P Y N S Q  
F \* K L I Q F G I V L F L L V L I I V R  
F E S \* S S L E \* C C F Y \* S L \* \* S E

FIG. 9 CONT.

## 153/201

17821 AACTATGTTGCTAAGCGTATTTTAGGGTGTTCAAACACAAACTGTTGATTCTGCTCAAGGT 17880  
N Y V A K R I L G V Q T Q T V D S A Q G  
T M L L S V F \* V F K H K L L I L L K V  
L C C \* A Y F R C S N T N C \* F C S R F

17881 TCTGAATATGATTATGTTATATATATTCACAAACAGCAGAAACAGCTCATTCTATTAATGTT 17940  
S E Y D Y V I Y S Q T A E T A H S I N V  
L N M I M L Y I H K Q Q K Q L I L L M L  
\* I \* L C Y I F T N S R N S S F Y \* C \*

17941 AATCGATTTAATGTTGCCATAACTAGAGCCAAGAAGGTATTTTCTGTGTTATGAGTAAT 18000  
N R F N V A I T R A K K G I F C V M S N  
I D L M L P \* L E P R R V F S V L \* V I  
S I \* C C H N \* S Q E G Y F L C Y E \* Y

18001 ATGCAATTATTGAATCTCTTAATTTTATTACTTTACCTTTAGATAAAAATTCAGAATCAA 18060  
M Q L F E S L N F I T L P L D K I Q N Q  
C N Y L N L L I L L L Y L \* I K F R I K  
A I I \* I S \* F Y Y F T F R \* N S E S N

18061 ACTTATCTCGTTTGCATTGTACTIONLFTKDCSKNFLL 18120  
T L S R L H C T T N L F K D C S K N F L  
L Y L V C I V L L I F L K I V V K I F \*  
F I S F A L Y Y \* S F \* R L \* \* K F F R

18121 GGTACCACCCAGCTCATGCTCCTTATTTTTATCAGTTGATGATAAATATAAGGTC AAC 18180  
G Y H P A H A P S F L S V D D K Y K V N  
V T T Q L M L L H F Y Q L M I N I R S T  
L P P S S C S F I F I S \* \* \* I \* G Q R

18181 GAAGATTTGGCTGTTTAAACATTTGTGAACCTGTTTAAACATATCTCGTTTAATA 18240  
E D L A V C L N I C E P V L T Y S R L I  
K I W L F V \* T F V N L F \* H I L V \* Y  
R F G C L F K H L \* T C F N I F S F N I

18241 TCTCTCATGGGGTTAAATTGGATTGACTCTTGATGGTATTCTAAATTTTTTATTACT 18300  
S L M G F K L D L T L D G Y S K F F I T  
L S W G L N W I \* L L M V I L N F L L L  
S H G V \* I G F D S \* W L F \* I F Y Y \*

18301 AAAGACGAAGCTATTAACGTGTAGAGGTTGGGTTGGTTTTGATGTAGAAGGAGCCCAT 18360  
K D E A I K R V R G W V G F D V E G A H  
K T K L L N V L E V G L V L M \* K E P M  
R R S Y \* T C \* R L G W F \* C R R S P C

FIG. 9 CONT.

## 154/201

18361 GCTACGCGTGACAACATTGGAACAACTTTCCATTGCAAATAGGTTTTTCAACTGGTGT 18420  
A T R D N I G T N F P L Q I G F S T G V  
L R V T T L E Q T F H C K \* V F Q L V L  
Y A \* Q H W N K L S I A N R F F N W C \*

18421 GATTTTGTAGTTGAAGCTACTGGCTTATTTGCTGAGAGAGATTGTTATATATTTAAAGA 18480  
D F V V E A T G L F A E R D C Y I F K R  
I L \* L K L L A Y L L R E I V I Y L K E  
F C S \* S Y W L I C \* E R L L Y I \* K N

18481 ACTGTTGCTAAAGCTCCTCCTGGTGATAACTTTAAACATTTAATACCCCTTATGTCGAAA 18540  
T V A K A P P G D N F K H L I P L M S K  
L L L K L L L V I T L N I \* Y P L C R K  
C C \* S S S W \* \* L \* T F N T P Y V E R

18541 GGTCAAAAGTGGGATGTTGTTAGAATCAGAATTGTTCAAATGTTGTCTGATTATCTTTTG 18600  
G Q K W D V V R I R I V Q M L S D Y L L  
V K S G M L L E S E L F K C C L I I F W  
S K V G C C \* N Q N C S N V V \* L S F G

18601 GATCTTTCTGATAGTGTAGTATTTATTA TACTTGGTCTGCCAGTTTGA ACTTACGTGTTTA 18660  
D L S D S V V F I T W S A S F E L T C L  
I F L I V \* Y L L L G L P V L N L R V \*  
S F \* \* C S I Y Y L V C Q F \* T Y V F K

18661 AGGTATTTTGCTAAATTAGGTAGAGAGCTCAATTGTGATGTGTGTCCTAATCGTGCAACA 18720  
R Y F A K L G R E L N C D V C P N R A T  
G I L L N \* V E S S I V M C V L I V Q H  
V F C \* I R \* R A Q L \* C V S \* S C N M

18721 TGCTATAATTCTAGA ACTGGTATTACGGTTGTTGGCGCCATAGTTATACTTGTGATTAT 18780  
C Y N S R T G Y Y G C W R H S Y T C D Y  
A I I L E L V I T V V G A I V I L V I M  
L \* F \* N W L L R L L A P \* L Y L \* L C

18781 GTGTATAACCCGCTTATTGTAGATATACAACAGTGGGGTTACACAGGTCTTTAACTAGT 18840  
V Y N P L I V D I Q Q W G Y T G S L T S  
C I T R L L \* I Y N S G V T Q V L \* L V  
V \* P A Y C R Y T T V G L H R F F N \* \*

18841 AATCATGATATAATTTGTAATGTACATAAAGGTGCACATGTTGCATCATCTGATGCAATT 18900  
N H D I I C N V H K G A H V A S S D A I  
I M I \* F V M Y I K V H M L H H L M Q L  
S \* Y N L \* C T \* R C T C C I I \* C N Y

FIG. 9 CONT.



## 155/201

18901 ATGACTCGGTGTTTAGCAATCTATGATTGTTTTGTAAATCTGTTAATTGGAATTTAGAG 18960  
M T R C L A I Y D C F C K S V N W N L E  
\* L G V \* Q S M I V F V N L L I G I \* S  
D S V F S N L \* L F L \* I C \* L E F R V

18961 TATCCAATAATTTCCAATGAGGTTAGTATAAATACATCTTGTAGGTTATTGCAGCGTGT 19020  
Y P I I S N E V S I N T S C R L L Q R V  
I Q \* F P M R L V \* I H L V G Y C S V L  
S N N F Q \* G \* Y K Y I L \* V I A A C Y

19021 ATGCTTAAAGCTGCCATGCTATGTAATAGATACAATTTATGTTATGACATTGGCAATCCT 19080  
M L K A A M L C N R Y N L C Y D I G N P  
C L K L P C Y V I D T I Y V M T L A I L  
A \* S C H A M \* \* I Q F M L \* H W Q S \*

19081 AAAGGTATTGCTTGTGTCAAAGATTATGAATTTAAATCTATGATGCTTCTCCTGTTGTC 19140  
K G I A C V K D Y E F K F Y D A S P V V  
K V L L V S K I M N L N S M M L L L L S  
R Y C L C Q R L \* I \* I L \* C F S C C Q

19141 AAGTCTGTTAAACAGTTGTTTTATGTTTATGATGTTTCATAAAGATAATTTAAGGATGGT 19200  
K S V K Q L F Y V Y D V H K D N F K D G  
S L L N S C F M F M M F I K I I L R M V  
V C \* T V V L C L \* C S \* R \* F \* G W F

19201 TTATGTATGTTTTGGAATTGTAATGTTGATAAATATCCATCTAATTC AATTGTTTGTAGA 19260  
L C M F W N C N V D K Y P S N S I V C R  
Y V C F G I V M L I N I H L I Q L F V D  
M Y V L E L \* C \* \* I S I \* F N C L \* I

19261 TTTGATACTCGGTATTAATAAATAAACCTCCCTGGATGTAATGGTGGTAGTTTGTAT 19320  
F D T R V L N K L N L P G C N G G S L Y  
L I L G Y \* I N \* T S L D V M V V V C M  
\* Y S G I K \* I K P P W M \* W W \* F V C

19321 GTTAATAAACATGCATTTACTACTAATCCTTTTACCAGAACGGTCTTTGAAAATCTTAAA 19380  
V N K H A F H T N P F T R T V F E N L K  
L I N M H F I L I L L P E R S L K I L N  
\* \* T C I S Y \* S F Y Q N G L \* K S \* T

19381 CCTATGCCATTTTTTACTATTTCAGATACTCCTTGTGTGTATGTAGATGGTTTGG AATCC 19440  
P M P F F Y Y S D T P C V Y V D G L E S  
L C H F F T I Q I L L V C M \* M V W N P  
Y A I F L L F R Y S L C V C R W F G I Q

## FIG. 9 CONT.

## 156/201

19441 AAACAAGTTGATTATGTGCCTTTAAGAAGCGCTACTTGTATCACACCGATGTAATTTAGGT 19500  
 K Q V D Y V P L R S A T C I T R C N L G  
 N K L I M C L \* E A L L V S H D V I \* V  
 T S \* L C A F K K R Y L Y H T M \* F R W

19501 GGTGCTGTTTGTTCCTAAGCATGCTGAAGATTATTGTAATATCTTGAGTCTTATAATGTA 19560  
 G A V C S K H A E D Y C K Y L E S Y N V  
 V L F V L S M L K I I V N I L S L I M \*  
 C C L F \* A C \* R L L \* I S \* V L \* C S

19561 GCTACTACAGCAGGCTTTACTTTTTGGGTTTATAAGACTTTTGATTTTTATAATTTATGG 19620  
 A T T A G F T F W V Y K T F D F Y N L W  
 L L Q Q A L L F G F I R L L I F I I Y G  
 Y Y S R L Y F L G L \* D F \* F L \* F M E

19621 AATACTTTCACTATGTTGCAGAGCTTAGAAAATGTAATATATAATTTGGTTAATGCTGGT 19680  
 N T F T M L Q S L E N V I Y N L V N A G  
 I L S L C C R A \* K M \* Y I I W L M L V  
 Y F H Y V A E L R K C N I \* F G \* C W S

19681 CATTATGATGGACGTATAGGTGAATTGCCTTGTGCTATTATGAATGACAAAGTTGTTGTT 19740  
 H Y D G R I G E L P C A I M N D K V V V  
 I M M D V \* V N C L V L L \* M T K L L L  
 L \* W T Y R \* I A L C Y Y E \* Q S C C \*

19741 AAGATTAATAATGTAGATACTGTTATTTTTAAAATAATACATCACTTCCTACTAATATA 19800  
 K I N N V D T V I F K N N T S L P T N I  
 R L I M \* I L L F L K I I H H F L L I \*  
 D \* \* C R Y C Y F \* K \* Y I T S Y \* Y S

19801 GCTGTTGAATTATTTACAAAACGTAGTATTGCCATCACCTGAACTTAAGATTCTTAGA 19860  
 A V E L F T K R S I R H H P E L K I L R  
 L L N Y L Q N V V F A I T L N L R F L E  
 C \* I I Y K T \* Y S P S P \* T \* D S \* K

19861 AATTTGAATATTGATATTTGTTGGAAGCATGTCCTTTGGGATTATGTTAAAGATAGTTTG 19920  
 N L N I D I C W K H V L W D Y V K D S L  
 I \* I L I F V G S M S F G I M L K I V C  
 F E Y \* Y L L E A C P L G L C \* R \* F V

19921 TTTTGTAGTTCTACCTATGGTGTCTGCAAATACACAGATTTAAATTTTATTGAAAATTTG 19980  
 F C S S T Y G V C K Y T D L N F I E N L  
 F V V L P M V S A N T Q I \* I L L K I \*  
 L \* F Y L W C L Q I H R F K F Y \* K F E

FIG. 9 CONT.

## 157/201

19981 AATGTACTTTTTGATGGTTCGTGACAATGGTGCTTTTAGAAGCTTTTAGAAAAGCAAGAAAT 20040  
 N V L F D G R D N G A L E A F R K A R N  
 M Y F L M V V T M V L \* K L L E K Q E M  
 C T F \* W S \* Q W C F R S F \* K S K K W

20041 GGTGTTTTTATTAGTACTGGAAAATTAAGTAGTTTGTCTATGATTAAAGGTCCGCAACGA 20100  
 G V F I S T G K L S S L S M I K G P Q R  
 V F L L V L E N \* V V C L \* L K V R N E  
 C F Y \* Y W K I K \* F V Y D \* R S A T S

20101 GCTGATTTAAATGGCGTAATTGTGGATAAAGTTGGAGAACTCAATGTTGAGTTTGGTTT 20160  
 A D L N G V I V D K V G E L N V E F W F  
 L I \* M A \* L W I K L E N S M L S F G L  
 \* F K W R N C G \* S W R T Q C \* V L V C

20161 GCTATGAGAAAAGATGGTGACGATGTTATCTTCAGCCGTGCAGACAGCCTAAGCCCAAGC 20220  
 A M R K D G D D V I F S R A D S L S P S  
 L \* E K M V T M L S S A V Q T A \* A Q A  
 Y E K R W \* R C Y L Q P C R Q P K P K P

20221 CATTACTGGAGCCCAAGGTAATCTAGGTGGTAATTGTGCAGGTAATGCCAGCGGTAAT 20280  
 H Y W S P Q G N L G G N C A G N A S G N  
 I T G A H K V I \* V V I V Q V M P A V M  
 L L E P T R \* S R W \* L C R \* C Q R \* \*

20281 GATGCTCTAGCGGTTTTACTATCTTTACTCAGAGTCGTGTATTGTCAACCTTTGAACCT 20340  
 D A L A R F T I F T Q S R V L S T F E P  
 M L \* R V L L S L L R V V Y C Q P L N L  
 C S S A F Y Y L Y S E S C I V N L \* T S

20341 CGCTCAGATTTAGAACGGGATTTTATGATATGGAGGATAGTCTGTTTATAGCCAAATAT 20400  
 R S D L E R D F I D M E D S L F I A K Y  
 A Q I \* N G I L L I W R I V C L \* P N M  
 L R F R T G F Y \* Y G G \* S V Y S Q I W

20401 GGTTTAGAAGATTATGCATTTGATCATATAGTTTATGGTAGTTTTAATTATAAAGTTATA 20460  
 G L E D Y A F D H I V Y G S F N Y K V I  
 V \* K I M H L I I \* F M V V L I I K L \*  
 F R R L C I \* S Y S L W \* F \* L \* S Y R

20461 GGAGGTTTGCACTTGCTTATAGGTTTATTTTCGTAGACTAAAAAATCTAATTTGGTAATT 20520  
 G G L H L L I G L F R R L K K S N L V I  
 E V C T C L \* V Y F V D \* K N L I W \* F  
 R F A L A Y R F I S \* T K K I \* F G N S

FIG. 9 CONT.

158/201

20521 CAAGAGTTTTGTCAGTATGATTCTAGTATTCATTCATATTTTCATTACTGATCAAGAGTGT 20580  
 Q E F L Q Y D S S I H S Y F I T D Q E C  
 K S F C S M I L V F I H I S L L I K S V  
 R V F A V \* F \* Y S F I F H Y \* S R V W

20581 GGTAGTAGTAAGAGTGTGTTGTACAGTTATTGATTTATTATTAGATGACTTTGTTGTTATT 20640  
 G S S K S V C T V I D L L L D D F V V I  
 V V V R V F V Q L L I Y Y \* M T L L L L  
 \* \* \* E C L Y S Y \* F I I R \* L C C Y C

20641 GTTAAGTCATTAATTTGAATTGTGTTAGTAAAGTTGTTAATATTAATGTTGACTTTAAG 20700  
 V K S L N L N C V S K V V N I N V D F K  
 L S H \* I \* I V L V K L L I L M L T L R  
 \* V I K F E L C \* \* S C \* Y \* C \* L \* G

20701 GACTTTC AATTTATGTTGTGGTGAATGATAATAAAATTATGACTTTTTATCCTAAAATG 20760  
 D F Q F M L W C N D N K I M T F Y P K M  
 T F N L C C G V M I I K L \* L F I L K C  
 L S I Y V V V \* \* \* \* N Y D F L S \* N A

20761 CAAGCTACTAGTACTGGAAACCTGGTTATTCTATGCCTGTTTATATAAGTATTTGAAT 20820  
 Q A T S D W K P G Y S M P V L Y K Y L N  
 K L L V T G N L V I L C L F Y I S I \* M  
 S Y \* \* L E T W L F Y A C F I \* V F E C

20821 GTCCATTAGAGAGAGTTTCTTTATGGAATTATGGTAAAGCTATTAATTTACCAACAGGT 20880  
 V P L E R V S L W N Y G K A I N L P T G  
 F H \* R E F L Y G I M V K L L I Y Q Q V  
 S I R E S F F M E L W \* S Y \* F T N R L

20881 TGTATGATGAATGTTGCTAAGTATACTCAATTATGTCAGTATTTAAATACTACAACATTA 20940  
 C M M N V A K Y T Q L C Q Y L N T T T L  
 V \* \* M L L S I L N Y V S I \* I L Q H \*  
 Y D E C C \* V Y S I M S V F K Y Y N I S

20941 GCTGTTCTGTTAATATGCGTGTCTTACACTTAGGTGCAGGATCTGATAAAGAAGTAGCC 21000  
 A V P V N M R V L H L G A G S D K E V A  
 L F L L I C V S Y T \* V Q D L I K K \* P  
 C S C \* Y A C L T L R C R I \* \* R S S P

21001 CCTGGTTCTGCTGTTTAAAGACAGTGGTTACCATCTGCTAGTATTCTGTAGATAATGAT 21060  
 P G S A V L R Q W L P S G S I L V D N D  
 L V L L F \* D S G Y H L V V F L \* I M I  
 W F C C F K T V V T I W \* Y S C R \* \* F

FIG. 9 CONT.

159/201

21061 TTAAATCCTTTTGTAGTATAGTTTAGTCACTTATTTTGGAGATTGTATGACTTTACCA 21120  
 L N P F V S D S L V T Y F G D C M T L P  
 \* I L L L V I V \* S L I L E I V \* L Y H  
 K S F C \* \* \* F S H L F W R L Y D F T I

21121 TTTGATTGTCATTGGGATCTGATAATATCTGATATGTATGATCCTCTTACTAAGAATATT 21180  
 F D C H W D L I I S D M Y D P L T K N I  
 L I V I G I \* \* Y L I C M I L L L R I L  
 \* L S L G S D N I \* Y V \* S S Y \* E Y W

21181 GGTGATTATAATGTGAGTAAGGATGGTTTCTTTACTTATATTTGTTATTTAATTCGTGAT 21240  
 G D Y N V S K D G F F T Y I C Y L I R D  
 V I I M \* V R M V S L L I F V I \* F V I  
 \* L \* C E \* G W F L Y L Y L L F N S \* \*

21241 AAATTATCTTTGGGTGGTAGTGTGCTATAAAAAATTACAGAATTTTCTTGGAAATGCTGAC 21300  
 K L S L G G S V A I K I T E F S W N A D  
 N Y L W V V V L L \* K L Q N F L G M L T  
 I I F G W \* C C Y K N Y R I F L E C \* L

21301 TTATATAAATTAATGAGTTATTTTGCATTCTGGACAGTTTTTTTGTACTAATGTAAATGCT 21360  
 L Y K L M S Y F A F W T V F C T N V N A  
 Y I N \* \* V I L H S G Q F F V L M \* M L  
 I \* I N E L F C I L D S F L Y \* C K C F

21361 TCTTCTAGTGAAGGGTTTTTAATAGGTATAAATTATTTGGGTAAGTCCTGCTTTGAAATA 21420  
 S S S E G F L I G I N Y L G K S C F E I  
 L L V K G F \* \* V \* I I W V S P A L K \*  
 F \* \* R V F N R Y K L F G \* V L L \* N R

21421 GATGGCAATGTTATGCATGCCAACTATTTGTTTTGGAGAAATAGTACAACATGGAATGCT 21480  
 D G N V M H A N Y L F W R N S T T W N G  
 M A M L C M P T I C F G E I V Q H G M V  
 W Q C Y A C Q L F V L E K \* Y N M E W W

21481 GGTGCTTATAGTTTATTTGATATGTCTAAATTTCTTTGAAATTGGCTGGCACTGCTGTA 21540  
 G A Y S L F D M S K F S L K L A G T A V  
 V L I V Y L I C L N F L \* N W L A L L \*  
 C L \* F I \* Y V \* I F F E I G W H C C S

21541 GTAAATTTAAGACCAGATCAATTAATGATTTAGTTTATTTCTTTATTGAAAGAGGTAAG 21600  
 V N L R P D Q L N D L V Y S L I E R G K  
 \* I \* D Q I N \* M I \* F I L L L K E V S  
 K F K T R S I K \* F S L F S Y \* K R \* V

FIG. 9 CONT.

## 160/201

21601 TTATTAGTGCCTGATACGCGTAAAGAAATTTTTGTGGTGATAGTCTTGTAACACTTGT 21660  
 L L V R D T R K E I F V G D S L V N T C  
 Y \* C V I R V K K F L L V I V L \* T L V  
 I S A \* Y A \* R N F C W \* \* S C K H L L

21661 TAGATCTTTCAGTTTGTAAATATTAATCTAAACTATGTTAATTATATTTTTATTTTTTA 21720  
 \* I F Q F V N I K S K L C \* L Y F Y F L  
 R S F S L L I L N L N Y V N Y I F I F \*  
 D L S V C \* Y \* I \* T M L I I F L F F N

21721 ATTTTTGTTATGGTTTTAATGAACCTTTGAATGTTGTGCTCATTAAACCATGACTGGT 21780  
 I F V M V L M N L \* M L C L I \* T M T G  
 F L L W F \* \* T F E C C V S F K P \* L V  
 F C Y G F N E P L N V V S H L N H D W F

21781 TTTTATTTGGTGATAGTCGTTCTGATTGTAACCATATTAATAATTTAAAATTTAAAAT 21840  
 F Y L V I V V L I V T I L I I \* K L K I  
 F I W \* \* S F \* L \* P Y \* \* F K N \* K L  
 L F G D S R S D C N H I N N L K I K N Y

21841 ATGGTTATTTGGATATTCACCCTAGTTTGTGTAATAATGGTAAAATTCATCTAGTGCTG 21900  
 M V I W I F T L V C V I M V K F H L V L  
 W L F G Y S P \* F V \* \* W \* N F I \* C W  
 G Y L D I H P S L C N N G K I S S S A G

21901 GTGATTCATTTTTTAAGAGTTATCATTTTACCCGTTTTATAATTACTGGCGAGGGTG 21960  
 V I L F L R V I I L P G F I I T L A R V  
 \* F Y F \* E L S F Y P V L \* L H W R G \*  
 D S I F K S Y H F T R F Y N Y T G E G D

21961 ATCAAATTATTTTTATGAGGGTGAATTTCAATCCTCATCATAGGTTAAGTGCTTCT 22020  
 I K L F F M R V L I S I L I I G L S A S  
 S N Y F L \* G C \* F Q S S S \* V \* V L L  
 Q I I F Y E G V N F N P H H R F K C F F

22021 TTAATGGTAGTAATGATGTATGGATTTTTAACAAGGTGAGGTTTTATCGTGCTTTATATT 22080  
 L M V V M M Y G F L T R \* G F I V L Y I  
 \* W \* \* \* C M D F \* Q G E V L S C F I F  
 N G S N D V W I F N K V R F Y R A L Y S

22081 CTAATATGGCTCTTTTCGCTATCTTACCTTTGTTGATATTCTTTACAATTTTTCTTTTT 22140  
 L I W L F F A I L P L L I F F T I F L F  
 \* Y G S F S L S Y L C \* Y S L Q F F F F  
 N M A L F R Y L T F V D I L Y N F S F S

FIG. 9 CONT.

161/201

22141 CTATTAAGGCTAATATTTGTAATAGTAATATTTTATCACTTAATAATCCTATTTTTATTA 22200  
 L L R L I F V I V I F Y H L I I L F L L  
 Y \* G \* Y L \* \* \* Y F I T \* \* S Y F Y \*  
 I K A N I C N S N I L S L N N P I F I S

22201 G TACTAATTATTCTAAGGACGTTTATTTCACTTTATCAGGGTGTTCTTTGTATTTAGTAC 22260  
 V L I I L R T F I S L Y Q G V L C I \* Y  
 Y \* L F \* G R L F H F I R V F F V F S T  
 T N Y S K D V Y F T L S G C S L Y L V P

22261 CTCTTTGTCTTTTTAAATCTAATTTTAGTCAGTACTATTATAATATGGATACTGGCTTTG 22320  
 L F V F L N L I L V S T I I I W I L A L  
 S L S F \* I \* F \* S V L L \* Y G Y W L C  
 L C L F K S N F S Q Y Y Y N M D T G F A

22321 CTTATGGTTATTCTAATTTTGTTCCTTCTGATTTAGATTGTACATATATTTCTCTTAAAC 22380  
 L M V I L I L F L L I \* I V H I F L L N  
 L W L F \* F C F F \* F R L Y I Y F S \* T  
 Y G Y S N F V S S D L D C T Y I S L K P

22381 CTGGTCTTATAAAAATTTTTCTACTGGTTTGTGTTTATCCATACCTACTAAAGCTCTTT 22440  
 L V L I K F F L L V L F Y P Y L L K L F  
 W F L \* N F F Y W F C F I H T Y \* S S L  
 G S Y K I F S T G F V L S I P T K A L C

22441 GCTTTAATAAATCTAAACAATTTGTACCCGTCAGGTTGTTGATTCTAGGTGGAACAATC 22500  
 A L I N L N N L Y P C R L L I L G G T I  
 L \* \* I \* T I C T R A G C \* F \* V E Q S  
 F N K S K Q F V P V Q V V D S R W N N L

22501 TTCGTGCATCGGATACTTCATTATCCGATGCATGTCAGTTGCCTTATTGTTATTTTCGCA 22560  
 F V H R I L H Y P M H V S C L I V I F A  
 S C I G Y F I I R C M S V A L L L F S Q  
 R A S D T S L S D A C Q L P Y C Y F R N

22561 ATTCTTCTGGTAATTATGTTGGCAAATATGATATTAATCATGGTGATAATGGTTTTACTT 22620  
 I L L V I M L A N M I L I M V I M V L L  
 F F W \* L C W Q I \* Y \* S W \* \* W F Y F  
 S S G N Y V G K Y D I N H G D N G F T S

22621 CTATTCATCTGGTCTTTTATATAATGTCTCTTGTATTTCTTATTATGGCTCCTTTTTGT 22680  
 L F Y L V F Y I M S L V F L I M A P F C  
 Y S I W S F I \* C L L Y F L L W L L F V  
 I L S G L L Y N V S C I S Y Y G S F L Y

FIG. 9 CONT.

162/201

22681 ATGACAATTTTACATCAATTTGGCCTCGTTTTCTTTTGGTAATTGTCCTACATCTGCTT 22740  
M T I L H Q F G L V F L L V I V L H L L  
\* Q F Y I N L A S F F F W \* L S Y I C L  
D N F T S I W P R F S F G N C P T S A Y

22741 ATATTAAATTAATTTGTTTCTATGATCCTTTGCCTATTATTTTACAAGGTATTTATTAT 22800  
I L N \* I V S M I L C L L F Y K V F Y Y  
Y \* I K L F L \* S F A Y Y F T R Y F I I  
I K L N C F Y D P L P I I L Q G I L L F

22801 TTTTAGCTTTTATGTTTATTGTGTTTTACTTTTTCTAGTTTACCATGGCTAATATTAAA 22860  
F \* L Y C L L C F Y F F \* F T M A N I K  
F S F I V Y C V F T F S S L P W L I L N  
L A L L F I V F L L F L V Y H G \* Y \* I

22861 TCTAAACATGTTTTAATTATTTTTATTTTGCCTACAACACTAGCTGTTATAGGTGATTT 22920  
S K H V F N Y F Y F A Y N T S C Y R \* F  
L N M F L I I F I L P T T L A V I G D F  
\* T C F \* L F L F C L Q H \* L L \* V I L

22921 TAATTGTAACACTCTTTTATTAATGATTATAATAAAAACCATTCGCGTATAAGCGAGGA 22980  
\* L Y \* L F Y \* \* L \* \* N H S A Y K R G  
N C T N S F I N D Y N K T I P R I S E D  
I V L T L L L M I I I K P F R V \* A R M

22981 TGTGTGATGATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTATTATTTAAA 23040  
C C \* C I S W F G H I L C S \* P C L F K  
V V D V S L G L G T Y Y V L N R V Y L N  
L L M Y L L V W A H I M F L T V F I \* I

23041 TACTACCTTGTTATTTACAGGTTATTTTCTAAATCTGGTGCTAATTTTAGAGACTTGGC 23100  
Y Y L V I Y R L F S \* I W C \* F \* R L G  
T T L L F T G Y F P K S G A N F R D L A  
L P C Y L Q V I F L N L V L I L E T W L

23101 TTTAAAGGGTCTAAATATTTGAGTACTCTCTGGTATAAACCACCTTTTCTGTCAGATTT 23160  
F K G F \* I F E Y S L V \* T T F S V R F  
L K G S K Y L S T L W Y K P P F L S D F  
\* R V L N I \* V L S G I N H L F C Q I L

23161 TAATAATGGTATTTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTA 23220  
\* \* W Y F F \* G \* E Y \* V I C \* \* Y F V  
N N G I F S K V K N T K L Y V N N T L Y  
I M V F F L R L R I L S Y M L I I L C I

FIG. 9 CONT.



163/201

23221 TAGTGAATTTAGTACTATAGTTATAGGTAGTGTTTTTGTTAATACTTCTTATACTATTGT 23280  
 \* \* I \* Y Y S Y R \* C F C \* Y F L Y Y C  
 S E F S T I V I G S V F V N T S Y T I V  
 V N L V L \* L \* V V F L L I L L I L L L

23281 TGTTCAACCTCACAATGGTATTTTGGAGATTACAGCTTGTCTAGTATACTATGTGTGAATA 23340  
 C S T S Q W Y F G D Y S L S V Y Y V \* I  
 V Q P H N G I L E I T A C Q Y T M C E Y  
 F N L T M V F W R L Q L V S I L C V N I

23341 TCCTCACACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCACATTGATTC 23400  
 S S H C L \* V \* G \* Y S \* \* I L A H \* F  
 P H T V C K S K G S I R N E S W H I D S  
 L T L F V S L R V V F V M N L G T L I L

23401 TTCGGAACCTTTATGCTTGTGTTAAGAAAAATTTTACTTATAATGTTTCTGCAGATTGGCT 23460  
 F G T F M L V \* E K F Y L \* C F C R L A  
 S E P L C L E K K N F T Y N V S A D W L  
 R N L Y A C L R K I L L I M F L Q I G C

23461 GTATTTTCATTTTATCAAGAACGTGGTGTTTTTTATGCATATTATGCAGATGTAGGTAT 23520  
 V F S F L S R T W C F L C I L C R C R Y  
 Y F H F Y Q E R G V F Y A Y Y A D V G M  
 I F I F I K N V V F F M H I M Q M \* V C

23521 GCCTACCACTTTCTTATTTAGTTTATATTTAGGTACTATTTTATCTCATTATTATGTTAT 23580  
 A Y H F L I \* F I F R Y Y F I S L L C Y  
 P T T F L F S L Y L G T I L S H Y Y V M  
 L P L S Y L V Y I \* V L F Y L I I M L C

23581 GCCTTGACTTGTAAGGCTATATCTTCAAATACTGACAATGAAACTTTAGAATATTGGGT 23640  
 A F D L \* G Y I F K Y \* Q \* N F R I L G  
 P L T C K A I S S N T D N E T L E Y W V  
 L \* L V R L Y L Q I L T M K L \* N I G L

23641 TACACCGCTATCTAGACGTCAGTATCTTCTTAATTTGATGAGCACGGTGTATTACTAA 23700  
 Y T A I \* T S V S S \* F \* \* A R C Y Y \*  
 T P L S R R Q Y L L N F D E H G V I T N  
 H R Y L D V S I F L I L M S T V L L L M

23701 TGCCGTTGATTGTTCAAGTAGTTTTCTTAGTGAGATTCAATGTAAAACCTCAATCTTTTGC 23760  
 C R \* L F K \* F S \* \* D S M \* N S I F C  
 A V D C S S S F L S E I Q C K T Q S F A  
 P L I V Q V V F L V R F N V K L N L L H

FIG. 9 CONT.

164/201

23761 ACCTAATACTGGTGTATGATTTGTCTGGTTTTACTGTAAAGCCTGTTGCAACTGTTTA 23820  
 T \* Y W C L \* F V W F Y C K A C C N C L  
 P N T G V Y D L S G F T V K P V A T V Y  
 L I L V F M I C L V L L \* S L L Q L F I

23821 TCGTCGGATTCCCTAATTTACCTGATTGTGACATTGACAACCTGGCTTAATAATGTTAGTGT 23880  
 S S D S \* F T \* L \* H \* Q L A \* \* C \* C  
 R R I P N L P D C D I D N W L N N V S V  
 V G F L I Y L I V T L T T G L I M L V Y

23881 ACCTTCACCTCTTAATTGGGAACGTAGAATTTTTCTAATTGTAACCTCAATTTAAGCAC 23940  
 T F T S \* L G T \* N F F \* L \* L Q F K H  
 P S P L N W E R R I F S N C N F N L S T  
 L H L L I G N V E F F L I V T S I \* A L

23941 TTTACTTCGTCTAGTTTCATGTTGATTCTTTTCTGTAATAATCTTGATAAATCTAAAAT 24000  
 F T S S S S C \* F F F L \* \* S \* \* I \* N  
 L L R L V H V D S F S C N N L D K S K I  
 Y F V \* F M L I L F L V I I L I N L K F

24001 TTTTGGTAGTTGCTTTAATAGTATTACTGTTGACAAGTTTGCTATACCTAATCGCAGACG 24060  
 F W \* L L \* \* Y Y C \* Q V C Y T \* S Q T  
 F G S C F N S I T V D K F A I P N R R R  
 L V V A L I V L L L T S L L Y L I A D E

24061 AGATGATTTGCAATTGGGCAGTTCTGGCTTTTGGCAATCATCTAATTACAAAATAGATAT 24120  
 R \* F A I G Q F W L F A I I \* L Q N R Y  
 D D L Q L G S S G F L Q S S N Y K I D I  
 M I C N W A V L A F C N H L I T K \* I F

24121 TTCTTCTAGTTCTTGCAATTGIATTATAGTTTACCTTTAGTTAATGTTACTATTATAATA 24180  
 F F \* F L S I V L \* F T F S \* C Y Y \* \*  
 S S S S C Q L Y Y S L P L V N V T I N N  
 L L V L V N C I I V Y L \* L M L L L I T

24181 CTTTAATCCATCTTCTTGAATAGGAGGTATGGTTTTGGTAGTTTTAATGTGTCTTCTTA 24240  
 L \* S I F L E \* E V W F W \* F \* C V F L  
 F N P S S W N R R Y G F G S F N V S S Y  
 L I H L L G I G G M V L V V L M C L L M

24241 TGACGTTGTTTATTCTGATCATTGTTTTCTGTTAACAGCGACTTTTGCCCTTGTGCAGA 24300  
 \* R C L F \* S L F F C \* Q R L L P L C R  
 D V V Y S D H C F S V N S D F C P C A D  
 T L F I L I I V F L L T A T F A L V Q I

FIG. 9 CONT.

165/201

24301 TCCGTCGTGTGTTAATTCTTGTGTTAAATCTAAGCCTCTTCTGCCATTTGCTCCTGCTGG 24360  
 S V C C \* F L C \* I \* A S F C H L S C W  
 P S V V N S C V K S K P L S A I C P A G  
 R L L L I L V L N L S L F L P F V L L V

24361 TACTAAATATCGTCATTGCGACTTGGATACTACTCTTTATGTTAATAACTGGGTAGATG 24420  
 Y \* I S S L R L G Y Y S L C \* \* L V \* M  
 T K Y R H C D L D T T L Y V N N W C R C  
 L N I V I A T W I L L F M L I T G V D V

24421 TTCTGTCTACCTGACCCCATTTCTACTTATTCTCCTAACACATGTCCTCAAAAGAAGGT 24480  
 F L S T \* P H F Y L F S \* H M S S K E G  
 S C L P D P I S T Y S P N T C P Q K K V  
 L V Y L T P F L L I L L T H V L K R R S

24481 CGTTGTGGTATAGGTGAACATTGTCCAGGTCTTGGTATTAATGAGGAAAAATGTGGTAC 24540  
 R C W Y R \* T L S R S W Y \* \* G K M W Y  
 V V G I G E H C P G L G I N E E K C G T  
 L L V \* V N I V Q V L V L M R K N V V H

24541 ACAATTAATCATAGTTCCTGTCTCTGTAGTCTGATGCCTTTTTGGGTTGGTCTTTTGA 24600  
 T I K S \* F L F L \* S \* C L F G L V F \*  
 Q L N H S S C S C S P D A F L G W S F D  
 N \* I I V P V L V V L M P F W V G L L I

24601 TAGTTGTATTAGTAATAATCGTTGCAATATTTTTCTAATTTATTTTAAATGAATTAA 24660  
 \* L Y \* \* \* S L Q Y F F \* F Y F \* W N \*  
 S C I S N N R C N I F S N F I F N G I N  
 V V L V I I V A I F F L I L F L M E L I

24661 TAGTGGCACCCTTGTCTAATGATTGTTATATTCTAACACTGAAGTTTCTACTGGTGT 24720  
 \* W H H L F \* \* F V I F \* H \* S F Y W C  
 S G T T C S N D L L Y S N T E V S T G V  
 V A P L V L M I C Y I L T L K F L L V F

24721 TTGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTTAAAGAAGTTTCTGC 24780  
 L C \* L \* S L W H H R P R Y F \* R S F C  
 C V N Y D L Y G I T G Q G I F K E V S A  
 V L I M I F M A S Q A K V F L K K F L R

24781 GGCTTATTATAATAATTGGCAGAATCTTTTGTATGATTCTAATGGTAATATTATTGGTTT 24840  
 G L L \* \* L A E S F V \* F \* W \* Y Y W F  
 A Y Y N N W Q N L L Y D S N G N I I G F  
 L I I I I G R I F C M I L M V I L L V L

FIG. 9 CONT.

166/201

24841 TAAAGATTTTTGACTAATAAACTTACACTATACTTCCTTGTATTCTGGTAGAGTGTC 24900  
 \* R F F D \* \* N L H Y T S L L F W \* S V  
 K D F L T N K T Y T I L P C Y S G R V S  
 K I F \* L I K L T L Y F L V I L V E C L

24901 TGCTGCATTTTATCAAATTCCTTCCACCAGCTTTGCTTTATCGTAATTTAAAGTG TAG 24960  
 C C I L S K F F F T S F A L S \* F K V \*  
 A A F Y Q N S S S P A L L Y R N L K C S  
 L H F I K I L L H Q L C F I V I \* S V V

24961 TTATGTTTTGAATAATATTTCTTTTATCTCACAACCATTTTATTTGATAGTTATCTTGG 25020  
 L C F E \* Y F F Y L T T I L F \* \* L S W  
 Y V L N N I S F I S Q P F Y F D S Y L G  
 M F \* I I F L L S H N H F I L I V I L V

25021 TTGTGTTTTGAATGCTGTTAATTTAACTAGCTATTCTGTATCCTCTTGTGATTTGCCGAT 25080  
 L C F E C C \* F N \* L F C I L L \* F A Y  
 C V L N A V N L T S Y S V S S C D L R M  
 V F \* M L L I \* L A I L Y P L V I C V W

25081 GGGTAGTGGGTTTTGTATTGATTATGCTTTACCTCTTCTCGGCGTAAGCGTAGAGGTAT 25140  
 G \* W V L Y \* L C F T L F S A \* A \* R Y  
 G S G F C I D Y A L P S S R R K R R G I  
 V V G F V L I M L Y P L L G V S V E V F

25141 TTCTTCTCCTTATCGCTTTGTAACCTTTGAACCTTTAATGTTAGTTTTGTTAACGATAG 25200  
 F F S L S L C N F \* T L \* C \* F C \* R \*  
 S S P Y R F V T F E P F N V S F V N D S  
 L L L I A L \* L L N P L M L V L L T I V

25201 TGTTGAAACTGTTGGTGGTTTTATTGAGATTCAGATTCCTACTAACTTTACCATAGCTGG 25260  
 C \* N C W W F I \* D S D S Y \* L Y H S W  
 V E T V G G L F E I Q I P T N F T I A G  
 L K L L V V Y L R F R F L L T L P \* L V

25261 TCATGAAGAATTTATTCAGACTAGTTCTCCTAAAGTTACTATTGATTGTTTCAGCTTTTGT 25320  
 S \* R I Y S D \* F S \* S Y Y \* L F S F C  
 H E E F I Q T S S P K V T I D C S A F V  
 M K N L F R L V L L K L L L I V Q L L F

25321 TTGCTCTAATTATGCTGCTTGTGTCATGATTTATTGTCGGAATATGGCACTTTTTCGATAA 25380  
 L L \* L C C L S \* F I V G I W H F L R \*  
 C S N Y A A C H D L L S E Y G T F C D N  
 A L I M L L V M I Y C R N M A L F A I I

FIG. 9 CONT.

167/201

25381 TATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTGCAGGTTGC 25440  
 Y \* \* Y F K \* S Q \* F T \* Y Y S V A G C  
 I N S I L N E V N D L L D I T Q L Q V A  
 L I V F \* M K S M I Y L I L L S C R L L

25441 TAATGCTTTAATGCAAGGTGTACTTACTTAGTTCTAATCTTAATACTAATCTACTACTCTGA 25500  
 \* C F N A R C Y T \* F \* S \* Y \* S T L \*  
 N A L M Q G V T L S S N L N T N L H S D  
 M L \* C K V L H L V L I L I L I Y T L M

25501 TGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTACAAATGTGGTTCTTC 25560  
 C \* \* Y R F \* I S S R L F R F T M W F F  
 V D N I D F K S L L G C L G S Q C G S S  
 L I I \* I L N L F \* V V \* V H N V V L R

25561 GTCTAGATCTTTGTTAGAGGATTTATTATTCAACAAGGTCAAACCTTTCAGATGTAGGTTT 25620  
 V \* I F V R G F I I Q Q G Q T F R C R F  
 S R S L L E D L L F N K V K L S D V G F  
 L D L C \* R I Y Y S T R S N F Q M \* V L

25621 TGTTGAAGCTTATAATAATTGCACTGGTGGTAGTGAATTAGAGATCTTCTCTGTGTGCA 25680  
 C \* S L \* \* L H W W \* \* N \* R S S L C A  
 V E A Y N N C T G G S E I R D L L C V Q  
 L K L I I I A L V V V K L E I F S V C N

25681 ATCTTTTAAATGGTATTTAAAGTATTACCTCCCATTTTATCTGAGACTCAAATTTCTGGCTA 25740  
 I F \* W Y \* S I T S H F I \* D S N F W L  
 S F N G I K V L P P I L S E T Q I S G Y  
 L L M V L K Y Y L P F Y L R L K F L A I

25741 TACTACAGCTGCTACTGTGGCGGCTATGTTTCCGCCATGGTCTGCTGCTGCTGGTGTACC 25800  
 Y Y S C Y C G G Y V S A M V C C C W C T  
 T T A A T V A A M F P P W S A A A G V P  
 L Q L L L W R L C F R H G L L L L V Y H

25801 ATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGATGTCTCTTAA 25860  
 I F S \* C T I \* N \* W F G C Y Y G C S \*  
 F S L N V Q Y R I N G L G V T M D V L N  
 F L L M Y N I E L M V W V L L W M F L I

25861 TAAGAATCAAAAGTTAATAGCTAATGCTTTTAAATAAAGCTCTTCTTCTATCCAGAATGG 25920  
 \* E S K V N S \* C F \* \* S S S F Y P E W  
 K N Q K L I A N A F N K A L L S I Q N G  
 R I K S \* \* L M L L I K L F F L S R M V

FIG. 9 CONT.

## 168/201

25921 TTTTACTGCTACTAACTCTGCTCTTGCTAAAATTCAAAGTGTGCTTAATGCTAATGCTCA 25980  
F Y C Y \* L C S C \* N S K C R \* C \* C S  
F T A T N S A L A K I Q S V V N A N A Q  
L L L L T L L L L K F K V S L M L M L K

25981 AGCACTTAATAGTTTGTACACAATTATTTAATAAATTTGGTGTATTAGTTCCTCTTT 26040  
S T \* \* F V T T I I \* \* I W C Y \* F F F  
A L N S L L Q Q L F N K F G A I S S S L  
H L I V C Y N N Y L I N L V L L V L L Y

26041 ACAAGAAATTTTGTCTCGCCTTGATAATTTAGAAGCTCAGTTCAGATTGATAGGCTCAT 26100  
T R N F V S P \* \* F R S S G S D \* \* A H  
Q E I L S R L D N L E A Q V Q I D R L I  
K K F C L A L I I \* K L R F R L I G S L

26101 TAATGGTCGTTTGACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGATATTACACT 26160  
\* W S F D C F K C L C F S T A \* \* Y Y T  
N G R L T A L N A Y V S Q Q L S D I T L  
M V V \* L L \* M L M F L N S L V I L H L

26161 TATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAAAGTCAATC 26220  
Y \* G W S F S C Y \* E G \* \* V C \* K S I  
I K A G A S R A I E K V N E C V K S Q S  
L R L E L L V L L R R L M S V L K V N P

26221 CCCTCGTATAAATTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAAATGCTCC 26280  
P S Y K F L W Q W \* P H F I I G S K C S  
P R I N F C G N G N H I L S L V Q N A P  
L V \* I F V A M V T T F Y H W F K M L L

26281 TTATGGTTTGCTTTTCATTCATTTTAGTTATAAACCTACTTCTTTTAAACTGTCTTAGT 26340  
L W F A F H S F \* L \* T Y F F \* N C L S  
Y G L L F I H F S Y K P T S F K T V L V  
M V C F S F I L V I N L L L L K L S \* \*

26341 AAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGTTATTTTAT 26400  
K S R F M F I R \* \* R Y C T \* A R L F Y  
S P G L C L S G D R G I A P K Q G Y F I  
V Q V Y V Y P V I E V L H L S K V I L L

26401 TAAACAAAATGATTCCTGGATGTTTACTGGTAGTTCCTATTATTACCCAGAACCAATTC 26460  
\* T K \* F L D V Y W \* F L L L P R T N F  
K Q N D S W M F T G S S Y Y Y P E P I S  
N K M I P G C L L V V P I I T Q N Q F Q

FIG. 9 CONT.

169/201

26461 AGATAAAAATGTTGTTTTCATGAATAGTTGCTCTGTTAATTTTACTAAAGCTCCATTTAT 26520  
R \* K C C F H E \* L L C \* F Y \* S S I Y  
D K N V V F M N S C S V N F T K A P F I  
I K M L F S \* I V A L L I L L K L H L F

26521 TTATCTAATAATTCTATACCAAATTTGTCTGATTTTGAAGCCGAGTTTTCTCTTTGGTT 26580  
L S \* \* F Y T K F V \* F \* S R V F S L V  
Y L N N S I P N L S D F E A E F S L W F  
I L I I L Y Q I C L I L K P S F L F G L

26581 TAAAAATCATACTTCTATAGCACCTAATTTAACCTTAAATTCATATTAATGCTACTTT 26640  
\* K S Y F Y S T \* F N L \* F S Y \* C Y F  
K N H T S I A P N L T F N S H I N A T F  
K I I L L \* H L I \* P L I L I L M L L F

26641 TTTAGATCTGTATTATGAAATGAATGTTATTCAGGAATCTATTAATCTTTGAACAGTAG 26700  
F R S V L \* N E C Y S G I Y \* I F E Q \*  
L D L Y Y E M N V I Q E S I K S L N S S  
\* I C I M K \* M L F R N L L N L \* T V V

26701 TTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGGCCTTGGTACAT 26760  
F Y \* S \* R N R Y L \* N V C \* M A L V H  
F I N L K E I G T Y E M Y V K W P W Y I  
L L I L K K \* V L M K C M L N G L G T F

26761 TTGGTTGTTAATTGTCATTTTATTTATAATTTTCTTATGATACTTTTCTTTATATGCTG 26820  
L V V N C H F I Y N F S Y D T F L Y M L  
W L L I V I L F I I F L M I L F F I C C  
G C \* L S F Y L \* F F L \* Y F S L Y A A

26821 CTGTACTGGTTGTGGTTCAGCATGTTTTAGTAAATGTCATAATTGTTGTGATGAGTATGG 26880  
L Y W L W F S M F \* \* M S \* L L \* \* V W  
C T G C G S A C F S K C H N C C D E Y G  
V L V V V Q H V L V N V I I V V M S M G

26881 GGGTCACAATGATTTTGTATTAAAGCATCTCATGATGATTAGATTTTAAATCTAAACTT 26940  
G S Q \* F C Y \* S I S \* \* L D F K S K L  
G H N D F V I K A S H D D \* I L N L N F  
V T M I L L L K H L M M I R F \* I \* T L

26941 TATATATGGAAGTTTGGAGGCCTAGCTATAAATATTCTTATTACTAGAGAATTTGGTG 27000  
Y I W K F G G L A I N I L L L L E N L V  
I Y G S L E A \* L \* I F S Y Y \* R I W C  
Y M E V W R P S Y K Y S L I T R E F G V

FIG. 9 CONT.

## 170/201

27001 TCACAGATCTTGAGGATTTGTGTTTTAAATATAATTATTGCCAACCTTGTGTTGGTTATT 27060  
 S Q I L R I C V L N I I I A N L V L V I  
 H R S \* G F V F \* I \* L L P T L C W L L  
 T D L E D L C F K Y N Y C Q P C V G Y C

27061 GTATTGTACCTTTAAACGTTTGGTGTGTAAGTTTGGTAAATTTGCTTCTTATTTTGTTT 27120  
 V L Y L \* T F G V V S L V N L L L I L F  
 Y C T F K R L V S \* V W \* I C F L F C F  
 I V P L N V W C R K F G K F A S Y F V L

27121 TACGTAGTCATGACACCTCTCATAAGAATAATTTGGTGTATAACTAGTTTACTAGTT 27180  
 Y V V M T P L I R I I L V L \* L V L L V  
 T \* S \* H L S \* E \* F W C Y N \* F Y \* L  
 R S H D T S H K N N F G V I T S F T S Y

27181 ATGGTAACACTGTTTCTGAGGCTGTTTCTAAATTAGTTGAATCAGCATCTGATTTTATCG 27240  
 M V T L F L R L F L N \* L N Q H L I L S  
 W \* H C F \* G C F \* I S \* I S I \* F Y R  
 G N T V S E A V S K L V E S A S D F I A

27241 CTTGGCGAGCTGAAGCACTTAATAAGTATGGTTGATGTATTTTTCACTGATACTGCTTGG 27300  
 L G E L K H L I S M V D V F F T D T A W  
 L A S \* S T \* \* V W L M Y F S L I L L G  
 W R A E A L N K Y G \* C I F H \* Y C L V

27301 TATGTAGGTCAGATTTTCTTTTGTAGTTTATCTTGTGTCATTTTCTTAATTTTGTGTT 27360  
 Y V G Q I F F L V L S C V I F L I F V V  
 M \* V R F S F \* F Y L V S F S \* F L L L  
 C R S D F L F S F I L C H F L N F C C C

27361 GCACTTTTAGCAACTATTAACCTTTGTATTCAAATTTGTGGTTTTGTAATATTTTATT 27420  
 A L L A T I K L C I Q I C G F C N I F I  
 H F \* Q L L N F V F K F V V F V I F L L  
 T F S N Y \* T L Y S N L W F L \* Y F Y Y

27421 ATTCACCTTCTGCCTATGTTTATAATAGAGGTAGACAGTTGTATAAGTCTTATAGTGAA 27480  
 I S P S A Y V Y N R G R Q L Y K S Y S E  
 F H L L P M F I I E V D S C I S L I V N  
 F T F C L C L \* \* R \* T V V \* V L \* \* T

27481 CATGTCATACCTTCTACTTTAGATGATTTAATTTAAATCTAAACATCATGAATGAATCAA 27540  
 H V I P S T L D D L I \* I \* T S \* M N Q  
 M S Y L L L \* M I \* F K S K H H E \* I N  
 C H T F Y F R \* F N L N L N I M N E S I

FIG. 9 CONT.



171/201

27541 TTTTTCCTCATTGGAATTCTGATCAAGCTATTACATTCTTAAAAGAAATGGAATTTCTCTT 27600  
 F F L I G I L I K L L H S \* K N G I S L  
 F S S L E F \* S S Y Y I L K R M E F L F  
 F P H W N S D Q A I T F L K E W N F S L

27601 TGGGTGTAATATTACTTCTCATTACTATCATACTGCAGTTTGGTTATACGAGTCGTAGTA 27660  
 W V \* Y Y F S L L S Y C S L V I R V V V  
 G C N I T S H Y Y H T A V W L Y E S \* Y  
 G V I L L L I T I I L Q F G Y T S R S M

27661 TGTTTGTATTCTTATTAAGATGATTATTCTTTGGCTTATGTGGCCATTGACCATTATCT 27720  
 C L F I L L R \* L F F G L C G H \* P L S  
 V C L S Y \* D D Y S L A Y V A I D H Y L  
 F V Y L I K M I I L W L M W P L T I I L

27721 TGA CTATATTTAATGCTTTTATGCTTTGAATAATATCTTTCTTGGGCTTTCTATACTGT 27780  
 \* L Y L I A F M L \* I I S F L G F L Y C  
 D Y I \* L L L C F E \* Y L S W A F Y T V  
 T I F N C F Y A L N N I F L G L S I L F

27781 TTACTATTATTCTATTGTTATATGGATTTTATATTTTGTCAACAGTATTGCGCTTTTTA 27840  
 L L L F L L L Y G F Y I L S T V F G F L  
 Y Y Y F Y C Y M D F I F C Q Q Y S A F Y  
 T I I S I V I W I L Y F V N S I R L F I

27841 TCAGAACTGGCAGTTGGTGGAGTTTTAAACCAGAGACTAATAATCTTATGTGTATTGATA 27900  
 S E L A V G G V L T Q R L I I L C V L I  
 Q N W Q L V E F \* P R D \* \* S Y V Y \* Y  
 R T G S W W S F N P E T N N L M C I D M

27901 TGAAAGGTAAGATGTATGTTAGGCCAGTTATTGAGGACTATCATACTTAACGGCTACTG 27960  
 \* K V R C M L G Q L L R T I I H \* R L L  
 E R \* D V C \* A S Y \* G L S Y I N G Y C  
 K G K M Y V R P V I E D Y H T L T A T V

27961 TTATCCGTGGTCATCTTTATATACAGGGTGTAAACTTGGCACTGGTTACACGCTTGCCG 28020  
 L S V V I F I Y R V L N L A L V T R L P  
 Y P W S S L Y T G C \* T W H W L H A C R  
 I R G H L Y I Q G V K L G T G Y T L A D

28021 ATTTGCCTGTTTATGTTACTGTAGCTAAGGTGCAAGTCCTCTGTACTTATAAACGTGCCT 28080  
 I C L F M L L \* L R C K S S V L I N V P  
 F A C L C Y C S \* G A S P L Y L \* T C L  
 L P V Y V T V A K V Q V L C T Y K R A F

FIG. 9 CONT.

## 172/201

28081 TTTTAGATAAGTTAGATGTTAATAGTGGTTTTGCTGTTTTTGTAAAGTCTAAAGTTGGTA 28140  
 F \* I S \* M L I V V L L F L L S L K L V  
 F R \* V R C \* \* W F C C F C \* V \* S W \*  
 L D K L D V N S G F A V F V K S K V G N

28141 ACTATCGTTTACCTTCTAGTAAATCTAGTGGTATGGATACTGCCTTGTTGAGAGCTTAAA 28200  
 T I V Y L L V N L V V W I L P C \* E L K  
 L S F T F \* \* I \* W Y G Y C L V E S L N  
 Y R L P S S K S S G M D T A L L R A \* I

28201 TCTAAACTATTAGGATGCTTATACTCCCGGTCATCATGCTGGAAGTAGAAGCTCCTCTG 28260  
 S K L L G C L I L P V I M L E V E A P L  
 L N Y \* D V L Y S R S S C W K \* K L L W  
 \* T I R M S Y T P G H H A G S R S S S G

28261 GAAATCGTTCAGGAATCCTCAAGAAAACCTTCTGGGTTGACCAATCTGAGCGAAGCCATC 28320  
 E I V Q E S S R K L L G L T N L S E A I  
 K S F R N P Q E N F L G \* P I \* A K P S  
 N R S G I L K K T S W V D Q S E R S H Q

28321 AAACCTATAATAGAGGCAGAAAACCCCAACCCAAATTCACTGTGTCTACTCAACCACAAG 28380  
 K P I I E A E N P N P N S L C L L N H K  
 N L \* \* R Q K T P T Q I H C V Y S T T R  
 T Y N R G R K P Q P K F T V S T Q P Q G

28381 GAAACCCTATCCACATTATTCCTGGTCTCTGGGATTACCCAATTTCAAAAAGGTAGAG 28440  
 E T L S H I I P G S L G L P N F K K V E  
 K P Y P T L F L V L W D Y P I S K R \* R  
 N P I P H Y S W F S G I T Q F Q K G R D

28441 ACTTTAAATTTCCAGATGGTCAAGGAGTACCCATTGCTTACGGGATACCCCTTCTGAAG 28500  
 T L N F Q M V K E Y P L L T G Y P L L K  
 L \* I S R W S R S T H C L R D T P F \* S  
 F K F P D G Q G V P I A Y G I P P S E A

28501 CAAAAGGATATTTGGTATAAACACAACCGGCGTCTTTTAAACAGCTGATGGTCAACAAA 28560  
 Q K D I G I N T T G V L L K Q L M V N K  
 K R I L V \* T Q P A F F \* N S \* W S T K  
 K G Y W Y K H N R R S F K T A D G Q Q K

28561 AGCAGTTGTTACCAAGATGGTATTTCTACTATCTCGGTACCGGTCCATATGCCAGTTCAT 28620  
 S S C Y Q D G I S T I S V P V H M P V H  
 A V V T K M V F L L S R Y R S I C Q F I  
 Q L L P R W Y F Y Y L G T G P Y A S S S

FIG. 9 CONT.

173/201

28621 CCTATGGTGATGCCACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGACACTTCTA 28680  
 P M V M P T K V S S G S L V T K L T L L  
 L W \* C P R R Y L L G R \* S P S \* H F Y  
 Y G D A H E G I F W V A S H Q A D T S I

28681 TTCCCTCCGATGTTTCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTT 28740  
 F P P M F R Q G I L L F K K L S L L G F  
 S L R C F G K G S Y Y S R S Y P Y \* V F  
 P S D V S A R D P T I Q E A I P T R F S

28741 CGCCTGGTACGATTTTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTA 28800  
 R L V R F C L K A I M L K A Q E G L L L  
 A W Y D F A S R L L C \* R L R K V C F \*  
 P G T I L P Q G Y Y V E G S G R S A S N

28801 ATAGCCGGCCAGGTTACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAA 28860  
 I A G Q V H V L N H V D P I I V H \* V E  
 \* P A R F T F S I T W T Q \* S F I K \* K  
 S R P G S R S Q S R G P N N R S L S R S

28861 GTAATTCTAATTTTAGACATTCTGATTCTATAGTGAACCTGATATGGCTGATGAGATTG 28920  
 V I L I L D I L I L \* \* N L I W L M R L  
 \* F \* F \* T F \* F Y S E T \* Y G \* \* D C  
 N S N F R H S D S I V K P D M A D E I A

28921 CTAGTCTTGTCCTGGCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTTACCAAGCAAA 28980  
 L V L S W P S L V K I L N L S K L P S K  
 \* S C L G Q A W \* R F \* T S A S Y Q A K  
 S L V L A K L G K D S K P Q Q V T K Q N

28981 ATGCTAAGGAAATTAGGCATAAAATTTAATGAAACCTCGCCAAAAGCGAACTCCTAATA 29040  
 M L R K L G I K F \* \* N L A K S E L L I  
 C \* G N \* A \* N F N E T S P K A N S \* \*  
 A K E I R H K I L M K P R Q K R T P N K

29041 AATTTTGTAAATGTTCAACAGTGTTTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATT 29100  
 N F V M F N S V L V K E D R S K T L V I  
 I L \* C S T V F W \* K R T A P K L W \* F  
 F C N V Q Q C F G K R G P L Q N F G N S

29101 CTGAAATGTTAAAGCTTGGTACTAATGATCCTCAATTCCTATTCTTGCTGAATTAGCCC 29160  
 L K C \* S L V L M I L N F L F L L N \* P  
 \* N V K A W Y \* \* S S I S Y S C \* I S P  
 E M L K L G T N D P Q F P I L A E L A P

FIG. 9 CONT.

174/201

29161 CTACACCAGGTGCTTTTTTCTTTGGCTCTAAATTAGAGTTGTTTAAAAGAGACTCTGATG 29220  
 L H Q V L F S L A L N \* S C L K E T L M  
 Y T R C F F L W L \* I R V V \* K R L \* C  
 T P G A F F F G S K L E L F K R D S D A

29221 CTGATTCACCTTCTAAAGACACTTTTGAACCTTCGTTATTCTGGTCTATTAGGTTTGATa 29280  
 L I H L L K T L L N F V I L V L L G L I  
 \* F T F \* R H F \* T S L F W F Y \* V \* \*  
 D S P S K D T F E L R Y S G S I R F D S

29281 GTACTTACCTGGTTTTGAGACAATTATGAAAGTCTTAAAGAGAATTTAGATGCTTATG 29340  
 V L Y L V L R Q L \* K F L K R I \* M L M  
 Y F T W F \* D N Y E S S \* R E F R C L C  
 T L P G F E T I M K V L K E N L D A Y V

29341 TTAATTCTAATCAGAACACTGTTTCTGGTTCGCTGAGTCCTAAACCTCAGCGTAAAAGAG 29400  
 L I L I R T L F L V R \* V L N L S V K E  
 \* F \* S E H C F W F A E S \* T S A \* K R  
 N S N Q N T V S G S L S P K P Q R K R G

29401 GTGTAAACAATCACCTGAATCGTTTGACTCTCTAATTTAAGTGCTGATACTCAGCACA 29460  
 V L N N H L N R L T L L I \* V L I L S T  
 C \* T I T \* I V \* L S \* F K C \* Y S A H  
 V K Q S P E S F D S L N L S A D T Q H I

29461 TTTCAAATGATTTTACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATG 29520  
 F Q M I L L L R I I V Y L L L L M I L M  
 F K \* F Y S \* G S \* F T C Y S \* \* S L C  
 S N D F T P E D H S L L A T L D D P Y V

29521 TAGAAGACTCTGTGCTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTC 29580  
 \* K T L L L N E N E S \* F D T R W \* P L  
 R R L C C L M R M N P N S T L G G N P S  
 E D S V A \* \* E \* I L I R H \* V V T P R

29581 GCTATTAGTCGGAATAGGACACTCTCTATCAGAATGAATCTTGCTGTTACAACAGATAG 29640  
 A I S R N R T L S I R M N S C C Y N R \*  
 L L V G I G H S L S E \* I L A V T T D R  
 Y \* S E \* D T L Y Q N E F L L L Q Q I E

29641 AGTAGGTTGTTGCAGACTATATATTAATTAGTAGAACTTTATATTTAAATATTTGATTG 29700  
 S R L L Q T I Y \* L V E T L Y L N I \* L  
 V G C C R L Y I N \* \* K L Y I \* I F D C  
 \* V V A D Y I L I S R N F I F K Y L I V

FIG. 9 CONT.

## 175/201

29701 TTAGAGTAGTTATAAGGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTAGCAATTAT 29760  
L E \* L \* G L A V V \* T P P G R A S N Y  
\* S S Y K V \* L \* Y K R L R E E L A I I  
R V V I R F S C S I N A S G K S \* Q L \*

29761 AGTATTTAATATATATATATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTA 29820  
S I \* Y I Y \* Y M I E I N Y S L L E E L  
V F N I Y I S I \* L K L I I A F W R N Y  
Y L I Y I L V Y D \* N \* L \* P F G G I T

29821 CAAAAAAAAAAAAAAAAA 29836  
Q K K K K X  
K K K K K  
K K K K

FIG. 9 CONT.

176/201




FIG. 10

177/201

Fig. 11. Multiple alignment of the replicase genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9 and 10.

```

Patient 7      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 9      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 10     TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 6      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 4      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 8      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 2      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 5      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 1      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
*****

Patient 7      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 9      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 10     CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 6      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 4      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 8      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 2      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 5      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 1      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACC 120
*****

Patient 7      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 9      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 10     AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 6      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 4      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 8      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 2      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 5      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 1      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
*****

Patient 7      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 9      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 10     GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 6      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 4      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 8      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 2      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 5      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
Patient 1      GACGACGGTAATAAATGGATAAAGTTCCTTGTGTGTCAAAAGAACAATTTAGAAGTTTAT 240
*****

Patient 7      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 9      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 10     AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 6      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 4      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 8      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 2      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 5      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 1      AATAAAGAGAAAACCTTATFATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
*****

Patient 7      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 9      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 10     TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 6      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 4      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 8      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 2      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 5      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 1      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
*****

Patient 7      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 9      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 10     AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 6      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 4      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 8      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 2      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420
Patient 5      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATGTTCA 420

```

FIG. 11

178/201

Patient 1 AAGTATACTATGTTAGATCCTTTGCTATGCATTGCGCCATTTTGATTGTAATGATTGTTC 420  
 \*\*\*\*\*

Patient 7 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 9 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 10 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 6 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 4 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 8 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 2 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 5 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 1 ATATTGCTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 \*\*\*\*\*

Patient 7 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 9 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 10 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 6 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 4 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 8 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 2 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 5 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 1 GATTGGTATGATTTTGTGAAAATCCTGATATATTAATATATATAAAAAATTAGGCCCT 540  
 \*\*\*\*\*

Patient 7 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 9 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 10 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 6 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 4 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 8 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 2 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 5 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 1 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600  
 \*\*\*\*\*

Patient 7 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 9 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 10 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 6 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 4 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 8 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 2 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 5 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 Patient 1 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTGGT 660  
 \*\*\*\*\*

Patient 7 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 9 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 10 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 6 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 4 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 8 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 2 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 5 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 Patient 1 GATTTTATACAAACAGCCCCAGGATTTGGTGTGGCAGTCCGAGATTCCTACTATTCCTAT 720  
 \*\*\*\*\*

Patient 7 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 9 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 10 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 6 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 4 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 8 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 2 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 5 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 Patient 1 ATGATGCCATGTTGACTATGTGCATGTATTAGATTGTGAATTTTGTAAATGATAGT 780  
 \*\*\*\*\*

Patient 7 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
 Patient 9 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
 Patient 10 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
 Patient 6 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
 Patient 4 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
 Patient 8 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
 Patient 2 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840

FIG. 11 CONT.



179/201

Patient 5 TATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840  
Patient 1 TATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTATAAGTTAGAAATGTTTAAAT 840  
\*\*\*\*\*  
Patient 7 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 9 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 10 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 6 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 4 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 8 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 2 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 5 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
Patient 1 AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAAATGAT 900  
\*\*\*\*\*  
Patient 7 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 9 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 10 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 6 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 4 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 8 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 2 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 5 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 1 AGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
\*\*\*\*\*  
Patient 7 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 9 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 10 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 6 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 4 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 8 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 2 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 5 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
Patient 1 TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTGTGTTTCTATT 1020  
\*\*\*\*\*  
Patient 7 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 9 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 10 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 6 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 4 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 8 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 2 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 5 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 1 GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
\*\*\*\*\*  
Patient 7 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 9 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 10 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 6 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 4 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 8 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 2 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 5 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 1 CGTTTGTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
\*\*\*\*\*  
Patient 7 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 9 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 10 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 6 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 4 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 8 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 2 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 5 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 1 GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
\*\*\*\*\*  
Patient 7 ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260  
Patient 9 ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260  
Patient 10 ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260  
Patient 6 ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260  
Patient 4 ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260  
Patient 8 ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260

FIG. 11 CONT.

180/201

Patient 2 ATAAAAATTCAAACTGTAAAACAGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 5 ATAAAAATTCAAACTGTAAAACAGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 1 ATAAAGTTTCAAACTGTAAAACAGGTAATTTAACCAAGATTTTATGAGTTTGTCAA 1260  
\*\*\*\*\*  
Patient 7 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 9 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 10 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 6 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 4 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 8 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 2 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 5 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
Patient 1 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTCTTTACTCAA 1320  
\*\*\*\*\*  
Patient 7 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 9 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 10 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 6 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 4 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 8 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 2 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 5 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
Patient 1 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
\*\*\*\*\*  
Patient 7 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 9 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 10 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 6 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 4 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 8 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 2 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 5 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
Patient 1 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAATTTATGAT 1440  
\*\*\*\*\*  
Patient 7 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 9 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 10 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 6 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 4 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 8 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 2 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 5 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
Patient 1 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
\*\*\*\*\*  
Patient 7 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 9 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 10 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 6 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 4 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 8 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 2 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 5 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
Patient 1 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
\*\*\*\*\*  
Patient 7 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 9 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 10 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 6 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 4 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 8 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 2 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 5 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
Patient 1 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
\*\*\*\*\*  
Patient 7 AAATATGCTATCAGTCTAAGAAATAGAGCTCGCACTGTAGCAGGTTTCTATTCTTAGT 1680  
Patient 9 AAATATGCTATCAGTCTAAGAAATAGAGCTCGCACTGTAGCAGGTTTCTATTCTTAGT 1680  
Patient 10 AAATATGCTATCAGTCTAAGAAATAGAGCTCGCACTGTAGCAGGTTTCTATTCTTAGT 1680  
Patient 6 AAATATGCTATCAGTCTAAGAAATAGAGCTCGCACTGTAGCAGGTTTCTATTCTTAGT 1680  
Patient 4 AAATATGCTATCAGTCTAAGAAATAGAGCTCGCACTGTAGCAGGTTTCTATTCTTAGT 1680

FIG. 11 CONT.

181/201

Patient 8 AAATATGCTATCAGTGCATAAGAAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
 Patient 2 AAATATGCTATCAGTGCATAAGAAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
 Patient 5 AAATATGCTATCAGTGCATAAGAAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
 Patient 1 AAATATGCTATCAGTGCATAAGAAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
 \*\*\*\*\*

Patient 7 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 9 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 10 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 6 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 4 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 8 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 2 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 5 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 1 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 \*\*\*\*\*

Patient 7 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 9 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 10 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 6 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 4 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 8 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 2 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 5 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 Patient 1 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTGGGACGATATGTTACGTCAT 1800  
 \*\*\*\*\*

Patient 7 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 9 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 10 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 6 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 4 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 8 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 2 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 5 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 1 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTGGGATTATCCTAAATGTGATCGT 1860  
 \*\*\*\*\*

Patient 7 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 9 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 10 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 6 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 4 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 8 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 2 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 5 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 1 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 \*\*\*\*\*

Patient 7 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 9 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 10 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 6 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 4 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 8 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 2 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 5 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 Patient 1 TGTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGT 1980  
 \*\*\*\*\*

Patient 7 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 9 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 10 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 6 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 4 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 8 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 2 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 5 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 1 GAAATAGTTATGTTGCGGTTGCTATTTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 \*\*\*\*\*

Patient 7 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100  
 Patient 9 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100  
 Patient 10 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100  
 Patient 6 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100

FIG. 11 CONT.

Patient 4 GCAACTACTGCTTTTGCCTAATTCGTTTTTAAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 8 GCAACTACTGCTTTTGCCTAATTCGTTTTTAAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 2 GCAACTACTGCTTTTGCCTAATTCGTTTTTAAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 5 GCAACTACTGCTTTTGCCTAATTCGTTTTTAAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 1 GCAACCCTGCTTTTGCCTAATTCGTTTTTAAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 \*\*\*\*\*

Patient 7 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 9 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 10 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 6 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 4 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 8 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 2 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 5 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 Patient 1 TGTTCCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
 \*\*\*\*\*

Patient 7 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 9 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 10 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 6 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 4 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 8 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 2 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 5 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 Patient 1 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
 \*\*\*\*\*

Patient 7 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 9 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 10 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 6 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 4 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 8 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 2 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 5 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 Patient 1 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280  
 \*\*\*\*\*

Patient 7 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 9 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 10 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 6 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 4 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 8 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 2 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 5 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 Patient 1 TGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA 2340  
 \*\*\*\*\*

Patient 7 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 9 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 10 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 6 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 4 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 8 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 2 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 5 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 Patient 1 GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
 \*\*\*\*\*

Patient 7 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 9 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 10 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 6 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 4 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 8 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 2 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 5 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 Patient 1 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
 \*\*\*\*\*

Patient 7 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAAATCTAGGAGCTGGTTGTTTTGTT 2520  
 Patient 9 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAAATCTAGGAGCTGGTTGTTTTGTT 2520  
 Patient 10 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAAATCTAGGAGCTGGTTGTTTTGTT 2520

FIG. 11 CONT.

183/201

Patient 6 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 4 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 8 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 2 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTTGTTTTGTT 2520  
Patient 5 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTTGTTTTGTT 2520  
Patient 1 GACTATGTTTATCTACCCTATCCAGACCCCTTCTAGAATTTAGGAGCTGGTTGTTTTGTT 2520  
\*\*\*\*\*  
Patient 7 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 9 GATGATTTATTGAAGACTGATAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 10 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 6 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 4 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 8 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 2 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 5 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 1 GATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
\*\*\*\*\*  
Patient 7 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 9 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 10 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 6 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 4 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 8 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 2 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 5 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 1 GATGCTTACCCTTTAGTATATCATGAAAAFGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
\*\*\*\*\*  
Patient 7 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 9 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 10 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 6 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 4 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 8 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 2 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 5 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 1 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
\*\*\*\*\*  
Patient 7 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 9 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 10 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 6 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 4 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 8 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 2 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 5 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
Patient 1 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTCACAAGAAATAG 2760  
\*\*\*\*\*  
Patient 7 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 9 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 10 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 6 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 4 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 8 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 2 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 5 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 1 TATTTAAAAAGTGCCGTGATGCAG 2784  
\*\*\*\*\*

FIG. 11 CONT.

184/201





FIG. 12

Fig. 13. Multiple alignment of the spike genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```

Patient 6      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 9      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 10     ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 5      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 4      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 7      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 2      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 1      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 8      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
*****

Patient 6      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 9      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 10     ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 5      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 4      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 7      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 2      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 1      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 8      ACTAATTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
*****

Patient 6      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 9      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 10     GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 5      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 4      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 7      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 2      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 1      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
Patient 8      GATGTTTCTTATGGTTTGGGTACATATATATACTTGATCGTGTGTTATTTAAATACTACT 180
*****

Patient 6      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 9      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 10     ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 5      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 4      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 7      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 2      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTAGGGATCTATCTTTAAAA 240
Patient 1      TTGTTATTTACAGGTTATTTCCCTAAATCTGGTGCTAATTTAGAGACTTGGCTTTAAAG 240
Patient 8      TTGTTATTTACAGGTTATTTCCCTAAATCTGGTGCTAATTTAGAGACTTGGCTTTAAAG 240
*****

Patient 6      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 9      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 10     GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 5      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 4      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 7      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 2      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATA 300
Patient 1      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTCTGATTTTAAATA 300
Patient 8      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTCTGATTTTAAATA 300
*****

Patient 6      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 9      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 10     GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 5      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 4      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 7      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 2      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 1      GGTATTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTATAGTGAA 360
Patient 8      GGTATTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTATAGTGAA 360
*****

Patient 6      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 9      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 10     TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 5      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 4      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 7      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 2      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 1      TTTAGTACTATAGTTATAGGTAGTGTGTTTTGTTAATACTTCTTATACTATTGTTGTTCAA 420

```

FIG. 13

186/201

Patient 8 TTTAGTACTATAGTTATAGGTAGTGTFTTTTGGTTAATACTTCTTATACTATTGTTGTTCAA 420  
 \*\*\*\*\*

Patient 6 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 9 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 10 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 5 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 4 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 7 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 2 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
 Patient 1 CCTCACAATGGTATTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAC 480  
 Patient 8 CCTCATAATGGTATTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAC 480  
 \*\*\*\*\*

Patient 6 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 9 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 10 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 5 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 4 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 7 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 2 ACTATTTGTAATCTAAAGGTAGTTCCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
 Patient 1 ACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCACATTGATTTCTCGGAA 540  
 Patient 8 ACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCACATTGATTTCTCGGAA 540  
 \*\*\* \*\*\*\*\* \*\*

Patient 6 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 9 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 10 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 5 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 4 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 7 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 2 CCTTTGTGCTCTGTTCAAGAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
 Patient 1 CCTTTATGCTTGTTTAAAGAAAATTTACTTATAATGTTTCTGCAGATTGGCTGTATTTT 600  
 Patient 8 CCTTTATGCTTGTTTAAAGAAAATTTACTTATAATGTTTCTGCAGATTGGCTGTATTTT 600  
 \*\*\*\*\*

Patient 6 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 9 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 10 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 5 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 4 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 7 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 2 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTTCTGGCATGCCACT 660  
 Patient 1 CATTTTTATCAAGAACGTGGTGTTTTTATGCTATTTATGCTGATTTAGGTATGCCCTACC 660  
 Patient 8 CATTTTTATCAAGAACGTGGTGTTTTTATGCTATTTATGCTGATTTAGGTATGCCCTACC 660  
 \*\*\*\*\*

Patient 6 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 9 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 10 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 5 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 4 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 7 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 2 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATATGTTTGGCCTTTG 720  
 Patient 1 ACTTTCTATTTAGTTTATTTAGGTACTATTTTATCTCATTATATGTTTATGCTTTG 720  
 Patient 8 ACTTTCTATTTAGTTTATTTAGGTACTATTTTATCTCATTATATGTTTATGCTTTG 720  
 \*\*\*\*\*

Patient 6 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 9 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 10 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 5 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 4 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 7 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 2 ACTTGTAAATGCTATATCTTCTAATACTGATAAATGAGACTTTACAATATGGGTCACACCT 780  
 Patient 1 ACTTGTAAAGGCTATATCTTCTAATACTGACAATGAACTTTAGAATATGGGTTACACCG 780  
 Patient 8 ACTTGTAAATGCTATATCTTCTAATACTGACAATGAACTTTAGAATATGGGTTACACCG 780  
 \*\*\*\*\*

Patient 6 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840  
 Patient 9 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840  
 Patient 10 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840  
 Patient 5 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840  
 Patient 4 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840  
 Patient 7 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840  
 Patient 2 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAAACCGTGGTGTATTACTAATGCTGT 840

FIG. 13 CONT.



187/201

Patient 1 CTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTTATTACTAATGCCGTT 840  
 Patient 8 CTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTTATTACTAATGCCGTT 840  
 \* \* \* \* \*

Patient 6 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 9 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 10 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 5 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 4 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 7 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 2 GATTGTTCTAGTAGTTCCTTTAGCGAGATTCAATGTA AAACTAAATCTTTATTACCTAAT 900  
 Patient 1 GATTGTTCAAGTAGTTCCTTTAGTGAGATTCAATGTA AAACTCAATCTTTTGCACCTAAT 900  
 Patient 8 GATTGTTCAAGTAGTTCCTTTAGTGAGATTCAATGTA AAACTCAATCTTTTGCACCTAAT 900  
 \* \* \* \* \*

Patient 6 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 9 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 10 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 5 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 4 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 7 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 2 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
 Patient 1 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTATCGTCGG 960  
 Patient 8 ACTGGTGTATGACTTATCTGGTTTTACTGTTAAGCCTGTTGCAACTGTATCGTCGG 960  
 \* \* \* \* \*

Patient 6 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 9 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 10 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 5 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 4 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 7 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 2 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 1 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 Patient 8 ATTCCGTATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020  
 \* \* \* \* \*

Patient 6 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 9 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 10 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 5 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 4 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 7 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 2 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 1 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 Patient 8 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
 \* \* \* \* \*

Patient 6 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 9 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 10 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 5 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 4 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 7 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 2 CGTTAGTTCATACTGATTCCTTTTCTTGTAATAAATTTTGATGAATCTAAGATATAATGGT 1140  
 Patient 1 CGTCTAGTTCATGTTGATTCCTTTTCTTGTAATAAATTTTGATAAATCTAAAATTTTGGT 1140  
 Patient 8 CGTCTAGTTCATGTTGATTCCTTTTCTTGTAATAAATTTTGATAAATCTAAAATTTTGGT 1140  
 \* \* \* \* \*

Patient 6 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 9 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 10 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 5 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 4 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 7 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 2 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 1 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 8 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACCTCCAGACGATCTGAT 1200  
 \* \* \* \* \*

Patient 6 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260  
 Patient 9 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260  
 Patient 10 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260  
 Patient 5 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260  
 Patient 4 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260  
 Patient 7 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260

FIG. 13 CONT.

188/201

Patient 2 TTGCAGTTGGGCAGTTCCTGGTTTTCTGCAATCTTCTAATATAAAAATGACACTACTTCT 1260  
Patient 1 TTGCAATTGGGCAGTTCCTGGTTTTCTGCAATCATCTAATACAAAATAGATATTTCTTCT 1260  
Patient 8 TTGCAATTGGGCAGTTCCTGGTTTTCTGCAATCATCTAATACAAAATAGATATTTCTTCT 1260  
\*\*\*\*\*  
Patient 6 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 9 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 10 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 5 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 4 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 7 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 2 AGTTCTTGTC AATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
Patient 1 AGTTCTTGTC AATTGTATTATAGTTTACCTTTAGTTAATGTTACTATTAATAACTTTAAT 1320  
Patient 8 AGTTCTTGTC AATTGTATTATAGTTTACCTTTAGTTAATGTTACTATTAATAACTTTAAT 1320  
\*\*\*\*\*  
Patient 6 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 9 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 10 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 5 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 4 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 7 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 2 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAAATTTAATTTGAGCTCTCATAGTGT 1380  
Patient 1 CCATCTTCTTGG AATAGAAGGTATGGTTTTGGTAGTTTAAATGTGCTCTTATGACGGT 1380  
Patient 8 CCATCTTCTTGG AATAGAAGGTATGGTTTTGGTAGTTTAAATGTGCTCTTATGACGGT 1380  
\*\*\*\*\*  
Patient 6 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 9 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 10 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 5 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 4 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 7 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 2 GTTACTCACGTTAT TGTTTTTCTGTTAATAAATACTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 1 GTTATCTGATCAT TGTTTTTCTGTTAACAGCGACTTTTGCCCTTGTGCAGATCCGTCT 1440  
Patient 8 GTTATCTGATCAT TGTTTTTCTGTTAACAGCGACTTTTGCCCTTGTGCAGATCCGTCT 1440  
\*\*\*\*\*  
Patient 6 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 9 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 10 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 5 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 4 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 7 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 2 TTTGCTTCAAGTTG CAAGAGTCATAAACACCCTTCTGCTTCCCTGCTTATTGGTACTAAT 1500  
Patient 1 GTTGTAAATCTTGTG TAAATCTAAGCCTCTTCTGCCATTTGCTTCCCTGCTTACTAAA 1500  
Patient 8 GTTGTAAATCTTGTG TAAATCTAAGCCTCTTCTGCCATTTGCTTCCCTGCTTACTAAA 1500  
\*\*\*\*\*  
Patient 6 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 9 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 10 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 5 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 4 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 7 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 2 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 1 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
Patient 8 TATCGTTCCTGTTG GAGAGTACTACTGTACTCGACCACACTGATTTGGTGTAGGTGTTCTTGT 1560  
\*\*\*\*\*  
Patient 6 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 9 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 10 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 5 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 4 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 7 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 2 TTACCTGATCCTATA AACTGCTTATGACCCTAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
Patient 1 CTACCTGACCCCATTTCTACTTATCTCTTACACATGCTCCTCAAAAAGAGGTCGTTGTT 1620  
Patient 8 CTACCTGACCCCATTTCTACTTATCTCTTACACATGCTCCTCAAAAAGAGGTCGTTGTT 1620  
\*\*\*\*\*  
Patient 6 GGTGTTGGTGAACATT GTGTCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 9 GGTGTTGGTGAACATT GTGTCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 10 GGTGTTGGTGAACATT GTGTCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 5 GGTGTTGGTGAACATT GTGTCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 4 GGTGTTGGTGAACATT GTGTCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680

FIG. 13 CONT.

189/201

Patient 7 GGTGTTGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
 Patient 2 GGTGTTGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
 Patient 1 GGTATAGGTGAACATTGTCCAGGCTCTGGTATTATGAGGAAAATGTGGTACAC----- 1675  
 Patient 8 GGTATAGGTGAACATTGTCCAGGCTCTGGTATTATGAGGAAAATGTGGTACAC----- 1675  
 \*\*\* \* \*\*\*\*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 9 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 10 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 5 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 4 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 7 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 2 GGATCATATAATGTTCTTGTCTTGTAGTACTGATGCCCTTCTAGGTGGTCTTATGAC 1740  
 Patient 1 -AATTAATCATAGTTCCTGTTCTTGTAGTACTGATGCCCTTTTGGGTGGTCTTTTGAT 1734  
 Patient 8 -AATTAATCATAGTTCCTGTTCTTGTAGTACTGATGCCCTTTTGGGTGGTCTTTTGAT 1734  
 \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 9 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 10 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 5 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 4 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 7 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 2 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1800  
 Patient 1 AGTTGTATTAGTATAAATCGTTGCAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1794  
 Patient 8 AGTTGTATTAGTATAAATCGTTGCAATATTTTTCTAATTTTATTTAAATGGTATCAAT 1794  
 \* \*\* \* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 9 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 10 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 5 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 4 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 7 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 2 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCTAATACTGAAAGTTTACTGATGTT 1860  
 Patient 1 AGTGGCACCCTTGTCTAATGATTTGTATATTTCTAACACTGAAAGTTTACTGATGTT 1854  
 Patient 8 AGTGGCACCCTTGTCTAATGATTTGTATATTTCTAACACTGAAAGTTTACTGATGTT 1854  
 \*\*\*\*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 9 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 10 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 5 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 4 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 7 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 2 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTCTGCT 1920  
 Patient 1 TGTGTTAATTTATGATCTTTATGGCATCACAGGCCAAGGTATTTTTAAAGAAGTTCTGCT 1914  
 Patient 8 TGTGTTAATTTATGATCTTTATGGCATCACAGGCCAAGGTATTTTTAAAGAAGTTCTGCT 1914  
 \*\*\*\*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 9 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 10 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 5 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 4 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 7 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 2 GTTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGCAACATTATGGTTTT 1980  
 Patient 1 GCTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGTAAATTTATGGTTTT 1974  
 Patient 8 GCTTATTATAAATAGTTGGCAAATCTTTGTATGATTTCTAATGGTAAATTTATGGTTTT 1974  
 \* \*\*\*\*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 9 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 10 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 5 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 4 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 7 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 2 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 1 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034  
 Patient 8 AAAGATTTTGTACTAATAAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034  
 \*\*\*\*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

Patient 6 GCTGCTTTTCATCAAAATGCTTCCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
 Patient 9 GCTGCTTTTCATCAAAATGCTTCCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
 Patient 10 GCTGCTTTTCATCAAAATGCTTCCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
 Patient 5 GCTGCTTTTCATCAAAATGCTTCCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100

FIG. 13 CONT.

190/201

Patient 4 GCTGCTTTTCATCAAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
Patient 7 GCTGCTTTTCATCAAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
Patient 2 GCTGCTTTTCATCAAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
Patient 1 GCTGCATTTTATCAAAAATGCTTCCTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094  
Patient 8 GCTGCATTTTATCAAAAATGCTTCCTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094  
\*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\*

Patient 6 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 9 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 10 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 5 TATGTTTTGAATAATATTCTTTAACTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 4 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 7 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 2 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 1 TATGTTTTGAATAATATTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGGT 2154  
Patient 8 TATGTTTTGAATAATATTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGGT 2154  
\*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\*

Patient 6 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 9 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 10 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 5 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 4 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 7 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 2 TCGGTTTTTAATGCTGATAATTTAACTGATTATCTGTTCTTCTTGCTCTTCGCGATG 2217  
Patient 1 TGTGTTTTGAATGCTGTTAATTTAACTAGCTATCTGATCCTCTTGATTTGCGGATG 2214  
Patient 8 TGTGTTTTGAATGCTGTTAATTTAACTAGCTATCTGATCCTCTTGATTTGCGGATG 2214  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\*

Patient 6 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 9 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 10 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 5 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 4 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 7 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 2 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTCTTCTCCTTCGCGTCTGTAACGT 2277  
Patient 1 GGTAGTGGTTTTGTGTTGATTATGCTTTACCCCTTCTCT-----CGGCGTAAGCGT 2265  
Patient 8 GGTAGTGGTTTTGTGTTGATTATGCTTTACCCCTTCTCT-----CGGCGTAAGCGT 2265  
\*\*\*\*\* \* \*\*\*\*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\*

Patient 6 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 9 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 10 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 5 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 4 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 7 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 2 AGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAAATGTCAGTTTGGT 2337  
Patient 1 AGAGTATTTCTTCTCCTTATCGTTTGAACCTTTTGAACCCCTTAAATGTCAGTTTGGT 2325  
Patient 8 AGAGTATTTCTTCTCCTTATCGTTTGAACCTTTTGAACCCCTTAAATGTCAGTTTGGT 2325  
\*\*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 9 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 10 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 5 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 4 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 7 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 2 AATGACAGTATTGAGTCTGTGGGTTGGTCTTTATGAGATCAAAAATCCCACATACTTTACT 2397  
Patient 1 AACGATAGTGTGAACTGTTGGTGGTATTATTTGAGATTGAGATTCCCTACTAATCTTACC 2385  
Patient 8 AACGATAGTGTGAACTGTTGGTGGTATTATTTGAGATTGAGATTCCCTACTAATCTTACC 2385  
\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 9 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 10 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 5 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 4 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 7 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 2 ATAGTTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCT 2457  
Patient 1 ATAGCTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCA 2445  
Patient 8 ATAGCTGGTCAAGAGGAATTTATTCAAACCTAATTCCTCAAAGTTACTATTGATTTGTTCA 2445  
\*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \* \*\* \*\*\*\*\*

Patient 6 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTT 2517  
Patient 9 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTT 2517  
Patient 10 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTT 2517

FIG. 13 CONT.

191/201

Patient 5 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACCCTTT 2517  
Patient 4 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACCCTTT 2517  
Patient 7 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACCCTTT 2517  
Patient 2 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACCCTTT 2517  
Patient 1 GCTTTTGTGTTGCTCTAATTATGCTGCTTGTGCATGATTTATTGTCGGAAATATGGCACCCTTT 2505  
Patient 8 GCTTTTGTGTTGCTCTAATTATGCTGCTTGTGCATGATTTATTGTCGGAAATATGGCACCCTTT 2505  
\*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\*\*\*\*

Patient 6 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 9 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 10 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 5 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 4 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 7 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 2 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 1 TGCATAATATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTG 2565  
Patient 8 TGCATAATATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTG 2565  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*

Patient 6 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 9 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 10 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 5 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 4 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 7 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 2 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
Patient 1 CAGGTTGCTAATGCTTTAATGCAAGGTGTTACACTTAGTCTAATCTTAATACTAATCTA 2625  
Patient 8 CAGGTTGCTAATGCTTTAATGCAAGGTGTTACACTTAGTCTAATCTTAATACTAATCTA 2625  
\*\* \* \*\* \* \*\* \* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*

Patient 6 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 9 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 10 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 5 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 4 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 7 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 2 CATTTTGATGTTGATAAATATTAATTTTAAATCCCTAGTTGGATGTTAGGTTCCACACTGC 2697  
Patient 1 CACTCTGATGTTGATAAATATAGATTTTAAATCTCTTCTAGGTTGTTAGGTTCCACAATGT 2685  
Patient 8 CACTCTGATGTTGATAAATATAGATTTTAAATCTCTTCTAGGTTGTTAGGTTCCACAATGT 2685  
\*\* \* \*\* \* \*\* \* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*

Patient 6 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 9 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 10 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 5 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 4 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 7 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 2 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2757  
Patient 1 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2745  
Patient 8 GGTTCCTCTCTCGTTCCTTTTTTGAAGATTTATGTTTGACAAAGTTAAACTTTCAGAT 2745  
\*\*\*\*\* \*\* \* \*\* \* \*\* \* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*

Patient 6 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 9 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 10 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 5 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 4 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 7 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 2 GTTGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2817  
Patient 1 GTFAGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2805  
Patient 8 GTFAGGTTTTGTTGAAGCTTATAACAATTTGACTGGTGGTAGTGAATTAGAGATCTTCTT 2805  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*

Patient 6 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 9 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 10 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 5 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 4 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 7 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 2 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 1 TGTGTACAATCCTTTAATGGTATTAAAGTTTACCTCCCATTTTATCTGAGACTCAAATT 2865  
Patient 8 TGTGTACAATCCTTTAATGGTATTAAAGTTTACCTCCCATTTTATCTGAGACTCAAATT 2865  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*

Patient 6 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 9 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937

FIG. 13 CONT.

192/201

Patient 10 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 5 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 4 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 7 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 2 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 1 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTTCCGCCATGGTCTGCTGCTGCT 2925  
Patient 8 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTTCCGCCATGGTCTGCTGCTGCT 2925  
\*\*\*\*\* \*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\* \*\*

Patient 6 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 9 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 10 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 5 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 4 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 7 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 2 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2997  
Patient 1 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2985  
Patient 8 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTGGGTGTTACTATGGAT 2985  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 9 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 10 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 5 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 4 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 7 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 2 GTTCTTAATAAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
Patient 1 GTTCTTAATAAAGATCAAAGTTAATAGCTAATGCTTTTAATAAAGCTCTTCTTCTATC 3045  
Patient 8 GTTCTTAATAAAGATCAAAGTTAATAGCTAATGCTTTTAATAAAGCTCTTCTTCTATC 3045  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 9 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 10 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 5 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 4 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 7 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 2 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
Patient 1 CAGAATGGTTTTACTGCTACTAECTCTGCTCTTGCTAAAATACAAAGTGTGTTAATTCT 3105  
Patient 8 CAGAATGGTTTTACTGCTACTAECTCTGCTCTTGCTAAAATACAAAGTGTGTTAATTCT 3105  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 9 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 10 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 5 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 4 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 7 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 2 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTCAATTAGT 3177  
Patient 1 AATGCTCAAGCACTTAATAGTTTGTACACAAATTAATTAATAAATTTGGTCAATTAGT 3165  
Patient 8 AATGCTCAAGCACTTAATAGTTTGTACACAAATTAATTAATAAATTTGGTCAATTAGT 3165  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 9 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 10 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 5 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 4 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 7 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 2 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 1 TCTTCTTTACAAGAAATTTTGTCTCGCCTTGATAATTTAGAAGCTCAGGTTCAGATTGAT 3225  
Patient 8 TCTTCTTTACAAGAAATTTTGTCTCGCCTTGATAATTTAGAAGCTCAGGTTCAGATTGAT 3225  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 9 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 10 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 5 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 4 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 7 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 2 AGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 1 AGGCTCATTAATGGTCGTTGACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGAT 3285  
Patient 8 AGGCTCATTAATGGTCGTTGACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGAT 3285  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 ATTTCTTTGTAARATTTGGTGTGCTTTAGCTATGGAGAAGTTAATGAGTGTGTTAAA 3357

FIG. 13 CONT.

Patient 9	ATTTCTCTTGAAAAATTTGGTGCCTTACGTTATGGAGAAGGTTAATGAGTGTGTAAA	3357
Patient 10	ATTTCTCTTGAAAAATTTGGTGCCTTACGTTATGGAGAAGGTTAATGAGTGTGTAAA	3357
Patient 5	ATTTCTCTTGAAAAATTTGGTGCCTTACGTTATGGAGAAGGTTAATGAGTGTGTAAA	3357
Patient 4	ATTTCTCTTGAAAAATTTGGTGCCTTACGTTATGGAGAAGGTTAATGAGTGTGTAAA	3357
Patient 7	ATTTCTCTTGAAAAATTTGGTGCCTTACGTTATGGAGAAGGTTAATGAGTGTGTAAA	3357
Patient 2	ATTTCTCTTGAAAAATTTGGTGCCTTACGTTATGGAGAAGGTTAATGAGTGTGTAAA	3357
Patient 1	ATTACACTTATTAAAGGCTGGAGCTTCTCGTGCATTGAGAAGGTTAATGAGTGTGTAAA	3345
Patient 8	ATTACACTTATTAAAGGCTGGAGCTTCTCGTGCATTGAGAAGGTTAATGAGTGTGTAAA	3345
	*** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	
Patient 6	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 9	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 10	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 5	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 4	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 7	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 2	AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATAGTTCAA	3417
Patient 1	AGTCAATCCCTCGTATAAATTTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAA	3405
Patient 8	AGTCAATCCCTCGTATAAATTTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAA	3405
	***** ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	
Patient 6	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 9	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 10	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 5	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 4	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 7	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 2	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3477
Patient 1	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3465
Patient 8	AATGCTCCTTATGGTTTGGTGGTTTATGCATTTTAGTTATAAACCTATTCTTTTAAAAC	3465
	***** ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	
Patient 6	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 9	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 10	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 5	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 4	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 7	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 2	GTTTTAGTAAGTCCCTGGTTTGGTGGTATATCAGGTGATGATAGGTATTGCACCTAAACAGGG	3537
Patient 1	GTCCTAGTAAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGT	3525
Patient 8	GTCCTAGTAAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGT	3525
	** ***** ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	
Patient 6	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 9	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 10	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 5	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 4	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 7	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 2	TATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGTTCTTACTATTATCCTGAA	3597
Patient 1	TATTTTATTAACAAAATGATTCCTGGATGTTTACTGGTAGTTCTTACTATTATACCAGAA	3585
Patient 8	TATTTTATTAACAAAATGATTCCTGGATGTTTACTGGTAGTTCTTACTATTATACCAGAA	3585
	***** ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	
Patient 6	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 9	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 10	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 5	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 4	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 7	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 2	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient 1	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3645
Patient 8	CCAATTTAGATAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3645
	***** ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	
Patient 6	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 9	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 10	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 5	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 4	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 7	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 2	CCTCTTGTTTATTTGAATCATTTCTGTACCAAATTTGCTGATTTTGAATCTGAGTTATCT	3717
Patient 1	CCATTTATTTATCTTAATAATTTCTATACCAAATTTGCTGATTTTGAAGCCGAGTTTCT	3705
Patient 8	CCATTTATTTATCTTAATAATTTCTATACCAAATTTGCTGATTTTGAAGCCGAGTTATCT	3705
	** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * ** * **	

FIG. 13 CONT.

194/201

Patient 6 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 9 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 10 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 5 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 4 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 7 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 2 CATTGGTTTAAAAATCAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 1 CTTTGGTTTAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTTCTCATA---TT 3762  
 Patient 8 CTTTGGTTTAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTTCTCATA---TT 3762  
 \* \*\*\*\*\* \*\* \*\* \*\* \* \*\*\*\*\* \*\* \*\* \*\* \*\*\*\*\* \*\*

Patient 6 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 9 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 10 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 5 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 4 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 7 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 2 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837  
 Patient 1 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3822  
 Patient 8 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3822  
 \*\*\*\*\* \* \*\*\*\*\* \*\* \*\* \*\* \* \*\*\*\*\* \*\* \*\* \*\* \*\*\*\*\* \*\*

Patient 6 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 9 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 10 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 5 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 4 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 7 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 2 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 1 TTGAACAGTAGTTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTAATAATGG 3882  
 Patient 8 TTGAACAGTAGTTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTAATAATGG 3882  
 \*\*\*\*\* \* \*\*\*\*\* \*\* \*\* \*\* \* \*\*\*\*\* \*\* \*\* \*\* \*\*\*\*\* \*\*

Patient 6 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 9 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 10 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 5 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 4 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 7 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 2 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTTATAAATATTCCTTGTATTGCTCTTT 3957  
 Patient 1 CCTTGGTACATTTGGTTGTTAATTTGTCATTTTATTATAAATTTTCTTATGATACTTTTTC 3942  
 Patient 8 CCTTGGTACATTTGGTTGTTAATTTGTCATTTTATTATAAATTTTCTTATGATACTTTTTC 3942  
 \*\*\*\*\* \* \*\*\*\*\* \*\* \*\* \*\* \* \*\*\*\*\* \*\* \*\* \*\* \*\*\*\*\* \*\*

Patient 6 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 9 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 10 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 5 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 4 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 7 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 2 TTTATATGTTGTTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4017  
 Patient 1 TTTATATGCTGCTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4002  
 Patient 8 TTTATATGCTGCTGTAAGTCTGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAAATGTTGT 4002  
 \*\*\*\*\* \* \*\*\*\*\* \*\* \*\* \*\* \* \*\*\*\*\* \*\* \*\* \*\* \*\*\*\*\* \*\*

Patient 6 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 9 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 10 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 5 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 4 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 7 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 2 GATGAGTATGGTGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4071  
 Patient 1 GATGAGTATGGGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4056  
 Patient 8 GATGAGTATGGGGTCAATCATGATTTTGTATCAAAACATCTCATGATGATTAG 4056  
 \*\*\*\*\* \* \*\*\*\*\* \*\* \*\* \*\* \* \*\*\*\*\* \*\* \*\* \*\* \*\*\*\*\* \*\*

FIG. 13 CONT.



195/201

Fig. 14. Multiple alignment of the nucleocapsid genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```

Patient 4      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 6      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 7      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 9      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 10     ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 2      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 5      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 1      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 8      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
*****

Patient 4      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 6      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 7      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 9      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 10     ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 2      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 5      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 1      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
Patient 8      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAAACGAAATACCAAACCTTTAATAGA 120
*****

Patient 4      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 6      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 7      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 9      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 10     GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 2      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 5      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 1      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 8      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
*****

Patient 4      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 6      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 7      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 9      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 10     CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 2      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 5      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 1      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 8      CATTATTCCTGGTTCCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
*****

Patient 4      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 6      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 7      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 9      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 10     GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 2      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 5      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 1      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 8      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
*****

Patient 4      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 6      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 7      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 9      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 10     TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 2      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 5      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 1      TATAAACACAACCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 8      TATAAACACAACCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
*****

Patient 4      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 6      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 7      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 9      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 10     AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 2      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 5      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 1      AGATGGTATTTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420

```

FIG. 14

Patient 8 AGATGGTATTCTACTATCTCGGTACCGGTCCATATGCCAGTTCATCCTATGGTGATGCC 420  
 \*\*\*\*\* \* \*\*\*\*\* \*\*

Patient 4 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 6 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 7 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 9 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 10 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 2 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 5 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 1 CACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGACACTTCTATCCCTCCGATGTT 480  
 Patient 8 CACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGATACTTCTATCCCTCCGATGTT 480  
 \* \*\*\*\*\* \* \*\*\*\*\* \*\*

Patient 4 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 6 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 7 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 9 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 10 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 2 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 5 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 1 TCGGCAAGGGATCCTACTATTCAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 8 TCGGCAAGGGATCCTACTATTCAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 \*\*\* \*\*\*\*\* \*\*

Patient 4 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 6 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 7 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 9 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 10 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 2 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 5 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 1 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 Patient 8 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTCGCTTCTAATAGTCGACCAGGT 600  
 \*\*\*\*\* \*\* \*\*\*\*\*

Patient 4 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 6 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 7 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 9 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 10 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 2 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 5 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 1 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 8 TCACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 \*\*\*\*\* \*\* \*\*\*\*\*

Patient 4 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 6 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 7 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 9 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 10 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 2 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 5 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 1 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 8 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 \*\*\*\*\* \* \*\*\*\*\* \*\*

Patient 4 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 6 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 7 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 9 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 10 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 2 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 5 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 1 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 Patient 8 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCRAAAATGCCAAGGAAAT 780  
 \*\*\*\*\* \* \*\*\*\*\* \*\*

Patient 4 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 6 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 7 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 9 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 10 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 2 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 5 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840

FIG. 14 CONT.

197/201

Patient 1 AGGCATAAAAATTTAATGAACCTCGCCAAAAGCGAACTCCTAATAAATTTTGTAAATGTT 840  
 Patient 8 AGGCATAAAAATTTAATGAACCTCGCCAAAAGCGAACTCCTAATAAATTTTGTAAATGTT 840  
 \*\*\*\*\*

Patient 4 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 6 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 7 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 9 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 10 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 2 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 5 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 1 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 8 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 \*\*\*\*\*

Patient 4 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 6 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 7 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 9 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 10 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 2 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 5 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 1 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 Patient 8 CTTGGTACTAATGATCCTCAGTTTCTTATTCCTTGCAGAAATTAGCTCCTACACCAGGTGCT 960  
 \*\*\*\*\*

Patient 4 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 6 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 7 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 9 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 10 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 2 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 5 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 1 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 Patient 8 TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCGAGGCTGACTCACCTGTT 1020  
 \*\*\*\*\*

Patient 4 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 6 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 7 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 9 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 10 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 2 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 5 AAAGATGTTTTGAACCTCATTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 1 AAAGACACTTTTGAACCTCGTTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCTGGT 1080  
 Patient 8 AAAGACACTTTTGAACCTCGTTATTCCTGGTTCTATTAGGTTTGATAGTACTTTACCTGGT 1080  
 \*\*\*\*\*

Patient 4 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 6 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 7 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 9 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 10 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 2 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 5 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTCATATCAG 1140  
 Patient 1 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAGATGCTTATGTTAATTCATATCAG 1140  
 Patient 8 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAGATGCTTATGTTAATTCATATCAG 1140  
 \*\*\*\*\*

Patient 4 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 6 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 7 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 9 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 10 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 2 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 5 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 1 AACACTGTTTCGTTTCGCTGAGTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200  
 Patient 8 AACACTGTTTCGTTTCGCTGAGTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200  
 \*\*\*\*\*

Patient 4 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGTTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 6 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGTTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 7 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGTTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 9 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGTTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 10 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGTTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 2 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGTTACTCAGCACATTTCAAATGATTTT 1260

FIG. 14 CONT.


198/201

Patient 5 CCAGAACAGTTGACTCTCTTAATTTAAGTGCCTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 1 CCTGAATCGTTTGACTCTCTTAATTTAAGTGCCTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 8 CCTGAATCGTTTGACTCTCTTAATTTAAGTGCCTGGTACTCAGCACATTTCAAATGATTTT 1260  
 \*\* \*\*

Patient 4 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 6 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 7 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 9 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 10 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 2 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 5 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 1 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 Patient 8 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320  
 \*\*\*\*\* \*\*

Patient 4 GCTTAA 1326  
 Patient 6 GCTTAA 1326  
 Patient 7 GCTTAA 1326  
 Patient 9 GCTTAA 1326  
 Patient 10 GCTTAA 1326  
 Patient 2 GCTTAA 1326  
 Patient 5 GCTTAA 1326  
 Patient 1 GCTTAA 1326  
 Patient 8 GCTTAA 1326  
 \*\*\*\*\*

FIG. 14 CONT.



200/201

	LPW1926	LPW1927	
HCoV-HKU1 (Patient 1)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 2)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 4)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 5)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 6)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 7)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 8)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 9)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-HKU1 (Patient 10)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
HCoV-OC43 (NC_005147)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATT	TTAGTATGATGAT	2258
SARS-CoV (NC_004718)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../TTACCTGTAAGCATT	TTAGTATGATGAT	2270
HCoV-229E (NC_002645)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../TTATTTGTAAGCATT	TTAGTATGATGAT	2255
HCoV-NL63 (NC_005831)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../TTATCTTGAAGCATT	TTAGTATGATGAT	2255

FIG. 16

201/201





FIG. 17

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CN2005/001088

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>  IPC <sup>7</sup> C12N 15/50 C12N 15/63 C12N 7/00 C07K14/165 A61K39/215 A61P11/00 G01N33/53 C12Q1/68 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>  Minimum documentation searched (classification system followed by classification symbols)  IPC <sup>7</sup> C12N, C07K, A61K, A61P, G01N, C12Q  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Data Base: EPODOC, WPI, CNPAT, CNKI, CA, BA; Search Terms: human, coronavirus, hcov, genomic sequence				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	US6057436A (PFIZER INC ET-AL) 2.MAY 2000 (02.05.2000), see the whole document	1-74		
A	WO0139797 A2 (CONSEJO SUPERIOR INVESTIGACIONES CIENTIF ET-AL) 7.JUN 2001 (07.06.2001), see the whole document	1-74		
A	CN1450173A (BENYUAN ZHENGYANG GENE TECHNOLOGY CO LTD) 22.OCT 2003(22.10.2003), see the whole document	1-74		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">                     * Special categories of cited documents:                      "A" document defining the general state of the art which is not considered to be of particular relevance                      "E" earlier application or patent but published on or after the international filing date                      "L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)                      "O" document referring to an oral disclosure, use, exhibition or other means                      "P" document published prior to the international filing date but later than the priority date claimed                 </td> <td style="width: 50%; border: none;">                     "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                      "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                      "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art                      "&amp;" document member of the same patent family                 </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 12.OCT 2005(12.10.2005)		Date of mailing of the international search report 27 · OCT 2005 (27 · 10 · 2005)		
Name and mailing address of the ISA/CN The State Intellectual Property Office, the P.R.China 6 Xitucheng Rd., Jimen Bridge, Haidian District, Beijing, China 100088 Facsimile No. 86-10-62019451		Authorized officer <div style="text-align: center;">                       Wang Qiyang                      Telephone No. (86-10)62085348                 </div>		



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/CN2005/001088

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
US6057436A	2.MAY 2000 (02.05.2000)	CA2096010A1 IE913948A1 WO9208487A1 AU9128691 A ZA9108988 A EP0557455 A1 CA2135200A1 WO9323423A1 AU4251593A JP6502768T NZ240558 A EP0640098 A1 JP7508421T JP3245169B2 AU666298B2 AU670092B2 KR204258B1 US6057436A US6280974B1 US6372224 B1 AT225805T DK640098T DE69332375 D1 PT640098T DE69332375T ES2182827T JP2003093078 A	17.MAY1992 (17.05.1992) 20.MAY1992 (20.05.1992) 29.MAY1992 (29.05.1992) 11.JUN 1992 (11.06.1992) 30.JUN 1992 (30.06.1992) 1.SEP 1993 (01.09.1993) 11.NOV 1993 (11.11.1993) 25.NOV 1993 25.11.1993) 13.DEC 1993 (13.12.1993) 31.MAR 1994 (31.03.1994) 25.NOV 1994 (25.11.1994) 1.MAR 1995 (01.03.1995) 21.SEP 1995 (21.09.1995) 7.JAN 2002 (07.01.2002) 8.FEB 1996 (08.02.1996) 4.JUL 1996 (04.07.1996) 15.JUN 1999 (15.06.1999) 2 .MAY 2000 (02.05.2000) 28 .AUG 2001 (28.08.2001) 16 .APR 2002 (16.04.2002) 15 .OCT 2002 (15.10.2002) 28.OCT 2002 (28.10.2002) 14 .NOV 2002 (14.11.2002) 31.JAN 2003(31.01.2003) 13 .FEB 2003 (13.02.2003) 16 .MAR 2003 (16.03.2003) 2 .APR 2003 (02.04.2003)
WO0139797 A2	7.JUN 2001 (07.06.2001)	AU200130051 A BR200016145 A ES2170622 A1 NO200202419 A EPI234024 A2 SK200200761 A3 CZ200201882 A3 KR2002060251 A HU200203305 A2 ZA200203560 A JP2003515335T T CN1402780 A US2003148325 A1 NZ518990 A US2004086846 A1 EP1234024 B1 ES2170622 B1 DE60010921E E EP1437400 A2	12.JUN 2001 (12.06.2001) 13.AUG 2002 (13.08.2002) 1.AUG 2002 (01.08.2002) 30.JUL 2002 (30.07.2002) 28.AUG 2002 (28.08.2002) 6.NOV 2002 (06.11.2002) 13.NOV 2002 (13.11.2002) 16.JUL 2002 (16.07.2002) 28.JAN 2003 (28.01.2003) 26.MAR 2003 (26.03.2003) 07.MAY 2003 (07.05.2003) 12.MAR2003 (12.03.2003) 07.AUG 2003 (07.08.2003) 26.MAR 2004 (26.03.2004) 6.MAY 2004 (06.05.2004) 19.MAY 2004 (19.05.2004) 16.MAY 2004 (19.05.2004) 24.JUN 2004 (24.06.2004) 14.JUL 2004 (14.07.2004)
CN1450173A	22.OCT 2003(22.10.2003)	NONE	